

ΜΑΡΙΟΣ ΔΗΜΟΠΟΥΛΟΣ  
ΦΥΣΙΚΟΠΑΘΗΤΙΚΟΣ

ΦΥΣΙΚΕΣ ΜΕΘΟΔΟΙ  
ΠΡΟΛΗΨΗΣ & ΑΝΤΙΜΕΤΩΠΙΣΗΣ  
ΤΟΥ ΚΑΡΚΙΝΟΥ

ΒΙΒΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ

ΕΚΔΟΣΕΙΣ ETRA

Τίτλος: Φυσικές μέθοδοι πρόληψης και αντιμετώπισης του καρκίνου  
Συγγραφέας: Μάριος Δημόλουος

ISBN: 978-618-5735-02-9

Επιμέλεια έκδοσης: Βάλλυ Καλοζούμη  
Εξώφυλλο: Γεράσιμος Ε. Κατραμάδος

2023 © Εκδόσεις ETRA  
Ευεργετών 7, Π. Φάληρο, 17563  
Τ: 210 9811753  
www.etra.gr

Βιβλιογραφικές αναφορές του βιβλίου:

ΜΕΡΟΣ 1.....	3
ΜΕΡΟΣ 2.....	24
ΜΕΡΟΣ 3.....	55
ΜΕΡΟΣ 4.....	60
ΜΕΡΟΣ 5.....	104
ΜΕΡΟΣ 6.....	212
ΜΕΡΟΣ 7.....	218
ΜΕΡΟΣ 8.....	224
ΜΕΡΟΣ 9.....	270

*Ο συγγραφέας αυτού του βιβλίου δεν παρέχει ιατρικές συμβουλές ούτε συνταγογραφεί τη χρήση οποιασδήποτε τεχνικής ως μορφή θεραπείας για σωματικά, συναισθηματικά ή ιατρικά προβλήματα χωρίς τη συμβουλή γιατρού, είτε άμεσα είτε έμμεσα. Η πρόθεση του συγγραφέα είναι μόνο να προσφέρει πληροφορίες γενικής φύσης για να σας βοηθήσει στην προσπάθειά σας για συναισθηματική, σωματική και πνευματική ευεξία. Σε περίπτωση που χρησιμοποιήσετε οποιαδήποτε από τις πληροφορίες αυτού του βιβλίου για τον εαυτό σας, ο συγγραφέας και ο εκδότης δεν αναλαμβάνουν καμία ευθύνη για τις ενέργειές σας.*

*Κανένα μέρος του παρόντος βιβλίου δεν επιτρέπεται να αναπαραχθεί με οποιαδήποτε μηχανική, φωτογραφική ή ηλεκτρονική διαδικασία ή με τη μορφή φωνογραφικής εγγραφής, ούτε να αποθηκευτεί σε σύστημα ανάκτησης, να μεταδοθεί ή να αντιγραφεί με οποιονδήποτε άλλο τρόπο για δημόσια ή ιδιωτική χρήση -εκτός από τη "θεμιτή χρήση" ως σύντομων αποσπασμάτων που ενσωματώνονται σε άρθρα και κριτικές- χωρίς προηγούμενη γραπτή άδεια του εκδότη.*

## **ΜΕΡΟΣ 1**

### **ΥΠΕΡΟΞΕΙΔΙΟ ΤΟΥ ΥΔΡΟΓΟΝΟΥ ΚΑΙ ΑΣΚΟΡΒΙΚΟ ΟΞΥ**

1. Halliwell B, Gutteridge JM. Free Radicals In Biology And Medicine. Oxford University Press, Oxford, England. 1998.
2. Nindl G. Hydrogen peroxide – from oxidative stressor to redox regulator, featured review. *Cellscience Reviews*. 2004, 1(2).
3. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res*. 1991, 51(3), 794-798.
4. Simizu S, Takada M, Umezawa K, Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. *J Biol Chem*. 1998, 273(41), 26900-26907.
5. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. *Ann NY Acad Sci*. 1998, 854, 328-335.
6. Anon. Questionable methods of cancer management: hydrogen peroxide and other 'hyperoxygenation' therapies. *CA Cancer J Clin*. 1993, 43(1), 47-56.
7. Schriener SE, Linford NJ, Martin GM, et al. Extension of murine lifespan by overexpression of catalase targeted to mitochondria. *Science*. 2005 Jun 24;308(5730):1909-11.
8. Loew O. Catalase – a new enzyme of general occurrence with special reference to the tobacco plant. US Department of Agriculture report. 1901, no 68.
9. Holman RA. The nature and functions of catalase, Mother Earth. *Journal of the Soil Association*. 1961, 6, 607-610.
10. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. *Physiol Rev*. 1979, 59(3), 527-605.
11. Holman RA. On the fundamental importance of the catalase peroxide mechanism in living cells with particular reference to the problem of cancer. *Symposium Internazionale De Medicina Ed Igene Sociale, Trieste*. 1957.
12. Szatrowski TR, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res*. 1991,

- 51(3), 794-798.
13. Oberley LW. Anticancer therapy by overexpression of superoxide dismutase. *Antioxid Redox Signal*. 2001, 3(3), 461-472.
  14. Deshpande NN, Sorescu D, Seshiah P, et al. Mechanism of hydrogen peroxide-induced cell cycle arrest in vascular smooth muscle. *Antioxid Redox Signal*. 2002, 4(5), 845-854.
  15. Laurent A, Nicco C, Chereau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. *Cancer Res*. 2005, 65, 948-956.
  16. Parchment RE. The implications of a unified theory of programmed cell death, polyamines, oxyradicals and histogenesis in the embryo. *Int J Dev Biol*. 1993, 37(1), 75-83.
  17. O'Donnell-Tormey J, DeBoer CJ, Nathan CF. Resistance of human tumor cells in vitro to oxidative cytolysis. *J Clin Invest*. 1985, 76(1), 80-86.
  18. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. *Breast Cancer Res*. 2001, 3(5), 323-327.
  19. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. *EMBO Reports*. 2002, 3(5), 420-425.
  20. Brar SS, Corbin Z, Kennedy TP, et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. *Am J Physiol Cell Physiol*. 2003, 285, C353-C369.
  21. Brar SS, Kennedy TP, Sturrock AB, et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. *Am J Physiol Cell Physiol*. 2002, 282(6), C1212-C1224.
  22. Nulton-Persson AC, Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. *J Biol Chem*. 2001, 276(26), 23357-23361.
  23. Lee S, Yang K, Kwon J, et al. Reversible inactivation of the tumor suppressor PTEN by H<sub>2</sub>O<sub>2</sub>. *J Biol Chem*. 2002, 277(23), 20336-20342.
  24. Lia J, Oberley LW, Fan M, Colbu NH. Inhibition of AP-1 and NF-B

- by manganese-containing superoxide dismutase in human breast cancer cells. *Faseb J.* 1998, 12, 1713-1723.
25. Manna SK, Zhang HJ, Yan T, et al. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-B and activated protein-1. *Biol Chem.* 1998, 273(21), 13245-13254.
  26. Zeisel SH. Antioxidants suppress apoptosis. *J Nutrition.* 2004, 134(11), 3179S-3180S.
  27. Vaquero EC, Edderkaoui M, Pandol SJ, et al. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. *J Biol Chem.* 2004, 279(33), 34643-34654.
  28. Oberley TD, Oberley LW. Antioxidant enzyme levels in cancer. *Histol Histopathol.* 1997, 12(2), 525-535.
  29. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. *Cancer Res.* 1999, 59, 602-606.
  30. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. *Integr Cancer Ther.* 2005, 4(1), 32-44.
  31. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of ascorbate's chemotherapeutic activity. *P R Health Sci J.* 2002, 21(1), 39-41.
  32. McCormick WJ. Ascorbic acid as a chemotherapeutic agent. *Arch Pediat.* 1952, 69, 151-155.
  33. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A.* 2005 Sep 20;102(38):13604-9.
  34. Fletcher AE, Breeze E, Shetty PS. Antioxidant vitamins and mortality in older persons: findings from the nutrition add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. *Am J Clin Nutr.* 2003, 78, 999-1010.
  35. Lee KW, Lee HJ, Surh YJ, Lee CY. Vitamin C and cancer

- chemoprevention: reappraisal. *Am J Clin Nutr.* 2003, 78, 1074-1078.
36. Gonzalez MJ, Mora E, Riordan HD, et al. Rethinking vitamin C and cancer: an update on nutritional oncology. *Cancer Prevention International.* 1998, 3, 215-234.
  37. Riordan NH, Riordan HD, Jackson JA, Casciari JP. Clinical and experimental experiences with intravenous vitamin C. *Journal of Orthomolecular Medicine.* 2000, 15(4), 201-213.
  38. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. *Int J Vitam Nutr Res Suppl.* 1982;23:103-13.
  39. Pauling L. Vitamin C therapy and advanced cancer (letter). *N Engl J Med.* 1980, 302, 694.
  40. Moertel CG, Creagan ET. Vitamin C therapy and advanced cancer (letter). *N Engl J Med.* 1980, 302, 694-695.
  41. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med.* 1985, 312, 137-141.
  42. Hoffer A, Pauling L. Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study, and a comparison of survival times of cancer patients receiving large regular doses of vitamin C and other nutrients with similar patients not receiving those doses. *Journal of Orthomolecular Medicine.* 1990, 5, 143-154.
  43. Hoffer A, Pauling L. Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving these doses. *Journal of Orthomolecular Medicine.* 1993, 8, 1547-1567.
  44. Riordan N, Jackson JA, Riordan HD. Intravenous vitamin C in a terminal cancer patient. *J Ortho Med.* 1996, 11, 80-82.

45. Riordan NH, Riordan HD, Meng X, et al. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. *Med Hypotheses*. 1995, 44, 207-213.
46. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of intravenous ascorbate's chemotherapeutic activity. *P R Health Sci J*. 2002, Mar, 21(1), 39-41.
47. Park CH, Aniare M, Savin MA, Hoogstraten B. Growth suppression of human leukemic cells in vitro by L-ascorbic acid. *Cancer Res*. 1980, 40, 1062-1065.
48. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med*. 2004, 140, 533-537.
49. Lee KW, Lee HJ, Kang KS, Lee CY. Preventive effects of vitamin C on carcinogenesis. *The Lancet*. 2002, 359, 9301.
50. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of ascorbate's chemotherapeutic activity. *P R Health Sci J*. 2002, 21(1), 39-41.
51. Ramp WK, Thornton PA. The effects of ascorbic acid on the glycolytic and respiratory metabolism of embryonic chick tibias. *Calcif Tissue Res*. 1968, 2, 77-82.
52. Poydock ME. Effect of combined ascorbic acid and B12 on survival of mice implanted with Erlich carcinoma and L1210 leukemia. *Am J Clin Nutr*. 1991, 54, 12615-12655.
53. Gardorov AK, Loshkomoeva IN. Free radical lipid peroxidation and several ways of regulating it with ascorbic acid. *Biofizika*. 1978, 23, 391-392.
54. Casciari JJ, Riordan HD, Miranda-Massari JR, Gonzalez MJ. Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. *P R Health Sci J*. 2005, 24(2), 145-150.
55. Leung PY, Miyashita K, Young M, Tsao CS. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. *Anticancer Res*. 1993, 13(2), 475-480.
56. DeLaurenzi V, Melino G, Savini I, et al. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell

- lines. *Eur J Cancer*. 1995, 31A(4), 463-466.
57. Tsao C, Dunham W, Leung P. Growth control of human colon tumor xenografts by ascorbic acid, copper, and iron. *The Cancer Journal*. 1995, 8, 157-163.
  58. Girgert R, Vogt Y, Becke D, et al. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. *Cancer Lett*. 1999, 137(2), 167-72.
  59. Paolini M, Pozzetti L, Pedulli GF, et al. The nature of prooxidant activity of vitamin C. *Life Sci*. 1999, 64, 273-278.
  60. Gonzalez MJ. Lipid peroxidation and tumor growth: an inverse relationship. *Med Hypotheses*. 1992, 38, 106-10.
  61. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1, 2, 4, -triazole. *Oncology*. 1969, 23, 33-43.
  62. Tsao CS, Dunham WB, Leung PY. In vivo antineoplastic activity of ascorbic acid for human mammary tumor. *In Vivo*. 1988, 2(2), 147-150.
  63. Noto V, Taper HS, Jiang YH. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. *Cancer*. 1989, 63, 901-906.)
  64. Kock GH, Biaglow JE. Toxicity, radiation sensitivity modification and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. *J Cell Physiol*. 1978, 94, 299-306.
  65. Kadiiska MB, Hanna PM, Hernandez L, Mason RP. In vivo evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: electron spin resonance spin-trapping investigation. *Molecular Pharmacol*. 1992, 42, 723-729.
  66. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of ascorbate's chemotherapeutic activity. *P R Health Sci J*. 2002, 21(1), 39-41.
  67. Margalioth EJ, Schenker JG, Chevion M. Copper and zinc levels in normal and malignant tissues. *Cancer*. 1983. 52(5), 868-872.
  68. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue.



- Cancer Research. 1984, 44(11), 5390-5394.
69. Gonzalez MJ, Mora E, Riordan NH, et al. Rethinking vitamin C and cancer: an update on nutritional oncology. *Cancer Prevention International*. 1998, 3, 215-234.
70. Riordan NH, Riordan HD, Meng X, et al. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. *Med Hypotheses*. 1995, 44, 207-213.
71. Riordan NH, Riordan HD, Jackson JA, Casciari JP. Clinical and experimental experiences with intravenous vitamin C. *Journal of Orthomolecular Medicine*. 2000, 15(4), 201-213.
72. Casciari JJ, Riordan NH, Schmidt TL, et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. *British Journal of Cancer*. 2001, 84, 11, 1544-1550.
73. Cameron E, Pauling L. *Cancer and Vitamin C*. Camino Books, Philadelphia, 1993.
74. Hoffer A. *Vitamin C and Cancer*. Quarry Health Books, Quebec, Canada, 2000.
75. Cameron E, Pauling L. *Cancer and Vitamin C*. Camino Books, Philadelphia. 1993.
76. Riordan HD, Riordan NH, Jackson JA, et al. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. *R Health Sci J*. 2004, 23(2), 115-118.
77. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. *Nature*. 1993, 364(6432), 79-82.
78. Rumsey SC, Kwon O, Xu GW, et al. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. *J Biol Chem*. 1997, 272(30), 18982-18989.
79. Rumsey SC, Daruwala R, Al-Hasani H, et al. Dehydroascorbic acid transport by GLUT4 in *Xenopus* oocytes and isolated rat adipocytes. *J Biol Chem*. 2000, 275(36), 28246-28253.
80. Langemann H, Torhorst J, Kabierrsch A. Quantitative determination of water- and lipid-soluble antioxidants in neoplastic and non-neoplastic human breast tissue. *Int J Cancer*. 1989, 43(6), 1169-1173.

81. Malo C, Wilson JX. Glucose modulates vitamin C transport in adult human small intestinal brush border membrane vesicles. *J Nutr.* 2000, 130(1), 63-69.
82. Lutsenko EA, Carcamo JM, Golde DW. A human sodium-dependent vitamin C transporter 2 isoform acts as a dominant-negative inhibitor of ascorbic acid transport. *Mol Cell Biol.* 2004, 24(8), 3150-3156.
83. Ely JTA. Glycemic modulation of tumor tolerance. *Journal of Orthomolecular Medicine.* 1996, 11(1), 23-34.
84. Baader SL, Bruchelt G, Trautner MC, et al. Uptake and cytotoxicity of ascorbic acid and dehydroascorbic acid in neuroblastoma (SK-N-SH) and neuroectodermal (SK-N-LO) cells. *Anticancer Res.* 1994, 14(1A), 221-227.
85. Nualart FJ, Rivas CI, Montecinos VP, et al. Recycling of vitamin C by a bystander effect. *J Biol Chem.* 2003, 278(12), 10128-10133.
86. Vera JC, Rivas CI, Zhang RH, et al. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. *Blood.* 1994, 84(5), 1628-1634.
87. Agus DB, Vera JC, Golde DW. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. *Cancer Res.* 1999, 59(18), 4555-4558.
88. Corti A, Raggi C, Franzini M, et al. Plasma membrane gamma-glutamyltransferase activity facilitates the uptake of vitamin C in melanoma cells. *Free Radic Biol Med.* 2004, 37(11), 1906-1915.
89. Spielholz C, Golde DW, Houghton AN, et al. Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. *Cancer Res.* 1997, 57(12), 2529-2537.
90. Cameron E, Pauling L., *Cancer and vitamin C*, 1979.
91. Cameron E, Rotman D. Ascorbic acid, cell proliferation, and cancer. *Lancet.* 1972 Mar 4;1(7749):542.
92. Cameron E., Pauling L., *Cancer and Vitamin C*, 1979.
93. Cameron E, Pauling L. The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. *Chem Biol Interact.*

- 1974 Oct;9(4):273-83.
94. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a review. *Cancer Res.* 1979 Mar;39(3):663-81.
  95. Cameron E., Pauling L., *Cancer and Vitamin C.*, 1979.
  96. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. *Int J Vitam Nutr Res Suppl.* 1982;23:103-13.
  97. Stone I., *The Healing Factor: Vitamin C Against Disease*, 1972.
  98. Goth A., Litmann I., Ascorbic acid content in human cancer tissue, *Cancer Research*, 1948. 8, 349-351.
  99. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. *Oncology.* 1969;23(1):33-43.
  100. Hoffer A., Pauling L., Hardin Jones biostatistical analysis of mortality data for cohorts of cancer patients with a large fraction surviving at the termination of the study, and a comparison of survival times of cancer patients receiving large regular oral doses of vitamin C and other nutrients with similar patients not receiving those doses, *Journal of Orthomolecular Medicine*, 1990, 5, 143-154.
  101. De Laurenzi V, Melino G, Savini I, et al. Cell death by oxidative stress and ascorbic acid regeneration in human neuroectodermal cell lines. *Eur J Cancer.* 1995, 31A(4), 463-466.
  102. Meadows GG, Pierson HF, Abdallah RM. Ascorbate in the treatment of experimental transplanted melanoma. *Am J Clin Nutr.* 1991, 54(6 Suppl), 1284S-1291S.
  103. Riordan HD, Jackson JA, Schultz M. Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. *J Ortho Med.* 1990, 5, 5-7.
  104. Riordan NH, Jackson JA, Riordan HD. Intravenous vitamin C in a terminal cancer patient. *J Ortho Med.* 1996, 11, 80-82.
  105. Riordan NH, Riordan HD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. *Med Hypotheses.* 1995 Mar;44(3):207-13.
  106. Riordan HD, Riordan NH, Meng X, Zhong J, Jackson JA.

- Improved microplate fluorometer counting of viable tumor and normal cells. *Anticancer Res.* 1994 May-Jun;14(3A):927-31.
107. Gonzalez MJ, Miranda-Massari JR, Mora EM, et al. Orthomolecular oncology: a mechanistic view of intravenous ascorbate's chemotherapeutic activity. *P R Health Sci J.* 2002, 21(1), 39-41.
108. Raic-Malic S, Svedruzic D, Gazivoda T, et al. Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4,5-didehydro-5,6-dideoxy-L-ascorbic acid. *J Med Chem.* 2001, 43(25), 4806-4811.
109. Tashiro F, Sugiyama A, Urano Y, Kochi M. Sodium 5, 6-benzylidene-L-ascorbate induces in vitro neuronal cell differentiation accompanying apoptosis and necrosis. *Anticancer Res.* 2002, 22(3), 1423-1431.
110. Esposito E, Cervellatti F, Menegatti E, et al. Spray dried Eudragit microparticles as encapsulation devices for vitamin C. *Int J Pharm.* 2002, 21, 242(1-2), 329-334.
111. Tschetter L, et al., A community-based study of vitamin C <ascorbic acid>-therapy in patients with advanced cancer, *Proceedings of the American Society of Clinical Oncology*, 1983, 2.
112. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1, 2, 4, -triazole. *Oncology.* 1969, 23, 33-43.
113. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. *Proc Natl Acad Sci U S A.* 2005 Sep 20;102(38):13604-9.
114. Padayatty SJ, Sun H, Wang Y, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann Intern Med.* 2004, 140, 533-537.
115. Clement MV, Ramalingam J, Long LH, Halliwell B. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. *Antioxid Redox Signal.* 2001, 3(1), 157-163.

116. Benade L, Howard T, Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1, 2, 4, -triazole. *Oncology*. 1969, 23, 33-43.
117. Bram S, Froussard P, Guichard M, et al. Vitamin C preferential toxicity for malignant melanoma cells. *Nature*. 1980, 284, 629-631.
118. Helgestad J, Pettersen R, Storm-Mathisen I, et al. Characterization of a new malignant human T-cell line (PPI-285) sensitive to ascorbic acid. *Eur J Haematol*. 1990, 44, 9-17.
119. Park CH, Aniare M, Savin MA, Hoogstraten B. Growth suppression of human leukemic cells in vitro by L-ascorbic acid. *Cancer Res*. 1980, 40, 1062-1065.
120. Zheng QS, Sun XI, Wang CH. Redifferentiation of human gastric cancer cells induced by ascorbic acid and sodium selenite. *Biomed Environ Sci*. 2002, 15(3), 223-232.
121. Riordan HD, Riordan NH, Jackson JA, et al. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. *R Health Sci J*. 2004, 23(2), 115-118.
122. Stephenson CM, Levin RD, Lis CG. Phase 1 trial of high-dose intravenous vitamin C treatment for patients with cancer. *J Am Osteopath Assoc*. 2007 Jun;107(6):212-3.
123. Briggs H. Vitamin C "gives chemotherapy a boost". *BBC News*, 9 February 2014. <https://www.bbc.com/news/health-26038460>
124. Doskey CM, Buranasudja V, Wagner BA, et al. Tumor cells have decreased ability to metabolize H<sub>2</sub>O<sub>2</sub>: Implications for pharmacological ascorbate in cancer therapy. *Redox Biol*. 2016 Dec;10:274-284.
125. Science Daily. Why high-dose vitamin C kills cancer cells. January 9, 2017. <https://www.sciencedaily.com/releases/2017/01/170109134014.htm>
126. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O<sub>2</sub> – and H<sub>2</sub> O<sub>2</sub> -Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. *Cancer Cell*, 2017.
127. Cell Press. High doses of vitamin C to improve cancer

- treatment passes human safety trial. ScienceDaily. ScienceDaily, 30 March 2017. <https://www.sciencedaily.com/releases/2017/03/170330142341.htm>
128. Sandoiu A. High-dose vitamin C makes cancer treatment more effective, trial shows. Medical News Today, 31 March 2017. <https://www.medicalnewstoday.com/articles/316643.php>
129. Sandoiu A. Vitamin C can target and kill cancer stem cells, study shows. Medical News Today, March 13, 2017. <https://www.medicalnewstoday.com/articles/316334>
130. Bonuccelli G., De Francesco E., de Boer R., et al. NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting “stemness”. *Oncotarget*. 2017; 8: 20667-20678.
131. Brazier Y. 300 oranges worth of vitamin C impairs cancer cells. Medical News Today, November 6, 2015. <https://www.medicalnewstoday.com/articles/302220>
132. Fritz H, Flower G, Weeks L, et al. Intravenous vitamin C and cancer: A systematic review. *Integrative Cancer Therapies*. 2014.
133. Clinical Trials Gov. IV Ascorbic acid in advanced gastric cancer. <https://clinicaltrials.gov/ct2/show/NCT03015675>
134. Riordan Clinic. IVC Protocol Vitamin C Research: The Riordan IVC protocol for adjunctive cancer care intravenous ascorbate as a chemotherapeutic and biological response modifying agent. <https://riordanclinic.org/research-study/vitamin-c-research-ivc-protocol/>
135. DiTano M, Raucci F, Vernieri C, et al. Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. *Nature communications*. 2020;11(1):2332.
136. Ely JTA. Inadequate levels of essential nutrients in developed nations as a risk factor for disease: a review. *Rev Environ Health*. 2003, 18(2), 111-29.
137. Vastag B. Obesity is now on everyone's plate. *JAMA*. 2004, 291, 1186-1188.
138. Sturm R. Increases in clinically severe obesity in the United

- States, 1986-2000. *Arch Intern Med.* 2000, 163, 2146-2148.
139. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. *JAMA.* 2004, 291, 1238-1245.
140. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med.* 2003, 348, 1625-1638.
141. Ely JTA. Inadequate levels of essential nutrients in developed nations as a risk factor for disease: a review. *Rev Environ Health.* 2003, 18(2), 111-29.
142. Yudkin J. *Sweet and Dangerous.* 1972. Bantam Books, New York.
143. Spitz DR, Sim JE, Ridnour LA, et al. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? *Ann NY Acad Sci.* 2000, 899, 349-362.
144. Hursting SD, Lavinge JA, Berrigan D, et al. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. *Annu Rev Med.* 2003, 54, 131-152.
145. Dirx MJ, Zeegers MP, Dangelie PC, et al. Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. *Int J Cancer.* 2003, 106, 766-770.
146. Harvell DM, Strecker TE, Xie B, et al. Dietary energy restriction inhibits estrogen-induced mammary, but not pituitary, tumorigenesis in the ACI rat. *Carcinogenesis.* 2002, 23, 161-169.
147. Matsuzaki J, Yamaji R, Kiyomiya K, et al. Implanted tumor growth is suppressed and survival is prolonged in sixty percent of food-restricted mice. *J Nutr.* 2000, 130, 111-115.
148. Michels KB, Ekblom A. Calorie restriction and incidence of breast cancer. *JAMA.* 2004, 291, 1226-1230.
149. Brand-Miller J, Wolever TMS, Foster-Powell K, Colagiuri S. *The New Glucose Revolution: The Authoritative Guide to the Glycemic Index – the Dietary Solution for Lifelong Health.* Marlowe & Co, New York, 2002.
150. Brand-Miller J, Foster-Powell K, Holt S, Burani J. *The New Glucose Revolution Complete Guide to Glycemic Index Values,* Marlowe & Co, New York, 2003.

151. Augustin LS, Gallus S, Negri E, La Vecchia C. Glycemic index, glycemic load and risk of gastric cancer. *Ann Oncol.* 2004, 15, 581-584.
152. Augustin LS, Gallus S, Franceschi S, et al. Glycemic index and load and risk of upper aero-digestive tract neoplasms (Italy). *Cancer Causes Control.* 2003, 14, 657-662.
153. Augustin LS, Gallus S, Bosetti C, et al. Glycemic index and glycemic load in endometrial cancer. *Int J Cancer.* 2003, 105, 404-407.
154. Augustin LS, Polesel J, Bosetti C, et al. Dietary glycemic index, glycemic load and ovarian cancer risk: a case-control study in Italy. 2003, 14, 78-84.
155. Franceschi S, Dal Maso L, Augustin L, et al. Dietary glycemic load and colorectal cancer risk. *Ann Oncol.* 2001, 12, 173-178.
156. Carroll KK. Dietary factors in hormone-dependent cancers. *Curr Concepts Nutr.* 1977, 6, 25-40.
157. Hems G. The contributions of diet and childbearing to breast cancer rates. *Br J Cancer.* 1978, 37, 974-982.
158. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst.* 1999, 91, 1147-1154.
159. McKcown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? *Cancer Epidemiology Biomarkers & Prevention.* 1994, 3(8), 687-695.
160. Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst.* 1999, 91, 542-547.
161. Colangelo LA, Gapstur SM, Gann PH, et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. *Cancer Epidemiol Biomarkers Prev.* 2002, 11, 385-391.
162. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol.* 2004, 159, 1160-1167.
163. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus



- and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* 1997, 6, 1007-1010.
164. Sandhu MS, Luben R, Khaw KT. Self-reported non-insulin dependent diabetes, family history, and risk of prevalent colorectal cancer: population based, cross sectional study. *J Epidemiol Community Health.* 2001, 55, 804-805.
  165. Anderson KE, Anderson E, Mink PJ, et al. Diabetes and endometrial cancer in the Iowa women's health study. *Cancer Epidemiol Biomarkers Prev.* 2001, 10, 611-616.
  166. Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. *Cancer Causes Control.* 1998, 9, 403-410.
  167. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol.* 2004, 159, 1160-1167.
  168. Bostick RM, Potter JD, Kushi LH, et al. Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). *Cancer Causes Control.* 1994, 5, 38-52.
  169. Frazier AL, Li L, Cho E, et al. Adolescent diet and risk of breast cancer. *Cancer Causes Control.* 2004, 15, 73-82.
  170. Higginbotham S, Zhang ZF, Lee LM, et al. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. *J Natl Cancer Inst.* 2004, 96, 229-233.
  171. Cho E, Spiegelman D, Hunter DJ, et al. Premenopausal dietary carbohydrate, glycemic index, glycemic load, and fiber in relation to risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2003, 12, 1153-1158.
  172. Folsom AR, Demissie Z, Harnack L. Glycemic index, glycemic load, and incidence of endometrial cancer: the Iowa women's health study. *Nutr Cancer.* 2003, 46, 119-124.
  173. Higginbotham S, Zhang ZF, Lee LM, et al. Dietary glycemic load and breast cancer risk in the Women's Health Study. *Cancer Epidemiol Biomarkers Prev.* 2004, 13, 65-70.
  174. Michaud DS, Liu S, Hankinson SE, et al. Dietary sugar, glycemic

- load, and pancreatic cancer risk in a prospective study. *J Natl Cancer Inst.* 2002, 94, 1293-1300.
175. Spitz DR, Sim JE, Ridnour LA, et al. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? *Ann NY Acad Sci.* 2000, 899, 349-362.
176. Lee YJ, Galoforo SS, Berns CM, et al. Glucose deprivation-induced cytotoxicity and alterations in mitogen-activated protein kinase activation are mediated by oxidative stress in multidrug-resistant human breast carcinoma cells. *J Biol Chem.* 1998, 273(9), 5294-5299.
177. Ahmad IM, Aykin-Burns N, Sim JE, et al. Mitochondria and H<sub>2</sub>O<sub>2</sub> mediate glucose deprivation-induced stress in human cancer cells. *J Biol Chem.* 2005, 280(6), 4254-4263.
178. Lin X, Zhang F, Bradbury CF, et al. 2-Deoxy-D-Glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. 2003, *Cancer Res.* 63, 3413-3417.
179. Younes M, Lechago LV, Somoano JR, et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. *Cancer Res.* 1996, 56(5), 1164-1167.
180. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. *Cancer.* 1993, 72(10), 2979-2985.
181. Yamamoto T, Scino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. 1990. 170(1), 223-230.
182. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. *J Nucl Med.* 1997, 38(9), 1344-1348.
183. Smith TA. Facilitative glucose transporter expression in human cancer tissue. *Br J Biomed Sci.* 1999, 56(4), 285-592.
184. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose. *J Comput Assist Tomogr.* 1993, 17(4), 582-589.
185. Flamen P, Stroobants S, Van Gutschem E, et al. Additional value of

- whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. *Journal of Clinical Oncology*. 1999, 17(3), 894-901.
186. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on 18(F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. *J Clin Oncol*. 1999, 17(10), 3201-3206.
187. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer – a PET study. *Journal of Nuclear Medicine*. 1993, 34(1), 1-6.
188. Tayck JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. *J Am College of Nutrition*. 1992, 11(4), 445-456.
189. Lundholm K, Edstrom S, Karlberg I, et al. Glucose turnover, gluconogenesis from glycerol, and estimation of net glucose cycling in cancer patients. *Cancer*. 1982, 50(6), 1142-1150.
190. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. *J Eur J Surg*. 1993, 159(2), 101-107.
191. Shaw JH, Wolfe RR. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding, and surgical resection. *Surgery*. 1987, 101(2), 181-191.
192. Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. *American Journal of Epidemiology*. 1992, 136(9), 1110-1114.
193. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa women's health study. *Cancer Epidemiology Biomarkers and Prevention*. 2005, 14, 133-137.
194. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA*. 2005, 293(2), 194-202.

195. Balkau B, Kahn HS, Courbon D, et al. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. The Paris prospective study. *Diabetes Care*. 2001, 24, 843-849.
196. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. *Am J Epidemiol*. 2003, 157, 1092-1100.
197. Aisenberg AC. *The Glycolysis and Respiration of Tumors*. Academic Press. London. 1961.
198. Nakashima RA, Paggi MG, Pedersen PL. Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells. *Cancer Res*. 1984, 44(12), 5702-5706.
199. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. *Proc Nat Acad Sci*. 1977, 74(9), 3735-3739.
200. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. *J Biol Chem*. 1981. 256(16), 8699-8704.
201. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence and activity of the promoter for type II hexokinase. *A.S.B.M.B*. 1995, 270(28), 16918-16925.
202. Nakashima RA, Mangan PS, Colombini M, Pedersen PL. Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. *Biochemistry*. 1986, 25(5), 1015-1021.
203. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. *J Biol Chem*. 1998, 263(33), 17422-17428.
204. Heiden MGV, Plas DR, Rathmell JC, et al. Growth factors can influence cell growth and survival through effects on glucose metabolism. *Molecular and Cellular Biology*. 2001, 21(17), 5899-

- 5912.
205. Floridi A, Paggi MG, Marcante ML, et al. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. *Natl Cancer Inst.* 1981, 66(3), 497-499.
206. Floridi A, Paggi MG, D' Atri S, et al. Effect of lonamide on the energy metabolism of Ehrlich ascites tumor cells. *Cancer Res.* 1981, 41(11), 4661-4666.
207. Parry DM, Pedersen PL. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. *J Biol Chem.* 1983, 258(18), 10904-10912.
208. Rose LA, Warms JVB. Mitochondrial hexokinase release, binding and location. *J Biol Chem.* 1967, 242, 1635-1645.
209. Arora KK, Pedersen PL. Glucose utilization by tumor cells: the enzyme hexokinase autophosphorylates both its N- and C-terminal halves. *Arch Biochem Biophys.* 1993, 304(2), 515-518.
210. Johansson T, Berrez JM, Nelson BD. Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. *Biochem Biophys Res Commun.* 1985, 133(2), 608-613.
211. Paggi MG, Fanciulli M, Del Carlo C, et al. Glucose utilization by tumor cells: a post-translational modification of mitochondrial hexokinase may play a regulatory role. *Biochem Biophys Res Commun.* 1991, 178(2), 648-655.
212. Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130, *FEBS Lett.* 1991, 291(1), 55-57.
213. Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form a mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. *Cancer Res.* 1988, 48, 913-919.
214. Thelen AP, Wilson JE. Complete amino acid sequence of the type II isozyme of rat hexokinase, deduced from the cloned cDNA: comparison with a hexokinase from novikoff ascites tumor. *Arch Biochem Biophys.* 1991, 286(2), 645-651.

215. Krone CA, Ely JTA. Controlling hyperglycemia as an adjunct to cancer therapy. *Integr Cancer Ther.* 2005, 4(1), 25-31.
216. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. *JAMA.* 2000, 283(19), 2552-2558.
217. Ely JTA. Protein glycation: ascorbate antagonism. *Bulletin Amer Physical Society.* 1988, 33(3), 296.
218. Krone C, Ely JTA. Vitamin C and glycohemoglobin revisited. *Clinical Chemistry.* 2001, 47, 148.
219. Krone C, Ely JTA. Glycohaemoglobin and ascorbic acid. *Journal of the New Zealand Medical Association.* 2002, 115(1160), 156.
220. Ely JTA. Unrecognized pandemic subclinical diabetes of the affluent nations: causes, cost and prevention. *J Ortho Med.* 1996, 11, 95-99.
221. Harman D. Aging: Overview. *Annals of the New York Academy of Sciences.* 2001, 928, 1-21.
222. Ely JTA. Hyperglycemia and major congenital anomalies. *N Engl J Med.* 1981, 305, 833.
223. Ely JTA, Krone C. Aging: predictions of a new perspective on old data. *Experimental Biology and Medicine.* 2002, 227, 939-942.
224. Ely JTA, Santisteban GA. Gross fetal malformations associated with maternal hyperglycemia. *Anatom Record.* 1983, 205, 54A.
225. Ely JTA. Inadequate levels of essential nutrients in developed nations as a risk factor for disease: a review. *Rev Environ Health.* 2003, 18(2), 111-29.
226. Cooper MR, McCall CE, DcChatelet LR. Stimulation of leukocytes hexose monophosphate shunt activity by ascorbic acid. *Infect Immun.* 1971, 3, 851-853.
227. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. *N Engl J Med.* 1971, 284, 621-627.
228. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence. *Diabetes.* 1978, 27, 677-681.
229. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function

- in patients with poorly controlled diabetes. *Diabetes*. 1974, 23, 9-15.
230. Nolan CM, Beaty HN, Bagdade JD. Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. *Diabetes*. 1978, 27, 889-894.
231. Goertzel T, Goertzel B. Linus Pauling. A life in science and politics. Basic Books, New York. 1995.
232. Robinson AR, Hunsberger A, Westall FC. Suppression of squamous cell carcinoma in hairless mice by dietary nutrient variation. *Mechanisms of Ageing and Development*. 1994, 76, 201-214.
233. Robinson A. Nutrition and cancer. Oregon Institute of Science and Medicine. 1999. <http://www.nutritionandcancer.org/view/nutritionandcancer/s99p1074.htm>
234. Ely JTA. Glycemic modulation of tumor tolerance. *Journal of Orthomolecular Medicine*. 1996, 11(1), 23-34.
235. Cheraskin E, Ringsdorf WM Jr, Hutchins K, et al. Effect of diet upon radiation response in cervical carcinoma of the uterus. *Acta Cyto*. 1968, 12, 433-438.
236. Marks PA, Bishop JS. Glucose metabolism in subjects with neoplastic disease response to insulin and glucose tolerance follow up studies. *Proc Am Assoc Canc Res*. 1957, 2, 228-229.
237. Ely JTA. Glycemic modulation of tumor tolerance. *Journal of Orthomolecular Medicine*. 1996, 11(1), 23-34.
238. Lupulescu A. The role of vitamins A, beta-carotene, E and C in cancer cell biology. *Int J Vit Nutr Res*. 1994, 63, 3-14.
239. Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. *Int J Cancer*. 2003, 107(5), 688-695.
240. Santisteban GA, Ely JTA, Hamel EE, et al. Glycemic modulation of tumor tolerance in a mouse model of breast cancer. *Biochem Biophys Res Commun*. 1985, 132(3), 1174-1179.

## ΜΕΡΟΣ 2

### **ΒΙΤΑΜΙΝΕΣ ΚΑΙ ΑΛΛΑ ΦΥΤΙΚΑ ΣΥΣΤΑΤΙΚΑ ΠΟΥ ΔΡΟΥΝ ΣΥΝΕΡΓΙΣΤΙΚΑ ΜΕ ΤΟ ΑΣΚΟΡΒΙΚΟ ΟΞΥ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ**

1. Mitchell JS, Simon-Reuss I. Combination of some effects of x-radiation and a synthetic vitamin K substitute. *Nature*. 1947, 160, 98-99.
2. Mitchell JS. Clinical trials of tetra-sodium 2-methyl-1:4-naphthohydroquinone diphosphate, in conjunction with x-ray therapy. *Brit J Cancer*. 1948, 2, 351-359.
3. Rannels SR, Gallaher KJ, Wallin R, Rannels DE. Vitamin K-dependent carboxylation of pulmonary surfactant-associated proteins. *Proc Natl Acad Sci U S A*. 1987, 84, 5952-5956.
4. Suttie JW. Synthesis of vitamin K-dependent proteins. *Faseb J*. 1993, 7, 445-452.
5. Douglas AS, Robins SP, Hutchison JD. Carboxylation of osteocalcin in post-menopausal osteoporotic women following vitamin K and D supplementation. *Bone*. 1995, 17, 15-20.
6. Schaafsma A, Muskiet FA, Storm H. Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin. *Eur J Clin Nutr*. 2000, 54, 626-631.
7. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. *Curr Opin Clin Nutr Metab Care*. 2000, 3, 433-438.
8. Wu FY, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. *Life Sci*. 1993, 52, 1797-1804.
9. Prasad KN, Edwards-Prasad J, Sakamoto A. Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. *Life Sci*. 1981, 29, 1387-1392.
10. Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. *Cancer Treat Rev*. 1985, 12, 49-63.



11. Noto V, Taper HS, Jiang YH. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. *Cancer*. 1989, 63, 901-906.
12. Ngo EO, Sun TP, Chang JY. Menadione induced DNA damage in a human tumor cell line. *Biochem Pharmacol*. 1991, 42, 1961-1968.
13. Wu FY, Chang NT, Chen WJ, Juan CC. Vitamin K3-induced cell cycle arrest and apoptotic cell death are accompanied by altered expression of c-fos and c-myc in nasopharyngeal carcinoma cells. *Oncogene*. 1993, 8, 2237-2244.
14. Su WC, Sun TP, Wu FY. The in vitro and in vivo cytotoxicity of menadione (vitamin K3) against rat transplantable hepatoma induced by 3'-methyl-4-dimethyl-aminoazobenzene. *Gaoxiong Yi Xue Ke Xue Za Zhi*. 1991, 7, 454-459.
15. Gold J. In vivo synergy of vitamin K3 and methotrexate in tumor-bearing animals. *Cancer Treat Rep*. 1986, 70, 1433-1435.
16. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamin K and their actions on gene expression. *Hepatology*. 1995, 22, 876-882.
17. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. *Blood*. 1990, 75, 1753-1762.
18. Cantoni O, Fiorani M, Cattabeni F, Bellomo G. DNA breakage caused by hydrogen peroxide produced during the metabolism of 2-methyl-1,4-naphthoquinone (menadione) does not contribute to the cytotoxic action of the quinone. *Biochem Pharmacol*. 1991, 42, S220-S222.
19. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamins K and their actions on gene expression. *Hepatology*. 1995, 22, 876-882.
20. Saxena SP, Israels ED, Israels LG. Novel vitamin K-dependent pathways regulating cell survival. *Apoptosis*. 2001, 6, 57-68.
21. Costa M, Bellosta P, Basilico C. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. *J Cell Physiol*. 1996, 168, 737-744.

22. Dormady SP, Zhang XM, Basch RS. Hematopoietic progenitor cells grow on 3T3 fibroblast monolayers that overexpress growth arrest-specific gene-6 (Gas6). *Proc Natl Acad Sci USA*. 2000, 97, 12260-12265.
23. Wimmel A, Rohner I, Ramaswamy A, et al. Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. *Cancer*. 1999, 86, 43-49.
24. Bellosta P, Zhang Q, Goff SP, Basilico C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. *Oncogene*. 1997, 15, 2387-2397.
25. Avanzi GC, Gallicchio M, Bottarel F, et al. Gas6 inhibits granulocyte adhesion to endothelial cells. *Blood*. 1998, 91, 2334-2340.
26. Ishimoto Y, Ohashi K, Mizuno K, Nakano T. Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, Gas6. *J Biochem (Tokyo)*. 2000, 127, 411-417.
27. Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. *Oncogene*. 1997, 14, 2033-2039.
28. Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. *Am J Hematol*. 1996, 51, 319-323.
29. Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr*. 2010;91(5):1348-1358.
30. Yoshida T, Miyazawa K, Kasuga I, et al. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer. *Int J Oncol*. 2003;23(3):627-632
31. Kiely M, Hodgins SJ, Merrigan BA, et al. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. *Nutr Res*. 2015;35(8):736-743.

32. Dasari S, Ali SM, Zheng G, et al. Vitamin K and its analogs: potential avenues for prostate cancer management. *Oncotarget*. 2017;8(34):57782-57799.
33. Jinghe X, Mizuta T, Ozaki I. Vitamin K and hepatocellular carcinoma: the basic and clinic. *World J Clin Cases*. 2015;3(9):757-764.
34. Ha TY, Hwang S, Hong HN, et al. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis. *Anticancer Res*. 2015;35(4):1985-1995.
35. Wu F.Y., Liao W.C., Chang H.M., Comparison of antitumor activity of vitamins K1, K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. *Life Sci*, 1993, 52, 1797-1804, 1993.
36. Prasad KN, Edwards-Prasad J, Sakamoto A. Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. *Life Sci*. 1891, 29, 1387-1392.
37. Chlebowski RT, Dietrich M, Akman S, Block JB. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. *Cancer Treat Rep*. 1985, 69, 527-532.
38. Wang Z, Wang M, Finn F, Carr BI. The growth inhibitory effects of vitamin K and their actions on gene expression. *Hepatology*. 1995, 22, 876-882.
39. Carr B.I., Suppression of DCP/PIVKA-2 and alpha-fetoprotein levels in human hepatocellular carcinoma (HCC) by high doses of vitamin K1 (VK1). *Hepatology*, 1996, 348A.
40. Carr B.I., A phase I/phase II study of high dose vitamin K (VK) to patients with advanced inoperable hepatocellular carcinoma (HCC): interim analysis. *Hepatology*, 1994, 20, 278A.
41. Zaniboni A., Biasi L., Graffeo M. et al., Phase II study of high-dose vitamin K1 in hepatocellular carcinoma: a GISCAD study. *ASCO*, 1998, 17, 1182.
42. Juanola-Falgarona M, Salas-Salvado J, Martinez-Gonzalez MA, et al. Dietary intake of vitamin K is inversely associated with mortality risk. *J Nutr*. 2014;144(5):743-750.
43. Dasari S, Ali SM, Zheng G, et al. Vitamin K and its analogs: potential avenues for prostate cancer management. *Oncotarget*.

- 2017;8(34):57782-57799.
44. Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr.* 2010;91(5):1348-1358.
  45. Lamson DW, Plaza SM. The anticancer effects of vitamin K. *Altern Med Rev.* 2003;8(3):303-318.
  46. Davidson RT, Foley AL, Engelke JA, Suttie JW. Conversion of dietary phylloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. *J Nutr.* 1998, 128, 220-223.
  47. Thijssen HH, Drittij-Reijnders MJ. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. *Br J Nutr.* 1996, 75, 121-127.
  48. Akedo Y., Hosoi T., Inoue S. et al., Vitamin K2 modulates proliferation and function of osteoblastic cells in vitro, *Biochem Biophys Res Commun*, 1992, 187, 814-820.
  49. Nishikawa Y., Wang Z., Kerns J. et al., Inhibition of hepatoma cell growth in vitro by arylating and non-arylated K vitamin analogs. Significance of protein tyrosine phosphatase inhibition, *J Biol Chem*, 1999, 274, 34803-34810.
  50. Wu FY, Liao WC, Chang HM. Comparison of antitumor activity of vitamins K1, K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. *Life Sci.* 1993, 52, 1797-1804.
  51. Yaguchi M, Miyazawa K, Otawa M, et al. Vitamin K2 therapy for a patient with myelodysplastic syndrome. *Leukemia.* 1999, 13, 144-145.
  52. Nishikawa Y, Carr BI, Wang M, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. *J Biol Chem.* 1995, 270, 28304-28310.
  53. Miyazawa K, Yaguchi M, Funato K, et al. Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. *Leukemia.* 2001, 15, 1111-1117.
  54. Sakai I, Hashimoto S, Yoda M, et al. Novel role of vitamin K2: a

- potent inducer of differentiation of various human myeloid leukemia cell lines. *Biochem Biophys Res Commun.* 1994, 205, 1305-1310.
55. Yaguchi M., Miyazawa K., Katagiri T. et al., Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all-trans retinoic acid, *Leukemia*, 1997, 11, 779-787.
  56. Yaguchi M, Miyazawa K, Otawa M, et al. Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptotic cells using APO2. 7 monoclonal antibody. *Leukemia.* 1998, 12, 1392-1397.
  57. Yokoyama T, Miyazawa K, Naito M, et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. *Autophagy.* 2008 Jul 1;4(5):629-40.
  58. Tsujioka T, Miura Y, Otsuki T, et al. The mechanisms of vitamin K2-induced apoptosis of myeloma cells. *Haematologica.* 2006 May;91(5):613-9.
  59. Ozaki I, Zhang H, Mizuta T, et al. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation. *Clin Cancer Res.* 2007 Apr 1;13(7):2236-45.
  60. Takami A., Nakao S., Ontachi Y. et al. Successful therapy of myelodiplastic syndrome with menatetrenone, a vitamin K2 analog, *Int J Hematol*, 1999, 69, 24-26.
  61. Fujita H., Tomiyama J., Tanaka T. Vitamin K2 combined with all-trans retinoic acid induced complete remission of relapsing acute promyeolytic leukemia, *Br J Haematol*, 1998, 103, 584-585.
  62. Yaguchi M., Miyazawa K., Otawa M. et al., Vitamin K2 therapy for a patient with myelodyplastic syndrome. *Leukemia.* 1999, 13, 144-145.
  63. Miyazawa K, Nishimaki J, Ohyashiki K, et al. Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan. *Leukemia.* 2000, 14, 1156-1157.

64. Jancin B. Vitamin K cuts hepatocellular CA mortality. *Fam Pract News*. 2002, 32, 16.
65. Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. *JAMA*. 2004 Jul 21;292(3):358-61.
66. Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. *Cancer*. 2006 Feb 15;106(4):867-72.
67. Zhong JH, Mo XS, Xiang BD, et al. Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. *PLoS One*. 2013;8(3):e58082.
68. Ishizuka M, Kubota K, Shimoda M, et al. Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. *Anticancer Res*. 2012;32(12):5415-5420.
69. Davidson RT, Foley AL, Engelke JA, Suttie JW. Conversion of dietary phyloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. *J Nutr*. 1998, 128, 220-223.
70. Taggart WV, Matschiner JT. Metabolism of menadione-6,7-311 in the rat. *Biochemistry*. 1969, 8, 1141-1146.
71. Prasad KN, Edwards-Prasad J, Sakamoto A. Vitamin K3 (menadione) inhibits the growth of mammalian tumor cells in culture. *Life Sci*. 1981, 29, 1387-1392.
72. Chlebowski RT, Dietrich M, Akman S, Block JB. Vitamin K3 inhibition of malignant murine cell growth and human tumor colony formation. *Cancer Treat Rep*. 1985, 69, 527-532.
73. Akman SA, Doroshov JH, Dietrich MF, et al. Synergistic cytotoxicity between menadione and dicumarol vs. murine leukemia L1210. *J Pharmacol Exp Ther*. 1987, 240, 486-491.
74. Akman SA, Dietrich M, Chlebowski R, et al. Modulation of cytotoxicity of menadione sodium bisulfite versus leukemia L1210 by the acid-soluble thiol pool. *Cancer Res*. 1985, 45, 5257-5262.
75. Wasman S, Bruckner H. The enhancement of 5-fluorouracil

- anti-metabolic activity by leucovorin, menadione and alpha-tocopherol. *Eur J Cancer Clin Oncol.* 1982, 18, 685-692.
76. Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. *Cancer Treat Rev.* 1985, 12, 49-63.
  77. Noto V, Taper HS, Jiang YH. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. *Cancer.* 1989, 63, 901-906.
  78. Su YZ, Duarte TE, Dill PL, Weisenthal IM. Selective enhancement by menadiol of in vitro drug activity in human lymphatic neoplasms. *Cancer Treat Rep.* 1987, 71, 619-625.
  79. Hitomi M, Yokoyama F, Kita Y, et al. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. *Int J Oncol.* 2005, 26(3), 713-720.
  80. Juan CC, Wu FY. Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34CDC2 kinase and phosphate. *Biochem Biophys Res Commun.* 1993, 190, 907-913.
  81. Nutter LM, Cheng AL, Hung HL, et al. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. *Biochem Pharmacol.* 1991, 41, 1283-1292.
  82. Parekh H.K., Mansuri-Torshizi H., Srivastava T.S., Chitnis M.P. Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (Vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells. *Cancer Lett,* 1992, 61, 147-156.
  83. Mitchell J.S., Brinkley D., Haybittle J.L. Clinical trial of radiosensitizers, including synkavit and oxygen inhaled at atmospheric pressure, *Acta Radiol Ther Phys Biol,* 1965, 3, 329-341.
  84. Su W.C., Sun T.P., Wu F.Y. The in vitro and in vivo cytotoxicity of menadione (vitamin K3) against rat transplantable hepatoma induced by 3'-methyl-4-dimethyl-aminoazobenzene, *Gaoxiong Yi Xue Ke Xue Za Zhi,* 1991, 7, 454-459.
  85. Taper H.S., Keyeux A., Roberfroid M. Potentiation of radiotherapy

- by nontoxic pre-treatment with combined vitamins C and K3 in mice bearing solid transplantable tumor, *Anticancer Res*, 1996, 16, 499-503.
86. Wasman S, Bruckner H. The enhancement of 5-fluorouracil anti-metabolic activity by leucovorin, menadione and alpha-tocopherol. *Eur J Cancer Clin Oncol*. 1982, 18, 685-692.
  87. Nutter LM, Cheng AL, Hung HL, et al. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. *Biochem Pharmacol*. 1991, 41, 1283-1292.
  88. Liao WC, Wu FY, Wu CW. Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CGI cells. *Int J Oncol*. 2000, 17, 323-328.
  89. Margolin KA, Akman SA, Leong LA, et al. Phase I study of mitomycin C and menadione in advanced solid tumors. *Cancer Chemother Pharmacol*. 1995, 36, 293-298.
  90. Tetef M, Margolin K, Ahn C, et al. Mitomycin C and menadione for the treatment for the treatment of lung cancer: a phase II trial. *Invest New Drugs*. 1995, 13, 157-162.
  91. Tetef M, Margolin K, Ahn C, et al. Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial. *J Cancer Res Clin Oncol*. 1995, 121, 103-106.
  92. Maeda M, Murakami M, Takegami T, Ota T. Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol. *Toxicol Appl Pharmacol*. 2008 Jun 1;229(2):232-8.
  93. Osada S, Tomita H, Tanaka Y, et al. The utility of vitamin K3 (menadione) against pancreatic cancer. *Anticancer Res*. 2008 Jan;28(1A):45-50.
  94. Hatomi M, Nonomura T, Yokoyama F, et al. In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma. *Int J Oncol*. 2005, 26(5), 1337-1344.
  95. Sun X, Ross D. Quinone-induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase mediated bioactivation. *Chem Biol Interact*. 1996, 100(3), 267-276.



96. Emdadul Haque M, Asanuma M, Higashi Y, et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. *Biochim Biophys Acta*. 2003, 1619(1), 39-52.
97. Calviello G, Di Nicuolo F, Piccioni E, et al. Gamma-Tocopheryl quinone induces apoptosis in cancer cells via caspase-9 activation and cytochrome c release. *Carcinogenesis*. 2003, 24(3), 427-433.
98. Henry TR, Wallace KB. Differential mechanisms of cell killing by redox cycling and arylating quinones. *Archives of Toxicology*. 1996, 70(8), 482-489.
99. Cai J, Jones DP. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. *J Biol Chem*. 1998, 273(19), 11401-11404.
100. Berlin V, Haseltine WA. Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. *J Biol Chem*. 1981, 256(10), 4747-4756.
101. Durse L, Rajagopalan S, Eliot HM, et al. DNA interstrand cross-link and free radical formation in a human multidrug-resistant cell line from mitomycin C and its analogues. *Cancer Res*. 1990, 50(3), 648-652.
102. Mans DR, Retel J, van Maanen JM, et al. Role of the the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. *Br J Cancer*. 1990, 62(1), 54-60.
103. Kagan VE, Yalowich JC, Borisenko GG, et al. Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. *Mol Pharmacol*. 1999, 56(3), 494-506.
104. Gant TW, Rao DN, Mason RP, Cohen GM. Redox cycling and sulphhydryl arylation; Their relative importance in the mechanism of quinone cytotoxicity to isolated hepatocytes. *Chem Biol Interact*. 1988, 65, 157-173.
105. Ross D, Thor H, Orrenius S, Moldeus P. Interaction of menadione

- (2-methyl-1,4-naphthoquinone) with glutathione. *Chem Biol Interact.* 1985, 55, 177-184.
106. Brown PC, Dulik DM, Jones TW. The toxicity of menadione (2-methyl-1,4-naphthoquinone) and two thioether conjugates studied with isolated renal epithelial cells. *Arch Biochem Biophys.* 1991, 285, 187-196.
107. Nutter LM, Ngo EO, Fisher GR, Gutierrez PL. DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase. *J Biol Chem.* 1992, 267, 2474-2479.
108. Ross D, Thor H, Threadgill MD, et al. The role of oxidative processes in the cytotoxicity of substituted 1,4-naphthoquinones in isolated hepatocytes. *Arch Biochem Biophys.* 1986, 248, 460-466.
109. Sun JS, Tsuang YH, Huang WC, et al. Menadione induced cytotoxicity to rat osteoblasts. *Cell Mol Life Sci.* 1997, 53, 967-976.
110. Byezkowski JZ, Gessner T. Inhibition of the redox cycling of vitamin K3 (menadione) in mouse liver microsomes. *Int J Biochem.* 1998, 20(10), 1073-1079.
111. Nishikawa Y, Carr BI, Wang M, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. *J Biol Chem.* 1995, 270, 28304-28310.
112. Juan C, Markovits J, Sun T, Wu F. Antitumor drug vitamin K3 inhibits both p34CDC2 kinase and protein tyrosine phosphatase by binding to the sulfhydryl groups of the enzymes. *Proc AACR.* 1996, 37, 2427.
113. Chung JH, Sco DC, Chung SH, et al. Metabolism and cytotoxicity of menadione and its metabolite in rat platelets. *Toxicol Appl Pharmacol.* 1997, 142, 378-385.
114. Thor H, Smith MT, Hartzell P, et al. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implications of oxidative stress in intact cells. *J Biol Chem.* 1982, 257, 12419-12425.
115. Nutter LM, Cheng AL, Hung HL, et al. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in

- human neoplastic cell lines. *Biochem Pharmacol.* 1991, 41, 1283-1292.
116. Wilson L, Wardman P, Lin TS, Sartorelli AC. Reactivity of thiols towards derivatives of 2- and 6-methyl-1,4-naphthoquinone bioreductive alkylating agents. *Chem Biol Interact.* 1987, 61, 229-240.
117. Morrison H, Jernstrom B, Nordenskjold M, et al. Induction of DNA damage by menadione (2-methyl-1,4-naphthoquinone) in primary cultures of rat hepatocytes. *Biochem Pharmacol.* 1984, 33, 1763-1769.
118. Ham SW, Song JH, Kim HI, Bull SJ. Mechanism of cell cycle arrest by menadione. *Korean Chem Soc.* 2000, 21(12), 1173-1174.
119. Lamson DW, Plaza SM. The anticancer effects of vitamin K. *Alternative Medicine Review.* 2003, 8(3), 303-318.
120. Nishikawa Y, Carr BI, Wang M, et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. *J Biol Chem.* 1995, 270(47), 28304-28310.
121. Nishikawa Y, Wang Z, Kerns J, et al. Inhibition of hepatoma cell growth in vitro by arylating and non-arylated K vitamin analogs. Significance of protein tyrosine phosphate inhibition. *J Biol Chem.* 1999, 274, 34803-34810.
122. Sata N, Klonowski-Stumpe H, Han B, et al. Menadione induces both necrosis and apoptosis in rat pancreatic acinar AR4-2J cells. *Free Radic Biol Med.* 1997, 23, 844-850.
123. De Loccker W, Janssens J, Bonte J, Taper HS. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro II, Synergism with combined chemotherapy action. *Anticancer Res.* 1993, 13(1), 103-106.
124. Gilloteaux J, Jamison JM, Venugopal M, et al. Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C - vitamin K3 combinations against human prostatic carcinoma cells. *Scanning Microsc.* 1995, 9(1), 159-173.
125. Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic

- antitumor activity of vitamin C and K3 on human urologic tumor cell lines. *Life Sci.* 1996, 59(17), 1389-1400.
126. Gilloteaux J, Jamison JM, Ervin E, et al. Scanning electron microscopy and transmission electron microscopy aspects of the synergistic antitumor activity of vitamin C/vitamin K3 combinations against human T24 bladder carcinoma: another kind of cell death? *Scanning.* 1998, 20, 208-209.
127. Jamison M, Gilloteaux J, Venugopal M, et al. Flow cytometric and ultrastructural aspects of the synergistic antitumor activity of vitamin C-vitamin K3 combinations against human prostatic carcinoma cells. *Tissue Cell.* 1996, 28(6), 687-701.
128. Noto V, Taper HS, Jiang YH. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. *Cancer.* 1989, 63, 901-906.
129. Juan CC, Wu FY. Vitamin K3 inhibits growth of human hepatoma HepG2 cells by decreasing activities of both p34CDC2 kinase and phosphatase. *Biochem Biophys Res Commun.* 1993, 190, 907-913.
130. Wu FY, Sun TP. Vitamin K3 induces cell cycle arrest and cell death by inhibiting CDC25 phosphatase. *Eur J Cancer.* 1999, 35, 1388-1393.
131. Ham SW, Park HJ, Lim DH. Studies on menadione as an inhibitor of the cdc25 phosphatase. *Bioorg Chem.* 1997, 25, 33-36.
132. Chyan C, Wu F. Vitamin K3 induces cell death by inhibiting dual specificity phosphatases. *Proc AACR.* 1999, 40, 80.
133. Wu FY, Chang NT, Chen WJ, Juan CC. Vitamin K3-induced cell cycle arrest and apoptotic cell death are accompanied by altered expression of e-fos and c-myc in nasopharyngeal carcinoma cells. *Oncogene.* 1993, 8, 2237-2244.
134. Bouchard C, Staller P, Eilers M. Control of cell proliferation by Myc. *Trends Cell Biol.* 1998, 8, 202-206.
135. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. *Oncogene.* 1999, 18, 2916-2924.

136. Bouzahzah B, Nishikawa Y, Simon D, Carr BI. Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. *J Cell Physiol.* 1995, 165, 459-467.
137. Hoffman B, Liebermann DA. The protooncogene c-myc and apoptosis. *Oncogene.* 1998, 17, 3351-3357.
138. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. *Cell.* 1992, 69, 119-128.
139. Caricchio R, Kovalenko D, Kaufmann WK, Cohen PL. Apoptosis provoked by the oxidative stress inducer menadione (Vitamin K(3)) is mediated by the Fas/Fas ligand system. *Clin Immunol.* 1999, 93, 65-74.
140. Gilloteaux J, Jamison J.M., Arnold D., et al. Cancer cell necrosis by autschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. *Scanning,* 1998, 20, 8, 564-575.
141. Sakagami H., Satoh K., Hakeda Y., Kumegawa M., Apoptosis-inducing activity of vitamin C and vitamin K, *Cell Mol Biol (Noisy-le-grand).* 2000, 46, 1, 129-143.
142. Jamison JM, Gilloteaux J, Taper HS, et al. Autoschizis: a novel cell death. *Biochem Pharmacol.* 2002, 15, 63(10), 1773-1783.
143. Gilloteaux J, Jamison JM, Arnold D, Summers JL. Autoschizis: another cell death for cancer cells induced by oxidative stress. *Ital J Anat Embryol.* 2001, 106(2 Suppl 1), 79-92.
144. Okayasu H, Ishihara M, Satoh K, Sakagami H. Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. *Anticancer Res.* 2001, 21(4A), 2387-2392.
145. Verrax J, Cadrobbi J, Delvaux M, et al. The association of vitamin C and K3 kills cancer cells mainly by autoschizis, a novel form of cell death. Basis for their potential use as coadjuvants in anticancer therapy. Invited review. *European Journal of Medicinal Chemistry.* 2003, 38, 451-457.
146. Calderon PB, Cadrobbi J, Marques C, et al. Potential therapeutic application of the association of vitamin C and K(3) in cancer treatment. *Curr Med Chem.* 2002, 9(24), 2271-2285.

147. Taper H.S., Jamison J.M., Gilloteaux J., et al. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination, *J Histochem Cytochem.* 2001, 49, 1, 109-120.
148. Lasalvia-Prisco E, Cucchi S, Vazquez J, et al. Serum markers variation consistent with autschizis induced by ascorbic acid-menadione in patients with prostatic cancer. *Med Oncol.* 2003, 20(1), 45-52.
149. Gilloteaux J., Jamison J.M., Arnold D., et al. Ultrastructural aspects of autschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. *Ultrastruct Pathol.* 2001, 25, 3, 183-192.
150. Taper HS, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. *Int J Cancer.* 1987, 40(4), 575-579.
151. Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. *Anticancer Res.* 1992, 12(5), 1651-1654.
152. Zhang W, Negoro T, Satoh K, et al. Synergistic cytotoxic action of vitamin C and vitamin K3. *Anticancer Res.* 2001, 21(5), 3439-3444.
153. Jiang Y, Satoh K, Aratsu C, et al. Combination effect of lignin F and natural products. *Anticancer Res.* 2001, 21(2A), 965-970.
154. Noto V., Taper HS., Jiang Y.H. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro, I. Synergism of combined vitamin C and K3 action. *Cancer.* 1989, 63, 901-906.
155. Lamson D.W., Plaza S.M. The anticancer effects of vitamin K, *Alternative Medicine Review.* 2003, 8, 3, 303-318.
156. Noto V., Taper HS., Jiang Y.H. Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro, I. Synergism of combined vitamin C and K3 action. *Cancer.* 1989, 63, 901-906.
157. Venugopal M, Jamison JM, Gilloteaux J, et al. Synergistic

- antitumour activity of vitamin C and K3 against human prostate carcinoma cell lines. *Cell Biol Int.* 1996, 20, 787-797.
158. Ervin E, Jamison JM, Gilloteaux J, et al. Characterization of the early events in vitamin C and K3-induced death of human bladder tumor cells. *Scanning.* 1998, 20, 210-211.
159. Taper H.S., Jamison J.M., Gilloteaux J., et al. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination, *J Histochem Cytochem.* 2001, 49, 1, 109-120.
160. Jamison JM, Gilloteaux J, Taper HS, Summers JL. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. *J Nutr.* 2001, 158S-160S.
161. Taper HS, Roberfroid M. Non-toxic sensitization of cancer chemotherapy by combined vitamin C and K3 pretreatment in a mouse tumor resistant to oncovin. *Anticancer Res.* 1992, 12(5), 1651-1654.
162. Taper H.S., Jamison J.M., Gilloteaux J., et al. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination, *J Histochem Cytochem.* 2001, 49, 1, 109-120.
163. Tareen B, Summers JL, Jamison JM, et al. A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. *Int J Med Sci.* 2008;5(2):62-7.
164. Carreau JP. Biosynthesis of lipoic acid via unsaturated fatty acids. *Methods Enzymol.* 1979, 62, 152-158.
165. Kramer K, Packer L. R-alpha-lipoic acid, In *Nutraceuticals in Health and Disease Prevention*, Eds Kramer K, Hoppe P, Packer L. Marcel Dekker. New York. 2001, 129-164.
166. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. *Nutrition.* 2001, 17(10), 888-895.
167. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. *Gen Pharmacol.* 1997, 29(3), 315-331.

168. Lodge JK, Youn HD, Handelman GJ, et al. Natural sources of lipoic acid: determination of lipoyllysine released from protease-digested tissues by high performance liquid chromatography incorporating electrochemical detection. *J Appl Nutr.* 1997, 49(1 & 2), 3-11.
169. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. *Gen Pharmacol.* 1997, 29(3), 315-331.
170. Hermann R, Niebch G, Borbe HO, et al. Enantioselective pharmacokinetics and bioavailability of different racemic a lipoic acid formulations in healthy volunteers. *Eur J Pharm Sci.* 1996, 4, 167-174.
171. Teichert J, Kern J, Tritschler HJ, et al. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. *Int J Clin Pharmacol Ther.* 1998, 36(12), 625-628.
172. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. *Nutrition.* 2001, 17(10), 888-895.
173. Marangon K, Devaraj S, Tirosh O, et al. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. *Free Rad Biol Med.* 1999, 27(9-10), 1114-1121.
174. Baur A, Harrer T, Peukert M, et al. Alpha-lipoic acid is an effective inhibitor of human immune-deficiency virus (HIV-1) replication. *Klin Wochenschr.* 1991, 69, 722-724.
175. Hermann R, Niebch G, Borbe HO, et al. Enantioselective pharmacokinetics and bioavailability of different racemic a lipoic acid formulations in healthy volunteers. *Eur J Pharm Sci.* 1996, 4, 167-174.
176. Streeper RS, Henriksen EJ, Jacob S, et al. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. *Am J Physiol.* 1997, 273(1 Pt 1), E185-191.
177. Packer L. Alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. *Drug Metab Rev.* 1998, 30(2), 245-275.



178. Jacob S, Rett K, Henriksen EJ, Haring HU. Thiotic acid – effects on insulin sensitivity and glucose-metabolism. *Biofactors*. 1999, 10(2-3), 169-174.
179. Thorne Research. Monograph alpha lipoic acid. *Alternative Medicine Review*. 1998, 3(4), 308-310.
180. Gal EM. Reversal of selective toxicity of  $\alpha$ -lipoic acid by thiamine-deficient rats. *Nature*. 1965, 205, 535.
181. Patrick L. Mercury toxicity and antioxidants: Part I: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. *Alternative Medicine Review*. 2002, 7(6), 456-471.
182. Suh JH, Shigeno ET, Morrow JD, et al. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)- (alpha)-lipoic acid. *Faseb J*. 2001, 15(3), 700-706.
183. Ou P, Nourooz-Zadeh J, Tritschler HJ, Wolff S. Activation of aldose reductase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. *Free Radic Res*. 1996, 25, 337-346.
184. Sigel JH, Prijs B, McCormick DB, Shih JCH. Stability of binary and ternary complexes of  $\alpha$ -lipoate and lipoate derivatives with  $Mn^{2+}$ ,  $Cu^{2+}$ , and  $Zn^{2+}$  in solution. *Arch Biochem Biophys*. 1978, 187, 208-214.
185. Grunert RR. The effect of DL  $\alpha$ -lipoic acid on heavy-metal intoxication in mice and dogs. *Arch Biochem Biophys*. 1960, 86, 190-194.
186. Biewenga GP, Haesen GR, Bast A. The pharmacology of the antioxidant lipoic acid. *Gen Pharmacol*. 1997, 29(3), 315-331.
187. Bustamante J, Lodge JK, Marcocci L, et al. Alpha-lipoic acid in liver metabolism and disease. *Free Rad Biol Med*. 1998, 24(6), 1023-1039.
188. Miura K, Clarkson TW. Reduced methylmercury accumulation in a methylmercuryresistant rat pheochromocytoma PC12 cell line. *Toxicol Appl Pharmacol*. 1993, 118, 39-45.
189. Muller L, Manzel H. Studies on the efficacy of lipoate and dihydrolipoate in the alteration pf cadmium toxicity in isolated hepatocytes. *Biochem Biophys Acta*. 1990, 1052, 386-391.

190. Keith RL, Setiarahardjo I, Fernando Q, et al. Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. *Toxicology*. 1997, 116, 67-75.
191. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. *Gen Pharmacol*. 1997, 29(3), 315-331.
192. Bast A, Haenen GR. Lipoic acid: a multifunctional nutraceutical, In: Kramer K, Hoppe P, Packer L, eds. *Nutraceuticals in Health and Disease Prevention*, Marcel Dekker, Inc, New York. 2001.
193. Packer L, Witt E, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. *Free Radic Biol Med*. 1995, 19, 227-250.
194. Handelman GJ, Han D, Tritschler H, Packer L.  $\alpha$ -Lipoic acid reduction by mammalian cells to the dithiol form and release into the culture medium. *Biochem Pharmacol*. 1994, 47, 1725-1730.
195. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. *Nutrition*. 2001, 17(10), 888-895.
196. Kagan V, Serbinova E, Packer L. Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling. *Biochem Biophys Res Comm*. 1990, 169, 851-857.
197. Busse E, Zimmer G, Schopohl B, et al. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. *Arzneimittel-Forschung*. 1992, 42, 829-831.
198. Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on  $\alpha$ -tocopherol. *Biochem Biophys Acta*. 1989, 1001, 256-261.
199. Scheer B, Zimmer G. Dihydrolipoic acid prevents hypoxic/reoxygenation and peroxidative damage in rat mitochondria. *Arch Biochem Biophys*. 1993, 302, 385-390.
200. Assadnazari H, Zimmer G, Freisleben HJ, et al. Cardioprotective efficiency of dihydrolipoic acid in working rat hearts during hypoxia and reoxygenation. P nuclear magnetic resonance investigations. *Arzneimittel-Forschung*. 1993, 43, 425-432.

201. Prehn JH, Karkoutly C, Nuglisch J, et al. Dihydrolipoate reduces neuronal injury after cerebral ischemia. *J Cereb Blood Flow Metab.* 1992, 12, 78-87.
202. Panigrahi M, Sadguna Y, Shivakumar BR et al. Alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. *Brain Res.* 1996, 717, 184-188.
203. Cao X, Phillis JW. The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. *Free Rad Res.* 1995, 23, 365-370.
204. Haramaki N, Assadnazari H, Zimmer G, et al. The influence of vitamin E and dihydrolipoic acid on cardiac energy and glutathione status under hypoxia-reoxygenation. *Biochem Mol Biol Int.* 1995, 37, 591-597.
205. Biewenga GP, Veening-Griffioen DH, Nicastia AJ, et al. Effects of dihydrolipoic acid on peptide methionine sulfoxide reductase, Implications for antioxidant drugs. *Arzneimittel-Forschung.* 1998, 48(2), 144-148.
206. Kramer K, Packer L. R-alpha-lipoic acid, In *Nutraceuticals in Health and Disease Prevention*, Eds Kramer K, Hoppe P, Packer L. Marcel Dekker, New York. 2001, 129-164.
207. Packer L. Alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. *Drug Metab Rev.* 1998, 30(2), 245-275.
208. Hinz M, Krappmann D, Eichten A, et al. NF-kappaB function in growth control: regulation in cyclin D1 expression and G0-G1-to-S-phase transition. *Mol Cell Biol.* 1999, 19(4), 2690-2698.
209. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. *Faseb J.* 2001, 15(13), 2423-2432.
210. Mizuno M, Packer L. Effects of alpha-lipoic acid and dihydrolipoic acid on expression of proto-oncogene c-fos. *Biochem Biophys Res Commun.* 1994, 200(2), 1136-1142.
211. Bast A, Haenen GR. Lipoic acid: a multifunctional nutraceutical. In: Kramer K, Hoppe P, Packer I, eds. *Nutraceuticals in Health and Disease Prevention*. Marcel Dekker, Inc, New York. 2001.

212. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in German: current evidence from clinical trials. *Exp Clin Endocrinol Diabetes*. 1999, 107(7), 421-430.
213. Maitra I, Serbinova E, Tritschler HJ, Packer L. Stereospecific effects of R-lipoic acid on buthionine sulfoximine-induced cataract formation in newborn rats. *Biochem Biophys Res Commun*. 1996, 221(2), 422-429.
214. Rett K, Wicklmayr E, Macrker P, et al. Effect of acute infusion of thiotic acid on oxidative and non-oxidative metabolism in obese subjects with NIDDM. *Diabetologia*. 1995, 38, A41.
215. Jacob S, Henriksen EJ, Schiemann AL, et al. Enhancement of glucose disposal in patients with type 2 diabetes by alpha lipoic acid. *Arzneimittel-Forschung*. 1995, 45, 872-874.
216. Konrad T, Vicini P, Kusterer K, et al. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. *Diabetes Care*. 1999, 22(2), 280-287.
217. Jacob S, Rett K, Henriksen EJ, Haring HU. Thiotic acid – effects on insulin sensitivity and glucose-metabolism. *Biofactors*. 1999, 10(2-3), 169-174.
218. Jacob S, Henriksen EJ, Tritschler HJ, et al. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thiotic acid. *Exp Clin Endocrinol Diabetes*. 1996, 104, 284-288.
219. Streeper RS, Henriksen EJ, Jacob S, et al. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. *Am J Physiol*. 1997, 273(I Pt 1), E185-191.
220. Estrada DE, Ewart HS, Tsakiridis T, et al. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thiotic acid: participation of elements of the insulin signaling pathway. *Diabetes*. 1996, 45(12), 1798-1804.
221. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor

- glycemic control and albuminuria. *Free Radic Biol Med.* 1999, 26(11-12), 1495-1500.
222. Androne L, Gavan NA, Veresiu LA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. *In Vivo.* 2000, 14(2), 327-330.
223. Ames BN. Micronutrients prevent cancer and delay aging. *Toxicol Lett.* 1998, 102-103, 5-18.
224. Exner R, Wessner B, Manhart N, Roth E. Therapeutic potential of glutathione. *Wien Klin Wochenschr.* 2000 Jul 28;112(14):610-6.
225. Pack RA, Hardy K, Madigan MC, Hunt NH. Differential effects of the antioxidant alpha-lipoic acid on the proliferation of mitogen-stimulated peripheral blood lymphocytes and leukaemic T cells. *Mol Immunol.* 2002 Feb;38(10):733-45.
226. Sokoloski, J., Hodnick, W., Mayne, S. et al. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-κB. *Leukemia.* 1997, 11, 1546–1553.
227. Culy CR, Clemett D, Wiseman LR. Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. *Drugs.* 2000, 60, 895-924.
228. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. *Alpha-Lipoic Acid in Diabetic Neuropathy.* *Diabetes Care.* 1999, 22(8), 1296-1301.
229. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. *J Clin Oncol.* 2002, 20(15), 3359-3361.
230. Gedlicka C, Kornek GV, Schmid K, Scheithauer W. Amelioration of docetaxel/cisplatin-induced cumulative polyneuropathy with alpha-lipoic acid. *J Clin Oncol.* 2002, 20(15), 3359-3361.
231. Somani SM, Husain K, Whitworth C, et al. Dose-dependent

- protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. *Pharmacol Toxicol.* 2000, 86(5), 234-241.
232. Dovinova I, Novotny L, Rauko P, Kvasnicka P. Combined effect of lipoic acid and doxorubicin in murine leukemia. *Neoplasma.* 1999, 46(4), 237-241.
233. Rybak LP, Husain K, Whitworth C, Somani SM, Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: Antioxidant defense system. *Toxicological Sciences.* 1999, 47, 195-202.
234. Gatei M, Shkedy D, Khanna KK, et al. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid. *Oncogene.* 2001, 20(3), 289-294.
235. van de Mark K, Chen JS, Steliou K, et al. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. *J Cell Physiol.* 2003, 194(3), 325-340.
236. Scott BC, Aruoma OI, Evans PJ, et al. Lipoic acid and dihydrolipoic acids as antioxidants. A critical evaluation. *Free Radic Res.* 1994, 20(2), 119-133.
237. Wenzel U, Nickel A, Daniel H. Alpha-lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O<sub>2</sub><sup>-</sup>, -generation. *Apoptosis.* 2005, 10(2), 359-368.
238. Pack RA, Hardy K, Madigan MC, Hunt NH. Differential effects of the antioxidant alpha-lipoic acid on the proliferation of mitogen-stimulated peripheral blood lymphocytes and leukemic T cells. *Mol Immunol.* 2002, 38(10), 733-745.
239. Sen CK, Sashwati R, Packer L. Fas mediated apoptosis of human Jurkat T-cells: intracellular events and potentiation by redox-active alpha-lipoic acid. *Cell Death Differ.* 1999, 6(5), 481-491.
240. Casciari JJ, Riordan NH, Schmidt TL, et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. *British Journal of Cancer.* 2001, 84, 11, 1544-1550.
241. Savvov VI, Karpov LM. Characteristics of 35S-lipoic acid

- absorption by the blood cells in breast cancer. *Vopr Onkol.* 1982, 28(7), 11-13.
242. Savvov VI, Karpov LM. Pyruvate oxidation and S35-lipoic acid fixation by breast tumor homogenates. *Vopr Onkol.* 1978, 24(8), 97-99.
243. Karpov LM, Dvuzhil'naia ED, Savvov VI, Anisimov VD. Permeability of the mitochondrial membranes of the organs of white rats inoculated with Walker carcinoma to lipoic acid and thiamine labelled with S35. *Vopr Onkol.* 1975, 21(8), 69-73.
244. Karpov LM, Rozanov A, Savvov VI. Effect of Walker carcinoma on the distribution of S35-lipoic acid in the body of white rats. *Vopr Onkol.* 1973, 19(12), 57-61.
245. Karpov LM, Dvuzhil'naia ED, Savvov VI, Phan Van Thuy. S35 lipoic acid distribution and its effect on pyruvate dehydrogenase activity in rats with Walker carcinoma. *Vopr Onkol.* 1977, 23(10), 87-90.
246. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. *Free Radic Biol Med.* 2014;72:76-90.
247. Zarogoulidis P, Cheva A, Zarambouka K, et al. Tocopherols and tocotrienols as anticancer treatment for lung cancer: future nutrition. *J Thorac Dis.* 2013;5(3):349-352.
248. Prasad KN, Kumar B, Yan XD, et al. Alpha-tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. *J Am Coll Nutr.* 2003, 22(2), 108-117.
249. Prasad KN, Ramanujam S, Gaudreau D. Vitamin E induces morphological differentiation and increases the effect of ionizing radiation on neuroblastoma cells in culture. *Proc Soc Exp Biol Med.* 1979, 161, 570-573.
250. Prasad KN, Edwards-Prasad J, Ramanujam S, Sakamoto A. Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture. *Proc Soc Exp Biol Med.* 1980. 164, 158-163.
251. Prasad KN, Edwards-Prasad J. Effects of tocopherol (vitamin

- E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture. *Cancer Res.* 1982, 42, 550-555.
252. Turley JM, Fu T, Ruscetti FW, et al. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. *Cancer Res.* 1997, 57(5), 881-890.
253. Zhao B, Yu W, Qian M, et al. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. *Mol Carcinog.* 1997, 19(3), 180-190.
254. Yu W, Heim K, Qian M, et al. Evidence for role of transforming growth factor-beta in RRR-alpha-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. *Nutr Cancer.* 1997, 27(3), 267-278.
255. Pussinen PJ, Lindner H, Glatter O, et al. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. *Biochim Biophys Acta.* 2000, 1485(2-3), 129-144.
256. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. *J Surg Res.* 2000, 93(1), 163-170.
257. Barnett KT, Fokum FD, Malafa MP. Vitamin E succinate inhibits colon cancer liver metastases. *J Surg Res.* 2002, 106(2), 292-298.
258. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. *Nutr Cancer.* 2000, 36(1), 90-100.
259. Kogure K, Hama S, Manabe S, et al. High cytotoxicity of alpha-tocopheryl hemisuccinate to cancer cells is due to failure of their antioxidative defense systems. *Cancer Lett.* 2002, 186(2), 151-156.
260. Kang Y, Lee E, Choi M, et al. Role of reactive oxygen species in the induction of apoptosis by alpha-tocopheryl succinate. *Int J Cancer.* 2004, 112(3), 385-392.
261. Wu Y, Zu K, Ni J, et al. Cellular and molecular effects of alpha-tocopheryloxybutyrate: lessons for the design of vitamin E analog for cancer prevention. *Anticancer Res.* 2004, 24(6), 3795-3802.



262. Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. *Faseb J*. 2001, 15(2), 403-415.
263. Weber T, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. *Clin Cancer Res*. 2002, 8(3), 863-869.
264. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by alpha-tocopheryl succinate. *Brit J Cancer*. 2001, 84, 87-89.
265. Israel K, Sanders BG, Kline K. RRR- $\alpha$ -Tocopheryl-Succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathway. *Nutr Cancer*. 1995, 24, 161-169.
266. Yu W, Sanders BG, Kline K. RRR- $\alpha$ -tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. *Nutr Cancer*. 1997, 27, 92-101.
267. Simmons-Menchaca M, Qian M, Yu W, et al. RRR- $\alpha$ -Tocopheryl succinate inhibits DNA synthesis and enhances the production and secretion of biologically active transforming growth factor- $\beta$  by avian retrovirus-transformed lymphoid cells. *Nutr Cancer*. 1995, 24, 171-185.
268. Wu K, Zhao Y, Liu BH, et al. RRR- $\alpha$ -tocopheryl succinate inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest. *World J Gastroenterol*. 2002, 8, 26-30.
269. Kim SJ, Bang OS, Lee YS, Kang SS. Production of inducible nitric oxide is required for monocytic differentiation of U937 cells induced by vitamin E-succinate. *J Cell Sci*. 1998, 111, 435-441.
270. You H, Yu W, Sanders BG, Kline K. RRR- $\alpha$ -tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. *Cell Growth Differ*. 2001, 12, 471-480.
271. Yu W, Sanders BG, Kline K. Modulation of murine EL-4 thymic lymphoma cell proliferation and cytokine production by Vitamin E succinate. *Nutr Cancer*. 1996, 25, 137-149.
272. Shklar G, Schwartz J, Trickler DP, Niukian K. Regression by

- vitamin E of experimental oral cancer. *J Natl Cancer Inst.* 1987, 78(5), 987-992.
273. Neuzil J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. *Br J Cancer.* 2003, 89(10), 1822-1826.
274. Meydani SN, Barklund MP, Liu S, et al. Vitamin E supplementation enhances cell-mediated immunity in healthy elderly subjects. *Am J Clin Nutr.* 1990 Sep;52(3):557-63.
275. Penn ND, Purkins L, Kelleher J, et al. The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. *Age Ageing.* 1991 May;20(3):169-74.
276. Odeleye OE, Eskelson CD, Mufti SI, Watson RR. Vitamin E inhibition of lipid peroxidation and ethanol-mediated promotion of esophageal tumorigenesis. *Nutr Cancer.* 1992;17(3):223-34.
277. Cook MG, McNamara P. Effect of dietary vitamin E on dimethylhydrazine-induced colonic tumors in mice. *Cancer Research,* 1980, 40, 4.
278. Record IR, Dreosti IE, Konstantinopoulos M, Buckley RA. The influence of topical and systemic vitamin E on ultraviolet light-induced skin damage in hairless mice. *Nutr. Cancer.* 1991, 16, 219-225.
279. Gonzalez ER. Vitamin E relieves most cystic breast disease; may alter lipids, hormones. *JAMA.* 1980 Sep 5;244(10):1077-8.
280. Panganamala RV, Cornwell DG. The effects of vitamin E on arachidonic acid metabolism. *Ann. N.Y. Acad. Sci.,* 1982, 393, 376-391.
281. Jandak J et al. Alpha tocopherol, an effective inhibitor of platelet adhesion. *Blood.* 1989 73:141-9, 1989.
282. Knekt P, Aromaa A, Maatela J, et al. Vitamin E and cancer prevention. *Am J Clin Nutr.* 1991 Jan;53(1 Suppl):283S-286S.
283. de Vries, N., Snow, G.B. Relationships of vitamins A and E and beta-carotene serum levels to head and neck cancer patients with and without second primary tumors. *Eur Arch Otorhinolaryngol.* 1990, 247, 368-370.

284. Shklar G, Schwartz J, Trickler DP, Niukian K. Regression by vitamin E of experimental oral cancer. *J. Nat. Cancer Inst.*, 1987, 78(5):987-992.
285. Paganelli GM, Biasco G, Brandi G, et al. Effect of Vitamin A, C, and E Supplementation on rectal cell proliferation in patients with colorectal adenomas. *Journal of the National Cancer Institute*, 1992, 84, 1, 47-52.
286. Longnecker MP, Martin-Moreno JM, Knekt P, et al. Serum alpha-tocopherol concentration in relation to subsequent colorectal cancer: pooled data from five cohorts. *J Natl Cancer Inst.* 1992 Mar 18;84(6):430-5.
287. Yano T, Obata Y, Yano Y, et al. Vitamin E acts as a useful chemopreventive agent to reduce spontaneous lung tumorigenesis in mice. *Cancer Letters*, 1994, 87, 2 205-210.
288. Signal PK, Tong J. Vitamine E deficiency accentuates adriamycin-induced cardiopathologic and cell surface changes. *Mol Cell Biochem.* 1988, 84:163-171.
289. Clemens MR, Ladner C, Ehninger G, et al. Plasma vitamin E and beta-carotene concentrations during radiochemotherapy preceding bone marrow transplantation. *Am J Clin Nutr.* 1990 Feb;51(2):216-9.
290. Shklar G, Schwartz JL, Trickler DP, Reid S. Prevention of experimental cancer and immunostimulation by vitamin E (immunosurveillance). *J Oral Pathol Med.* 1990 Feb;19(2):60-4.
291. Geetha A, Catherine J, Shyamala Devi CS. Effect of  $\alpha$ -tocopherol on doxorubicin induced alterations in glucose metabolism – A pilot study. *J Biosci* 14. 1989, 243-247.
292. Ripoll EAP, Rama BN, Webber M. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. *J. Urol.* 1986, 136, 529.
293. Wood LA. Possible prevention of adriamycin-induced alopecia by tocopherol. *N Engl J Med.* 1985;312(16):1060.
294. Washio M, Nanishi F, Okuda S, et al. Alpha tocopherol improves focal glomerulosclerosis in rats with adriamycin-induced progressive renal failure nephron. *Nephron.* 1994;68:347-352.

295. Van Vleet JF, Greenwood L, Ferrans VJ, Rebar AH. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. *Am J Vet Res.* 1978 Jun;39(6):997-1010.
296. Van Vleet JF, Ferrans VJ. Evaluation of vitamin E and selenium protection against chronic adriamycin toxicity in rabbits. *Cancer Treat Rep.* 1980 Feb-Mar;64(2-3):315–317.
297. Prasad KN, Ramanujam S, Gaudreau D. Vitamin E induces morphological differentiation and increases the effect of ionizing radiation on neuroblastoma cells in culture. *Proc. Soc. Exper. Biol. Med.* 1979, 161, 570.
298. Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. *Am J Med.* 1992 May;92(5):481-4.
299. Comstock GW, Helzlsouer KJ, Bush TL. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. *Am J Clin Nutr.* 1991 Jan;53(1 Suppl):260S-264S.
300. Longnecker M.P., Martin-Morreno J.M., Knekt P, Nomura A.M., Schober S.E., Staheii H.B., Wald N.J., Gey K.F., Willet W.C., Serum alpha-tocopherol concentrations in relation to subsequent colorectal cancer: Pooled data from five cohorts, *Journal of the National Cancer Institute.* 1992, 84, 430-435.
301. Knekt P. Role of vitamin E in the prophylaxis of cancer. *Ann Med.* 1991 Feb;23(1):3-12.
302. LeGardeur B.Y., Lopez A, Johnson W.D., A case-control study of serum vitamins A, E, and C in lung cancer patients, *Nutrition and Cancer.* 1990,14, 133-140.
303. Wright ME, Lawson KA, Weinstein SJ, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Am J Clin Nutr.* 2006 Nov;84(5):1200-7.
304. Dong Y, Liu Y, Shu Y, et al. Link between risk of colorectal cancer and serum vitamin E levels: a meta-analysis of case-control studies. *Medicine (Baltimore).* 2017;96(27):e7470.

305. Chen J, Jiang W, Shao L, et al. Association between intake of antioxidants and pancreatic cancer risk: a meta-analysis. *Int J Food Sci Nutr*. 2016;67(7):744-753.
306. Yang CS, Suh N. Cancer prevention by different forms of tocopherols. *Top Curr Chem*. 2013;329:21-33.
307. Das Gupta S, Suh N. Tocopherols in cancer: an update. *Mol Nutr Food Res*. 2016;60(6):1354-1363.
308. Abraham A, Kattoor AJ, Saldeen T, Mehta JL. Vitamin E and its anticancer effects. *Crit Rev Food Sci Nutr*. May 2018:1-23.
309. Jiang Q, Wong J, Ames BN. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via Caspase-dependent and independent mechanisms. *Ann N Y Acad Sci*. 2004, 1031, 399-400.
310. Jiang Q. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. *Free Radic Biol Med*. 2014;72:76-90.
311. Prasad KN, Hernandez C, Edwards-Prasad J, et al. Modification of the effect of tamoxifen, cisplatin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. *Nutr Cancer*. 1994, 22(3), 233-245.
312. Prasad KN, Kumar R. Effect of individual and multiple antioxidant vitamins on growth and morphology of human nontumorigenic and tumorigenic parotid acinar cells in culture. *Nutr Cancer*. 1996, 26, 11-19.
313. Young SW, Qing F, Harriman A, et al. Gadolinium (III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MEI. *Proc Natl Acad Sci U S A*. 1996, 93(13), 6610-6615.
314. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-TeX), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. *Clin Cancer Res*. 1999, 5(4), 739-745.
315. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. *J Clin Oncol*. 2001, 19(7), 2074-2083.
316. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of

- gadolinium (III) texaphyrin complex. A new paramagnetic contrast agent for magnetic resonance imaging. *Invest Radiol.* 1994, 29(3), 330-338.
317. Xu S, Zakian K, Thaler H, et al. Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity. *Int J Radiat Oncol Biol Phys.* 2001, 49(5), 1381-1390.
318. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. *J Clin Oncol.* 2001, 19(7), 2074-83.
319. Mehta MP, Suh JH. Novel radiosensitizers for tumors of the central nervous system. *Curr Opin Investig Drugs.* 2004, 5(12), 1284-1291.
320. Magda D, Lepp C, Gerasimechuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. *Int J Radiol Oncol Biol Phys.* 2001, 51(4), 1025-1036.
321. Evens AM, Lecane P, Magda D, et al. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple cells. *Blood.* 2005, 105(3), 1265-1273.
322. Renschler MF. The emerging role of reactive oxygen species in cancer therapy. *Eur J Cancer.* 2004, 40(13), 1934-1940.
323. Biaglow JE. The thioredoxin reductase/thioredoxin system: novel redox species in cancer therapy. *Eur J Cancer.* 2004, 40(13), 1934-1940.
324. Evens AM. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. *Curr Opin Oncol.* 2004, 16(6), 576-580.
325. Magda D, Miller RA. Motexafin gadolinium: a novel redox active drug for cancer therapy. *Semin Cancer Biol.* 2006 Dec;16(6):466-76.
326. Richards G, Mehta M. Motexafin gadolinium in the treatment of brain metastases. *Expert Opinion on Pharmacotherapy.* 2007, 8 (3): 351–9.

### **ΜΕΡΟΣ 3**

#### **ΚΕΤΟΓΟΝΙΚΗ ΔΙΑΤΡΟΦΗ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΚΑΡΚΙΝΟΥ**

1. Aft RL, Zhang FW, Gius D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. *Br J Cancer*. 2002 Sep 23;87(7):805-12.
2. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. *Oncogene*. 2006 Aug 7;25(34):4633-46.
3. Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. *Aust J Exp Biol Med Sci*. 1979 Oct;57(5):529-39.
4. Fine EJ, Miller A, Quadros EV, et al. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. *Cancer Cell Int*. 2009 May 29;9:14.
5. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. *J Pediatr Surg*. 2009 Jan;44(1):212-6; discussion 216.
6. Stafford P, Abdelwahab MG, Kim DY, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. *Nutr Metab (Lond)*. 2010 Sep 10;7:74.
7. Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. *BMC cancer*. May 13 2016;16(1):310.
8. Varshneya K, Carico C, Ortega A, Patil CG. The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature. *Cureus*. Feb 2015;7(2):e251.
9. Klement RJ, Champ CE, Otto C, Kammerer U. Anti-Tumor Effects of Ketogenic Diets in Mice: A Meta-Analysis. *PLoS One*. 2016;11(5):e0155050.
10. Shelton LM, Huysentruyt LC, Mukherjee P, Seyfried TN. Calorie

- restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. *ASN Neuro*. Jul 23 2010;2(3):e00038.
11. Zhou W, Mukherjee P, Kiebish MA, et al. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. *Nutr Metab (Lond)*. 2007 Feb 21;4:5.
  12. Freedland SJ, Mavropoulos J, Wang A, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. *Prostate*. 2008 Jan 1;68(1):11-9.
  13. Otto C, Kaemmerer U, Illert B, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. *BMC Cancer*. 2008 Apr 30;8:122.
  14. Seyfried TN, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? *Epilepsy Res*. 2012 Jul;100(3):310-26.
  15. Abdelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. *PLoS One*. 2012;7(5):e36197.
  16. Poff AM, Ari C, Seyfried TN, D'Agostino DP. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. *PLoS One*. 2013 Jun 5;8(6):e65522.
  17. Champ CE, Palmer JD, Volek JS, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. *Journal of neuro-oncology*. Mar 2014;117(1):125-31.
  18. Meidenbauer JJ, Mukherjee P, Seyfried TN. The glucose ketone index calculator: a simple tool to monitor therapeutic efficacy for metabolic management of brain cancer. *Nutr Metab (Lond)*. 2015;12(1):12.
  19. Klement RJ. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. *Medical oncology (Northwood, London, England)*. Aug 2017;34(8):132.
  20. Lin S. Ketogeic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma: a Pilot Study. [ClinicalTrials.gov](http://ClinicalTrials.gov)



- [Internet]. Bethesda (MD): National Library of Medicine. Identifier: NCT02939378. <https://clinicaltrials.gov/ct2/show/NCT02939378?term=ketogenic&recrs=abdef&type=Intr&cond=glioblastoma&phase=01&rank=1>. Last updated 10/20/2016. Accessed 1/16/2018.
21. Klein P. Ketogenic Diet as Adjunctive Treatment in Refractory/ End-stage Glioblastoma Multiforme: a Pilot Study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Identifier: NCT01865162. <https://clinicaltrials.gov/ct2/show/NCT01865162?term=ketogenic&recrs=abdef&type=Intr&cond=glioblastoma&phase=01&rank=2>. Last updated 3/18/2016. Accessed 1/16/2018.
  22. Klein P. Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. Identifier: NCT02302235. <https://clinicaltrials.gov/ct2/show/NCT02302235?term=ketogenic&recrs=abdef&type=Intr&cond=glioblastoma&phase=01&rank=3>. Last updated 3/18/2016. Accessed 1/16/2018.
  23. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. *BMC Res Notes*. 2016 Mar 5;9:143.
  24. Kato I, Dyson G, Snyder M, et al. Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer. *J Radiat Oncol*. 2016 Sep;5(3):279-286.
  25. Maroon JC, Seyfried TN, Donohue JP, Bost J. The role of metabolic therapy in treating glioblastoma multiforme. *Surg Neurol Int*. 2015;6:61.
  26. Seyfried TN, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? *Epilepsy Res*. Jul 2012;100(3):310-26.
  27. Tan-Shalaby JL, Carrick J, Edinger K, et al. Modified Atkins diet in advanced malignancies - final results of a safety and feasibility

- trial within the Veterans Affairs Pittsburgh Healthcare System. *Nutr Metab (Lond)*. 2016;13(1):52.
28. Klement RJ. The influence of ketogenic therapy on the 5 R's of radiobiology. *Int J Radiat Biol*. Apr 2019;95(4):394-407.
  29. Seyfried TN, Shelton L, Arismendi-Morillo G, et al. Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma? *Neurochem Res*. Oct 2019;44(10):2392-2404.
  30. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer – Where do we stand? : Elsevier GmbH; 2020. p. 102-121.
  31. Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. *J Am Coll Nutr*. 1995 Apr;14(2):202-8.
  32. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. *Nutr Metab (Lond)*. 2010 Apr 22;7:33.
  33. Elsakka AMA, Bary MA, Abdelzaher E, et al. Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up. *Frontiers in nutrition*. 2018;5:20.
  34. O'Flanagan CH, Smith LA, McDonnell SB, Hursting SD. When less may be more: calorie restriction and response to cancer therapy. *BMC Medicine*. May 24 2017;15(1):106.
  35. Simone BA, Dan T, Palagani A, Jin L, et al. Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. *Cell Cycle*. Sep 2016;15(17):2265-2274.
  36. Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. *Nutrition*. Oct 2012;28(10):1028-1035.
  37. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary

- manipulation. *Cancer Metastasis Reviews*. Mar 2014;33(1):217-229.
38. Seyfried TN, Shelton L, Arismendi-Morillo G, et al. Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma? *Neurochem Res*. Oct 2019;44(10):2392-2404.
  39. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in the treatment of cancer - Where do we stand? *Mol Metab*. 2020 Mar;33:102-121.
  40. Fine EJ, Segal-Isaacson CJ, Feinman RD, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. *Nutrition*. Oct 2012;28(10):1028-1035.
  41. Magee BA, Potezny N, Rofe AM, Conyers RA. The inhibition of malignant cell growth by ketone bodies. *Aust J Exp Biol Med Sci*. 1979 Oct;57(5):529-39.
  42. Skinner R, Trujillo A, Ma X, Beierle EA. Ketone bodies inhibit the viability of human neuroblastoma cells. *J Pediatr Surg*. 2009 Jan;44(1):212-6; discussion 216.
  43. Poff AM, Ari C, Arnold P, et al. Ketone supplementation decreases tumor cell viability and prolongs survival of mice with metastatic cancer. *Int J Cancer*. 2014 Oct 1;135(7):1711-20.
  44. Poff A, Kesl S, Ward N, D'Agostino D. Metabolic effects of exogenous ketone supplementation – an alternative or adjuvant to the ketogenic diet as a cancer therapy. *FASEB Journal*. 2016, 30, suppl 1:1167.2.
  45. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate «fuel» tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell Cycle*. 2010 Sep 1;9(17):3506-14.
  46. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite  $\beta$ -hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat Med*. 2015 Mar;21(3):263-9.
  47. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. *J Clin Invest*. 2014 Jan;124(1):30-9.

48. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. *Prostaglandins Leukot Essent Fatty Acids*. 2004 Mar;70(3):309-19.
49. Kemper MF, Miller A, Pawlosky RJ, Veech R. Administration of a novel  $\beta$ -hydroxybutyrate ester after radiation exposure suppresses in vitro lethality and chromosome damage, attenuates bone marrow suppression in vivo. *FASEB Journal*. 2016, 30, suppl 1:627.3.

#### **ΜΕΡΟΣ 4**

#### **ΔΙΑΤΡΟΦΗ ΓΙΑ ΠΡΟΛΗΨΗ ΤΟΥ ΚΑΡΚΙΝΟΥ**

1. King RJB. *Cancer Biology*. Pearson Education. Prentice Hall, Essex, England, 2000.
2. Fung T, Hu FB, Fuchs C, et al. Major dietary patterns and the risk of colorectal cancer in women. *Arch Intern Med*. 2003, 163, 309-314.
3. Ames BN, Wakimoto P. Are vitamin and mineral deficiencies a major cancer risk? *Nature Reviews Cancer*. 2002, 2, 694-704.
4. Donaldson MS. Nutrition and cancer: a review of the evidence for an anticancer diet. *Nutrition Journal*. 2004, 3(1), 19.
5. Platz EA, Willet WC, Colditz GA, et al. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. *Cancer Causes Control*. 2000, 11, 579-588.
6. WCRF/AICR. *Food, nutrition and the prevention of cancer: a global perspective: World Cancer Research Fund / American Institute for Cancer Research*. 1997.
7. Ames BN, Wakimoto P. Are vitamin and mineral deficiencies a major cancer risk? *Nature Reviews Cancer*. 2002, 2, 694-704.
8. Donaldson MS. Nutrition and cancer: a review of the evidence for an anticancer diet. *Nutrition Journal*. 2004, 3(1), 19.
9. Riboli E, Norat T. Epidemiological evidence of the protective effect of fruit and vegetables on cancer risk. *Am J Clin Nutr*. 2003,

- 78, 559S-569S.
10. Bingham SA, Luben R, Welch A, et al. Are imprecise methods obscuring a relation between fat and breast cancer? *Lancet*. 2003, 362, 212-214.
  11. Key TJ, Schatzkin A, Willet WC, et al. Diet, nutrition and the prevention of cancer. *Public Health Nutr*. 2004, 7(1A), 187-200.
  12. Joshi AD, Corral R, Catsburg C, et al. Red meat and poultry, cooking practices, genetic susceptibility and risk of prostate cancer: results from a multiethnic case-control study. *Carcinogenesis*. 2012 Nov;33(11):2108-18.
  13. Punnen S, Hardin J, Cheng I, et al. Impact of meat consumption, preparation, and mutagens on aggressive prostate cancer. *PLoS One*. 2011 6(11):e27711.
  14. John EM, Stern MC, Sinha R, Koo J. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. *Nutr Cancer*. 2011 63(4):525-37.
  15. Richman EL, Kenfield SA, Stampfer MJ, et al. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. *Cancer Prev Res (Phila)*. 2011 Dec;4(12):2110-21.
  16. Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst*. 2013 Aug 7;105(15):1132-41.
  17. Cancer Council Australia. Is it true that men who take fish oil supplements or eat fatty fish are more likely to develop prostate cancer? <https://www.cancer.org.au/iheard/is-it-true-that-men-who-take-fish-oil-supplements-or-eat-fatty-fish-are-more-likely-to-develop-prostate-cancer>
  18. Song Y, Chavarro JE, Cao Y, et al. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. *J Nutr*. 2013 Feb;143(2):189-96.
  19. Newcomer LM, King IB, Wicklund KG, Stanford JL. The association of fatty acids with prostate cancer risk. *Prostate*. 2001 Jun 1;47(4):262-8.
  20. Leitzmann MF, Stampfer MJ, Michaud DS, et al. Dietary intake of

- n-3 and n-6 fatty acids and the risk of prostate cancer. *Am J Clin Nutr.* 2004 Jul;80(1):204-16.
21. Pelsler C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. *Cancer Epidemiol Biomarkers Prev.* 2013 Apr;22(4):697-707.
  22. Hassan S, Carraway RE. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. *Regul Pept.* 2006 Jan 15;133(1-3):105-14.
  23. Moretti RM, Montagnani MM, Sala A, et al. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. *Int J Cancer.* 2004 Oct 20;112(1):87-93.
  24. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. *Proc Natl Acad Sci U S A.* 1998 Oct 27;95(22):13182-7.
  25. Ritch CR, Wan RL, Stephens LB, et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. *J Urol.* 2007 Jan;177(1):97-101; discussion 101.
  26. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of *Boswellia serrata* in patients with chronic colitis. *Planta Med.* 2001 Jul;67(5):391-5.
  27. Fowler ME, Akinyemiju TF. Meta-analysis of the association between dietary inflammatory index (DII) and cancer outcomes. *International Journal of Cancer.* Dec 01 2017;141(11):2215-2227.
  28. Tabung FK, Steck SE, Liese AD, et al. Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. *British Journal of Cancer.* May 24 2016;114(11):1277-1285.
  29. Shivappa N, Sandin S, Lof M, et al. Prospective study of dietary inflammatory index and risk of breast cancer in Swedish women. *British Journal of Cancer.* Sep 29 2015;113(7):1099-1103.
  30. Stoll BA. Breast cancer and the western diet: role of fatty acids and antioxidant vitamins. *European Journal of Cancer (Oxford, England: 1990).* Nov 1998;34(12):1852-1856.

31. Stoll BA. Western diet, early puberty, and breast cancer risk. *Breast Cancer Res Treat.* Jun 1998;49(3):187-193.
32. Link LB, Canchola AJ, Bernstein L, et al. Dietary patterns and breast cancer risk in the California Teachers Study cohort. *The American Journal of Clinical Nutrition.* Dec 2013;98(6):1524-1532.
33. Nicholson A. Diet and the prevention and treatment of breast cancer. *Altern Ther Health Med.* Nov 1996;2(6):32-38.
34. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *CA: A Cancer Journal for Clinicians.* Jan-Feb 2016;66(1):43-73.
35. Kroenke CH, Fung TT, Hu FB, Holmes MD. Dietary patterns and survival after breast cancer diagnosis. *Journal of Clinical Oncology.* Dec 20 2005;23(36):9295-9303.
36. Chlebowski RT, Aragaki AK, Anderson GL, et al. Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. *Journal of Clinical Oncology.* Sep 01 2017;35(25):2919-2926.
37. Brennan SF, Woodside JV, Lunny PM, et al. Dietary fat and breast cancer mortality: A systematic review and meta-analysis. *Critical Reviews in Food Science and Nutrition.* Jul 03 2017;57(10):1999-2008.
38. Slomski A. Low-Fat Diet Reduces Mortality After Breast Cancer. *JAMA.* Sep 26 2017;318(12):1099.
39. Kroenke CH, Kwan ML, Sweeney C, et al. High- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis. *Journal of the National Cancer Institute.* May 1 2013;105(9):616-623.
40. Sulaiman S, Shahril MR, Wafa SW, et al. Dietary carbohydrate, fiber and sugar and risk of breast cancer according to menopausal status in Malaysia. *Asian Pacific Journal of Cancer Prevention.* 2014;15(14):5959-5964.
41. Steck SE, Gaudet MM, Eng SM, et al. Cooked meat and risk of breast cancer--lifetime versus recent dietary intake.

- Epidemiology (Cambridge, Mass.). May 2007;18(3):373-382.
42. Kim JH, Lee J, Jung SY, Kim J. Dietary Factors and Female Breast Cancer Risk: A Prospective Cohort Study. *Nutrients*. Dec 7 2017;9(12).
  43. Parada H, Jr., Steck SE, Bradshaw PT, et al. Grilled, Barbecued, and Smoked Meat Intake and Survival Following Breast Cancer. *J Natl Cancer Inst*. Jun 2017;109(6).
  44. Whitley AC., Sweet DH, Walle T. The dietary polyphenol ellagic acid is a potent inhibitor of hOAT1. *Drug Metabolism and Disposition*. 2005, 33(8): 1097-1100.
  45. Del Rio D, Borges G, Crozier A. Berry flavonoids and phenolics: bioavailability and evidence of protective effects. *Br J Nutr*. 2010 Oct;104 Suppl 3:S67-90.
  46. Linsalata M, Orlando A, Messa C, et al. Quercetin inhibits human DLD-1 colon cancer cell growth and polyamine biosynthesis. *Anticancer Res*. 2010 Sep;30(9):3501-7.
  47. Yang CS, Wang H, Li GX, et al. Cancer prevention by tea: Evidence from laboratory studies. *Pharmacol Res*. 2011 Aug;64(2):113-22.
  48. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. *J Postgrad Med*. 2003 Jul-Sep;49(3):222-8.
  49. Ferrucci LM., Daniel CR, Kapur K, et al. Measurement of spices and seasonings in India: opportunities for cancer epidemiology and prevention. *Asian Pac J Cancer Prev*. 2010, 11(6): 1621-1629.
  50. Fung TT, Hu FB, Wu K, et al. The Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets and colorectal cancer. *Am J Clin Nutr*. 2010 Dec;92(6):1429-35.
  51. Hur J, Otegbeye E, Joh HK, et al. Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women. *Gut*. May 6 2021.
  52. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA*. 2007 Aug 15;298(7):754-64.
  53. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. *J Obes*. 2013;2013:291546.
  54. Strom SS, Oum R, Elhor Gbito KY, et al. De novo acute myeloid



- leukemia risk factors: a Texas case-control study. *Cancer*. Sep 15 2012;118(18):4589-4596.
55. Kasim K, Levallois P, Abdous B, et al. Lifestyle factors and the risk of adult leukemia in Canada. *Cancer causes & control: CCC*. Jun 2005;16(5):489-500.
56. Yamamura Y, Oum R, et al. Dietary intake of vegetables, fruits, and meats/beans as potential risk factors of acute myeloid leukemia: a Texas case-control study. *Nutr Cancer*. 2013;65(8):1132-40.
57. Liu CY, Hsu YH, Wu MT, et al. Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. *BMC cancer*. 2009;9:15.
58. Kwan ML, Jensen CD, Block G, et al. Maternal diet and risk of childhood acute lymphoblastic leukemia. *Public health reports (Washington, D.C. : 1974)*. Jul-Aug 2009;124(4):503-514.
59. Petridou E, Ntouvelis E, Dessypris N, et al. Maternal diet and acute lymphoblastic leukemia in young children. *Cancer Epidemiology, Biomarkers & Prevention*. Aug 2005;14(8):1935-1939.
60. Jensen CD, Block G, Buffler P, et al. Maternal dietary risk factors in childhood acute lymphoblastic leukemia (United States). *Cancer Causes & Control*. Aug 2004;15(6):559-570.
61. Thompson JR, Gerald PF, Willoughby ML, Armstrong BK. Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukaemia in childhood: a case-control study. *Lancet*. Dec 8 2001;358(9297):1935-1940.
62. Bailey HD, Miller M, Langridge A, et al. Maternal dietary intake of folate and vitamins B6 and B12 during pregnancy and the risk of childhood acute lymphoblastic leukemia. *Nutrition and Cancer*. 2012;64(7):1122-1130.
63. Skibola CF. Obesity, diet and risk of non-Hodgkin lymphoma. *Cancer Epidemiology, Biomarkers & Prevention*. Mar 2007;16(3):392-395.
64. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin's lymphoma: a meta-analysis. *International Journal of Cancer*. Oct 1 2007;121(7):1564-1570.

65. Aschebrook-Kilfoy B, Ward MH, Dave BJ, et al. Dietary nitrate and nitrite intake and risk of non-Hodgkin lymphoma. *Leuk Lymphoma*. 2013 May;54(5):945-50.
66. Mozaheb Z, Aledavood A, Farzad F. Diet and non-Hodgkin's lymphoma risk. *Pan Afr Med J*. 2012;12:53.
67. Charbonneau B, O'Connor HM, Wang AH, et al. Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma. *J Nutr*. 2013 May;143(5):672-81.
68. Schernhammer ES, Bertrand KA, Birmann BM, et al. Consumption of artificial sweetener- and sugar-containing soda and risk of lymphoma and leukemia in men and women. *Am J Clin Nutr*. 2012 Dec;96(6):1419-28.
69. Chen GC, Lv DB, Pang Z, Liu QF. Fruits and vegetables consumption and risk of non-Hodgkin's lymphoma: a meta-analysis of observational studies. *Int J Cancer* 2013 Jul;133(1):190-200.
70. Thompson CA, Habermann TM, Wang AH, et al. Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. *Int J Cancer*. 2010 Feb 15;126(4):992-1003.
71. Kabat GC, Kim MY, Wactawski-Wende J, et al. Intake of antioxidant nutrients and risk of non-Hodgkin's Lymphoma in the Women's Health Initiative. *Nutr Cancer*. 2012;64(2):245-54.
72. Hosgood HD, 3rd, Baris D, Zahm SH, et al. Diet and risk of multiple myeloma in Connecticut women. *Cancer Causes & Control*. 2007;18(10):1065-1076.
73. Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. *Cancer Causes & Control*. 2001;12(2):117-125.
74. Lee DH, Fung TT, Tabung FK, et al. Dietary pattern and risk of multiple myeloma in two large prospective US cohort studies. *JNCI Cancer Spectr*. 2019;3(2):pkz025-pkz025.
75. Gnagnarella P, Maisonneuve P, Bellomi M, et al. Red meat, Mediterranean diet and lung cancer risk among heavy

- smokers in the COSMOS screening study. *Ann. Oncol.* Oct 2013;24(10):2606-2611.
76. Zhong GC, Li QJ, Yang PF, et al. Low-carbohydrate diets and the risk of pancreatic cancer: a large prospective cohort study. *Carcinogenesis.* May 28 2021;42(5):724-732.
  77. Bao Y, Hu FB, Giovannucci EL, et al. Nut consumption and risk of pancreatic cancer in women. *Br J Cancer.* Nov 26 2013;109(11):2911-6.
  78. Li LY, Luo Y, Lu MD, et al. Cruciferous vegetable consumption and the risk of pancreatic cancer: a meta-analysis. *World J Surg Oncol.* 2015 Feb 12;13:44.
  79. Holick CN, Smith SG, Giovannucci E, Michaud DS. Coffee, tea, caffeine intake, and risk of adult glioma in three prospective cohort studies. *Cancer Epidemiology, Biomarkers & Prevention.* Jan 2010;19(1):39-47.
  80. Xue N, Zhou Q, Ji M, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizing macrophage from M2 to M1 phenotype. *Sci Rep.* Jan 3 2017;7:39011.
  81. Belkaid A, Currie JC, Desgagnes J, Annabi B. The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. *Cancer Cell International.* Mar 27 2006;6:7.
  82. Block G. Foods contributing to energy intake in the US: data from NHANES III and NHANES 1999-2000 *Journal of Food Composition and Analysis: an Official Publication of the United Nations University, International Network of Food Data Systems.* 2004 ;17(3-4):439-447.
  83. Salehi M, Moradi-Lakeh M, Salehi MH, Nojomi M, Kolehdooz F. Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis. *Nutr Rev.* 2013 May;71(5):257-67.
  84. Huang W, Han Y, Xu J, Zhu W, Li Z. Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies. *Cancer Causes Control.* 2013 Jan;24(1):193-201.
  85. Qu X, Ben Q, Jiang Y. Consumption of red and processed meat

- and risk for esophageal squamous cell carcinoma based on a meta-analysis. *Ann Epidemiol.* 2013 Dec;23(12):762-770.e1.
86. Jiang G, Li B, Liao X, Zhong C. Poultry and fish intake and risk of esophageal cancer: A meta-analysis of observational studies. *Asia Pac J Clin Oncol.* 2016 Mar;12(1):e82-91.
  87. Howe GR, Burch JD. Nutrition and pancreatic cancer. *Cancer Causes Control.* 1996 Jan;7(1):69-82.
  88. Goodman MT, Hankin JH, Wilkens LR, Lyu LC, McDuffie K, Liu LQ, Kolonel LN. Diet, body size, physical activity, and the risk of endometrial cancer. *Cancer Res.* 1997.
  89. Destefani E, Deneopellegrini H, Mendilaharsu M, Ronco A. Meat intake, heterocyclic amines and risk of colorectal cancer. *Int J Oncol.* 1997.
  90. Nothlings U, Yamamoto JF, Wilkens LR, Murphy SP, Park SY, Henderson BE, Kolonel LN, Le Marchand L. Meat and heterocyclic amine intake, smoking, NAT1 and NAT2 polymorphisms, and colorectal cancer risk in the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev.* 2009 Jul;18(7):2098-106.
  91. Parnaud G, Corpet DE. Cancer colorectal: le rôle controversé de la consommation de viande [Colorectal cancer: controversial role of meat consumption]. *Bull Cancer.* 1997 Sep;84(9):899-911.
  92. Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T. Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PLoS One.* 2011;6(6):e20456.
  93. Deneo-Pellegrini H, De Stefani E, Ronco A, Mendilaharsu M, Carzoglio JC. Meat consumption and risk of lung cancer; a case-control study from Uruguay. *Lung Cancer.* 1996 Jun;14(2-3):195-205.
  94. Alavanja MC, Field RW, Sinha R, Brus CP, Shavers VL, Fisher EL, Curtin J, Lynch CF. Lung cancer risk and red meat consumption among Iowa women. *Lung Cancer.* 2001 Oct;34(1):37-46.
  95. Sinha R, Kulldorff M, Curtin J, Brown CC, Alavanja MC, Swanson CA. Fried, well-done red meat and risk of lung cancer in women (United States). *Cancer Causes Control.* 1998 Dec;9(6):621-30.

96. Yang WS, Wong MY, Vogtman E, et al. Meat consumption and risk of lung cancer: evidence from observational studies. *Ann Oncol.* 2012 Dec;23(12):3163-3170.
97. Chen H, Ward MH, Graubard BI, Heineman EF, Markin RM, Potischman NA, Russell RM, Weisenburger DD, Tucker KL. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. *Am J Clin Nutr.* 2002 Jan;75(1):137-44.
98. Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst.* 2006 Mar 1;98(5):345-54.
99. Bosetti C, Negri E, Franceschi S, et al. Diet and ovarian cancer risk: a case-control study in Italy. *Int J Cancer.* 2001 Sep;93(6):911-5.
100. Kolaheer F, van der Pols JC, Bain CJ, et al. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr.* 2010 Jun;91(6):1752-63.
101. Bosetti C, La Vecchia C, Talamini R, Negri E, Levi F, Dal Maso L, Franceschi S. Food groups and laryngeal cancer risk: a case-control study from Italy and Switzerland. *Int J Cancer.* 2002 Jul 20;100(3):355-60.
102. Hebert JR, Hurley TG, Ma Y. The effect of dietary exposures on recurrence and mortality in early stage breast cancer. *Breast Cancer Res Treat.* 1998 Sep;51(1):17-28.
103. Linos E, Willett WC, Cho E, et al. Red meat consumption during adolescence among premenopausal women and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2008 Aug;17(8):2146-51.
104. Science Daily. Meat and cheese may be as bad for you as smoking. March 4, 2014. <http://www.sciencedaily.com/releases/2014/03/140304125639.htm>
105. Sinha R, Cross AJ, Graubard BI, et al. Meat intake and mortality: a prospective study of over half a million people. *Arch Intern Med.* 2009 Mar 23;169(6):562-71.

106. Perlmutter D. Dangerous Meat and Dairy? March 7, 2014. <http://www.drperlmutter.com/dangerous-meat-dairy/#more-2253>
107. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 2008; 359:229-241.
108. Roberts RO, Roberts LA, Geda YE, et al. Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia. *J Alzheimers Dis.* 2012;32(2):329-39.
109. Is gluten bad for you? Interview with Dr Perlmutter <http://ithp.org/articles/isglutenbadforyouandrperlmutter.htm>
110. Blythman J. Why almost everything you've been told about unhealthy foods is wrong. *The Guardian.* 23 Mar 2014. <http://www.theguardian.com/lifeandstyle/2014/mar/23/everything-you-know-about-unhealthy-foods-is-wrong>
111. Johnston BC, Zeraatkar D, Han MA, et al. Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. *Ann Intern Med.* 2019 Nov 19;171(10):756-764.
112. Wilson C. Avoiding red or processed meat doesn't seem to give health benefits. *NewScientist.* 30 September 2019. <https://www.newscientist.com/article/2217915-avoiding-red-or-processed-meat-doesnt-seem-to-give-health-benefits/>
113. Stringer C, Andrews P. *The Complete World of Human Evolution.* 2005
114. Πουλιανός Α. *Η προέλευση των Ελλήνων,* 2004
115. Staff T. For 2 million years, humans ate meat and little else – study. 4 April 2021. <https://www.timesofisrael.com/for-2-million-years-humans-ate-meat-and-little-else-study/>
116. Weston P, *Nutrition and Physical Degeneration,* 2004
117. Abrams L., *The preference for animal protein and fat: A cross-cultural survey,* in *Food and Evolution, Toward a Theory of Human Food Habits,* 1987
118. *To Study Eskimo Life,* *New York Times,* September 1921
119. Cleave T.L., *The Saccharine Disease,* 1974

120. American Indian/Alaska native profile, The office of Minority Health
121. We have the power to prevent diabetes, National Diabetes Education Program, May 2008
122. The Diabetes epidemic among American Indians and Alaska natives, May 2008
123. American Indian/Alaska native profile, The office of Minority Health
124. The Heart, the Drum, National Heart, Lung and Blood Institute, May 2008
125. O'Dea K., Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle, *Diabetes*, 33:596-603, 1984
126. Hegsted M., et al., Urinary calcium and calcium balance in young men as affected by level of protein and phosphorus intake, *Journal of Nutrition*, 111(3), 553-562, 1981
127. Spencer H., Further studies of the effect of a high protein diet as meat on calcium metabolism, *American Journal of Clinical Nutrition*, 37(6), 924-929, 1983
128. Hannan M., et al., Effect of dietary protein on bone loss in elderly men and women: The Framingham Osteoporosis Study, *Journal of Bone and Mineral Research*, 15(12), 2504-2512, 2000
129. Dawson-Hughes B., Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women, *American Journal of Clinical Nutrition*, 75(4), 773-779, 2002
130. Dawson-Hughes B., et al., Effect of dietary protein supplements on calcium excretion in healthy older men and women, *Journal of Clinical Endocrinology and Metabolism*, 89(3), 1169-1173, 2004
131. Fallon S., Nasty, Brutish and Short?, *The Ecologist*, 29:1, Jan/Feb 1999
132. Weston P., *Nutrition and Physical Degeneration*, 2004
133. Shelton H., *Human Life Its Philosophy and Laws: An Exposition of the Principles and Practices of Orthopathy*, 1928

134. Rohrmann S., Meat consumption and mortality. Results from the European Prospective Investigation into Cancer and Nutrition, *BMC Medicine*, 11:63, 2013
135. Nothlings U., et al., Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study, *J Natl Cancer Inst*, 97(19):1458-65, 2005
136. Larson S.C., Wolk A., Red and processed meat and risk of pancreatic cancer: meta-analysis of prospective studies, *British Journal of Cancer*, 106, 603-607, 2012
137. Larsson S.C., Wolk A., Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies, *International Journal of Cancer*, 119:2657-2664, 2006
138. Santarelli R.L., et al., Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence, *Nutr Cancer*, 60(2):131-144, 2008
139. Larson S.C., et al., Processed meat and stomach cancer risk: a meta-analysis, *J Natl Cancer Inst*, 98(15):1078-87, Aug 2006
140. Chen-yu Liu, et al., Cured meat, vegetables, and bean-curd foods in relations to childhood acute leukemia risk: A population based case-control study, *BMC Cancer*, 9:15, 2009
141. Preston-Martin S., et al., N-nitroso compounds and childhood brain tumors: A case-control study, *Cancer Research*, 42:5240-5, 1982
142. Murray M., *How to Prevent and Treat Cancer with Natural Medicine*, 2002
143. Fritz W., Soos K., Smoked meat and cancer, *Bibl Nutr Dieta*, 29, 57-64, 1980
144. Knapton S., Long term vegetarian diet changes human DNA raising risk of cancer and heart disease. *Telegraph*. 29 March 2016. <https://www.telegraph.co.uk/news/2016/03/29/long-term-vegetarian-diet-changes-human-dna-raising-risk-of-canc/>
145. Burkert N.T, Muckenhuber J, Großschadl F, et al. Nutrition and Health – The Association between eating behavior and various health parameters: A matched sample study, *PLoS One*. 2014; 9(2): e88278.



146. Independent, Vegetarians are 'less healthy and have a lower quality of life than meat-eaters,' scientists say, Thursday 3 April 2014, <https://www.independent.co.uk/news/science/vegetarians-are-less-healthy-and-have-a-lower-quality-of-life-than-meateaters-scientists-say-9236340.html>
147. Key TJ, Appleby PN, Spencer EA, et al. Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). *Am J Clin Nutr.* 2009 May;89(5):1620S-1626S.
148. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. *Nutr Cancer.* 1992;18(1):1-29.
149. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. *J Am Diet Assoc.* 1996 Oct;96(10):1027-39.
150. Vainio H, Weiderpass E. Fruit and vegetables in cancer prevention. *Nutr Cancer.* 2006;54(1):111-42.
151. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. *JAMA.* 2007 Aug 15;298(7):754-64.
152. Pierce JP. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. *Journal of Clinical Oncology.* 2007
153. Rock CL, Demark-Wahnefried W. Can lifestyle modification increase survival in women diagnosed with breast cancer? *J Nutr.* 2002 Nov;132(11 Suppl):3504S-3507S.
154. Pierce JP. Diet and breast cancer prognosis: making sense of the Women's Healthy Eating and Living and Women's Intervention Nutrition Study trials. *Curr Opin Obstet Gynecol.* 2009 Feb;21(1):86-91.
155. Jackson SJ, Singletary KW. Sulforaphane inhibits human MCF-7 mammary cancer cell mitotic progression and tubulin polymerization. *J Nutr.* 2004 Sep;134(9):2229-36.
156. Meng Q, Qi M, Chen DZ, et al. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. *J*

- Mol Med (Berl). 2000;78(3):155-65.
157. Dong Z. Effects of food factors on signal transduction pathways. *Biofactors*. 2000;12(1-4):17-28.
  158. Schatzkin A, et al. Dietary fiber and whole-grain consumption in relation to colorectal cancer in the NIH-AARP diet and health study. *American Journal of Clinical Nutrition* 2007
  159. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. *BMJ*. 2011 Nov 10;343:d6617.
  160. Kyro C, Skeie G, Loft S, et al. Intake of whole grains from different cereal and food sources and incidence of colorectal cancer in the Scandinavian HELGA cohort. *Cancer Causes Control*. 2013 Jul;24(7):1363-74.
  161. Oh H, Kim H, Lee DH, Lee A, Giovannucci EL, Kang SS, Keum N. Different dietary fibre sources and risks of colorectal cancer and adenoma: a dose-response meta-analysis of prospective studies. *Br J Nutr*. 2019 Sep 28;122(6):605-615.
  162. Jacobs DR, Whole-grain consumption is associated with a reduced risk of noncardiovascular, noncancer death attributed to inflammatory diseases in Iowa Women's Health Study. *American Journal of Clinical Nutrition*. 2007.
  163. Hajishafiee M, Saneei P, Benisi-Kohansal S, Esmailzadeh A. Cereal fibre intake and risk of mortality from all causes, CVD, cancer and inflammatory diseases: a systematic review and meta-analysis of prospective cohort studies. *Br J Nutr*. 2016 Jul;116(2):343-52.
  164. Braly J, Hoggan R. *Dangerous Grains*. 2002.
  165. Maruyama S, Fujimoto N, Asano K, Ito A. Suppression by estrogen receptor  $\beta$  of AP-1 mediated transactivation through estrogen receptor  $\alpha$ . *The Journal of Steroid Biochemistry and Molecular Biology*. 2001, 78, 2, 177-184.
  166. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. *Mol Pharmacol*. 1998;54(1):105-

- 112.
167. Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. *Cancer Res.* 2000 Jun 15;60(12):3175-82.
168. Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer protection. *Environ Health Perspect.* 1995 Oct;103 Suppl 7(Suppl 7):103-12.
169. Suthar AC, Banavalikar MM, Biyani MK. Pharmacological activities of Genistein, an isoflavone from soy (*Glycine max*): Part I-Anti-cancer activity. *NISCAIR Online Periodicals Repository.* 2001, 511-519.
170. Qadir MI, Cheema BN. Phytoestrogens and related food components in the prevention of cancer. *Crit Rev in Eukaryot Gene Expr.* 2017;27(2):99-112.
171. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. *Cancer Invest.* 2003;21(5):744-757.
172. Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. *Cancer Metastasis Rev.* 2002;21(3-4):265-280.
173. Uifalean A, Schneider S, Ionescu C, et al. Soy isoflavones and breast cancer cell lines: molecular mechanisms and future perspectives. *Molecules.* 2015;21(1):E13.
174. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. *J Steroid Biochem Mol Biol.* 2014;140:116-132.
175. Varinska L, Gal P, Mojziso G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. *Int J Mol Sci.* 2015;16(5):11728-11749.
176. Lephart ED. Modulation of aromatase by phytoestrogens. *Enzyme Res.* 2015;2015:594656.
177. Liu MM, Huang Y, Wang J. Developing phytoestrogens for breast cancer prevention. *Anticancer Agents Med Chem.* 2012;12(10):1306-1313.

178. Pistelli M, Mora AD, Ballatore Z, Berardi R. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. *Curr Oncol.* 2018;25(2):e168-e175.
179. Li Y, Sarkar FH. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. *Cancer Letters.* 2002. 186, 2, 157-164.
180. Shen JC, Klein RD, Wei Q. Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells. *Molecular Carcinogenesis.* 2000, 29, 2, 92-102.
181. Schleicher RL, Lamartiniere CA, Zheng M, Zhang M. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. *Cancer Letters.* 1999, 136, 2, 195-201.
182. Farhan H, Wahala K, Cross HS. Genistein inhibits Vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. *The Journal of Steroid Biochemistry and Molecular Biology.* 2003, 84, 4, 423-429.
183. Zhou JR, Yu L, Zhong Y, et al. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. *The Prostate.* 2002. 53, 2, 143-153.
184. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. *Molecular and Cellular Endocrinology.* 2002, 186, 1, 89-99.
185. Hong SJ, Kim SI, Kwon SM, et al. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. *Yonsei Medical Journal* 2002; 43(2): 236-241.
186. Geller J, Sionit L, Partido C, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. *Prostate.* 1998 Feb 1;34(2):75-9.
187. Schleicher RL, Lamartiniere CA, Zheng M, Zhang M. The

- inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. *Cancer Letters*. 1999, 136, 2, 195-201.
188. Dalu A, Haskell JF, Coward L, Lamartiniere CA. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. *The Prostate*. 1998, 37, 1, 36-43.
189. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. *Cancer Epidemiol Biomarkers Prev*. 2000 Aug;9(8):795-804.
190. Hwang KA, Choi KC. Anticarcinogenic effects of dietary phytoestrogens and their chemopreventive mechanisms. *Nutr Cancer*. 2015;67(5):796-803.
191. Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutr Cancer*. 2007;59(1):1-7.
192. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. *Am J Clin Nutr*. 2009;89(4):1155-1163.
193. Applegate CC, Rowles JL, Ranard KM, et al. Soy consumption and the risk of prostate cancer: an updated systematic review and meta-analysis. *Nutrients*. 2018;10(1).
194. Lesinski GB, Reville PK, Mace TA, et al. Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells. *Cancer Prev Res (Phila)*. 2015;8(11):1036-1044.
195. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. *J Steroid Biochem Mol Biol*. 2014;140:116-132.
196. Karsli-Ceppioglu S, Ngollo M, Adjakly M, et al. Genome-wide DNA methylation modified by soy phytoestrogens: role for epigenetic therapeutics in prostate cancer? *OMICS*. 2015;19(4):209-219.
197. Pendleton JM, Tan WW, Anai S, et al. Phase II trial of isoflavone

- in prostate-specific antigen recurrent prostate cancer after previous local therapy. *BMC Cancer*. 2008;8:132.
198. Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. *Eur Urol*. 2005;48(6):922-930.
199. Grainger EM, Schwartz SJ, Wang S, et al. A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. *Nutr Cancer*. 2008;60(2):145-154.
200. Zhou JR, Yu L, Mai Z, Blackburn GL. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. *International Journal of Cancer*. 2004, 108, 1, 8-14.
201. Adlercreutz H. Phytoestrogens and breast cancer. *J Steroid Biochem Mol Biol*. 2002 Dec;83(1-5):113-8.
202. Brueggemeier RW, Gu X, Mobley JA, et al. Effects of phytoestrogens and synthetic combinatorial libraries on aromatase, estrogen biosynthesis, and metabolism. College of Pharmacy and OSU Comprehensive Cancer Center, The Ohio State University. 2001. <http://herbpedia.wdfiles.com/local--files/attachments/PMID11795395-17bHSD2-Genistein-ANYAS.pdf>
203. Mueller SO, Simon S, Chae K, et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor  $\alpha$ (ER $\alpha$ ) and ER $\beta$  in human cells. *Toxicological Sciences*. 2004, 80, 14-25.
204. Nagata C, Takatsuka N, Inaba S, et al. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. *Journal of the National Cancer Institute*. 1998, 90, 23, 1830-1835.
205. Brooks JD, Thompson LU. Mammalian lignans and genistein decrease the activities of aromatase and 17 $\beta$ -hydroxysteroid dehydrogenase in MCF-7 cells. *J Steroid Biochem Mol Biol*. 2005 Apr;94(5):461-7.
206. Kao YC, Zhou C, Sherman M, et al. Molecular basis of the

- inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. *Environ Health Perspect.* 1998;106(2):85-92.
207. Jin Z, MacDonald RS, Soy isoflavones increase latency of spontaneous mammary tumors in mice. *The Journal of Nutrition.* 2002, 132, 10, 3186-3190.
208. Enan E, Matsumura F. Activation of c-Neu tyrosine kinase by *o,p'*-DDT and beta-HCH in cell-free and intact cell preparations from MCF-7 human breast cancer cells. *J Biochem Mol Toxicol.* 1998;12(2):83-92.
209. Shao ZM, Wu J, Shen ZZ, Barsky SH. Genistein exerts multiple suppressive effects on human breast carcinoma cells. *Cancer Research.* 1998, 58, 21.
210. Santell RC, Kieu N, Helferich WG, Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. *The Journal of Nutrition.* 2000, 130, 7, 1665-1669.
211. Jin Z, MacDonald RS, Soy isoflavones increase latency of spontaneous mammary tumors in mice. *The Journal of Nutrition.* 2002, 132, 10, 3186-3190.
212. Cline JM, Soderqvist G, Register TC, et al. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. *Toxicologic Pathology.* 2001, 29, 1.
213. Guha N, Kwan ML, Quesenberry CP Jr, et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat.* 2009;118(2):395-405.
214. Messina M. Impact of soy foods on the development of breast cancer and the prognosis of breast cancer patients. *Forsch Komplementmed.* 2016;23(2):75-80.
215. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. *Am J Clin Nutr.* 2012;96(1):123-132.
216. Zhang FF, Haslam DE, Terry MB, et al. Dietary isoflavone intake

- and all-cause mortality in breast cancer survivors: the Breast Cancer Family Registry. *Cancer*. 2017;123(11):2070-2079.
217. Mense SM, Hei TK, Ganju RK, Bhat HK. Phytoestrogens and breast cancer prevention: possible mechanisms of action. *Environ Health Perspect*. 2008;116(4):426-433.
218. Wei Y, Lv J, Guo Y, et al. Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis. *Eur J Epidemiol*. 2020 Jun;35(6):567-578.
219. Spagnuolo C, Russo GL, Orhan IE, et al. Genistein and cancer: current status, challenges, and future directions. *Adv Nutr*. 2015;6(4):408-419.
220. Fritz H, Seely D, Flower G, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. *PLoS One*. 2013;8(11):e81968.
221. Magee PJ, Rowland I. Soy products in the management of breast cancer. *Curr Opin Clin Nutr Metab Care*. 2012;15(6):586-591.
222. Baltuch GH, Yong VW. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. *Brain Research*. 1996, 710, 1-2, 143-149.
223. Tu MT, Luo SF, Wang CC, et al. P2Y2 receptor-mediated proliferation of C6 glioma cells via activation of Ras/Raf/MEK/MAPK pathway. *British Journal of Pharmacology*. 2000, 129, 1481-1489.
224. Khoshyomn S, Nathan D, Manske GC, et al. Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells. *J Neurooncol*. 2002 May;57(3):193-200.
225. Theodorescu D, Laderoute KR, Calaoagan JM, Gulding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. *Int. J. Cancer*. 1998, 78:775-782.
226. Zhou JR, Mukherjee P, Gugger ET, et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the



- cell cycle, apoptosis, and angiogenesis. *Cancer Res.* 1998 Nov 15;58(22):5231-8.
227. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. *Cancer Res.* 1993 Dec 1;53(23):5815-21.
228. Nagata C, Takatsuka N, Kawakami N, et al. A prospective cohort study of soy product intake and stomach cancer death. *Br J Cancer.* 2002, 87, 31-36.
229. Darbon JM, Penary M, Escalas N, et al. Distinct Chk2 activation pathways are triggered by genistein and DNA-damaging agents in human melanoma cells. *Journal of Biological Chemistry.* 2000, 275, 20, P15363-15369.
230. Record IR, Broadbent JL, King RA, et al. Genistein inhibits growth of B16 melanoma cells in vivo and in vitro and promotes differentiation in vitro. *Int. J. Cancer.* 1997, 72:860–864.
231. Wietrzyk J, Boratynski J, Gryniewicz G. Antiangiogenic and antitumour effects in vivo of genistein applied alone or combined with cyclophosphamide. *Anticancer Research.* 2001, 21(6A):3893-6.
232. Tallett A, Chilvers ER, Hannan S, et al. Inhibition of neuropeptide-stimulated tyrosine phosphorylation and tyrosine kinase activity stimulates apoptosis in small cell lung cancer cells. *Cancer Research.* 1996, 56, 18.
233. Wietrzyk J, Opolski A, Madej J, Radzikowski C. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors. *Acta Pol Pharm.* 2000 Nov;57 Suppl:5-8.
234. Lian F, Li Y, Bhuiyan M, Sarkar FH. p53-independent apoptosis induced by genistein in lung cancer cells. *Nutrition and Cancer.* 1999, 33, 2.
235. Wakai K, Ohno Y, Genka K, et al. Risk modification in lung cancer by a dietary intake of preserved foods and soyfoods: findings from a case-control study in Okinawa, Japan. *Lung Cancer.* 1999, 25, 3, 147-159.
236. Yang WS, Va P, Wong MY, et al. Soy intake is associated with lower

- lung cancer risk: results from a meta-analysis of epidemiologic studies. *Am J Clin Nutr.* 2011;94(6):1575-1583.
237. Wu SH, Liu Z. Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies. *Nutr Cancer.* 2013;65(5):625-632.
238. Zhu Q, Meisinger J, Van Thiel DH, et al. Effects of soybean extract on morphology and survival of Caco-2, SW620, and HT-29 cells. *Nutrition and Cancer.* 2002, 42, 1.
239. Di Domenico M, Castoria G, Bilancio A, et al. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. *Cancer Research.* 1996, 56, 19.
240. Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor  $\beta$  mRNA in colon cancer Cells: growth effects of estrogen and genistein. *Biochemical and Biophysical Research Communications.* 2000, 270, 2, 425-431.
241. Booth C, Hargreaves D, Hadfield J, et al. Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. *Br J Cancer.* 1999, 80, 1550-1557.
242. Sorensen IK, Kristiansen E, Mortensen A, et al. The effect of soy isoflavones on the development of intestinal neoplasia in ApcMin mouse. *Cancer Lett.* 1998 Aug 14;130(1-2):217-25.
243. Davies MJ, Bowey EA, Adlercreutz H, et al. Effects of soy or rye supplementation of high-fat diets on colon tumour development in azoxymethane-treated rats. *Carcinogenesis.* 1999 Jun;20(6):927-31.
244. Horn-Ross PL, Hoggatt KJ, Lee MM. Phytoestrogens and thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. *Cancer Epidemiol Biomarkers Prev.* 2002 Jan;11(1):43-9.
245. Hirota A, Taki S, Kawall S, et al. 1,1-diphenyl-2-picrylhydrazyl radical-scavenging compounds from soybean miso and antiproliferative activity of isoflavones from soybean miso toward the cancer cell lines. *Bioscience, Biotechnology, and Biochemistry.* 2000, 64, 5, 1038-1040.
246. Nagasawa K, Natazuka T, Chihara K et al. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake

- and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. *Cancer Chemother Pharmacol.* 1996, 37, 297-304.
247. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. *Cancer Res.* 1989 Apr 1;49(7):1857-60.
248. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. *Cancer Epidemiol Biomarkers Prev.* 2000 Aug;9(8):795-804.
249. Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. *J Natl Cancer Inst.* 1998 Nov 4;90(21):1637-47.
250. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. *Cancer Sci.* 2004 Mar;95(3):238-42.
251. Zhou JR, Yu L, Zhong Y, Blackburn GL. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. *J Nutr.* 2003 Feb;133(2):516-21.
252. Adlercreutz H. Phyto-oestrogens and cancer. *Lancet Oncol.* 2002 Jun;3(6):364-73.
253. Setchell KD, Borriello SP, Hulme P, et al. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. *Am J Clin Nutr.* 1984 Sep;40(3):569-78.
254. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. *Nutr Cancer.* 1997;28(3):236-47.
255. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. *Ann Pharmacother.* 2001 Sep;35(9):1118-21.
256. Dees C, Foster JS, Ahamed S, Wimalasena J. Dietary estrogens stimulate human breast cells to enter the cell cycle. *Environ Health Perspect.* 1997 Apr;105 Suppl 3(Suppl 3):633-6.
257. Nagata C. Ecological study of the association between soy

- product intake and mortality from cancer and heart disease in Japan. *Int J Epidemiol*. 2000 Oct;29(5):832-6.
258. Hirayama T. Epidemiology of prostate cancer with special reference to the role of diet. *Natl Cancer Inst Monogr*. 1979 Nov;(53):149-55.
259. Kolonel LN, Hankin JH, Whittemore AS, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. *Cancer Epidemiol Biomarkers Prev*. 2000 Aug;9(8):795-804.
260. Hebert JR, Hurley TG, Olendzki BC, et al. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. *J Natl Cancer Inst*. 1998 Nov 4;90(21):1637-47.
261. Oishi K, Okada K, Yoshida O, et al. A case-control study of prostatic cancer with reference to dietary habits. *Prostate*. 1988;12(2):179-90.
262. Lee MM, Wang RT, Hsing AW, Gu FL, Wang T, Spitz M. Case-control study of diet and prostate cancer in China. *Cancer Causes Control*. 1998 Dec;9(6):545-52.
263. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. *Cancer Sci*. 2004 Mar;95(3):238-42.
264. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. *Cancer Res*. 1989 Apr 1;49(7):1857-60.
265. Shen JC, Klein RD, Wei Q, et al. Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. *Mol Carcinog*. 2000 Oct;29(2):92-102.
266. Mitchell JH, Duthie SJ, Collins AR. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. *Nutr Cancer*. 2000;38(2):223-8.
267. Geller J, Sionit L, Partido C, et al. Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture. *Prostate*. 1998 Feb 1;34(2):75-9.

268. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. *Mol Pharmacol.* 1997 Feb;51(2):193-200.
269. Choi YH, Lee WH, Park KY, Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. *Jpn J Cancer Res.* 2000;91(2):164-173.
270. Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. *Nutr Cancer.* 1998;32(3):123-31.
271. Schleicher RL, Lamartiniere CA, Zheng M, Zhang M. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. *Cancer Lett.* 1999 Mar 1;136(2):195-201.
272. Zhou JR, Gugger ET, Tanaka T, et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. *J Nutr.* 1999 Sep;129(9):1628-35.
273. Onozawa M, Kawamori T, Baba M, et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. *Jpn J Cancer Res.* 1999 Apr;90(4):393-8.
274. Landstrom M, Zhang JX, Hallmans G, et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. *Prostate.* 1998 Aug 1;36(3):151-61.
275. Bylund A, Zhang JX, Bergh A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. *Prostate.* 2000 Mar 1;42(4):304-14.
276. Cohen LA, Zhao Z, Pittman B, Scimeca J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. *Prostate.* 2003 Feb 15;54(3):169-80.

277. Jenkins DJ, Kendall CW, D'Costa MA, et al. Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. *J Urol*. 2003 Feb;169(2):507-11.
278. Adams KF, Chen C, Newton KM, et al. Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. *Cancer Epidemiol Biomarkers Prev*. 2004 Apr;13(4):644-8.
279. Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. *J Urol*. 2001 Jan;165(1):294-300.
280. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents, *Jpn J Clin Oncol*. 2004, 34, 2, 86-89.
281. Akaza H, Miyanaga N, Takashima N, et al. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. *Jpn J Clin Oncol*. 2002 Aug;32(8):296-300.
282. Miyanaga N, Akaza H, Takashima N, et al. Higher consumption of green tea may enhance equol production. *Asian Pac J Cancer Prev*. 2003 Aug-Dec;4(4):297-301.
283. Pollard M, Wolter W, Sun L. Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats. *In Vivo*. 2000 May-Jun;14(3):389-92.
284. Pollard M, Wolter W, Sun L. Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. *Cancer Lett*. 2001 Nov 28;173(2):127-31.
285. Weber KS, Setchell KD, Stocco DM, Lephart ED. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5 $\alpha$ -reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats. *J Endocrinol*. 2001 Sep;170(3):591-9.
286. Doerge DR, Chang HC. Inactivation of thyroid peroxidase

- by soy isoflavones, in vitro and in vivo. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2002 Sep 25;777(1-2):269-79.
287. Lephart ED, Adlercreutz H, Lund TD. Dietary soy phytoestrogen effects on brain structure and aromatase in Long-Evans rats. *Neuroreport.* 2001 Nov 16;12(16):3451-5.
288. Spentzos D, Mantzoros C, Regan MM, et al. Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. *Clin Cancer Res.* 2003 Aug 15;9(9):3282-7.
289. Probst-Hensch NM, Wang H, Goh VH, et al. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. *Cancer Epidemiol Biomarkers Prev.* 2003 Aug;12(8):739-46.
290. Hirano T, Oka K, Akiba M. Antiproliferative effects of synthetic and naturally occurring flavonoids on tumor cells of the human breast carcinoma cell line, ZR-75-1. *Res Commun Chem Pathol Pharmacol.* 1989 Apr;64(1):69-78.
291. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. *Biochem Biophys Res Commun.* 1991 Aug 30;179(1):661-7.
292. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. Growth-inhibitory effects of the natural phytoestrogen genistein in MCF-7 human breast cancer cells. *Eur J Cancer.* 1994;30A(11):1675-82.
293. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. *Endocrinology.* 1978 Nov;103(5):1860-7.
294. Welshons WV, Murphy CS, Koch R, Calaf G, Jordan VC. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. *Breast Cancer Res Treat.* 1987 Nov;10(2):169-75.
295. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive

- human breast cancer (MCF-7) cells in vitro and in vivo. *Cancer Res.* 1998 Sep 1;58(17):3833-8.
296. Barnes S, Grubbs C, Setchell KD, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. *Prog Clin Biol Res.* 1990;347:239-53.
297. Troll W, Wiesner R, Shellabarger CJ, et al. Soybean diet lowers breast tumor incidence in irradiated rats. *Carcinogenesis.* 1980 Jun;1(6):469-72.
298. Gotoh T, Yamada K, Yin H, et al. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A. *Jpn J Cancer Res.* 1998 Feb;89(2):137-42.
299. Cohen LA, Zhao Z, Pittman B, Scimeca JA. Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis. *Carcinogenesis.* 2000 May;21(5):929-35.
300. Gallo D, Giacomelli S, Cantelmo F, et al. Chemoprevention of DMBA-induced mammary cancer in rats by dietary soy. *Breast Cancer Res Treat.* 2001 Sep;69(2):153-64.
301. Appelt LC, Reicks MM. Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. *J Nutr.* 1999 Oct;129(10):1820-6.
302. Hakkak R, Korourian S, Shelnut SR, et al. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. *Cancer Epidemiol Biomarkers Prev.* 2000 Jan;9(1):113-7.
303. Ju YH, Allred CD, Allred KF, et al. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. *J Nutr.* 2001 Nov;131(11):2957-62.
304. Allred CD, Ju YH, Allred KF, et al. Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. *Carcinogenesis.* 2001 Oct;22(10):1667-73.
305. Allred CD, Allred KF, Ju YH, et al. Soy diets containing varying



- amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. *Cancer Res.* 2001 Jul 1;61(13):5045-50.
306. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. *Cancer Res.* 2002 May 1;62(9):2474-7.
307. Allred CD, Allred KF, Ju YH, et al. Soy processing influences growth of estrogen-dependent breast tumors. *Carcinogenesis.* 2004, 25, 9, 1649-1657.
308. Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. *J Clin Endocrinol Metab.* 1999 Nov;84(11):4017-24.
309. McMichael-Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. *Am J Clin Nutr.* 1998 Dec;68(6 Suppl):1431S-1435S.
310. Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 1996 Oct;5(10):785-94.
311. Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. *J Natl Cancer Inst.* 2001 Dec 5;93(23):1791-8.
312. den Tonkelaar I, Keinan-Boker L, Veer PV, Arts CJ, Adlercreutz H, Thijssen JH, Peeters PH. Urinary phytoestrogens and postmenopausal breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2001 Mar;10(3):223-8.
313. Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH. Dietary phytoestrogens and breast cancer risk. *Am J Clin Nutr.* 2004 Feb;79(2):282-8.
314. Ziegler RG. Comments on phytoestrogens and breast cancer. *Am J Clin Nutr.* 2004, 79, 2, 183-184.
315. Nagata C. Ecological study of the association between soy

- product intake and mortality from cancer and heart disease in Japan. *Int J Epidemiol*. 2000 Oct;29(5):832-6.
316. McKeown-Eyssen GE, Bright-See E. Dietary factors in colon cancer: international relationships. *Nutr Cancer*. 1984;6(3):160-70.
317. Nomura AM, Hankin JH, Kolonel LN, et al. Case-control study of diet and other risk factors for gastric cancer in Hawaii (United States). *Cancer Causes Control*. 2003 Aug;14(6):547-58.
318. Chyou PH, Nomura AM, Hankin JH, Stemmermann GN. A case-cohort study of diet and stomach cancer. *Cancer Res*. 1990 Dec 1;50(23):7501-4.
319. You WC, Blot WJ, Chang YS, et al. Diet and high risk of stomach cancer in Shandong, China. *Cancer Res*. 1988 Jun 15;48(12):3518-23.
320. Lee JK, Park BJ, Yoo KY, Ahn YO. Dietary factors and stomach cancer: a case-control study in Korea. *Int J Epidemiol*. 1995 Feb;24(1):33-41.
321. Galanis DJ, Kolonel LN, Lee J, Nomura A. Intakes of selected foods and beverages and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. *Int J Epidemiol*. 1998 Apr;27(2):173-80.
322. Hu JF, Liu YY, Yu YK, et al. Diet and cancer of the colon and rectum: a case-control study in China. *Int J Epidemiol*. 1991 Jun;20(2):362-7.
323. Gao CM, Takezaki T, Ding JH, et al. Protective effect of allium vegetables against both esophageal and stomach cancer: a simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China. *Jpn J Cancer Res*. 1999 Jun;90(6):614-21.
324. Takezaki T, Gao CM, Ding JH, et al. Comparative study of lifestyles of residents in high and low risk areas for gastric cancer in Jiangsu Province, China; with special reference to allium vegetables. *J Epidemiol*. 1999 Nov;9(5):297-305.
325. Ji BT, Chow WH, Yang G, et al. Dietary habits and stomach cancer in Shanghai, China. *Int J Cancer*. 1998 May 29;76(5):659-64.

326. Lee JK, Park BJ, Yoo KY, Ahn YO. Dietary factors and stomach cancer: a case-control study in Korea. *Int J Epidemiol.* 1995 Feb;24(1):33-41.
327. Ngoan LT, Mizoue T, Fujino Y, et al. Dietary factors and stomach cancer mortality. *Br J Cancer.* 2002 Jul 1;87(1):37-42.
328. Ahn YO. Diet and stomach cancer in Korea. *Int J Cancer.* 1997;Suppl 10:7-9.
329. Steele VE, Pereira MA, Sigman CC, Kelloff GJ. Cancer chemoprevention agent development strategies for genistein. *J Nutr.* 1995 Mar;125(3 Suppl):713S-716S.
330. Thiagarajan DG, Bennink MR, Bourquin LD, Kavas FA. Prevention of precancerous colonic lesions in rats by soy flakes, soy flour, genistein, and calcium. *Am J Clin Nutr.* 1998 Dec;68(6 Suppl):1394S-1399S.
331. Sorensen IK, Kristiansen E, Mortensen A, et al. The effect of soy isoflavones on the development of intestinal neoplasia in ApcMin mouse. *Cancer Lett.* 1998 Aug 14;130(1-2):217-25.
332. McIntosh GH, Regester GO, Le Leu RK, Royle PJ, Smithers GW. Dairy proteins protect against dimethylhydrazine-induced intestinal cancers in rats. *J Nutr.* 1995 Apr;125(4):809-16.
333. Davies MJ, Bowey EA, Adlercreutz H, et al. Effects of soy or rye supplementation of high-fat diets on colon tumour development in azoxymethane-treated rats. *Carcinogenesis.* 1999 Jun;20(6):927-31.
334. Rao CV, Wang CX, Simi B, et al. Enhancement of experimental colon cancer by genistein. *Cancer Res.* 1997 Sep 1;57(17):3717-22.
335. Govers MJ, Lapre JA, De Vries HT, Van der Meer R. Dietary soybean protein compared with casein damages colonic epithelium and stimulates colonic epithelial proliferation in rats. *J Nutr.* 1993 Oct;123(10):1709-13.
336. Fuchs CS, Willett WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. *Cancer Epidemiol Biomarkers Prev.* 2002 Mar;11(3):227-34.

337. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. *J Natl Cancer Inst.* 1993 Jun 2;85(11):875-84.
338. Park JH, Oh EJ, Choi YH, et al. Synergistic effects of dexamethasone and genistein on the expression of Cdk inhibitor p21WAF1/CIP1 in human hepatocellular and colorectal carcinoma cells. *Int J Oncol.* 2001 May;18(5):997-1002.
339. Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. *Biochem Biophys Res Commun.* 2000 Apr 13;270(2):425-31.
340. Salti GI, Grewal S, Mehta RR, et al. Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells. *Eur J Cancer.* 2000 Apr;36(6):796-802.
341. Sun CL, Yuan JM, Arakawa K, et al. Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. *Cancer Epidemiol Biomarkers Prev.* 2002 Dec;11(12):1674-7.
342. Sun CL, Yuan JM, Wang XL, et al. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. *Int J Cancer.* 2004 Nov 1;112(2):319-23.
343. Abe T. Infantile leukemia and soybeans – a hypothesis. *Leukemia.* 1999, 13, 317-320.
344. Hengstler JG, Heimerdinger CK, Schiffer IB, et al. Dietary topoisomerase II-poisons: contribution of soy products to leukemia? *EXCLI Journal.* 2002, 1, 8-14.
345. McCarrison R. The goitrogenic action of soybean and groundnut. *Indian J Med Res.* 1933, 21:179.
346. Sharpless GR, Pearsons J, Prato GS. Production of goiter in rats with raw and with treated soybean flour. *J Nutr.* 1939, 17, 545-555.
347. Patton AR, Wilgus HS, Harshfield GS. The production of goiter in chickens. *Science.* 1939, 89, 162.
348. Block RJ, Mandl RH, Howard HW, et al. The curative action of iodine on soybean goiter and the changes in the distribution of iodoamino acids in the serum and in thyroid gland digests. *Arch*

- Biochem Biophysics, 1961, 93, 15-21.
349. Kay T, Kimura M, Nishino K, Itokowa Y. Soybean, goitre, and prevention. *J Trop Pediatr*. 1988, 34, 110-113.
350. Kimura S, Suwa J, Ito M, Sato H. Development of malignant goiter by defatted soybean with iodine-deficient diet in rats. *Gann*. 1976, 67:763-765.
351. Liener IE, Kakade ML. Protease inhibitors. In Irvin E. Liener, ed. *Toxic Constituents of Plant Foodstuffs* (NY, Academic Press, Second edition, 1980).
352. Roebuck BD, Kaplita PV, MacMillan DL. Interaction of dietary fat and soybean isolate (SBI) on azerine-induced pancreatic carcinogenesis. *Plant Foods Hum Nutr* 1985, 35: 323-9.
353. Myers BA, Hathcock J, Shiekh N, Roebuck BD. Effects of dietary soya bean trypsin inhibitor concentrate on initiation and growth of putative preneoplastic lesions in the pancreas of the rat. *Food Chem Toxicol*. 1991 Jul;29(7):437-43.
354. Liener IE. Possible adverse effects of soybean anticarcinogens. *J Nutr*. 1995, 125, 7445-7505.
355. Levison DA, Morgan RG, Brimacombe JS, et al. Carcinogenic effects of Di(2-hydroxypropyl)nitrosamine (DHPN) in male Wistar rats: promotion of pancreatic cancer by a raw soya flour diet. *Scand J Gastroenterol*. 1979;14(2):217-24.
356. Morgan RGH, Levinson DA, Hopwood D. et al. Potentiation of the effect of the action of azaserine on the rat pancreas by raw soya bean flours. *Cancer Lett*. 1977, 3, 87-90.
357. McGuinness EE, Morgan RGH, Levinson DA, et al. The effects of long-term feeding of soya flour on the rat pancreas. *Scand J Gastroenterol*. 1980, 15, 497-502.
358. Rackis JJ, Gumbmann MR, Liener IE. The USDA Trypsin Inhibitor Study. I. Background, objectives and procedural details. *Plant Foods Hum Nutr*. 1985, 35, 213-242.
359. Liener IE, Nitsan Z, Srisangnam, C, et al. The USDA Trypsin Inhibitor Study. II. Timed related biochemical changes in the pancreas of rats. *Plant Foods Hum Nutr*. 1985, 35, 243-257.
360. Spangler WL, Gumbmann MR, Liener, I.E, et al. The USDA

- Trypsin Inhibitor Study. III. Sequential development of pancreatic pathology in rats. *Plant Foods Hum Nutr.* 1985, 35, 259-274.
361. Gumbmann MR, Spangler WI, Dugan GM, et al. The USDA Trypsin Inhibitor Study. IV. The chronic effects of soy flour and soy protein isolate on the pancreas in rats after two years. *Plant Foods Hum Nutr.* 1985, 35, 275-314.
362. Roebuck BD. Trypsin Inhibitors: potential concern for humans? *J Nutr.* 1987, 117, 398-400.
363. Myers BA, Hathcock J, Shiekh N, Roebuck BD. Effects of dietary soya bean trypsin inhibitor concentrate on initiation and growth of putative preneoplastic lesions in the pancreas of the rat. *Food Chem Toxicol.* 1991 Jul;29(7):437-43.
364. Liener IE. Possible adverse effects of soybean anticarcinogens. *J Nutr.* 1995, 125, 7445-7505.
365. Temler RS, Dormond CA, Simon E, Morel B. The effect of feeding soybean trypsin inhibitor and repeated injections of cholecystokinin on rat pancreas. *J Nutr.* 1984 Jun;114(6):1083-91.
366. Calam J, Bojarski JC, Springer CJ. Raw soya-bean flour increases cholecystokinin release in man. *Br J Nutr.* 1987 Sep;58(2):175-9.
367. Fushiki T, Iwai K. Two hypotheses on the feedback regulation of pancreatic enzyme secretion. *FASEB J.* 1989 Feb;3(2):121-6.
368. Smith JP, Kramer ST, Solomon TE. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. *Regul Pept.* 1991 Feb 26;32(3):341-9.
369. Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. *Dig Dis Sci.* 1990 Nov;35(11):1377-84.
370. Liener IE, Goodale RL, Deshmukh A, et al. Effect of a trypsin inhibitor from soybeans (Bowman-Birk) on the secretory activity of the human pancreas. *Gastroenterology.* 1988 Feb;94(2):419-27.
371. Holm H, Reseland JE, Thorsen LI, et al. Raw soybeans stimulate human pancreatic proteinase secretion. *J Nutr.* 1992, 122, 1407-1416.

372. Calam J, Bojarski JC, Springer CJ. Raw soya-bean flour increases cholecystokinin release in man. *Br J Nutr.* 1987 Sep;58(2):175-9.
373. Lebenthal E, Choi TS, Lee PC. The development of pancreatic function in premature infants after milk-based and soy-based formulas. *Pediatr Res.* 1981 Sep;15(9):1240-4.
374. Klein SL, Wisniewski AB, Marson AL, et al. Early exposure to genistein exerts long-lasting effects on the endocrine and immune systems in rats. *Mol Med.* 2002;8(11):742-749.
375. Yellayi S, Naaz A, Szewczykowski MA, et al. The phytoestrogen genistein induces thymic and immune changes: a human health concern? *Proc Natl Acad Sci U S A.* 2002 May 28;99(11):7616-21.
376. Schmitt E, Metzler M, Jonas R, et al. Genotoxic activity of four metabolites of the soy isoflavone daidzein. *Mutat Res.* 2003 Dec 9;542(1-2):43-8.
377. Kulling SE, Lehmann L, Metzler M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2002 Sep 25;777(1-2):211-8.
378. Tsutsui T, Tamura Y, Yagi E, et al. -transforming activity and mutagenicity of 5 phytoestrogens in cultured mammalian cells. *Int J Cancer.* 2003 Jun 20;105(3):312-20.
379. Kulling SE, Rosenberg B, Jacobs E, Metzler M. The phytoestrogens coumestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. *Arch Toxicol.* 1999 Feb;73(1):50-4.
380. Morris SM, Chen JJ, Domon OE, et al. p53, mutations, and apoptosis in genistein-exposed human lymphoblastoid cells. *Mutat Res.* 1998 Aug 31;405(1):41-56.
381. Di Virgilio AL, Iwami K, Watjen W, et al. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. *Toxicol Lett.* 2004 Jun 15;151(1):151-62.
382. Choi EJ, Lee BH. Evidence for genistein mediated cytotoxicity and apoptosis in rat brain. *Life Sci.* 2004 Jun 11;75(4):499-509.
383. University of Copenhagen. Specific sugar molecule causes growth of cancer cells. *ScienceDaily.* 16 September 2013. <http://>

- [www.sciencedaily.com/releases/2013/09/130916103646.htm](http://www.sciencedaily.com/releases/2013/09/130916103646.htm)
384. Graham N.A., et al., Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death, *Molecular Systems Biology*, 8, 2012.
385. Wolf R., *The Paleo Solution. The Original Human Diet*, 2010.
386. Klement R.J., Kammerer U., Is there a role for carbohydrate restriction in the treatment and prevention of cancer?, *Nutr. Metab.*, October 2011.
387. Mantovani A., et al., Cancer-related inflammation, *Nature*, 24;454(7203):436-44, 2008.
388. Ho V.W., et al., A low carbohydrate, high protein diet slows tumor growth and prevents initiation, *Cancer Res*, 71;4484, 2011.
389. Ranc K., et al., Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment, *Diabetologia*, 2014.
390. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. *Diabetes Metab.* 2014;38(5):330-6.
391. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. *Diabetes care.* May 2001;24(5):843-849.
392. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. *British journal of cancer.* Feb 2 2001;84(3):417-422.
393. Muntoni S, Muntoni S, Draznin B. Effects of chronic hyperinsulinemia in insulin-resistant patients. *Curr Diabetes Reports.* 2008;8:233-238.
394. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? *Am J Pathol.* 2006;169(5):1505-1522.
395. Orgel E, Mittelman SD. The links between insulin resistance, diabetes, and cancer. *Curr Diab Rep.* 2013;13(2):213-22.
396. Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. *Endocr Relat Cancer.* 2013;20:R1-R17.



397. Belfiore A, Malaguarnera R. Insulin receptor and cancer. *Endocrine-Related Cancer*. 2011;18:R125-R147.
398. Wang X, Yu C, Zhang B, Wang Y. The injurious effects of hyperinsulinism on blood vessels. *Cell biochemistry and biophysics*. Jun 2014;69(2):213-218.
399. Lee Y, Berglund ED, XinXin Y, et al. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. *Proc Natl Acad Sci USA*. 2014;111(36):13217-13222.
400. Kelly CT, Mansoor J, Dohm GL, Chapman WH, 3rd, Pender JRt, PoriesWJ. Hyperinsulinemic syndrome: the metabolic syndrome is broader than you think. *Surgery*. Aug 2014;156(2):405-411.
401. Soranna D, Scotti L, Zambon A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. *Oncologist*. 2012;17(6):813-22.
402. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia*. 2009;52:1766-1777.
403. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. *Diabetes Care*. 2006;29(2):254-8.
404. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. *Metabolism: clinical and experimental*. Jul 2013;62(7):922-934.
405. Higginbotham S, Zhang ZF, Lee IM, et al. Dietary Glycemic Load and Risk of Colorectal Cancer in the Women's Health Study. *JNCI Journal of the National Cancer Institute*. 2004. 96 (3): 229-3.
406. Bradshaw PT, Sagiv SK, Kabat GC, et al. Consumption of sweet foods and breast cancer risk: a case-control study of women on Long Island, New York. *Cancer Causes Control*. 2009;20(8):1509-1515.
407. Folsom AR, Demissie Z, Harnack L; Iowa Women's Health Study. Glycemic index, glycemic load, and incidence of endometrial cancer: the Iowa women's health study. *Nutr*

- Cancer. 2003;46(2):119-24.
408. Michaud DS, Liu S, Giovannucci E, et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. *J Natl Cancer Inst.* 2002 Sep 4;94(17):1293-300.
409. Larsson SC, Bergkvist L, Wolk A. Consumption of sugar and sugar-sweetened foods and the risk of pancreatic cancer in a prospective study. *The American Journal of Clinical Nutrition.* 2006, 84, 5, 1171-1176.
410. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA.* 2005 Jan 12;293(2):194-202.
411. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. *Diabetes Care.* 2007 Mar;30(3):561-7.
412. Stocks T, Rapp K, Bjorge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. *PLoS Med.* 2009;6(12):e1000201.
413. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. *J Nutr Biochem.* 2006 Mar;17(3):145-56.
414. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. *Am J Clin Nutr.* 2007 Sep;86(3):s836-42.
415. Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: a review. *Am J Med Sci.* 2011 Mar;341(3):227-31.
416. Newsholme R..A., Mechanism for starvation suppression and refeeding activity of infection, *Lancet*, i:654, 1977
417. Pearce M.L., Dayton S., Incidence of cancer in men on a diet high in polyunsaturated fat, *Lancet*, i:464, 1971
418. Kearney R., Promotion and prevention of tumor growth – effects of endotoxin, inflammation and dietary lipids, *Int Clin Nutr Rev*, 7: 157, 1987
419. Wolk A, et al., A prospective study of association of monounsaturated fat and other types of fat with risk of breast cancer, *Arch Intern Med*, 158: 41-45, 1998

420. Mackie BS. Do polyunsaturated fats predispose to malignant melanoma. *Med J Aust.* 1976 Nov 20;2(21):806.
421. Hakansson N., et al., Occupational sunlight exposure and cancer incidence among Swedish construction workers, *Epidemiology*, 12, 5, 552-7, 2001
422. Kaskel P., et al., Outdoor activities in childhood: a protective factor in 271 matched pairs, *Br Aj Dermatol*, 145, 4, 602-9, 2001
423. Kennedy C., et al., The influence of painful sunburns and lifetime exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi and skin cancer, *Journal of Investigative Dermatology*, 120, 1087-1093, 2003
424. Berwick M., et al., Sun exposure and mortality from melanoma, *Journal of National Cancer Institute*, 97, 1-15 2005
425. Carroll K.K., Dietary fats and cancer, *American Journal of Clinical Nutrition*, 53:1064S, 1991
426. Dunaif GE, Campbell TC. Relative contribution of dietary protein level and aflatoxin B1 dose in generation of presumptive preneoplastic foci in rat liver. *J Natl Cancer Inst.* 1987 Feb;78(2):365-9.
427. Youngman LD, Campbell TC. Inhibition of aflatoxin B1-induced gamma-glutamyltranspeptidase positive (GGT+) hepatic preneoplastic foci and tumors by low protein diets: evidence that altered GGT+ foci indicate neoplastic potential. *Carcinogenesis*. 1992 Sep;13(9):1607-13.
428. Qin LQ, He K, Xu JY. Milk consumption and circulating insulin-like growth factor-I level: a systematic literature review. *Int J Food Sci Nutr.* 2009;60 Suppl 7:330-40.
429. Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. *Expert Opin Ther Targets.* 2013 Mar;17(3):307-20.
430. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp Biol Med (Maywood).* 2008 Jun;233(6):674-88.
431. de Lorgeril M, Salen P. New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated

- fatty acids. *BMC Med.* 2012 May 21;10:50.
432. Leiber F, Kreuzer M, Nigg D, Wettstein HR, Scheeder MR. A study on the causes for the elevated n-3 fatty acids in cows' milk of alpine origin. *Lipids.* 2005 Feb;40(2):191-202.
433. Hebeisen DF, Hoeflin F, Reusch HP, Junker E, Lauterburg BH. Increased concentrations of omega-3 fatty acids in milk and platelet rich plasma of grass-fed cows. *Int J Vitam Nutr Res.* 1993;63(3):229-33.
434. Turner K. *Radical Remission: Surviving Cancer Against All Odds.* HerperCollins Publishers. New York. 2014.
435. Vinson F, Merhi M, Baldi I, Raynal H, Gamet-Payrastre L. Exposure to pesticides and risk of childhood cancer: a meta-analysis of recent epidemiological studies. *Occup Environ Med.* 2011 Sep;68(9):694-702.
436. Falck F Jr, Ricci A Jr, Wolff MS, Godbold J, Deckers P. Pesticides and polychlorinated biphenyl residues in human breast lipids and their relation to breast cancer. *Arch Environ Health.* 1992 Mar-Apr;47(2):143-6.
437. Aronson KJ, Miller AB, Woolcott CG, et al. Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2000 Jan;9(1):55-63.
438. Smith-Spangler C, Brandeau ML, Hunter GE, et al. Are organic foods safer or healthier than conventional alternatives?: a systematic review. *Ann Intern Med.* 2012 Sep 4;157(5):348-66.
439. Baudry J, Assmann KE, Touvier M, et al. Association of frequency of organic food consumption with cancer risk findings From the NutriNet-Santé Prospective Cohort Study. *JAMA Intern Med.* 2018;178(12):1597-1606.
440. Popa ME, Mitelut AC, Popa EE, et al. Organic foods contribution to nutritional quality and value. *Trends in Food Science & Technology.* 2019, 84, February 2019, 15-18.
441. Organic vs non-organic food, Newcastle University, 8 October 2015 <https://www.ncl.ac.uk/press/articles/archive/2015/10/organicvsnon-organicfood/>

442. Barański M, Srednicka-Tober D, Volakakis N, et al. Higher antioxidant and lower cadmium concentrations and lower incidence of pesticide residues in organically grown crops: a systematic literature review and meta-analyses. *Br J Nutr.* 2014 Sep 14;112(5):794-811.
443. Srednicka-Tober D, Baranski M, Seal CJ, et al. Higher PUFA and n-3 PUFA, conjugated linoleic acid,  $\alpha$ -tocopherol and iron, but lower iodine and selenium concentrations in organic milk: a systematic literature review and meta- and redundancy analyses. *Br J Nutr.* 2016 Mar 28;115(6):1043-60.
444. Srednicka-Tober D, Baranski M, Seal C, et al. Composition differences between organic and conventional meat: a systematic literature review and meta-analysis. *Br J Nutr.* 2016 Mar 28;115(6):994-1011.
445. Bassin EB, Wypij D, Davis RB, Mittleman MA. Age-specific fluoride exposure in drinking water and osteosarcoma (United States). *Cancer Causes Control.* 2006 May;17(4):421-8.
446. Alatise OI, Schrauzer GN. Lead exposure: a contributing cause of the current breast cancer epidemic in Nigerian women. *Biol Trace Elem Res.* 2010 Aug;136(2):127-39.
447. Knekt P, Vitamin E and cancer prevention, *Natural Antioxidants in Human Health and Disease*, 199-238, 1994
448. Fontham E.T.H., Vitamin C, vitamin C rich foods, and cancer: epidemiological studies, *Natural Antioxidants in Human Health and Disease*, 157-197, 1994
449. Patterson R.E., White E., Kristal A.R., et al., Vitamin supplementation and cancer risk: the epidemiological evidence, *Cancer Causes Control*, 8: 786-802, 1997
450. Bostick R.M., Potter J.D., et al., Reduced risk of colon cancer with high intakes of vitamin E: the Iowa women's health study, *Cancer Res.*, 53:4230-4237, 1993
451. Patterson R.E., White E., Kristal A.R., et al., Vitamin supplementation and cancer risk: the epidemiological evidence, *Cancer Causes Control*, 8, 786-802, 1997
452. Hunter D.J., et al., A prospective study of the intake of vitamins

- C, E, A and the risk of breast cancer, *New England Journal of Medicine*, 329:234-240, 1993
453. Ennever F.K., Pasket, Vitamins and breast cancer, *New England Journal of Medicine*, 329, 1579-1580, 1993
454. Jumann A., Holmberg L., et al., Carotene intake and the risk of postmenopausal breast cancer, *Epidemiology*, 10, 49-53, 1999
455. Bohlke K., Spiegelman D., et al., Vitamins A, C, and E and the risk of breast cancer, *British Journal of Cancer*, 79, 23-29, 1999
456. Verhoeven D.T.H., Asses N., et al., Vitamin C and E, retinal, carotene, and dietary fibre in relation to breast cancer risk, *British Journal of Cancer*, 75, 149-155, 1997
457. Negri E., LaVecchio C., et al., Intake of selected micronutrients and the risk of breast cancer, *Int J Cancer*, 65, 140-144, 1996
458. Punnonen R., et al., Activities of antioxidant enzymes and lipid peroxidation in endometrial cancer, *European Journal of Cancer*, 29, 266-269, 1993
459. Palan P.R., et al., Beta-carotene levels in exfoliated cervical vaginal epithelial cells in cervical intra-epithelial neoplasia and cervical cancer, *Am J Obstet-Gynecol*, 167, 1899-1903, 1992
460. Gridley G., et al., Vitamin supplement use and reduced risk of oral and pharyngeal cancer, *American Journal of Epidemiology*, 135, 1083-1092, 1992
461. Zheng W., et al., Serum micronutrients and subsequent risk of oral and pharyngeal cancer, *Cancer Res*, 53, 795-798, 1993
462. Barone J., et al., Vitamin supplement use and risk for oral and esophageal cancer, *Nutr Cancer*, 18, 1, 31-41, 1992
463. Shibata A., et al., Intake of vegetables, fruits, beta-carotene, vitamin C, and vitamin supplements and cancer incidence among the elderly: A prospective study, *British Journal of Cancer*, 66:673-679, 1992
464. LeMarchand L., et al., Intake of specific carotenoids and lung cancer risk, *Cancer Epidemiol Biomarkers Prevent*, 2:183-187, 1993
465. Knekt P., et al., Dietary antioxidants and the risk of lung cancer, *American Journal of Epidemiology*, 134, 5, 471-479, 1991

466. Stahelin H.B., et al., Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year follow up of the prospective Basel Study, *American Journal of Epidemiology*, 133, 8, 766-775, 1994
467. Prestin-Martin S., Pogoda J.M., et al., Prenatal vitamin supplementation and risk of childhood brain tumors, *Int J Cancer*, 11, 17-22, 1998
468. Eichholzer M., Stahelin H.B., et al., Prediction of male cancer mortality by plasma levels of interacting vitamins: 17 year follow-up of the prospective Basel study, *Int J Cancer*, 66, 145-150, 1996
469. Gann P.H., Ma J., et al., Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis, *Cancer Res*, 59, 1225-1230, 1999
470. Patterson R.E., White E., Kristal A.R., et al., Vitamin supplementation and cancer risk: the epidemiological evidence, *Cancer Causes Control*, 8:786-802, 1997
471. Chen J., et al., Antioxidant status and cancer mortality in China, *Int J Epidemiol*, 21, 4, 625-635, 1992
472. Blot W.J., et al., Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin-mineral combinations, cancer incidence, and disease specific mortality in the general population, *JNCI*, 85, 18, 1483-1492, 1993
473. Smigel K., Dietary supplements reduce cancer deaths in China, *JNCI*, 85, 18, 1448-1450, 1993)
474. Jaakkola, et al., Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation therapy in patients with small cell lung cancer, *Anticancer Research*, 12, 3, 599-606, 1992
475. Li J.Y., et al., Nutrition intervention trials in Linxian, China: Multiple vitamin and mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia, *JNCI*, 85, 1492-1498, 1993
476. Lippman S., et al., Comparison of low dose isotretinoin with beta-carotene to prevent oral carcinogenesis, *New England Journal of Medicine*, 328, 15-20, 1993

477. Toma S., et al., GI Treatment of oral leukoplakia with beta-carotene, *Oncology*, 49, 77-81, 1992
478. Benner S., et al., Regression of oral leukoplakia with alpha-tocopherol, *JNCI*, 85, 44-47, 1993

## **ΜΕΡΟΣ 5**

### **ΔΙΑΤΡΟΦΙΚΑ ΣΥΜΠΛΗΡΩΜΑΤΑ ΚΑΙ ΑΛΛΑ ΦΥΤΙΚΑ ΣΥΣΤΑΤΙΚΑ ΠΟΥ ΠΡΟΣΤΑΤΕΥΟΥΝ ΑΠΟ ΤΟΝ ΚΑΡΚΙΝΟ**

1. Yamamoto T. [Chemoprevention and FAR therapy regimen comprised of 5-fluorouracil, vitamin A and radiation]. *Gan To Kagaku Ryoho*. 2001 Apr;28(4):454-60.
2. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. *Critical Reviews in Oncology/Hematology*. 2002, 41, 1, 41-55.
3. Eisenhauer EA, Lippman SM, Kavanagh JJ, et al. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. *Leukemia*. 1994 Oct;8(10):1622-5.
4. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13- cis -Retinoic Acid Plus Interferon  $\alpha$  -2a: Highly Active Systemic Therapy for Squamous Cell Carcinoma of the Cervix. *J Natl Cancer Inst*. 1992, 84:241-245.
5. Dahiya R, Park HD, Cusick J, et al. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. *International Journal of Cancer*. 1994, 59, 1, 126-132.
6. Pili R, Kruszewski MP, Hager BW, et al. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. *Cancer Res*. 2001 Feb 15;61(4):1477-85.
7. Cortes J, Kantarjian H, O'Brien S, et al. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. *Leukemia*. 1997, 11, 929-932.
8. Marley SB, Davidson RJ, Goldman JM, Gordon MY. Effects of combinations of therapeutic agents on the proliferation of



- progenitor cells in chronic myeloid leukaemia. *BJHaem.* 2002, 116, 1, 162-165.
9. Aebi S, Kroning R, Cenni B, et al. all-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. *Clin Cancer Res.* 1997 Nov;3(11):2033-8.
  10. Todesco A, Carli M, Iacona I, et al. All-trans retinoic acid and interferon-alpha in the treatment of a patient with resistant metastatic osteosarcoma. *Cancer.* 2000 Dec 15;89(12):2661-6.
  11. Tasoriere L, Ciaccio M, Valenza M, et al. Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. *Journal of Pharmacology and Experimental Therapeutics.* 1994, 269 (1) 430-436.
  12. Redlich CA, Rockwell S, Chung JS, et al. Vitamin A inhibits radiation-induced pneumonitis in rats. *J Nutr.* 1998 Oct;128(10):1661-4.
  13. Fiedor J, Burda K. Potential role of carotenoids as antioxidants in human health and disease. *Nutrients.* 2014;6(12):466-488.
  14. Murillo AG, DiMarco DM, Fernandez ML. The potential of non-provitamin A carotenoids for the prevention and treatment of non-alcoholic fatty liver disease. *Biology (Basel).* 2016;5(4). pii: E42.
  15. Tang G. Bioconversion of dietary provitamin A carotenoids to vitamin A in humans. *Am J Clin Nutr.* 2010;91(5):1468s-1473s.
  16. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. *Molecules.* 2012;17(3):3202-3242.
  17. Milani A, Basirnejad M, Shahbazi S, Bolhassani A. Carotenoids: biochemistry, pharmacology and treatment. *Br J Pharmacol.* 2017;174(11):1290-1324.
  18. Woodside JV, McGrath AJ, Lyner N, McKinley MC. Carotenoids and health in older people. *Maturitas.* 2015;80(1):63-68.
  19. Xavier AA, Perez-Galvez A. Carotenoids as a source of antioxidants in the diet. *Subcell Biochem.* 2016;79:359-375.
  20. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.

- Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):861-8.
21. Burney PG, Comstock GW, Morris JS, Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. *The American Journal of Clinical Nutrition*. 1989, 49, 5, 895–900.
  22. De Stefani E, Oreggia F, Boffetta P, et al. Tomatoes, tomato-rich foods, lycopene and cancer of the upper aerodigestive tract: a case-control in Uruguay. *Oral Oncol*. 2000 Jan;36(1):47-53.
  23. Nair S, Norkus EP, Hertan H, Pitchumoni CS. Serum and colon mucosa micronutrient antioxidants: differences between adenomatous polyp patients and controls. *The American Journal of Gastroenterology*. 2001, 94, 12, 3400-3405.
  24. Slattery ML, Benson J, Curtin K, et al. Carotenoids and colon cancer. *Am J Clin Nutr*. 2000 Feb;71(2):575-82.
  25. Palozza P, Maggiano N, Calviello G, et al. Canthaxanthin induces apoptosis in human cancer cell lines. *Carcinogenesis*. 1998, 19, 2, 373–376.
  26. Toniolo P, Van Kappel AL, Akhmedkhanov A, et al. Serum carotenoids and breast cancer. *Am J Epidemiol*. 2001 Jun 15;153(12):1142-7.
  27. Hulten K, Van Kappel AL, Winkvist A, et al. Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in northern Sweden. *Cancer Causes Control*. 2001 Aug;12(6):529-37.
  28. Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with *Spirulina fusiformis*. *Nutr Cancer*. 1995;24(2):197-202.
  29. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. *Oral Oncol*. 1997 Jul;33(4):231-6.
  30. D'Avanzo B, Ron E, La Vecchia C, Francaschi S, Negri E, Zleglar R. Selected micronutrient intake and thyroid carcinoma risk. *Cancer*. 1997 Jun 1;79(11):2186-92.
  31. Huncharek M, Klassen H, Kupelnick B. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: a meta-analysis

- of 3,782 subjects from five observational studies. *In Vivo*. 2001 Jul-Aug;15(4):339-43.
32. Wang Y, Cui R, Xiao et al. Effect of carotene and lycopene on the risk of prostate cancer: a systematic review and dose-response meta-analysis of observational studies. *PLoS One*. 2015;10(9):e0137427.
  33. Rowles JL 3rd, Ranard KM, Smith JW, et al. Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2017;20(4):361-377.
  34. Gajowik A, Dobrzynska MM. Lycopene - antioxidant with radioprotective and anticancer properties. A review. *Rocz Panstw Zakl Hig*. 2014;65(4):263-271.
  35. Bhatia N, Gupta P, Singh B, Koul A. Lycopene enriched tomato extract inhibits hypoxia, angiogenesis, and metastatic markers in early stage N-nitrosodiethylamine induced hepatocellular carcinoma. *Nutr Cancer*. 2015;67(8):1268-1275.
  36. Giovannucci E, Ascherio A, Rimm EB, et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*. 1995 Dec 6;87(23):1767-76.
  37. Zhang X, Yang Y, Wang Q. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. *Chin Med J (Engl)*. 2014;127(11):2143-6.
  38. Agarwal S, Rao AV. Tomato lycopene and its role in human health and chronic diseases. *CMAJ*. 2000 Sep 19;163(6):739-44.
  39. Ansari MS, Gupta NP. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. *Urol Oncol*. 2004;22(5):415-420.
  40. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. *Cancer Epidemiol Biomarkers Prev*. 2001;10(8):861-868.
  41. Ansari MS, Gupta NP. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. *BJU Int*. 2003;92(4):375-378.
  42. Vaishampayan U, Hussain M, Banerjee M, et al. Lycopene and

- soy isoflavones in the treatment of prostate cancer. *Nutr Cancer*. 2007;59(1):1-7.
43. Paur I, Lilleby W, Bøhn SK, et al. Tomato-based randomized controlled trial in prostate cancer patients: effect on PSA. *Clin Nutr*. 2017;36(3):672-679.
  44. Antwi SO, Steck SE, Su LJ, et al. Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). *Prostate*. 2016;76(12):1053-1066.
  45. Puri T, Goyal S, Julka PK, et al. Lycopene in treatment of high-grade gliomas: a pilot study. *Neurol India*. 2010;58(1):20-23.
  46. Mahmoodnia L, Mohammadi K, Masumi R. Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient. *J Nephrothol*. 2017;6(3):144-149.
  47. Zhang L, Wang H. Multiple mechanisms of anti-cancer effects exerted by astaxanthin. *Mar Drugs*. 2015;13(7):4310-4330.
  48. Nagendraprabhu P, Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFκB and COX-2. *Invest New Drugs*. 2011;29(2):207-224.
  49. Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. *Cancer Immunol Res*. 2014;2(9):823-830.
  50. Wu C, Zhang J, Liu T, et al. Astaxanthin inhibits proliferation and promotes apoptosis of A549 lung cancer cells via blocking JAK1/STAT3 pathway [in Chinese]. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 2016;32(6):784-788.
  51. Li J, Dai W, Xia Y, et al. Astaxanthin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells via inhibition of Nf-Kappab P65 and Wnt/Beta-Catenin in vitro. *Mar Drugs*. 2015;13(10):6064-6081.
  52. Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target. *Biochim Biophys Acta*. 2005;1740(2):170-178.

53. Kowshik J, Baba AB, Giri H, et al. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. *PLoS One*. 2014;9(10):e109114.
54. Chen YT, Kao CJ, Huang HY, et al. Astaxanthin reduces MMP expressions, suppresses cancer cell migrations, and triggers apoptotic caspases of in vitro and in vivo models in melanoma. *J Funct Foods*. 2017;31:20-31.
55. Park JS, Chyun JH, Kim YK, et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. *Nutr Metab (Lond)*. 2010;7:18.
56. Lin KH, Lin KC, Lu WJ, et al. Astaxanthin, a carotenoid, stimulates immune responses by enhancing IFN-gamma and IL-2 secretion in primary cultured lymphocytes in vitro and ex vivo. *Int J Mol Sci*. 2015;17(1).
57. Krinsky NI. Effects of carotenoids in cellular and animal systems. *Amer. J. Clin. Nutr*, 1991, 53, 238S-246S.
58. Zhang LX, Cooney RV, Bertram JS. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. *Carcinogenesis*. 1991 Nov;12(11):2109-14.
59. Schwartz J.L, Singh RP, Teicher B, et al. Induction of a 70kD protein associated with the selective cytotoxicity of beta-carotene in human epidermal carcinoma. *Biochem. Biophys. Res. Comm*, 1990, 169, 3, 941-946.
60. Mathews-Roth MM, Krinsky NI. Carotenoid dose level and protection against UV-B induced skin tumors. *Photochem. Photobiol*, 1985, 42, 1, 35-38.
61. Garewal HS, Schantz S. Emerging role of beta-carotene and antioxidant nutrients in prevention of oral cancer. *Arch Otolaryngol Head Neck Surg*. 1995 Feb;121(2):141-4.
62. Seifter E, Rettura G, Padawer J, Stratford F, Goodwin P, Levenson SM. Regression of C3HBA mouse tumor due to X-ray therapy combined with supplemental beta-carotene or vitamin A. *J Natl Cancer Inst*. 1983 Aug;71(2):409-17.

63. Shklar G, Schwartz J. Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta-carotene, canthaxanthin and algae extract. *Eur. J. Cancer.* 1988, 24, 5, 839-850.
64. Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. *Br J Cancer.* 1988 Apr;57(4):416-7.
65. Nagasawa H, Konishi R, Sensui N, et al. Inhibition by beta-carotene-rich algae *Dunaliella* of spontaneous mammary tumourigenesis in mice. *Anticancer Research,* 1989, 9(1):71-75.
66. Ben-Amotz, A., Yatziv, S., Sela, M. et al. Effect of natural b-carotene supplementation in children exposed to radiation from the Chernobyl accident. *Radiat Environ Biophys.* 1998, 37, 187–193.
67. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N Engl J Med.* 1996 May 2;334(18):1150-5.
68. Shekelle RB, Lepper M, Liu S, et al. Dietary vitamin A and risk of cancer in the Western Electric study. *Lancet.* 1981 Nov 28;2(8257):1185-90.
69. BBC News. Vitamin cocktail cuts cancer deaths. 4 August, 2003. <http://news.bbc.co.uk/1/hi/health/3122033.stm>
70. Baron JA, Cole BF, Mott L, et al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. *J Natl Cancer Inst.* 2003 May 21;95(10):717-22.
71. Neuhauser ML, Patterson RE, Thornquist MD, et al. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). *Cancer Epidemiol Biomarkers Prev.* 2003;12(4):350-358.
72. Shareck M, Rousseau MC, Koushik A, et al. Inverse association between dietary intake of selected carotenoids and vitamin C and risk of lung cancer. *Front Oncol.* 2017;7:23.
73. Abar L, Vieira AR, Aune D, et al. Blood concentrations of carotenoids and retinol and lung cancer risk: an update of the

- WCRF-AICR systematic review of published prospective studies. *Cancer Med.* 2016;5(8):2069-2083.
74. Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. *Cancer.* 2008;113(1):150-157.
  75. Kaul L, Heshmat MY, Kovi J, et al. The role of diet in prostate cancer. *Nutr. Cancer*, 9, 123-128, 1987
  76. Kjellen E., Pero R.W., Cameron R., Ranstam J., Radiosensitizing effects of nicotinamide on a C3H mouse mammary adenocarcinoma, *Acta Radiologica Oncology*, 25, 281-284, 1986
  77. Kjellen E., Joiner M.C., Collier J.M., Johns H., Rojas A., A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments, *Radiotherapy and Oncology*, 22, 81-91, 1991
  78. Chaplin D.J., Horsman M.P., Aoki D.S., Nicotinamide, Fluosol D.A., and Carbogen: A strategy to reoxygenate acutely and chronically hypoxic cells in vivo, *British Journal of Cancer*, 63, 109-113, 1990
  79. Chaplin D.J., Peters C.E., Horsman M.R., Trotter M.J., Drug induced perturbations in tumor blood flow: Therapeutic potential and possible limitations, *Radiotherapy and Oncology*, 20, Supp 1, 93-101, 1991
  80. Chen G., Pan Q.C., Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide, *Cancer, Chemotherapy and Pharmacology*, 22, 303-307, 1988
  81. Streffer C., The biosynthesis of NAD in the liver of irradiated mice, *Journal of Vitaminology*, 14, 130-134, 1968
  82. Gotoh H., Nomura T., Nakajima C., Hasegawa C., Sakamoto Y., Inhibiting effects of nicotinamide on urethane-induced malformations and tumors in mice, *Mutation Research*, 199, 55-63, 1988
  83. Scheulen M.E., Schmitt-Graff A., Schmidt C.G., Reduction of adriamycin cardiotoxicity by niacin and isocitrate, *Proceedings of the 74th Annual Meeting, American Association for Cancer Research*, 24, 251, 1983

84. Schmitt-Graff A., Scheulen M.E., Prevention of adriamycin cardiotoxicity by niacin, isocitrate or N-acetyl-cysteine in mice, *Path. Res. Pract.*, 181, 168-174, 1986
85. Lamm D.L., et al., Megadose vitamin in bladder cancer: a double-blind clinical trial, *J. Urol.*, 151, 21-26, 1994
86. Ladner HA, Salkeld RM. Vitamin B6 status in cancer patients: effect of tumor site, irradiation, hormones and chemotherapy. *Prog Clin Biol Res.* 1988;259:273-81.
87. Johansson M, Relton C, Ueland PM, et al. Serum B vitamin levels and risk of lung cancer. *JAMA.* 2010 Jun 16;303(23):2377-85.
88. Theodoratou E., Farrington S.M., Tenesa A., et al., Dietary vitamin B6 intake and the risk of colorectal cancer, *Cancer Epidemiology Biomarkers & Prevention*, 17, 1, 171-82, Jan. 2008
89. Matsubara K., Komatsu S., Oka T., Kato N., Vitamin B6-mediated suppression of colon tumorigenesis, cell proliferation, and angiogenesis, *J. Nutr. Biochem.*, 14, 5, 246-50, May 2003
90. Zhang S.M., et al., Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women, *Am. J. Epidemiol.*, 163, 2, 108-115, Jan. 2006
91. Wei EK, Giovannucci E, Selhub J, et al. Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. *Journal of the National Cancer Institute.* 97, 9, 684-692. 2005
92. Larsson SC, Orsini N, Wolk A. Vitamin B6 and risk of colorectal cancer: a meta-analysis of prospective studies. *JAMA.* 2010 Mar 17;303(11):1077-83.
93. Ebbing M, Bonna KH, Nygard O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. *JAMA.* 2009 Nov 18;302(19):2119-26.
94. Giovannucci E., Stampfer M.J., Colditz G.A., et al., Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study, *Ann. Intern. Med.*, 129, 517-524, 1998
95. Jacobs E.J., Connell C.J., Patel A.V., et al., Multivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States), *Cancer Causes Control.*, 12, 927-934, 2001
96. Terry P., Jain M., Miller A.B., et al., Dietary intake of folic acid and



- colorectal cancer risk in a cohort of women, *Int. J. Cancer*, 97, 864-7, 2002
97. Paspatis G.A., Karamanolis D.G., Folate supplementation and adenomatous colonic polyps, *Dis Colon Rectum*, 37, 1340-1, 1994
  98. Kim Y.I., Baik H.W., Fawaz K., et al., Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial, *Am. J. Gastroenterol.*, 96, 184-95, 2001
  99. Knock E., et al., Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like Kinase 1 and cell division cycle 25c, *Cancer Research*, 66, 10349-56, Nov. 2006
  100. Kato I., et al., Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study, *British Journal of Cancer*, 79, 11/12, 1917-21, April 1999
  101. Tseng, Marilyn, et al., Micronutrients and the risk of colorectal adenomas, *American Journal of Epidemiology*, 144, 11, 1005-14, Dec. 1996
  102. Weir, Donald G and Scott, John M., Colonic mucosal folate concentrations and their association with colorectal cancer, *American Journal of Clinical Nutrition*, 68, 763-64, Oct. 1998
  103. Kim, Young-In, et al., Colonic mucosal concentrations of folate correlate well with blood measurements of folate status in persons with colorectal polyps, *American Journal of Clinical Nutrition*, 68, 866-72, Oct. 1998
  104. Giovannucci, Edward, et al., Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men, *Journal of the National Cancer Institute*, 87, 4, 265-73, Feb. 1995
  105. Zhang S.M., Willet W.C., Selhub J., Hunter D.J., Giovannucci E.L., Holmes M.D., Golditz G.A., Hankinson S.E., Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer, *J. Natl. Cancer Inst.*, 95, 5, 373-80, Mar. 2003
  106. Shrubsole, Martha J., et al., Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study,

- Cancer Research, 61, 7136-41, Oct. 2001
107. Larsson S.C., Giovannucci E., Wolk A., Dietary folate intake and incidence of ovarian cancer: the Sweddisch Mammography Cohort, *J. Natl. Cancer Inst.*, 96, 396-402, 2004
  108. Xiao SD, Meng XJ, Shi Y, Hu YB, Zhu SS, Wang CW. Interventional study of high dose folic acid in gastric carcinogenesis in beagles. *Gut.* 2002;50(1):61-64.
  109. Thompson, Judith R., et al., Maternal folate supplementation in pregnancy and protection against acute lymphoblastic leukemia in childhood: a case-control study, *The Lancet*, 358, 1935-40, Dec. 2001
  110. Butterworth CE Jr, Hatch KD, Gore H, et al. Improvement in cervical dysplasia associated with folic acid therapy in users of oral contraceptives. *Am J Clin Nutr.* 1982 Jan;35(1):73-82.
  111. Poydock ME. Effect of combined ascorbic acid and B-12 on survival of mice with implanted Ehrlich carcinoma and L1210 leukemia. *Am J Clin Nutr.* 1991 Dec;54(6 Suppl):1261S-1265S.
  112. Wu K, Helzlsouer KJ, Comstock GW, et al. A prospective study on folate, B12, and pyridoxal 5-phosphate (B6) and breast cancer. *Cancer Epidemiol Biomarkers Prev.* 1999 Mar;8(3):209-17.
  113. Lajous M, Lazcano-Ponce E, Hernandez-Avila M, et al. Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women. *Cancer Epidemiol Biomarkers Prev.* 2006 Mar;15(3):443-8.
  114. Ainsleigh HG. Beneficial effects of sun exposure on cancer mortality. *Prev Med.* 1993 Jan;22(1):132-40.
  115. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. *Cancer.* 1992, 70, 2861-2869.
  116. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. *Int J Epidemiol.* 1994, 23, 1133-1136.
  117. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. *Int J Epidemiol.* 1990, 19, 820-824.
  118. Grant WB. Ecologic studies of solar UV-B radiation and cancer

- mortality rates. In: Reichrath J., Tilgen W., Friedrich M. (eds) Vitamin D Analogs in Cancer Prevention and Therapy. Recent Results Cancer Res. 2003, 164, 371-377.
119. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B-radiation. *Cancer*. 2002, 94, 1867-1875.
120. Grant WB. An ecological study of cancer mortality rates in the United States with respect to solar ultraviolet-B doses, smoking, alcohol consumption and urban/rural residence. *Dermatoendocrinol*. 2010;2(2):68-76.
121. Salazar-Martinez E, Lazcano-Ponce E, Sanchez-Zamorano LM, et al. Dietary factors and endometrial cancer risk. Results of a case-control study in Mexico. *Int J Gynecol Cancer*. 2005;15:938-945.
122. Launoy G, Milan C, Day NE, et al. Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study. *Int J Cancer*. 1998;76:7-12.
123. Bosetti C, Scotti L, Maso LD, et al. Micronutrients and the risk of renal cell cancer: A case-control study from Italy. *Int J Cancer*. 2007;120:892-896.
124. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, et al. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. *Oncology*. 2002;63:151-157.
125. Skinner HG, Michaud DS, Giovannucci E, et al. Vitamin D intake and the risk of pancreatic cancer in two cohort studies. *Cancer Epidemiol Biomarkers Prevention*. 2006;15:1688-1695.
126. Bao Y, Ng K, Wolpin BM, et al. Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. *Br J Cancer*. 2010;102:1422-1427.
127. Polesel J, Talamini R, Montella M, et al. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. *Ann Oncol*. 2006;17:713-718.
128. Bretherton-Watt D, Given-Wilson R, Mansi JL, et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. *Br J Cancer*. 2001 Jul

- 20;85(2):171-5.
129. Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. *Exp Mol Med*. 2003 Dec 31;35(6):550-5.
  130. van den Bemd GJ, Chang GT. Vitamin D and vitamin D analogs in cancer treatment. *Curr Drug Targets*. 2002 Feb;3(1):85-94.
  131. Basak R, Basu M, Chatterjee M. Combined supplementation of vanadium and 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> inhibit diethylnitrosamine-induced rat liver carcinogenesis. *Chemico-Biological Interactions*. 2000, 128, 1, 1-18.
  132. Kensler TW, Dolan PM, Gange SJ, et al. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. *Carcinogenesis*. 2000 Jul;21(7):1341-5.
  133. Agoston ES, Hatcher MA, Kensler TW, Posner GH. Vitamin D analogs as anti-carcinogenic agents. *Anticancer Agents Med Chem*. 2006 Jan;6(1):53-71.
  134. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. *Am J Public Health*. 2006;96(2):252-261.
  135. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr*. 2007 Jun;85(6):1586-91.
  136. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D<sub>3</sub> supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. *J Clin Endocrinol Metab*. 2012;97(7):2315-2324.
  137. John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. *J Steroid Biochem Mol Biol*. 2004 May;89-90(1-5):549-52.
  138. John EM, Koo J, Schwartz GG. Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. *Cancer Epidemiol Biomarkers Prev*. 2007 Jun;16(6):1283-6.
  139. Ahonen MH, Tenkanen L, Teppo L, et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control*. 2000, 11, 847-852.

140. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. *Int J Cancer*. 2004, 79, 362-371.
141. Schwartz GG. Vitamin D, sunlight, and the epidemiology of prostate cancer. *Anticancer Agents Med Chem*. 2013 Jan;13(1):45-57.
142. John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: the NHANES I Epidemiologic follow-up study, 1971-1975 to 1992. National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev*. 1999, 8, 399-406.
143. Colston KW. Vitamin D and breast cancer risk. *Best Pract Res Clin Endocrinol Metab*. 2008 Aug;22(4):587-99.
144. Hines SL, Jorn HK, Thompson KM, Larson JM. Breast cancer survivors and vitamin D: a review. *Nutrition*. 2010 Mar;26(3):255-62.
145. Skinner HG, Michaud DS, Giovannucci E, et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. *Cancer Epidemiol Biomarkers Prev*. 2006 Sep;15(9):1688-95.
146. American Association for Cancer Research. Vitamin D May Cut Pancreatic Cancer Risk By Nearly Half. *ScienceDaily*, 12 September 2006.
147. McCullough ML, Robertson AS, Rodriguez C, et al. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). *Cancer Causes Control*. 2003 Feb;14(1):1-12.
148. Huncharek M, Muscat J, Kupelnick B. Colorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies. *Nutr Cancer*. 2009;61(1):47-69.
149. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I., Prospective study of serum vitamin D and cancer mortality in the United States, *Journal of the National Cancer Institute*. 2007, 99, 21, 1594-1602.
150. Lieberman DA, Prindiville S, Weiss DG, Willett W; VA Cooperative

- Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. *JAMA*. 2003 Dec 10;290(22):2959-67.
151. Wei MY, Garland CF, Gorham ED, et al. Vitamin D and prevention of colorectal adenoma: a meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2008 Nov;17(11):2958-69.
152. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. *J Natl Cancer Inst*. 2003 Dec 3;95(23):1765-71.
153. Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. *Lancet*. 1985, 1, 307-309.
154. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eighty-year prospective study. *Lancet*. 1989, 2, 1176-1178.
155. Martinez ME, Giovannucci EL, Colditz GA, et al. Calcium, vitamin D, and the occurrence of colorectal cancer among women. *J Natl Cancer Inst*. 1996, 88, 1375-1382.
156. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. *Br J Cancer*. 2007;97(3):446-451.
157. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. *J Clin Oncol*. 2011 Oct 1;29(28):3775-82.
158. Choi YJ, Kim YH, Cho CH, Kim SH, Lee JE. Circulating levels of vitamin D and colorectal adenoma: A case-control study and a meta-analysis. *World J Gastroenterol*. 2015 Aug 7;21(29):8868-77.
159. Maalmi H, Walter V, Jansen L, et al. Association between Blood 25-Hydroxyvitamin D Levels and Survival in Colorectal Cancer Patients: An Updated Systematic Review and Meta-Analysis. *Nutrients*. 2018 Jul 13;10(7):896.
160. Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. *J Natl Cancer Inst*. 2003, 95, 1765-1771.

161. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. *Am J Clin Nutr.* 2004, 79, 362-371.
162. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. *Nutr J.* 2004, 3, 8.
163. Schwartz GG, Whitlatch LW, Chen TC, et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. *Cancer Epidemiol Biomarkers Prev.* 1998, 7, 391-395.
164. Tangpricha V, Flanagan JN, Whitlatch LW, et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. *Lancet.* 2001, 357, 1673-1674.
165. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. *Cancer Epidemiol Biomarkers Prev.* 2000, 9, 265-270.
166. Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxyvitamin D. *Cancer Epidemiol Biomarkers Prev.* 2002, 11, 113-119.
167. Friedrich M, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. *Recent Results Cancer Res.* 2003, 164, 239-246.
168. Schwartz GG, Eads D, Rao A, et al. Pancreatic cancer cells express 25-hydroxyvitamin D-1alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. *Carcinogenesis.* 2004, 25, 1015-1026.
169. Ness RA, Miller DD, Li W. The role of vitamin D in cancer prevention. *Chinese Journal of Natural Medicines.* 2015, 13, 7, 481-497.
170. Holick M. Cancer, sunlight and vitamin D. *Journal of Clinical & Translational Endocrinology.* 2014, 1, 4, 179-186.
171. Ordonez-Moran P, Larriba MJ, Palmer HG, et al. RhoA-ROCK and

- p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. *J Cell Biol.* 2008 Nov 17;183(4):697-710.
172. NBCNEWS. Vitamin D may play key role in fighting cancer. April 19, 2005. <https://www.nbcnews.com/health/health-news/vitamin-d-may-play-key-role-fighting-cancer-flna1c9443444>
173. Gardner A. Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients. ABCNews. 17 May 2008. <https://abcnews.go.com/Health/Healthday/story?id=4870955&page=1>
174. Holick MF. Does vitamin D have a role in cancer prevention? Cancer Network. January 25, 2019. <https://www.cancernetwork.com/view/does-vitamin-d-have-role-cancer-prevention>
175. Moukayed M, Grant WB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: a review of the epidemiology, clinical trials, and mechanisms. *Rev Endocr Metab Disord.* 2017;18(2):167-182.
176. Hu K, Callen DF, Li J, Zheng H. Circulating vitamin D and overall survival in breast cancer patients: a dose-response meta-analysis of cohort studies. *Integr Cancer Ther.* 2018;17(2):217-225.
177. Samji V, Haykal T, Zayed Y, et al. Role of vitamin D supplementation for primary prevention of cancer: Meta-analysis of randomized controlled trials. *Journal of Clinical Oncology.* 2019;37(15\_suppl):1534-1534.
178. Grant WB. Ecological studies of the UVB-vitamin D-cancer hypothesis. *Anticancer Res.* 2012;32(1):223-236.
179. Moukayed M, Grant WB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: a review of the epidemiology, clinical trials, and mechanisms. *Rev Endocr Metab Disord.* 2017;18(2):167-182.
180. Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence. *J Cancer.* 2016;7(3):232-240.
181. Pandolfi F, Franza L, Mandolini C, Conti P. Immune modulation by vitamin D: special emphasis on its role in prevention and treatment of cancer. *Clin Ther.* 2017;39(5):884-893.



182. Brenner H, Jansen L, Saum KU, et al. Vitamin D supplementation trials aimed at reducing mortality have much higher power when focusing on people with low serum 25-hydroxyvitamin D concentrations. *J Nutr.* 2017;147(7):1325-1333.
183. Bjorkhem-Bergman L, Bergman P. Vitamin D and patients with palliative cancer. *BMJ Support Palliat Care.* 2016;6(3):287-291.
184. Helde-Frankling M, Hoijer J, Bergqvist J, Bjorkhem-Bergman L. Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study. *PLoS One.* 2017;12(8):e0184208.
185. Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. *Calcif Tiss Int.* 2018;102(2):251-264.
186. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. *J Bone Oncol.* 2017;7:1-12.
187. Chandler PD, Chen WY, Ajala ON, et al. VITAL Research Group. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. *JAMA Netw Open.* 2020 Nov 2;3(11):e2025850.
188. Vimalaswaran KS, Berry DJ, Lu C, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med.* 2013;10(2):e1001383.
189. Vaughan-Shaw PG, Buijs LF, Blackmur JP, et al. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials. *Br J Cancer.* 2020, 123, 1705–1712.
190. Zhang X, Niu W. Meta-analysis of randomized controlled trials on vitamin D supplement and cancer incidence and mortality. *Biosci Rep.* 2019;39(11):BSR20190369.
191. McDonnell SL, Baggerly CA, French CB, et al. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations  $\geq 60$  vs  $< 20$  ng/ml (150 vs 50 nmol/L): Pooled analysis of two

- randomized trials and a prospective cohort. *PLoS One*. 2018 Jun 15;13(6):e0199265.
192. Lowe LC, Guy M, Mansi JL, et al. Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. *Eur J Cancer*. 2005 May;41(8):1164-9.
193. GrassrootsHealth. Another Study Found Similar Results with Breast Cancer Reduction and Vitamin D. October 20, 2020. <https://www.grassrootshealth.net/blog/another-study-found-similar-results-breast-cancer-reduction-vitamin-d/>
194. Song D, Deng Y, Liu K, et al. Vitamin D intake, blood vitamin D levels, and the risk of breast cancer: a dose-response meta-analysis of observational studies. *Aging (Albany NY)*. 2019 Dec 28;11(24):12708-12732.
195. GrassrootsHealth. Analysis of 70 Studies Finds 71% Lower Breast Cancer Risk With Vitamin D Level of 60 vs. 20 ng/ml. October 27, 2020. <https://www.grassrootshealth.net/blog/analysis-70-studies-finds-71-lower-breast-cancer-risk-vitamin-d-level-60-vs-20-ng-ml/>
196. Fakhri MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. *Int J Colorectal Dis*. 2009 Feb;24(2):219-24.
197. Jacot W, Poudroux S, Thezenas S, et al. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. *Breast Cancer Res Treat*. 2012 Jul;134(2):709-17.
198. Seyedalipour F, Mansouri A, Vaezi M, et al. High prevalence of vitamin D deficiency in newly diagnosed acute myeloid leukemia patients and its adverse outcome. *Int J Hematol Oncol Stem Cell Res*. 2017;11(3):209-216.
199. Fakhri MG, Andrews C, McMahon J, Muindi JR. A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: evidence of a chemotherapy-response interaction. *Anticancer Res*. 2012 Apr;32(4):1333-8.

200. Peppone LJ, Huston AJ, Reid ME, et al. The effect of various vitamin D supplementation regimens in breast cancer patients. *Breast Cancer Res Treat.* 2011 May;127(1):171-7.
201. Qureshi AA, Qureshi N, Hasler-Rapacz JO, et al. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipemias, *The American Journal of Clinical Nutrition.* 1991, 53, 4, 1042S–1046S.
202. Komiyama K, Iizuka K, Yamaoka M, et al. Studies on the biological activity of tocotrienols. *Chem Pharm Bull (Tokyo).* 1989 May;37(5):1369-71.
203. Tan B. Antitumor effects of palm carotenes and tocotrienols in HRS/J hairless female mice. *Nutrition Research.* 1992, 12, 1, S163-S173.
204. Abraham A, Kattoor AJ, Saldeen T, Mehta JL. Vitamin E and its anticancer effects. *Crit Rev Food Sci Nutr.* May 2018:1-23.
205. Jiang Q. Natural forms of vitamin E as effective agents for cancer prevention and therapy. *Adv Nutr.* 2017;8(6):850-867.
206. Husain K, Centeno BA, Coppola D, et al. delta-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. *Oncotarget.* 2017;8(19):31554-31567.
207. De Silva L, Chuah LH, Meganathan P, Fu JY. Tocotrienol and cancer metastasis. *Biofactors.* 2016;42(2):149-162.
208. Kline K, Yu W, Sanders BG. Vitamin E: mechanisms of action as tumor cell growth inhibitors. *J Nutr.* 2001 Jan;131(1):161S-163S.
209. Rahmat A, Ngah WZ, Shamaan NA, et al. Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. *Nutrition.* 1993 May-Jun;9(3):229-32.
210. Ong FB, Wan Ngah WZ, Shamaan NA, et al. Glutathione S-transferase and gamma-glutamyl transpeptidase activities in cultured rat hepatocytes treated with tocotrienol and tocopherol. *Comp Biochem Physiol C Comp Pharmacol Toxicol.* 1993 Sep;106(1):237-40.

211. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. *J Nutr.* 1997 May;127(5):668-74.
212. Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. *Lipids.* 1995 Dec;30(12):1139-43.
213. Nesaretnam K, Stephen R, Dils R, Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. *Lipids.* 1998 May;33(5):461-9.
214. Nesaretnam K, Dorasamy S, Darbre PD. Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. *Int J Food Sci Nutr.* 2000;51 Suppl:S95-103.
215. Yu W, Simmons-Menchaca M, Gapor A, et al. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. *Nutr Cancer.* 1999;33(1):26-32.
216. Nakagawa K, Shibata A, Yamashita S, et al. In vivo angiogenesis is suppressed by unsaturated vitamin E, tocotrienol. *Journal of Nutrition.* 2007, 137, 1938-1943.
217. Sun W, Xu W, Liu H, et al.  $\gamma$ -Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. *The Journal of Nutritional Biochemistry.* 2009, 20, 4, 276-284.
218. Springett GM, Husain K, Neuger A, et al. A phase I safety, pharmacokinetic, and pharmacodynamic presurgical trial of vitamin E delta-tocotrienol in patients with pancreatic ductal neoplasia. *EBioMedicine.* 2015;2(12):1987-1995.
219. Sailo BL, Banik K, Padmavathi G, et al. Tocotrienols: the promising analogues of vitamin E for cancer therapeutics. *Pharmacol Res.* 2018;130:259-272.
220. Sato C, Kaneko S, Sato A, et al. Combination effect of delta-tocotrienol and gamma-tocopherol on prostate cancer cell growth. *J Nutr Sci Vitaminol (Tokyo).* 2017;63(5):349-354.
221. Whanger PD. Selenium and its relationship to cancer: an update. *Br J Nutr.* 2004 Jan;91(1):11-28.
222. Semnani S, Roshandel G, Zendeabad A, et al. Soils selenium

- level and esophageal cancer: an ecological study in a high risk area for esophageal cancer. *J Trace Elem Med Biol.* 2010;24(3):174-177.
223. Cech I, Holguin A, Sokolow H, Smith V. Selenium availability in Texas: possible clinical significance. *South Med J.* 1984;77(11):1415-1420.
224. Cui Z, Liu D, Liu C, Liu G. Serum selenium levels and prostate cancer risk: a MOOSE-compliant meta-analysis. *Medicine (Baltimore).* 2017;96(5):e5944.
225. Shamberger RJ, Tytko SA, Willis CE. Antioxidants and cancer. Part VI. Selenium and age-adjusted human cancer mortality. *Arch Environ Health.* 1976 Sep-Oct;31(5):231-5.
226. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. *Lancet.* 1983 Jul 16;2(8342):130-4.
227. Amaral AF, Cantor KP, Silverman DT, Malats N. Selenium and bladder cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2010 Sep;19(9):2407-15.
228. Foster H.D., *Health, Disease and the Environment*, Boca Raton, FL: CRC Press, 1992
229. Hoffer A., Pauling L., *Healing cancer. Complementary vitamin and drug treatments*, 54, 2004.
230. Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. *Cancer Epidemiol Biomarkers Prev.* 2002, 11, 630-639.
231. Clark LC, Combs GF, Krongrad A, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA*, 1996, 276, 1957-1963.
232. Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU Int.* 2003;91(7):608-

- 612.
233. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. *J Natl Cancer Inst.* 2004, 96, 696-703.
234. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev.* 2003, 12, 866-871.
235. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. *J Urol.* 2001, 166, 2034-2038.
236. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst.* 2000, 92, 2018-2023.
237. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. *J Natl Cancer Inst.* 1998, 90, 1219-1224.
238. Criqui MH, Bangdiwala S, Goodman DS, et al. Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. *Ann Epidemiol.* 1991, 1, 385-393.
239. Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. *Int J Cancer.* 2005 Aug 20;116(2):182-6.
240. Hurst R, Hooper L, Norat T, et al. Selenium and prostate cancer: systematic review and meta-analysis. *Am J Clin Nutr.* 2012;96(1):111-122.
241. Nicastro HL, Dunn BK. Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT). *Nutrients.* 2013 Apr 3;5(4):1122-48.
242. Wright ME, Lawson KA, Weinstein SJ, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Am J Clin Nutr.* 2006

- Nov;84(5):1200-7.
243. Ghadirian P, Maisonneuve P, Perret C, et al. A case-control study of toenail selenium and cancer of the breast, colon, and prostate. *Cancer Detect Prev.* 2000, 24, 305-313.
244. van den Brandt PA, Goldbohm RA, van't Veer P, et al. Toenail selenium levels and the risk of breast cancer. *Am J Epidemiol.* 1994, 140, 20-26.
245. Hunter DJ, Morris JS, Stampfer MJ, et al. A prospective study of selenium status and breast cancer risk. *JAMA.* 1990, 264, 1128-1131.
246. van't Veer P, van der Wielen RP, Kok FJ, et al. Selenium in diet, blood, and toenails in relation to breast cancer: a case-control study. *Am J Epidemiol.* 1990, 131, 987-994.
247. van Noord PA, Collette HJ, Maas MJ, de Waard F. Selenium levels in nails of premenopausal breast cancer patients assessed prediagnostically in a cohort-nested case-referent study among women screened in the DOM project. *Int J Epidemiol.* 1987, 16, 318-322.
248. Ghadirian P, Maisonneuve P, Perret C, et al. A case-control study of toenail selenium and cancer of the breast, colon, and prostate. *Cancer Detect Prev.* 2000, 24, 305-313.
249. Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. *Cancer Epidemiol Biomarkers Prev.* 2002, 11, 1285-1291.
250. van den Brandt PA, Goldbohm RA, van't Veer P, et al. A prospective cohort study on selenium status and the risk of lung cancer. *Cancer Res.* 1993, 53, 4860-4865.
251. Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA. Prediagnostic toenail selenium and risk of bladder cancer. *Cancer Epidemiol Biomarkers Prev.* 2002 Nov;11(11):1292-7.
252. Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ. Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study. *Gastroenterology.* 2010 May;138(5):1704-13.

253. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA*. 1996 Dec 25;276(24):1957-63.
254. Brooks JD, Metter EJ, Chan DW, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. *J Urol*. 2001 Dec;166(6):2034-8.
255. Davis CD, Zeng H, Finley JW, Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. *The Journal of Nutrition*. 2002, 132, 2, 307-309.
256. Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. *J Natl Cancer Inst*. 2000 Nov 1;92(21):1753-63.
257. Ou Y, Jiang B, Wang X, et al. Selenium and colorectal adenomas risk: a meta-analysis. *Nutr Cancer*. 2012;64(8):1153-1159.
258. Lubinski J, Marciniak W, Muszynska M, et al. Serum selenium levels and the risk of progression of laryngeal cancer. *PLoS One*. 2018;13(1):e0184873.
259. Hawkes WC, Kelley DS, Taylor PC. The effects of dietary selenium on the immune system in healthy men. *Biol Trace Elem Res*. 2001 Sep;81(3):189-213.
260. Foster HD. Landscapes of longevity: the calcium-selenium-mercury connection in cancer and heart disease. *Med Hypotheses*. 1997 Apr;48(4):355-60.
261. Coudray C, Mouhieddine S, Richard MJ, et al. Effects of adriamycin on chronic cardiotoxicity in selenium-deficient rats. *Basic Res Cardiol*. 1992, 87, 173-183.
262. Sundstrom H, Korpela H, Sajanti E, Kauppila A. Supplementation with selenium, vitamin E and their combination in gynaecological cancer during cytotoxic chemotherapy. *Carcinogenesis*. 1989 Feb;10(2):273-8.
263. Ohkawa K, Tsukada Y, Dohzono H, et al. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. *Br J Cancer*. 1988, 58,



- 38–41.
264. Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. *Anticancer Res.* 2000 May-Jun;20(3A):1391-414.
265. Lawson T, Birt DF. Enhancement of the repair of carcinogen-induced DNA damage in the hamster pancreas by dietary selenium. *Chemico-Biological Interactions.* 1983, 45, 1, 95-104.
266. Milner JA., Hsu CY. Inhibitory effects of selenium on the growth of LI210 leukemic cells. *Cancer Research.* 1981, 41, 1652-1656.
267. Passwater R., *Cancer and its nutritional therapies*, 149, 1983.
268. Asfour IA, El Shazly S, Fayek MH, et al. Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients. *Biol Trace Elem Res.* 2006 Apr;110(1):19-32.
269. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA.* 1996 Dec 25;276(24):1957-63.
270. Clark LC. The epidemiology of selenium and cancer. *Fed Proc.* 1985 Jun;44(9):2584-9.
271. Toma S, Micheletti A, Giacherro P, et al. Selenium therapy in patients with precancerous and malignant oral cavity lesions: Preliminary results, *Cancer Detection and Prevention.* 1991, 15, 491-494.
272. Yu SY, Mao BL, Xiao P, et al. Intervention trial with selenium for the prevention of lung cancer among tin miners in Yunnan, China. A pilot study. *Biol Trace Elem Res.* 1990 Feb;24(2):105-8.
273. Burke KE. Oral and topical L-selenomethionine protection from ultraviolet-induced sunburn, tanning and skin cancer. *Journal of Orthomolecular Medicine.* 1992.
274. Burke KE, Combs GF Jr, Gross EG, et al. The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. *Nutr Cancer.* 1992;17(2):123-37.

275. Fernandes AP, Gandin V. Selenium compounds as therapeutic agents in cancer. *Biochim Biophys Acta*. 2015;1850(8):1642-1660.
276. Gandin V, Khalkar P, Braude J, Fernandes AP. Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. *Free Radic Biol Med*. May 8, 2018.
277. Chen YC, Prabhu KS, Mastro AM. Is selenium a potential treatment for cancer metastasis? *Nutrients*. 2013;5(4):1149-1168.
278. Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its' role in the maintenance of genomic stability. *Mutat Res*. 2012;733(1-2):100-110.
279. Werbach M.R., *Nutritional Influences on Illness: A Sourcebook of Clinical Research*, Tarzana, CA: Third Line Press, 1987
280. Barch DH, Esophageal cancer and microelements. *J. Am. Coll. Nutr.*, 8, 2, 1989
281. Allen JI, Bell E, Boosalis MG, et al. Association between urinary zinc excretion and lymphocyte dysfunction in patients with lung cancer. *Am. J. Med.*, 79, 2, 209-215, 1985
282. Whelan P, Walker BE, Kelleher J. Zinc, vitamin A and prostatic cancer. *Br J Urol*. 1983 Oct;55(5):525-8.
283. Feustel A, Wennrich R. Determination of the distribution of zinc and cadmium in cellular fractions of BPH, normal prostate and prostatic cancers of different histologies by atomic and laser absorption spectrometry in tissue slices. *Urol Res*. 1984;12(5):253-6.
284. Trivers ER. *Zinc, An Essential Trace Element*, Buena Park, CA: Committee for World Health, 1991
285. Foster HD. *Health, Disease and The Environment*, Boca Raton, FL: CRC Press, 1992
286. Rogers MA, Thomas DB, Weiss NS, et al. A case control study of oral cancer and prediagnostic concentrations of selenium and zinc in nail tissue, *International Journal of Cancer*, 48, 182-188, 1991
287. Gupta SK, Shukla VK, Vaidya MP, et al. Serum trace elements and Cu/Zn ratio in breast cancer patients. *J Surg Oncol*. 1991

- Mar;46(3):178-81.
288. Chen CA, Hwang JL, Kuo C.Y, et al. Serum copper and zinc levels in patients with cervical cancer. *Journal of Formosan Medical Association.* 8, 677-682, 1990
289. Heath DA. Hypercalcaemia in malignancy. *Br Med J.* 1989;298:1468-9.
290. Sorenson AW, Slattery ML, Ford MH. Calcium and colon cancer: a review. *Nutr Cancer.* 1988;11(3):135-45.
291. Garland C, Shekelle RB, Barrett-Connor E, et al. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. *Lancet.* 1985 Feb 9;1(8424):307-9.
292. Wargovich MJ, Lynch PM, Levin B. Modulating effects of calcium in animal models of colon carcinogenesis and short-term studies in subjects at increased risk for colon cancer. *Am J Clin Nutr.* 1991 Jul;54(1 Suppl):202S-205S.
293. Wargovich MJ. New dietary anticarcinogens and prevention of gastrointestinal cancer. *Dis Colon Rectum.* 1988 Jan;31(1):72-5.
294. Wargovich MJ. Calcium and colon cancer. *J. Am. Coll. Nutr.* 1988, 7, 295-300.
295. Buset M, Lipkin M, Winawer S, Swaroop S, Friedman E. Inhibition of human colonic epithelial cell proliferation in vivo and in vitro by calcium. *Cancer Res.* 1986 Oct;46(10):5426-30.
296. Rodriguez C, McCullough ML, Mondul AM, et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. *Cancer Epidemiol Biomarkers Prev.* 2003 Jul;12(7):597-603.
297. Ghent WR, Eskin BA, Low DA, Hill LP. Iodine replacement in fibrocystic disease of the breast. *Can J Surg.* 1993 Oct;36(5):453-60.
298. Zhang Z.F., et al., Boron is associated with decreased risk of human prostate cancer, *FASEB J.* 15: A 1089, 2001
299. Gallardo-Williams M.T., et al., Effects of boron supplementation on the morphology, PSA levels, and proliferative activity of LNCaP tumors in nude mice, *Proc Amer Assoc Cancer Res* 43: 77, 2002

300. Webber M.M., Waghray A., Bello D., Prostate- specific antigen, a serine protease, facilitates human prostate cancer cell invasion, *Clin Cancer Res* 1: 1089-94, 1995
301. Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. *Cell Biosci.* 2017;7:50.
302. Sung B, Chung HY, Kim ND. Role of apigenin in cancer prevention via the induction of apoptosis and autophagy. *J Cancer Prev.* 2016;21(4):216-226.
303. Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. *Anticancer Agents Med Chem.* 2013;13(7):971-978.
304. Hoensch H, Groh B, Edler L, Kirch W. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. *World J Gastroenterol.* 2008;14(14):2187-2193.
305. Mani R, Natesan V. Chrysin: sources, beneficial pharmacological activities, and molecular mechanism of action. *Phytochemistry.* 2018;145:187-196.
306. George VC, Dellaire G, Rupasinghe HPV. Plant flavonoids in cancer chemoprevention: role in genome stability. *J Nutr Biochem.* 2017;45:1-14.
307. Kasala ER, Bodduluru LN, Madana RM, et al. Chemopreventive and therapeutic potential of chrysin in cancer: mechanistic perspectives. *Toxicol Lett.* 2015;233(2):214-225.
308. Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. *Int J Nanomedicine.* 2017;12:2689-2702.
309. Walle T, Otake Y, Brubaker JA, et al. Disposition and metabolism of the flavonoid chrysin in normal volunteers. *Br J Clin Pharmacol.* 2001;51(2):143-146.
310. Campbell DR, Kurzer MS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. *J Steroid Biochem Mol Biol.* 1993;46(3):381-388.

311. van Meeuwen JA, Nijmeijer S, Mutarapat T, et al. Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts – a comparative study. *Toxicol Appl Pharmacol.* 2008;228(3):269-276.
312. Mohammed HA, Ba LA, Burkholz T, et al. Facile synthesis of chrysin-derivatives with promising activities as aromatase inhibitors. *Nat Prod Commun.* 2011;6(1):31-34.
313. Pistelli M, Mora AD, Ballatore Z, Berardi R. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects. *Curr Oncol.* 2018;25(2):e168-e175.
314. Manna PR, Molehin D, Ahmed AU. Dysregulation of aromatase in breast, endometrial, and ovarian cancers: an overview of therapeutic strategies. *Prog Mol Biol Transl Sci.* 2016;144:487-537.
315. Anand David AV, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. *Pharmacogn Rev.* 2016;10(20):84-89.
316. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M. Anticancer efficacy of polyphenols and their combinations. *Nutrients.* 2016;8(9).
317. Khan F, Niaz K, Maqbool F, et al. Molecular targets underlying the anticancer effects of quercetin: an update. *Nutrients.* 2016;8(9).
318. Kashyap D, Mittal S, Sak K, et al. Molecular mechanisms of action of quercetin in cancer: recent advances. *Tumour Biol.* 2016;37(10):12927-12939.
319. Stavic B. Quercetin in our diet: from potent mutagen to probable anticarcinogen. *Clin Biochem.* 1994 Aug;27(4):245-8.
320. Verma AK, Johnson JA, Gould MN, Tanner MA. Inhibition of 7,12-dimethylbenz(a)anthracene- and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. *Cancer Res.* 1988 Oct 15;48(20):5754-8.
321. Ranelletti FO, Ricci R, Larocca LM, Maggiano N, et al. Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary

- colorectal tumors. *Int J Cancer*. 1992 Feb 1;50(3):486-92.
322. Gibellini L, Pinti M, Nasi M, et al. Quercetin and cancer chemoprevention. *Evid Based Complement Alternat Med*. 2011;2011:591356.
323. Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. *Altern Med Rev*. 2000 Jun;5(3):196-208.
324. Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. *Mol Med Rep*. 2012;5(3):822-826.
325. Granado-Serrano AB, Martin MA, Bravo L, et al. Quercetin modulates Nrf2 and glutathione-related defenses in HepG2 cells: involvement of p38. *Chem Biol Interact*. 2012;195(2):154-164.
326. Granado-Serrano AB, Martin MA, Bravo L, et al. Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-kappaB pathway. *Nutr Cancer*. 2012;64(4):588-598.
327. Granado-Serrano AB, Martin MA, Bravo L, et al. Quercetin modulates NF-kappa B and AP-1/JNK pathways to induce cell death in human hepatoma cells. *Nutr Cancer*. 2010;62(3):390-401.
328. Senthilkumar K, Arunkumar R, Elumalai P, et al. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). *Cell Biochem Funct*. 2011;29(2):87-95.
329. Chou CC, Yang JS, Lu HF, et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. *Arch Pharm Res*. 2010;33(8):1181-1191.
330. Yuan H, Young CY, Tian Y, et al. Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. *Mol Cell Biochem*. 2010;339(1-2):253-262.
331. Nair HK, Rao KV, Aalinkeel R, et al. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates

- with modulation of specific regulatory genes. *Clin Diagn Lab Immunol.* 2004;11(1):63-69.
332. Wang H, Tao L, Qi K, et al. Quercetin reverses tamoxifen resistance in breast cancer cells. *J BUON.* 2015;20(3):707-713.
333. Li SZ, Li K, Zhang JH, Dong Z. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells. *Anticancer Agents Med Chem.* 2013;13(2):352-355.
334. Li X, Zhou N, Wang J, et al. Quercetin suppresses breast cancer stem cells (CD44+/CD24-) by inhibiting the PI3K/Akt/mTOR-signaling pathway. *Life Sci.* 2018;196:56-62.
335. Wang R, Yang L, Li S, et al. Quercetin inhibits breast cancer stem cells via downregulation of aldehyde dehydrogenase 1A1 (ALDH1A1), chemokine receptor type 4 (CXCR4), mucin 1 (MUC1), and epithelial cell adhesion molecule (EpCAM). *Med Sci Monit.* 2018;24:412-420.
336. Carrasco-Torres G, Monroy-Ramírez HC, Martínez-Guerra AA, et al. Quercetin reverses rat liver preneoplastic lesions induced by chemical carcinogenesis. *Oxid Med Cell Longev.* 2017;2017:4674918.
337. Dai W, Gao Q, Qiu J, et al. Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma. *Tumour Biol.* 2016;37(5):6307-6313.
338. Zhong X, Wu K, He S, et al. Effects of quercetin on the proliferation and apoptosis in transplantation tumor of breast cancer in nude mice [in Chinese]. *Sichuan Da Xue Xue Bao Yi Xue Ban.* 2003;34(3):439-442.
339. Du G, Lin H, Yang Y, et al. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. *Int Immunopharmacol.* 2010;10(7):819-826.
340. Luzzi C, Brisdelli F, Cinque B, et al. Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HBS-2) leukemia cells. *Biochem Pharmacol.* 2004, 68(10), 2019-2030.
341. Mahyar-Rocmer M, Katsen A, Mestres P, Roemer K. Resveratrol

- induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. *Int J Cancer*. 2001, 94(5), 615-622.
342. Kang JH, Park YH, Choi SW, et al. Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells. *Exp Mol Med*. 2003, 35(6), 467-474.
343. Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. *Eur J Nutr*. 2004, 43(5), 275-284.
344. Laux MT, Aregullin M, Berry JP, et al. Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol. *J Altern Complement Med*. 2004, 10(2), 235-239.
345. Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. *Oncol Rep*. 2004, 11(2), 441-446.
346. Scarlatti F, Sala G, Somenzi G, et al. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signalling. *Faseb J*. 2003, 17(15), 2339-2341.
347. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. *J Cell Physiol*. 1999, 179(3), 297-304.
348. Kim YA, Rhee SH, Park KY, Choi YH. Antiproliferative effect of resveratrol in human prostate carcinoma cells. *J Med Food*. 2003, 6(4), 273-280.
349. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. *Anticancer Res*. 2004, 24(5A), 2783-2840.
350. Joc AK, Liu H, Suzui M, et al. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. *Clin Cancer Res*. 2002, 8(3), 893-903.
351. Bernhard D, Tinhofer I, Tonko M, et al. Resveratrol causes arrest



- in the S-phase prior to Fas-independent apoptosis in CEM-C7112 acute leukemia. *Cell Death and Differentiation*. 2000, 7, 834-842.
352. Atten MJ, Godoy-Romero E, Attar BM, et al. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. *Invest New Drugs*. 2005, 23(2), 111-119.
353. Chen Y, Tseng SH, Lai HS, Chen WJ. Resveratrol induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. *Surgery*. 2004, 136(1), 57-66.
354. Tseng SH, Lin SM, Chen JC, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. *Clin Cancer Res*. 2004, 10(6), 2190-2202.
355. Liu HS, Pau CE, Yang W, Liu NM. Antitumor and immunomodulatory activity of resveratrol in experimentally implanted tumor of 1122 in Ball/c mice. *World J Gastroenterol*. 2003, 9(7), 1474-1476.
356. Seifo C, Candile V, Russo A, et al. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. *Oncol Res*. 2004, 14(9), 415-426.
357. Fuggetta MP, D'Atri S, Lanzilli G, et al. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. *Melanoma Res*. 2004, 14(3), 189-196.
358. Surh YJ, Hurh YJ, Kang JY, et al. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. *Cancer Lett*. 1999, 140(1-2), 1-10.
359. Tsan MF, White JE, Maheshwari JG, Chikkappa G. Anti-leukemia effect of resveratrol. *Leuk Lymphoma*. 2002, 43(5), 883-987.
360. Roman Y, Billard C, Kern C, et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukemia. *Br J Haematol*. 2002, 117(4), 842-851.
361. Lee EJ, Min HY, Joo Park H, et al. G2/M cell cycle arrest and induction of apoptosis by a stilbenoid, 3,4,5-trimethoxy-4'-bromo-cis-stilbene, in human lung cancer cells. *Life Sci*. 2004, 75(23), 2829-2839.

362. Gautam SC, Xu YX, Dumaguin M, et al. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. *Bone Marrow Transplant*. 2000, 25(6), 639-645.
363. Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. *Free Radic Biol Med*. 2002, 33(3), 387-398.
364. Gao X, Xu YX, Divine G, et al. Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. *J Nutr*. 2002, 132(7), 2076-2081.
365. Rimando AM, Cuender M, Desmarchelier C, et al. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogic of resveratrol. *J Agric Food Chem*. 2002, 50(12), 3453-3457.
366. Jang D-S, Kang B-S, Ryu SY, et al. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. *Biochemical Pharmacology*. 1999. 57, 6, 705-712.
367. Subbaramaiah K, Michaluart P, Chung WJ, et al. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. *Ann NY Acad Sci*. 1999;889:214-23.
368. Dybkowska E, Sadowska A, Swiderski F, et al. The occurrence of resveratrol in foodstuffs and its potential for supporting cancer prevention and treatment. A review. *Rocz Panstw Zakl Hig*. 2018;69(1):5-14.
369. Ren Z, Wang L, Cui J, et al. Resveratrol inhibits NF-κB signaling through suppression of p65 and IκappaB kinase activities. *Pharmazie*. 2013;68(8):689-694.
370. Kang J, Park Y, Choi S, et al. Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells. *Exp Mol Med*. 2003, 35, 467-474.
371. Asou H, Koshizuka K, Kyo T. et al. Resveratrol, a Natural Product Derived from Grapes, Is a New Inducer of Differentiation in Human Myeloid Leukemias. *Int J Hematol*. 2002, 75, 528-533.
372. Tsan M-f, White JE, Maheshwari JG, Chikkappa G. Anti-leukemia effect of resveratrol. *Leukemia & Lymphoma*. 2002, 43, 5.
373. Tessitore L, Davit A, Sarotto I, Caderni G. Resveratrol depresses

- the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. *Carcinogenesis*. 2000 Aug;21(8):1619-22.
374. Nakagawa H, Kiyozuka Y, Uemura Y, et al. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. *J Cancer Res Clin Oncol*. 2001, 127, 258–264.
375. Kimura Y, Okuda H. Resveratrol isolated from *Polygonum cuspidatum* root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. *The Journal of Nutrition*. 2001, 131, 6, 1844–1849.
376. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. *Nutrition and Cancer*. 2000, 37, 2.
377. Agarwal C, Sharma Y, Agarwal R. Anticarcinogenic effect of a polyphenolic fraction isolated from grape seeds in human prostate carcinoma DU145 cells: modulation of mitogenic signaling and cell-cycle regulators and induction of G1 arrest and apoptosis. *Molecular Carcinogenesis*. 2000, 28, 3, 129-138.
378. Tsan M-F, White JE, Maheshwari JG, et al. Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. *British Journal of Haematology*. 2000, 109, 2, 405-412.
379. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. *Blood*. 1998 Aug 1;92(3):996-1002.
380. Bernhard D, Tinhofer I, Tonko M, et al. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. *Cell Death Differ*. 2000, 7, 834–842.
381. Gao X, Xu YX, Janakiraman N, et al. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. *Biochem Pharmacol*. 2001 Nov 1;62(9):1299-308.
382. Ko JH, Sethi G, Um JY, et al. The role of resveratrol in cancer therapy. *Int J Mol Sci*. 2017;18(12).

383. Delmas D, Solary E, Latruffe N. Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. *Curr Med Chem*. 2011;18(8):1100-1121.
384. Zhu W, Qin W, Zhang K, et al. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. *Nutr Cancer*. 2012;64(3):393-400.
385. Chen F, Wen Q, Jiang J, et al. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? *J Ethnopharmacol*. 2016;179:253-264.
386. Stevens JF, Maier CS. The chemistry of gut microbial metabolism of polyphenols. *Phytochem Rev*. 2016;15(3):425-444.
387. Bode LM, Bunzel D, Huch M, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. *Am J Clin Nutr*. 2013;97(2):295-309.
388. Katiyar S, Mukhtar H. Tea in chemoprevention of cancer. *Int J Oncol*. 1996 Feb;8(2):221-38.
389. Koide T, Kamei H, Hashimoto Y, et al. Antitumor effect of hydrolyzed anthocyanin from grape rinds and red rice. *Cancer Biotherapy & Radiopharmaceuticals*. 1996, 11, 4, 273-277.
390. LeBon AM, Siess MH, Suschetet M. Inhibition of microsome-mediated binding of benzo[a]pyrene to DNA by flavonoids either in vitro or after dietary administration to rats. *Chem Biol Interactions*. 1992, 83, 1 65-71.
391. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. *Biochem Pharmacol*. 1983 Apr 1;32(7):1141-8.
392. Fujiki H. Plant flavonoids in biology and medicine. Biochemical, pharmacological, and structure-activity relationships. Proceedings of a symposium. Buffalo, New York, July 22-26, 1985. *Prog Clin Biol Res*. 1986;213:1-592.
393. Wattenberg L, Leong JL. Inhibition of the carcinogenic action of benzo(a)pyrene by flavones. *Cancer Research*. 1970, 30, 7.
394. Bray TM, Taylor CG. Enhancement of tissue glutathione for antioxidant and immune functions in malnutrition. *Biochem. Pharmacol*. 1994, 47, 12, 2113-2123.

395. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. *Pharmacol Ther.* 1991 Dec;52(3):287-305.
396. Beutler E, Gelbert T. Plasma glutathione in health and in patients with malignant diseases. *J Lab Clin Med.* 1985;105:581-584.
397. Hercbergs A, Brok-Simoni F, Holtzman F, et al. Erythrocyte glutathione and tumour response to chemotherapy. *Lancet.* 1992, 339, 8801, 1074-1076.
398. Di Re F, Bohm S, Oriana S, et al. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. *Cancer Chemother Pharmacol.* 1990;25(5):355-60.
399. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. *J Clin Oncol.* 1995 Jan;13(1):26-32.
400. Trickler D, Shklar G, Schwartz J. Inhibition of oral carcinogenesis by glutathione. *Nutr Cancer.* 1993;20(2):139-44.
401. Shklar G, Schwartz J, Trickler D, Cheverie SR. The effectiveness of a mixture of beta-carotene, alpha-tocopherol, glutathione, and ascorbic acid for cancer prevention. *Nutr Cancer.* 1993;20(2):145-51.
402. Novi AM. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. *Science.* 1981 May 1;212(4494):541-2.
403. Dalhoff K, Ranek L, Manton M, Poulsen HE. Glutathione treatment of hepatocellular carcinoma. *Liver.* 1992, 12, 5, 341-343.
404. Lash LH, Hagen TM, Jones DP. Exogenous glutathione protects intestinal epithelial cells from oxidative injury. *Proc. Natl. Acad. Sci.* 1986, 83, 4641-4645.
405. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. *Eur J Clin Pharmacol.* 1992;43(6):667-9.
406. Hagen TM, Wierzbicka GT, Sillau AH, et al. Bioavailability of

- dietary glutathione: effect on plasma concentration. *Am J Physiol.* 1990 Oct;259(4 Pt 1):G524-9.
407. Brittenden J, Park KG, Heys SD, et al. L-arginine stimulates host defenses in patients with breast cancer. *Surgery.* 1994 Feb;115(2):205-12.
408. Muhling J, Fuchs M, Fleck C, et al. Effects of arginine, L-alanyl-L-glutamine or taurine on neutrophil (PMN) free amino acid profiles and immune functions in vitro. *Amino Acids.* 2002;22(1):39-53.
409. Heys SD, Segar A, Payne A, et al. Dietary supplementation with l-arginine: Modulation of tumour-infiltrating lymphocytes in patients with colorectal cancer. *British Journal of Surgery.* 1997, 84, 2, 238–241.
410. Klimberg VS, Kornbluth J, Cao Y, et al. Glutamine suppresses PGE2 synthesis and breast cancer growth. *Journal of Surgical Research.* 1996, 63, 1, 293-297.
411. Klimberg VS, McClellan JL. Glutamine, cancer, and its therapy. *The American Journal of Surgery.* 1996, 172, 5, 418-424.
412. Klimberg VS, Nwokedi E, Hutchins LF, et al. Glutamine facilitates chemotherapy while reducing toxicity. *Journal of Parenteral and Enteral Nutrition.* 1992, 16, 65.
413. Yoshida S, Matsui M, Shirouzu Y, et al. Effects of glutamine supplements and radiochemotherapy on systemic immune and gut barrier function in patients with advanced esophageal cancer. *Ann Surg.* 1998;227(4):485-491.
414. Anderson PM, Ramsay NK, Shu XO, et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. *Bone Marrow Transplant.* 1998 Aug;22(4):339-44.
415. Morini M, Cai T, Aluigi MG, et al. The role of the thiol N-acetylcysteine in the prevention of tumor invasion and angiogenesis. *Int J Biol Markers.* 1999 Oct-Dec;14(4):268-71.
416. De Flora S, Izzoti A, D' Agostini F, Balansky RM. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. *Carcinogenesis.* 2001, 22, 7, 999–1013.

417. van Zandwijk N. N-Acetylcysteine for lung cancer prevention. *Chest Journal*. 1995, 107, 5, P1437-1441.
418. Albini A, D'Agostini F, Giunciuglio D, et al. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. *International Journal of Cancer*. 1995, 61, 1, 121-129.
419. Silva EO, Bracarense AP. Phytic acid: from antinutritional to multiple protection factor of organic systems. *J Food Sci*. 2016;81(6):R1357-R1362.
420. Bohn L, Meyer AS, Rasmussen SK. Phytate: impact on environment and human nutrition. A challenge for molecular breeding. *J Zhejiang Univ Sci B*. 2008;9(3):165-191.
421. Jariwalla RJ. Inositol hexaphosphate (IP6) as an anti-neoplastic and lipid-lowering agent. *Anticancer Res*. 1999, 19(5A), 3699-3702.
422. Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. *Anticancer Res*. 1999, 19(5A), 3671-3674.
423. Deschasaux M, Pouchieu C, His M, et al. Dietary total and insoluble fiber intakes are inversely associated with prostate cancer risk. *J Nutr*. 2014;144(4):504-510.
424. Pan P, Yu J, Wang LS. Colon cancer: what we eat. *Surg Oncol Clin N Am*. 2018;27(2):243-267.
425. Wang CH, Qiao C, Wang RC, Zhou WP. Dietary fiber intake and pancreatic cancer risk: a meta-analysis of epidemiologic studies. *Sci Rep*. 2015;5:10834.
426. Chen S, Chen Y, Ma S, et al. Dietary fibre intake and risk of breast cancer: a systematic review and meta-analysis of epidemiological studies. *Oncotarget*. 2016;7(49):80980-80989.
427. Tuan J, Chen YX. Dietary and lifestyle factors associated with colorectal cancer risk and interactions with microbiota: fiber, red or processed meat and alcoholic drinks. *Gastrointest Tumors*. 2016;3(1):17-24.
428. Shamsuddin AM. Metabolism and cellular functions of IP6: a review. *Anticancer Res*. 1999, 19(5A), 3733-3736.
429. Shamsuddin AM, Vucenik I, Cole KE. IP6: a novel anti-cancer

- agent. *Life Sci.* 1997, 61(4), 343-354.
430. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. *J Nutr.* 2003, 133(11 Suppl 1), 3778S-3784S.
431. Sakamoto K, Vucenik I, Shamsuddin AM. [<sup>3</sup>H]phytic acid (inositol hexaphosphate) is absorbed and distributed to various tissues in rats. *J Nutr.* 1993, 123(4), 713-720.
432. Vucenik I, Shamsuddin AM. [<sup>3</sup>H]inositol hexaphosphate (phytic acid) is rapidly absorbed and metabolized by murine and human malignant cells in vitro. *J Nutr.* 1994, 124(6), 861-868.
433. Shamsuddin AM, Baten A, Lalwani ND. Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. *Cancer Lett.* 1992, 64(3), 195-202.
434. Deliliers GL, Servida F, Fracchiola NS, et al. Effect of inositol hexaphosphate (IP(6)) on human normal and leukemic hematopoietic cells. *Br J Haematol.* 2002, 117(3), 577-587.
435. Sakamoto K, Venkatraman G, Shamsuddin AM. Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). *Carcinogenesis.* 1993, 14(9), 1815-1819.
436. Yang GY, Shamsuddin AM. IP-6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates. *Anticancer Res.* 1995, 15(6B), 2479-2487.
437. Vucenik I, Tantivejkul K, Zhang ZS, et al. IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. *Anticancer Res.* 1998, 18(6A), 4083-4090.
438. Shamsuddin AM, Yang GY, Vucenik I. Novel anti-cancer functions of IP6: growth inhibition and differentiation of human mammary cancer cell lines in vitro. *Anticancer Res.* 1996, 16(6A), 3287-3292.
439. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. *Carcinogenesis.* 1995, 16(8), 1975-1979.



440. Nawrocka-Musial D, Latocha M. Phytic acid – anticancer nutraceutical [in Polish]. *Pol Merkur Lekarski*. 2012;33(193):43-47.
441. Silva EO, Bracarense AP. Phytic acid: from antinutritional to multiple protection factor of organic systems. *J Food Sci*. 2016;81(6):R1357-R1362.
442. Bizzarri M, Dinicola S, Bevilacqua A, Cucina A. Broad spectrum anticancer activity of myo-inositol and inositol hexakisphosphate. *Int J Endocrinol*. 2016;2016:5616807.
443. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum and neoplastic agent: a systematic review. *Complement Ther Med*. 2002, 10(4), 229-234.
444. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. *J Nutr*. 2003, 133(11 Suppl 1), 3778S-3784S.
445. Bacic I, Druzijanic N, Karlo R, et al. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. *J Exp Clin Cancer Res*. 2010;29:12.
446. Druzijanic N, Juricic J, Perko Z, Kraljevic D. IP6 + inositol as adjuvant to chemotherapy of colon cancer: our clinical experience. *Anticancer Res*. 2004;24(5D)(suppl):3474. Abstract 125.
447. Juricic J, Druzijanic N, Perko Z, et al. IP6 + inositol in treatment of ductal invasive breast carcinoma: our clinical experience. *Anticancer Res*. 2004;24(5):3475.
448. Graf E, Eaton JW. Antioxidant functions of phytic acid. *Free Radic Biol Med*. 1990, 8(1), 61-69.
449. Baten A, Ullah A, Tomazic VJ, Shamsuddin AM, Inositol-phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression. *Carcinogenesis*. 1989, 10, 9, 1595-1598.
450. Sakamoto K, Venkatraman G, Shamsuddin AM, Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). *Carcinogenesis*. 1993, 14, 9, 1815-1819.

451. Shamsuddin AM, Ullah A. Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. *Carcinogenesis*. 1989 Mar;10(3):625-6.
452. Shamsuddin AM, Yang GY, Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. *Carcinogenesis*. 1995, 16, 8, 1975-1979.
453. Shamsuddin AM. Metabolism and cellular functions of IP6: a review. *Anticancer Research*. 1999, 19, 3733-3736.
454. Verghese M, Rao DR, Chawan CB, et al. Anticarcinogenic effect of phytic acid (IP6): Apoptosis as a possible mechanism of action. *WT- Food Science and Technology*. 2006, 39(10):1093-1098.
455. Deliliers GL, Servida F, Fracchiolla NS, et al. Effect of inositol hexaphosphate (IP6) on human normal and leukaemic haematopoietic cells. *British Journal of Haematology*. 2002, 117, 3, 577-587.
456. Shamsuddin AM, Baten A, Lalwani ND. Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. *Cancer Letters*. 1992, 64, 3, 195-202.
457. Vucenik I, Druzijanic A, Druzijanic J, et al. Inositol hexaphosphate (IP6) and colon cancer: from concepts and first experiments to clinical application. *Molecules* 2020, 25, 5931.
458. Liu X, Liu C, Chen C, et al. Combination of inositol hexaphosphate and inositol inhibits liver metastasis of colorectal cancer in mice through the Wnt/ $\beta$ -catenin pathway. *Onco Targets Ther*. 2020 Apr 16;13:3223-3235.
459. Raz A, Lotan R, Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. *Cancer Metastasis Rev*. 1987, 6(3): 433-52.
460. Bresalier RS, et al. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. *Cancer*. 1997. 80(4): 776-87.
461. Leclere L, Cutsem PV, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. *Front Pharmacol*. 2013;4:128.
462. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic

- properties: one bullet, multiple targets. *Carbohydr Res.* 2009;344(14):1788-1791.
463. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. *World J Gastroenterol.* 2008;14(48):7386-7391.
464. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. *J Natl Cancer Inst.* 1995;87(5):348-353.
465. Pienta KJ, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. *J Natl Cancer Inst.* 1995, 87(5):348-53.
466. Strum S. et al. Modified citrus pectin slows PSA doubling time: a pilot clinical trial, Paper presented at: International Conference on Diet and Prevention of Cancer, May 1999, Tampere, Finland
467. Guess BW, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. *Prostate Cancer Prostatic Dis.* 2003, 6(4):301-4.
468. Eliaz I., Modified citrus pectin in the prevention and treatment of cancer: recent promising results. *Better health Pub, Research Update*, Feb 2003.
469. Nangia-Makker P. et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. *J Natl Cancer Inst.* 2002, 94(24): 1854-62.
470. Leclere L, Cutsem PV, Michiels C. Anti-cancer activities of pH- or heat-modified pectin. *Front Pharmacol.* 2013;4:128.
471. Keizman D, Frenkel MA, Edwards TM, et al. Effect of PectaSol-C modified citrus pectin (P-MCP) treatment (tx) on PSA dynamics in patients (pts) with nonmetastatic, biochemically relapsed prostate cancer (BRPC): results of the interim analysis of a prospective phase II study. *J Clin Oncol.* 2017;35(15 suppl):e16588.
472. Ooi SL, McMullen D, Golombick T, et al. Evidence-based review of BioBran/MGN-3 arabinoxylan compound as a complementary therapy for conventional cancer treatment. *Integr Cancer Ther.* 2018;17(2):165-178.

473. Badr El-Din NK, Abdel Fattah SM, Pan D, Tolentino L, Ghoneum M. Chemopreventive activity of MGN-3/Biobran against chemical induction of glandular stomach carcinogenesis in rats and its apoptotic effect in gastric cancer cells. *Integr Cancer Ther.* 2016;15(4):NP26-NP34.
474. Badr El-Din NK, Noaman E, Ghoneum M. In vivo tumor inhibitory effects of nutritional rice bran supplement MGN-3/Biobran on Ehrlich carcinoma-bearing mice. *Nutr Cancer.* 2008;60(2):235-244.
475. Kim HY, Kim JH, Yang SB, et al. A polysaccharide extracted from rice bran fermented with *Lentinus edodes* enhances natural killer cell activity and exhibits anticancer effects. *J Med Food.* 2007;10(1):25-31.
476. Noaman E, Badr El-Din NK, Bibars MA, et al. Antioxidant potential by arabinoxylan rice bran, MGN-3/biobran, represents a mechanism for its oncostatic effect against murine solid Ehrlich carcinoma. *Cancer Lett.* 2008;268(2):348-359.
477. Ghoneum M, Agrawal S. Activation of human monocyte-derived dendritic cells in vitro by the biological response modifier arabinoxylan rice bran (MGN-3/Biobran). *Int J Immunopathol Pharmacol.* 2011;24(4):941-948.
478. Ghoneum M, Jewett A. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. *Cancer Detect Prev.* 2000;24(4):314-324.
479. Ghoneum M, Abedi S. Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). *J Pharm Pharmacol.* 2004;56(12):1581-1588.
480. Cholujova D, Jakubikova J, Sedlak J. BioBran-augmented maturation of human monocyte-derived dendritic cells. *Neoplasma.* 2009;56(2):89-95.
481. Cholujova D, Jakubikova J, Czako B, et al. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. *Cancer Immunol Immunother.* 2013;62(3):437-445.

482. Zhu X, Okubo A, Igari N, et al. Modified rice bran hemicellulose inhibits vascular endothelial growth factor-induced angiogenesis in vitro via VEGFR2 and its downstream signaling pathways. *Biosci Microbiota Food Health*. 2017;36(2):45-53.
483. Bang MH, Van Riep T, Thinh NT, et al. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. *Anticancer Res*. 2010;30(12):5145-5151.
484. Gollapudi S, Ghoneum M. MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. *Cancer Detect Prev*. 2008;32(1):1-6.
485. Ghoneum M, Badr El-Din NK, Ali DA, El-Dein MA. Modified arabinoxylan from rice bran, MGN-3/biobran, sensitizes metastatic breast cancer cells to paclitaxel in vitro. *Anticancer Res*. 2014;34(1):81-87.
486. Badr El-Din NK, Ali DA, Alaa El-Dein M, Ghoneum M. Enhancing the apoptotic effect of a low dose of paclitaxel on tumor cells in mice by arabinoxylane rice bran (MGN-3/Biobran). *Nutr Cancer*. 2016;68(6):1010-1020.
487. Ghoneum M, Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro. *Neoplasma*. 2011;58(2):118-123.
488. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Addition of rice bran arabinoxylan to curcumin therapy may be of benefit to patients with early-stage B-cell lymphoid malignancies (monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia): a preliminary clinical study. *Integr Cancer Ther*. 2016;15(2):183-189.
489. Goyal A, Sharma V, Upadhyay N, Gill S, Sihag M. Flax and flaxseed oil: an ancient medicine & modern functional food. *J Food Sci Technol*. 2014;51(9):1633-1653.
490. Adolphe JL, Whiting SJ, Juurlink BH, et al. Health effects with

- consumption of the flax lignan secoisolariciresinol diglucoside. *Br J Nutr.* 2010;103(7):929-938.
491. Lecomte S, Demay F, Ferrière F, Pakdel F. Phytochemicals targeting estrogen receptors: beneficial rather than adverse effects? *Int J Mol Sci.* 2017;18(7).
492. Landete JM, Gaya P, Rodriguez E, et al. Probiotic bacteria for healthier aging: immunomodulation and metabolism of phytoestrogens. *Biomed Res Int.* 2017;2017:5939818.
493. Landete JM, Arques J, Medina M, Gaya P, de Las Rivas B, Munoz R. Bioactivation of phytoestrogens: intestinal bacteria and health. *Crit Rev Food Sci Nutr.* 2016;56(11):1826-1843.
494. Flower G, Fritz H, Balneaves LG, et al. Flax and breast cancer: a systematic review. *Integr Cancer Ther.* 2014;13(3):181-192.
495. Calado A, Neves PM, Santos T, Ravasco P. The effect of flaxseed in breast cancer: a literature review. *Front Nutr.* 2018;5:4.
496. DeLuca JAA, Garcia-Villatoro EL, Allred CD. Flaxseed bioactive compounds and colorectal cancer prevention. *Curr Oncol Rep.* 2018;20(8):59.
497. Neill AS, Ibiebele TI, Lahmann PH, et al. Dietary phytoestrogens and the risk of ovarian and endometrial cancers: findings from two Australian case-control studies. *Br J Nutr.* 2014;111(8):1430-1440.
498. Horn-Ross PL, John EM, Canchola AJ, et al. Phytoestrogen intake and endometrial cancer risk. *J Natl Cancer Inst.* 2003;95(15):1158-1164.
499. He J, Wang S, Zhou M, et al. Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies. *World J Surg Oncol.* 2015;13:231.
500. Thompson LU, Chen JM, Li T, et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. *Clin Cancer Res.* 2005;11(10):3828-3835.
501. Azrad M, Vollmer RT, Madden J, et al. Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. *J Med Food.* 2013;16(4):357-360.

502. McCann SE, Thompson LU, Nie J, et al. Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. *Breast Cancer Res Treat.* 2010;122(1):229-235.
503. Buck K, Vrieling A, Zaineddin AK, et al. Serum enterolactone and prognosis of postmenopausal breast cancer. *J Clin Oncol.* 2011;29(28):3730-3738.
504. Seibold P, Vrieling A, Johnson TS, et al. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. *Int J Cancer.* 2014;135(4):923-933.
505. Mason JK, Thompson LU. Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? *Appl Physiol Nutr Metab.* 2014;39(6):663-678.
506. Fowke J.H., et al., Urinary isothiocyanate levels, brassica, and human breast cancer, *Cancer Res*, 63(14): 3980-6, 2003
507. Kim Y.S., Milner J.A., Targets for indole-3-carbinol in cancer prevention, *J Nutr Biochem*, 16(2):65-73, 2005
508. Michnovicz J.I., Bradlow H.L., Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol, *Nutr Cancer*, 16 (1) : 59 - 66, 1991
509. Telang N.T., et al., Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol, *Proc Soc Exp Biol Med*, 216(2):246-52, 1997
510. Aggarwal B.B., Ichikawa H., Molecular targets and anticancer potential of indole-3-carbinol and its derivatives, *Cell Cycle*, 4(9):1201-15, 2005
511. Nachshon-Kedmi M., et al., Indole-3-carbinol and 3,3-diindolylmethane induce apoptosis in human prostate cancer cells, *Food Chem Toxicol*, 41(6):745-52, 2003
512. Zhang Y., et al., Selected isothiocyanates rapidly induce growth inhibition of cancer cells, *Mol Cancer Thes* 2(10): 1045-52, 2003
513. Cover C.M., et al., Indole-3-carbinol inhibits the expression of

- cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling, *J Biochem*, 273(7):3838-47, 1998
514. Sarkar F.H., Rahman K.M., L.Y., Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells, *J Nutr*. 133(7 suppl): 2434S-9S, 2003
515. Muti O., et al., Estrogen metabolism and the risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women, *Epidemiology*, 11(6):635-40, 2000
516. Michnovicz J.J. et al., Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans, *J Natl Cancer Inst*, 89(10):718-23, 1997
517. Michnovicz J.J., Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol, *Int J Obes Relat Metab Disord*, 22(3): 227-9, 1998
518. Bradlow H.L., et al., 2-hydroxyestrone: the "good" estrogen, *J Endocrinol*, 150 Suppl, S259-65, 1996
519. Yoo H.J. et al., Estrogen metabolism as a risk factor for head and neck cancer, *Otolaryngol Head Neck Surg*, 124(3): 241-7, 2001
520. Jin L., et al., Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16(HPV16) transgenic mice, *Cancer Res*, 59(16):3991-7, 1999
521. Telang N.T., et al., Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol, *Proc Soc Exp Biol Med*, 216(2):246-52, 1997
522. Carter T.H., et al., Diindolymethane alters gene expression in human keratinocytes in vitro, *J Nutr*, 137(11):3314-24, 2002
523. Xue L., et al., DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways, *Oncogene*, 24(14): 2343-53, 2005
524. Sun S., et al., Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolymethane



- in vitro, *Cell Stress Chaperones*, 9(1): 76-87, 2004
525. Nachschon-Kedmi M., et al., Indole-3-carbinol and 3,3-diindolylmethane induce apoptosis in human prostate cancer cells, *Food Chem Toxicol*, 41(6):745-52, 2003
526. Li Y., et al., Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappa B pathways in prostate cancer cells, *Front Biosci*, 10:236-43, 2005
527. Chang X., et al., 3,3-diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice, *Carcinogenesis*, 26(4):771-8, 2005
528. Johanningsmeier SD, Harris GK. Pomegranate as a functional food and nutraceutical source. *Annu Rev Food Sci Technol*. 2011;2:181-201.
529. Syed DN, Chamcheu JC, Adhami VM, Mukhtar H. Pomegranate extracts and cancer prevention: molecular and cellular activities. *Anticancer Agents Med Chem*. 2013;13(8):1149-1161.
530. Turrini E, Ferruzzi L, Fimognari C. Potential effects of pomegranate polyphenols in cancer prevention and therapy. *Oxid Med Cell Longev*. 2015;2015:938475.
531. Wang L, Martins-Green M. Pomegranate and its components as alternative treatment for prostate cancer. *Int J Mol Sci*. 2014;15(9):14949-14966.
532. Adhami VM, Siddiqui IA, Syed DN, et al. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. *Carcinogenesis*. 2012;33(3):644-651.
533. Albrecht M, Jiang W, Kumi-Diaka J, et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. *J Med Food*. 2004;7(3):274-283.
534. Lansky EP, Jiang W, Mo H, et al. Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. *Invest New Drugs*. 2005;23(1):11-20.
535. Hong MY, Seeram NP, Heber D. Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. *J Nutr Biochem*. 2008;19(12):848-855.

536. Rettig MB, Heber D, An J, et al. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. *Mol Cancer Ther.* 2008;7(9):2662-2671.
537. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. *Clin Cancer Res.* 2006;12(13):4018-4026.
538. Paller CJ, Ye X, Wozniak PJ, et al. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. *Prostate Cancer Prostatic Dis.* 2013;16(1):50-55.
539. Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (*Punica granatum*) for human breast cancer. *Breast Cancer Res Treat.* 2002;71(3):203-217.
540. Mehta R, Lansky EP. Breast cancer chemopreventive properties of pomegranate (*Punica granatum*) fruit extracts in a mouse mammary organ culture. *Eur J Cancer Prev.* 2004;13(4):345-348.
541. Grossmann ME, Mizuno NK, Schuster T, Cleary MP. Punicic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation. *Int J Oncol.* 2010;36(2):421-426.
542. Toi M, Bando H, Ramachandran C, et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. *Angiogenesis.* 2003;6(2):121-128.
543. Banerjee S, Kambhampati S, Haque I, Banerjee SK. Pomegranate sensitizes Tamoxifen action in ER- $\alpha$  positive breast cancer cells. *J Cell Commun Signal.* 2011 Dec;5(4):317-24.
544. Kohno H, Suzuki R, Yasui Y, et al. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. *Cancer Sci.* 2004;95(6):481-486.
545. Waly MI, Ali A, Guizani N, et al. Pomegranate (*Punica granatum*) peel extract efficacy as a dietary antioxidant against azoxymethane-induced colon cancer in rat. *Asian Pac J Cancer Prev.* 2012;13(8):4051-4055.

546. Husari A, Hashem Y, Zaatari G, El Sabban M. Pomegranate juice prevents the formation of lung nodules secondary to chronic cigarette smoke exposure in an animal model. *Oxid Med Cell Longev.* 2017;2017:6063201.
547. Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H. Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. *Cancer Res.* 2007;67(7):3475-3482.
548. Khan N, Hadi N, Afaq F, et al. Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. *Carcinogenesis.* 2007;28(1):163-173.
549. Adams LS, Seeram NP, Aggarwal BB, et al. Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. *J Agric Food Chem.* 2006;54(3):980-985.
550. Larrosa M, Tomas-Barberan FA, Espin JC. The dietary hydrolysable tannin punicalagin releases ellagic acid that induces apoptosis in human colon adenocarcinoma Caco-2 cells by using the mitochondrial pathway. *J Nutr Biochem.* 2006;17(9):611-625.
551. Adams LS, Zhang Y, Seeram NP, et al. Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. *Cancer Prev Res (Phila).* 2010;3(1):108-113.
552. Gaascht F, Dicato M, Diederich M. Coffee provides a natural multitarget pharmacopeia against the hallmarks of cancer. *Genes Nutr.* 2015;10(6):51.
553. Caporaso N, Genovese A, Canela MD, et al. Neapolitan coffee brew chemical analysis in comparison to espresso, moka and American brews. *Food Res Int.* 2014;61:152-160.
554. Rodrigues NP, Toledo Benassi M, Bragagnolo N. Scavenging capacity of coffee brews against oxygen and nitrogen reactive species and the correlation with bioactive compounds by multivariate analysis. *Food Res Int.* 2013;61:228-235.
555. Vicente SJV, Queiroz YS, Gotlieb SLD, Torres EAFdS. Stability of

- phenolic compounds and antioxidant capacity of regular and decaffeinated coffees. *Braz Arch Biol Technol.* 2014;57:110–118.
556. Bravo J, Arbillaga L, de Pena MP, Cid C. Antioxidant and genoprotective effects of spent coffee extracts in human cells. *Food Chem Toxicol.* 2013;60:397–403.
557. Bakuradze T, Lang R, Hofmann T, et al. Consumption of a dark roast coffee decreases the level of spontaneous DNA strand breaks: a randomized controlled trial. *Eur J Nutr.* 2015;54:149–156.
558. Cheong MW, Tong KH, Ong JJM, et al. Volatile composition and antioxidant capacity of Arabica coffee. *Food Res Int.* 2013;51:388–396.
559. Niseteo T, Komes D, Belscak-Cvitanovic A, et al. Bioactive composition and antioxidant potential of different commonly consumed coffee brews affected by their preparation technique and milk addition. *Food Chem.* 2012;134:1870–1877.
560. Perrone D, Farah A, Donangelo CM. Influence of coffee roasting on the incorporation of phenolic compounds into melanoidins and their relationship with antioxidant activity of the brew. *J Agric Food Chem.* 2012;60:4265–4275.
561. Troup GJ, Navarini L, Suggi Liverani F, Drew SC. Stable radical content and anti-radical activity of roasted Arabica coffee: from in-tact bean to coffee brew. *PLoS One.* 2015;10:e0122834.
562. Del Pino-Garcia R, Gonzalez-SanJose ML, Rivero-Perez MD, Muniz P. Influence of the degree of roasting on the antioxidant capacity and genoprotective effect of instant coffee: contribution of the melanoidin fraction. *J Agric Food Chem.* 2012;60:10530–10539.
563. Ferk F, et al. Protective effects of coffee against induction of DNA damage and pre-neoplastic foci by aflatoxin B1. *Mol Nutr Food Res.* 2014;58:229–238.
564. Majer BJ, et al. Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2) *Food Chem Toxicol.* 2005;43:433–441.

565. Lee KJ, Jeong HG. Protective effects of kahweol and cafestol against hydrogen peroxide-induced oxidative stress and DNA damage. *Toxicol Lett.* 2007;173:80–87.
566. Bichler J, et al. Coffee consumption protects human lymphocytes against oxidative and 3-amino-1-methyl-5H-pyrido[4,3-b]indole acetate (Trp-P-2) induced DNA-damage: results of an experimental study with human volunteers. *Food Chem Toxicol.* 2007;45:1428–1436.
567. Huber WW, Scharf G, Nagel G, et al. Coffee and its chemopreventive components kahweol and cafestol increase the activity of O6-methylguanine-DNA methyltransferase in rat liver—comparison with phase II xenobiotic metabolism. *Mutat Res.* 2003;522:57–68.
568. Silva JA, Borges N, Santos A, Alves A. Method validation for cafestol and kahweol quantification in coffee brews by HPLC-DAD. *Food Anal Methods.* 2012;5:1404–1410.
569. Tsabar M, et al. Caffeine impairs resection during DNA break repair by reducing the levels of nucleases Sae2 and Dna2. *Nucleic Acids Res.* 2015;43:6889.
570. Alao JP, Sunnerhagen P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. *Radiat Oncol.* 2009;4:51.
571. Bufalo MC, et al. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF- $\kappa$ B and MAPK activation in macrophages. *J Ethnopharmacol.* 2013;149:84–92.
572. Sato Y, et al. In vitro and in vivo antioxidant properties of chlorogenic acid and caffeic acid. *Int J Pharm.* 2011;403:136–138.
573. Bacanlı M, Taner G, Goktaş HG, et al. The protective role of ferulic acid on sepsis-induced oxidative damage in Wistar albino rats. *Environ Toxicol Pharmacol.* 2014;38:774–782.
574. Maurya DK, Devasagayam TPA. Ferulic acid inhibits gamma radiation-induced DNA strand breaks and enhances the survival of mice. *Cancer Biother Radiopharm.* 2013;28:51–57.
575. Ambothi K, Nagarajan RP. Ferulic acid prevents ultraviolet-B

- radiation induced oxidative DNA damage in human dermal fibroblasts. *Int J Nutr Pharmacol Neurol Dis.* 2014;4:203.
576. Winkler S, et al. Modulation of inflammatory gene transcription after long-term coffee consumption. *Food Res Int.* 2014;63:428–438.
577. Moreira MEC, et al. Anti-inflammatory effect of aqueous extracts of roasted and green *Coffea arabica* L. *J Funct Foods.* 2013;5:466–474.
578. Cardenas C, Quesada AR, Medina MA. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. *PLoS One.* 2011;6:e23407.
579. Kim HG, et al. The coffee diterpene kahweol inhibits metastasis by modulating expressions of MMPs and VEGF via STAT3 inactivation. *Food Chem.* 2012;133:1521–1529.
580. Boettler U, et al. Coffees rich in chlorogenic acid or N-methylpyridinium induce chemopreventive phase II-enzymes via the Nrf2/ARE pathway in vitro and in vivo. *Mol Nutr Food Res.* 2011;55:798–802.
581. Volz N, et al. Effect of coffee combining green coffee bean constituents with typical roasting products on the Nrf2/ARE pathway in vitro and in vivo. *J Agric Food Chem.* 2012;60:9631–9641.
582. Bufalo MC, et al. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF- $\kappa$ B and MAPK activation in macrophages. *J Ethnopharmacol.* 2013;149:84–92.
583. Hwang SJ, Kim YW, Park Y, Lee HJ, Kim KW. Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells. *Inflamm Res.* 2014;63:81–90.
584. Kwak SC, et al. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor  $\kappa$ -B ligand-induced nuclear factor of activated T cells c1 expression. *Biol Pharm Bull.* 2013;36:1779–1786.
585. Shi H, et al. Chlorogenic acid reduces liver inflammation

- and fibrosis through inhibition of toll-like receptor 4 signaling pathway. *Toxicology*. 2013;303:107–114.
586. Barcelos RP, et al. Caffeine intake may modulate inflammation markers in trained rats. *Nutrients*. 2014;6:1678–1690.
587. Shim SG, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. *J Gastroenterol Hepatol*. 2013;28:1877–1884.
588. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. *Hepatology*. 2010;51:201–209.
589. Chu YF, Hu K, Hatzold T, Black RM, Chen D. Flaking process increases the NF- $\kappa$ B inhibition activity and melanoidin extractability of coffee. *Food Sci Nutr*. 2013;1:363–368.
590. Chen Y, Brown PH, Hu K, et al. Supercritical CO<sub>2</sub> decaffeination of unroasted coffee beans produces melanoidins with distinct NF- $\kappa$ B inhibitory activity. *J Food Sci*. 2011;76:H182–H186.
591. Kim HG, et al. The coffee diterpene kahweol inhibits metastasis by modulating expressions of MMPs and VEGF via STAT3 inactivation. *Food Chem*. 2012;133:1521–1529.
592. Rosendahl AH, et al. Caffeine and caffeic acid inhibit growth and modify estrogen receptor (ER)- $\alpha$  and insulin-like growth factor I receptor (IGF-IR) levels in human breast cancer. *Cancer Res*. 2014;74:4685.
593. Lu G-Y, Huang S-M, Liu S-T, et al. Caffeine induces tumor cytotoxicity via the regulation of alternative splicing in subsets of cancer-associated genes. *Int J Biochem Cell Biol*. 2014;47:83–92.
594. Styer AM, Roesch SL, Argyropoulos G. Modulation of fibroblast growth factor 19 expression by bile acids, meal replacement and energy drinks, milk, and coffee. *PLoS One*. 2014;9:e85558.
595. Chen J-C, Hwang J-H, Chiu W-H, Chan Y-C. Tetrandrine and caffeine modulated cell cycle and increased glioma cell death via caspase-dependent and caspase-independent apoptosis pathways. *Nutr Cancer*. 2014;66:700–706.
596. Saiki S, et al. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. *Autophagy*.

- 2011;7:176.
597. Zhao L, Su J, Li L, et al. Mechanistic elucidation of apoptosis and cell cycle arrest induced by 5-hydroxymethylfurfural, the important role of ROS-mediated signaling pathways. *Food Res Int.* 2014;66:186–196.
598. Oleaga C, Noe V, Izquierdo-Pulido M. Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells. *Oxid Med Cell Longev.* 2012.
599. Janicke B, Hegardt C, Krogh M, et al. The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells. *Nutr Cancer.* 2011;63:611–622.
600. Prabhakar MM, Vasudevan K, Karthikeyan S, et al. Anti-cell proliferative efficacy of ferulic acid against 7, 12-dimethylbenz (a) anthracene induced hamster buccal pouch carcinogenesis. *Asian Pac J Cancer Prev.* 2012;13:5207–5211.
601. Langner E, Nunes FM, Pożarowski P, et al. Melanoidins isolated from heated potato fiber (Potex) affect human colon cancer cells growth via modulation of cell cycle and proliferation regulatory proteins. *Food Chem Toxicol.* 2013;57:246–255.
602. Cardenas C, Quesada AR, Medina MA. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. *PLoS One.* 2011;6:e23407.
603. Kim HG, et al. The coffee diterpene kahweol inhibits metastasis by modulating expressions of MMPs and VEGF via STAT3 inactivation. *Food Chem.* 2012;133:1521–1529.
604. Wang S, Yoon YC, Sung MJ, et al. Antiangiogenic properties of cafestol, a coffee diterpene, in human umbilical vein endothelial cells. *Biochem Biophys Res Commun.* 2012;421:567–571.
605. Li H, Jin SY, Son HJ, Seo JH, Jeong GB. Caffeine-induced endothelial cell death and the inhibition of angiogenesis. *Anat Cell Biol.* 2013;46:57–67.
606. Yeh CH, et al. Caffeine treatment disturbs the angiogenesis of zebrafish embryos. *Drug Chem Toxicol.* 2012;35:361–365.
607. Kim C, Yu HG, Sohn J. The anti-angiogenic effect of chlorogenic



- acid on choroidal neovascularization. *Korean J Ophthalmol.* 2010;24:163–168.
608. Kong CS, Jeong CH, Choi JS, et al. Antiangiogenic effects of p-coumaric acid in human endothelial. *Cells Phytother Res.* 2013;27:317–323.
609. Liu WH, Chang LS. Caffeine induces matrix metalloproteinase-2 (MMP-2) and MMP-9 down-regulation in human leukemia U937 cells via Ca<sup>2+</sup>/ROS-mediated suppression of ERK/c-fos pathway and activation of p38 MAPK/c-jun pathway. *J Cell Physiol.* 2010;224:775–785.
610. Lu G-Y, Huang S-M, Liu S-T, et al. Caffeine induces tumor cytotoxicity via the regulation of alternative splicing in subsets of cancer-associated genes. *Int J Biochem Cell Biol.* 2014;47:83–92.
611. Chen Y, Chou W-C, Ding Y-M, Wu Y-C. Caffeine inhibits migration in glioma cells through the ROCK-FAK pathway. *Cell Physiol Biochem.* 2014;33:1888–1898.
612. Cardenas C, Quesada AR, Medina MA. Anti-angiogenic and anti-inflammatory properties of kahweol, a coffee diterpene. *PLoS One.* 2011;6:e23407.
613. Kim C, Yu HG, Sohn J. The anti-angiogenic effect of chlorogenic acid on choroidal neovascularization. *Korean J Ophthalmol.* 2010;24:163–168.
614. Kang NJ, et al. Coffee phenolic phytochemicals suppress colon cancer metastasis by targeting MEK and TOPK. *Carcinogenesis.* 2011;32:921–928.
615. Alicandro G, Tavani A, La Vecchia C. Coffee and cancer risk: a summary overview. *Eur J Cancer Prev.* 2017;26(5):424-432.
616. Arab L. Epidemiologic evidence on coffee and cancer. *Nutr Cancer.* 2010;62(3):271-283.
617. Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. *J Natl Cancer Inst.* 2011;103(11):876-884.
618. Guercio BJ, Sato K, Niedzwiecki D, et al. Coffee intake, recurrence, and mortality in stage III colon cancer: results from CALGB 89803 (Alliance). *J Clin Oncol.* 2015;33(31):3598-3607.

619. Hu Y, Ding M, Yuan C, et al. Association between coffee intake after diagnosis of colorectal cancer and reduced mortality. *Gastroenterology*. 2018;154(4):916-926.e9.
620. Rosendahl AH, Perks CM, Zeng L, et al. Caffeine and caffeic acid inhibit growth and modify estrogen receptor and insulin-like growth factor I receptor levels in human breast cancer. *Clin Cancer Res*. 2015;21(8):1877-1887.
621. Simonsson M, Soderlind V, Henningson M, et al. Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status. *Cancer Causes Control*. 2013;24(5):929-940.
622. Nkondjock A, Ghadirian P, Kotsopoulos J, et al. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Cancer*. 2006;118(1):103-107.
623. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. *BMC Cancer*. 2011;11:96.
624. Ferrucci LM, Cartmel B, Molinaro AM, et al. Tea, coffee, and caffeine and early-onset basal cell carcinoma in a case-control study. *Eur J Cancer Prev*. 2014;23:296–302.
625. Giri A, Sturgeon SR, Luisi N, et al. Caffeinated coffee, decaffeinated coffee and endometrial cancer risk: a prospective cohort study among US postmenopausal women. *Nutrients*. 2011;3:937–950.
626. Hildebrand JS, Patel AV, McCullough ML, et al. Coffee, tea, and fatal oral/pharyngeal cancer in a large prospective US cohort. *Am J Epidemiol*. 2013;177:50–58.
627. Nakano H, Namatame K, Nemoto H, et al. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. *Hepatogastroenterology*. 1999 Jul-Aug;46(28):2662-8.
628. Oba K, Kobayashi M, Matsui T, et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric

- cancer. *Anticancer Res.* 2009 Jul;29(7):2739-45.
629. Han J. Traditional Chinese medicine and the search for new antineoplastic drugs. *J Ethnopharmacol.* 1988 Sep;24(1):1-17.
630. Nanba H. Antitumor activity of orally administered "D-fraction" from maitake mushroom (*grifola frondosa*), *J. Naturopathic Med* 1993; (4) 1: 10-15.
631. Adachi K, Nanba H, Kuroda H. Potentiation of host-mediated antitumor activity in mice by beta-glucan obtained from *Grifola frondosa* (maitake). *Chem Pharm Bull (Tokyo).* 1987 Jan;35(1):262-70.
632. Nanba H., Maitake mushroom: Immune therapy to prevent cancer growth and metastasis, *Explore.* 1995, 6(1): 17.
633. Nanba H. Maitake D-fraction: Healing and Preventive Potential for Cancer. *J. Orthomolecular Med,* 1997, 12, 43.
634. Bishop KS, Kao CH, Xu Y, et al. From 2000 years of *Ganoderma lucidum* to recent developments in nutraceuticals. *Phytochemistry.* 2015;114:56-65.
635. Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, et al. *Ganoderma lucidum* (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. *Nutr Cancer.* 2011;63(7):1085-1094.
636. Willard T., *Reishi Mushroom. Herb of Spiritual Potency and Medical Wonder,* 1990
637. Wang S.Y., et al., The role of *Ganoderma Lucidum* in immunopotential: effect on cytokine release from human macrophages and T-lymphocytes, *From Program and Abstracts of the '94 International Symposium on Ganoderma Research.* Beijing: Beijing University, 1994
638. Pandya U, Dhuldhaj U, Sahay NS. Bioactive mushroom polysaccharides as antitumor: an overview. *Nat Prod Res.* 2018:1-13.
639. Boh B. *Ganoderma lucidum*: a potential for biotechnological production of anti-cancer and immunomodulatory drugs. *Recent Pat Anticancer Drug Discov.* 2013;8(3):255-287.
640. Xu Z, Chen X, Zhong Z, et al. *Ganoderma lucidum*

- polysaccharides: immunomodulation and potential anti-tumor activities. *Am J Chin Med.* 2011;39(1):15-27.
641. Zhu XL, Chen AF, Lin ZB. Ganoderma lucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. *J Ethnopharmacol.* 2007;111(2):219-226.
642. Kladar NV, Gavaric NS, Bozin BN. Ganoderma: insights into anticancer effects. *Eur J Cancer.* 2016;25(5):462-471.
643. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. *Cochrane Database Syst Rev.* 2016;(4):Cd007731.
644. Zhang K, Liu Y, Zhao X, et al. Anti-inflammatory properties of GLPss58, a sulfated polysaccharide from Ganoderma lucidum. *Int J Biol Macromol.* 2018;107(pt A):486-493.
645. Zeng P, Guo Z, Zeng X, et al. Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China. *J Cell Mol Med.* 2018;22(7):3278-3297.
646. Rossi P, Diffrancia R, Quagliariello V, et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. *Oncotarget.* 2018;9(37):24837-24856.
647. Ma B, Ren W, Zhou Y, et al. Triterpenoids from the spores of Ganoderma lucidum. *N Am J Med Sci.* 2011;3(11):495-498.
648. Sanodiya BS, Thakur GS, Baghel RK, et al. Ganoderma lucidum: a potent pharmacological macrofungus. *Curr Pharm Biotechnol.* 2009;10(8):717-742.
649. Wu GS, Guo JJ, Bao JL, et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum – a review. *Expert Opin Investig Drugs.* 2013;22(8):981-992.
650. Cor D, Knez Ž, Knez Hrnčić M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of Ganoderma lucidum terpenoids and polysaccharides: a review. *Molecules.* 2018;23(3).
651. Dudhgaonkar S, Thyagarajan A, Sliva D. Suppression of

- the inflammatory response by triterpenes isolated from the mushroom *Ganoderma lucidum*. *Int Immunopharmacol*. 2009;9(11):1272-1280.
652. Chiu HF, Fu HY, Lu YY, et al. Triterpenoids and polysaccharide peptides-enriched *Ganoderma lucidum*: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. *Pharm Biol*. 2017;55(1):1041-1046.
653. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. *Ganoderma lucidum* (Reishi mushroom) for cancer treatment. *Cochrane Database Syst Rev*. 2016;(4):Cd007731.
654. Rossi P, Difrancia R, Quagliariello V, et al. B-glucans from *Grifola frondosa* and *Ganoderma lucidum* in breast cancer: an example of complementary and integrative medicine. *Oncotarget*. 2018;9(37):24837-24856.
655. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of ganopoly (a *Ganoderma lucidum* polysaccharide extract) on the immune functions in advanced-stage cancer patients. *Immunol Invest*. 2003;32(3):201-215.
656. Oka S, Tanaka S, Yoshida S, et al. A water-soluble extract from culture medium of *Ganoderma lucidum* mycelia suppresses the development of colorectal adenomas. *Hiroshima J Med Sci*. 2010;59(1):1-6.
657. Chen X, Hu ZP, Yang XX, et al. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. *Int Immunopharmacol*. 2006;6(3):499-508.
658. Chang Y, Zhang M, Jiang Y, et al. Preclinical and clinical studies of *Coriolus versicolor* polysaccharopeptide as an immunotherapeutic in China. *Discov Med*. 2017;23(127):207-219.
659. Pandya U, Dhuldhaj U, Sahay NS. Bioactive mushroom polysaccharides as antitumor: an overview. *Nat Prod Res*. 2018:1-13.
660. Saleh MH, Rashedi I, Keating A. Immunomodulatory properties of *Coriolus versicolor*: the role of polysaccharopeptide. *Front*

- Immunol. 2017;8:1087.
661. Kang DH, Weaver MT, Park NJ, et al. Significant impairment in immune recovery after cancer treatment. *Nursing Res.* 2009;58(2):105-114.
662. Hogan BV, Peter MB, Shenoy HG, et al. Surgery induced immunosuppression. *Surgeon.* 2011;9(1):38-43.
663. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. *Anticancer Res.* 2002 May-Jun;22(3):1737-54.
664. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. *Lancet.* 1994 May 7;343(8906):1122-6.
665. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. *Cancer Immunol Immunother.* 2007 Jun;56(6):905-11.
666. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. *Cancer Immunol Immunother.* 1990;31(5):261-8.
667. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). *Dis Colon Rectum.* 1992 Feb;35(2):123-30.
668. Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (*Coriolus versicolor*) on survival in cancer patients: systematic review and meta-analysis. *Recent Pat Inflamm Allergy Drug Discov.* 2012;6(1):78-87.
669. Chay WY, Tham CK, Toh HC, et al. *Coriolus versicolor* (Yunzhi) use as therapy in advanced hepatocellular carcinoma patients with poor liver function or who are unfit for standard therapy. *J Altern Complement Med.* 2017;23(8):648-652.

670. Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. *Integr Cancer Ther.* 2015;14(3):201-211.
671. Ma Y, Wu X, Yu J, Zhu J, Pen X, Meng X. Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? A systematic review and network meta-analysis. *Oncotarget.* 2017;8(51):89108-89118.
672. Yoshitani S, Takashima S. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. *Cancer Biother Radiopharm.* 2009;24(1):35-40.
673. Okazaki A, Mitsuhashi N, Yamakawa M, Nozaki M, Takeuchi M, Niibe H. The effects of PS-K on long-term survival of uterine cervical cancer patients treated with radiation [in Japanese]. *Gan No Rinsho.* 1986;32(2):181-185.
674. Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom *Coriolus versicolor* (Basidiomycetes: Polyporaceae). *Gen Pharmacol.* 1998 Jan;30(1):1-4.
675. Tsang KW, Lam CL, Yan C, et al. *Coriolus versicolor* polysaccharide peptide slows progression of advanced non-small cell lung cancer. *Respir Med.* 2003 Jun;97(6):618-24.
676. Coles M, Toth B. Lack of prevention of large intestinal cancer by VPS, an extract of *Coriolus versicolor* mushroom. *In Vivo.* 2005 Sep-Oct;19(5):867-71.
677. Toth B, Coles M, Lynch J. Effects of VPS extract of *Coriolus versicolor* on cancer of the large intestine using a serial sacrifice technique. *In Vivo.* 2006 May-Jun;20(3):341-6.
678. Albar AH, Almehdar HA, Uversky VN, Redwan EM. Structural heterogeneity and multifunctionality of lactoferrin. *Curr Protein Pept Sci.* 2014;15(8):778-797.
679. Hao L, Shan Q, Wei J, et al. Lactoferrin: major physiological functions and applications. *Curr Protein Pept Sci.* May 14, 2018.
680. Iigo M, Kuhara T, Ushida Y, et al. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. *Clin*

- Exp Metastasis. 1999 Feb;17(1):35-40.
681. Masuda C, Wanibuchi H, Sekine K, et al. Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced rat bladder carcinogenesis. *Jpn J Cancer Res.* 2000 Jun;91(6):582-8.
682. Tsuda H, Sekine K, Fujita KI, Iigo M. Cancer prevention by bovine lactoferrin and underlying mechanisms – a review of experimental and clinical studies. *Biochemistry and Cell Biology*, 2002, 80, 1.
683. Tung YT, Chen HL, Yen CC, et al. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. *Journal of Dairy Science.* 2013, 96, 4, 2095-2106.
684. Giansanti F, Panella G, Leboffe L, Antonini G. Lactoferrin from milk: nutraceutical and pharmacological properties. *Pharmaceuticals (Basel).* 2016;9(4). pii: E61.
685. Drago-Serrano ME, Campos-Rodriguez R, Carrero JC, de la Garza M. Lactoferrin and peptide-derivatives: antimicrobial agents with potential use in nonspecific immunity modulation. *Curr Pharm Des.* 2018;24(10):1067-1078.
686. Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, et al. Immunomodulatory effects of lactoferrin. *Acta Pharmacol Sin.* 2014;35(5):557-566.
687. Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin a multiple bioactive protein: an overview. *Biochim Biophys Acta.* 2012;1820(3):226-236.
688. Hill DR, Newburg DS. Clinical applications of bioactive milk components. *Nutr Rev.* 2015;73(7):463-476.
689. Yin CM, Wong JH, Xia J, Ng TB. Studies on anticancer activities of lactoferrin and lactoferricin. *Curr Protein Pept Sci.* 2013;14(6):492-503.
690. Dial EJ, Lichtenberger LM. Effect of lactoferrin on *Helicobacter felis* induced gastritis. *Biochem Cell Biol.* 2002;80(1):113-117.
691. Ogasawara Y, Imase M, Oda H, et al. Lactoferrin directly scavenges hydroxyl radicals and undergoes oxidative self-



- degradation: a possible role in protection against oxidative DNA damage. *Int J Mol Sci.* 2014;15(1):1003-1013.
692. Tsuda H, Sekine K, Ushida Y, et al. Milk and dairy products in cancer prevention: focus on bovine lactoferrin. *Mutat Res.* 2000 Apr;462(2-3):227-33.
693. Cutone A, Rosa L, Ianiro G, et al. Lactoferrin's anti-cancer properties: safety, selectivity, and wide range of action. *Biomolecules* 2020, 10(3), 456.
694. Kozu T, Iinuma G, Ohashi Y, et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. *Cancer Prev Res (Phila).* 2009;2(11):975-983.
695. Iigo M, Alexander DB, Xu J, et al. Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine. *Biometals* 2014, 27, 1017-1029.
696. Sun X, Jiang R, Przepiorski A, et al. «Iron-saturated» bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. *BMC Cancer.* 2012;12:591.
697. Cutone A, Rosa L, Ianiro G, et al. Lactoferrin's anti-cancer properties: safety, selectivity, and wide range of action. *Biomolecules* 2020, 10(3), 456.
698. Walker CG, West AL, Browning LM, et al. The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. *Nutrients.* 2015;7(8):6281-6293.
699. Calder PC. Omega-3 fatty acids and inflammatory processes. *Nutrients.* 2010;2(3):355-374.
700. D'Eliseo D, Velotti F. Omega-3 fatty acids and cancer cell cytotoxicity: implications for multi-targeted cancer therapy. *J Clin Med.* 2016;5(2). doi:10.3390/jcm5020015.
701. Turk HF, Chapkin RS. Membrane lipid raft organization is uniquely modified by n-3 polyunsaturated fatty acids. *Prostaglandins Leukot Essent Fatty Acids.* 2013;88(1):43-47.
702. Lee EJ, Yun UJ, Koo KH, et al. Down-regulation of lipid raft-

- associated onco-proteins via cholesterol-dependent lipid raft internalization in docosahexaenoic acid-induced apoptosis. *Biochim Biophys Acta*. 2014;1841(1):190-203.
703. Nabavi SF, Bilotto S, Russo GL, et al. Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. *Cancer Metastasis Rev*. 2015;34(3):359-380.
704. Manzi L, Costantini L, Molinari R, Merendino N. Effect of dietary omega-3 polyunsaturated fatty acid DHA on glycolytic enzymes and Warburg phenotypes in cancer. *Biomed Res Int*. 2015;2015:137097.
705. Lee JY, Sim TB, Lee JE, Na HK. Chemopreventive and chemotherapeutic effects of fish oil derived omega-3 polyunsaturated fatty acids on colon carcinogenesis. *Clin Nutr Res*. 2017;6(3):147-160.
706. Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. *Breast Cancer Res*. 2015;17:62.
707. Weylandt KH, Serini S, Chen YQ, et al. Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence. *Biomed Res Int*. 2015;2015:143109.
708. Lenihan-Geels G, Bishop KS, Ferguson LR. Cancer risk and eicosanoid production: interaction between the protective effect of long chain omega-3 polyunsaturated fatty acid intake and genotype. *J Clin Med*. 2016;5(2). doi:10.3390/jcm5020025.
709. Corsetto PA, Colombo I, Kopecka J, et al.  $\omega$ -3 long chain polyunsaturated fatty acids as sensitizing agents and multidrug resistance revertants in cancer therapy. *Int J Mol Sci*. 2017;18(12).
710. Hajjaji N, Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids: a review. *Cancer Treat Rev*. 2013;39(5):473-488.
711. Song EA, Kim H. Docosahexaenoic acid induces oxidative DNA damage and apoptosis, and enhances the chemosensitivity of cancer cells. *Int J Mol Sci*. 2016;17(8).
712. Cai F, Sorg O, Granci V, et al. Interaction of omega-3 polyunsaturated fatty acids with radiation therapy in two

- different colorectal cancer cell lines. *Clin Nutr.* 2014;33(1):164-170.
713. Murphy RA, Mourtzakis M, Chu QS, et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. *Cancer.* 2011;117(16):3774-3780.
714. Camargo Cde Q, Mocellin MC, Pastore Silva Jde A, et al. Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. *Nutr Cancer.* 2016;68(1):70-76.
715. Eltweri AM, Thomas AL, Metcalfe M, et al. Potential applications of fish oils rich in omega-3 polyunsaturated fatty acids in the management of gastrointestinal cancer. *Clin Nutr.* 2017;36(1):65-78.
716. Alfano CM, Imayama I, Neuhouser ML, et al. Fatigue, inflammation, and  $\omega$ -3 and  $\omega$ -6 fatty acid intake among breast cancer survivors. *J Clin Oncol.* 2012;30(12):1280-1287.
717. Miyata H, Yano M, Yasuda T, et al. Randomized study of the clinical effects of  $\omega$ -3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Nutrition.* 2017;33:204-210.
718. Trabal J, Leyes P, Forga M, Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. *Nutr Hosp.* 2010;25(5):736-740.
719. Fietkau R, Lewitzki V, Kuhnt T, et al. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. *Cancer.* 2013;119(18):3343-3353.
720. Zhang C, Chen B, Jiao A, et al. The benefit of immunonutrition in patients undergoing hepatectomy: a systematic review and meta-analysis. *Oncotarget.* 2017;8(49):86843-86852.
721. Cockbain AJ, Volpato M, Race AD, et al. Anticolorectal

- cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. *Gut*. 2014;63(11):1760-1768.
722. Begin ME, Ells G, Das UN. Selected fatty acids as possible intermediates for selective cytotoxic activity of anticancer agents involving oxygen radicals. *Anticancer Research*, 01 Mar 1986, 6(2):291-295.
723. Takeda S, Sim PG, Horrobin DF, et al. Intracellular free fatty-acid release and lipid-peroxidation in cultured human breast-cancer cells in response to gamma0linolenic acid with iron (GLA + FE). *International Journal of Oncology*. 1992, 1, 7, 759-763.
724. Van der Merwe CF, Booyens J, Katzeff IE. Oral gamma-linolenic acid in 21 patients with untreatable malignancy. An ongoing pilot open clinical trial. *Br J Clin Pract*. 1987 Sep;41(9):907-15.
725. Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. *J Natl Cancer Inst*. 1986 Nov;77(5):1053-62.
726. Lehn TE, da Silva MR, Camacho A, et al. A review on effects of conjugated linoleic fatty acid (CLA) upon body composition and energetic metabolism. *J Int Soc Sports Nutr*. 2015;12:36.
727. Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. *J Nutr*. 2002;132(10):2995-2998.
728. Lee KW, Lee HJ, Cho HY, Kim YJ. Role of the conjugated linoleic acid in the prevention of cancer. *Crit Rev Food Sci Nutr*. 2005;45(2):135-144.
729. Friedlander B. Butter enhanced with natural fatty acid reduces breast cancer risk in animals, Cornell and Roswell Park researchers find. *Cornell Chronicle*. November 24, 1999. <https://news.cornell.edu/stories/1999/11/natural-fatty-acid-reduces-breast-cancer-risk>
730. Ip C, Banni S, Angioni E, et al. Conjugated linoleic acid-enriched butter fat alters mammary gland morphogenesis and reduces cancer risk in rats. *The Journal of Nutrition*. 1999, 129, 12, 2135-2142.

731. Visonneau S, Cesano A, Tepper SA, et al. Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. *Anticancer Res.* 1997 Mar-Apr;17(2A):969-73.
732. Cesano A, Visonneau S, Scimeca JA, et al. Opposite effects of linoleic acid and conjugated linoleic acid on human prostatic cancer in SCID mice. *Anticancer Res.* 1998, 18, 1429-1434.
733. Ip C, Ip MM, Loftus T, et al. Induction of apoptosis by conjugated linoleic acid in cultured mammary tumor cells and premalignant lesions of the rat mammary gland. *Cancer Epidemiology, Biomarkers & Prevention.* 2000, 9, 7.
734. Miller A, Stanton C, Devery R. Modulation of arachidonic acid distribution by conjugated linoleic acid isomers and linoleic acid in MCF-7 and SW480 cancer cells. *Lipids.* 2001, 36, 1161-1168.
735. Urquhart P, Parkin SM, Rogers JS, et al. The effect of conjugated linoleic acid on arachidonic acid metabolism and eicosanoid production in human saphenous vein endothelial cells. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.* 2002, 1580, 2-3, 150-160.
736. McGowan MM, Eisenberg BL, Lewis LD, et al. A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue. *Breast Cancer Res Treat.* 2013;138(1):175-183.
737. Kim JH, Kim YJ, Park Y. Conjugated linoleic acid and postmenopausal women's health. *J Food Sci.* 2015;80(6):R1137-R1143.
738. Wang J, Liu X, Zhang X, et al. Induction of apoptosis by c9, t11-CLA in human endometrial cancer RL 95-2 cells via ER $\alpha$ -mediated pathway. *Chem Phys Lipids.* 2013;175-176:27-32.
739. Mohammadzadeh M, Faramarzi E, Mahdavi R, et al. Effect of conjugated linoleic acid supplementation on inflammatory factors and matrix metalloproteinase enzymes in rectal cancer patients undergoing chemoradiotherapy. *Integr Cancer Ther.* 2013;12(6):496-502.
740. Ebrahimi-Mameghani M, Jamali H1, Mahdavi R, et al. Conjugated linoleic acid improves glycemic response, lipid

- profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial. *Croat Med J.* 2016;57(4):331-342.
741. Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. *J Steroid Biochem Mol Biol.* 2015;154:94-103.
742. Zhao F, Xie P, Jiang J, et al. The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro. *Int J Mol Sci.* 2014;15(3):4019-4030.
743. Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. *Hepatobiliary Surg Nutr.* 2015;4(2):101-108.
744. Walaszek Z, Szemraj J, Narog M, et al. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. *Cancer Detect Prev.* 1997;21(2):178-90.
745. Walaszek Z. Potential use of d-glucaric acid derivatives in cancer prevention. *Cancer Letters.* 1990, 54, 1-2, 1-8.
746. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. *Isr J Med Sci.* 1995 Feb-Mar;31(2-3):101-5.
747. Walaszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. *Carcinogenesis.* 1986 Sep;7(9):1463-6.
748. Folkers K, Osterborg A, Nylander M, et al. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. *Biochem Biophys Res Commun.* 1997, 234(2), 296-299.
749. Palan PR, Mikhail MS, Shaban DW, Romney SL. Plasma concentrations of coenzyme Q10 and tocopherols in cervical intraepithelial neoplasia and cervical cancer. *Eur J Cancer Prev.* 2003, 12(4), 321-326.
750. Folkers K. Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy. *Biochem Biophys Res Commun.* 1996, 224(2), 358-361.
751. Langsjoen H, Langsjoen P, Langsjoen P, et al. Usefulness of

- coenzyme Q10 in clinical cardiology: a long-term study. *Mol Aspects Med.* 1994, 15 Suppl, s165-175.
752. Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. *Mol Aspects Med.* 1994, 15 Suppl, S265-272.
753. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Mol Aspects Med.* 1994, 15 Suppl, s207-212.
754. Olson RE. Karl August Folkers (1906-1997). *J Nutr.* 2001, 131(9), 2227-2230.
755. Lockwood K, Mocsgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Mol Aspects Med.* 1994, 15 Suppl, s231-240.
756. Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. *Biochem Biophys Res Commun.* 1995, 212(1), 172-177.
757. Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. *Biochem Biophys Res Commun.* 1993, 192(1), 241-245.
758. Hodges S, Hertz N, Lockwood K, Lister R. CoQ10: could it have a role in cancer management? *Biofactors.* 1999, 9(2-4), 365-370.
759. Damkier A, Jensen AB, Rose C. Use of Q10 in cancer patients. 1994, 156(6), 813-818.
760. Hertz N, Lister RE. Improved survival in patients with end-stage cancer treated with coenzyme Q10 and other antioxidants: a pilot study. *J Int Med Res.* 2009;37(6):1961-1971.
761. Ely JTA. Protein glycation: ascorbate antagonism. *Bulletin Amer Physical Society.* 1988. 33(3), 296.
762. Lopez-Lluch G, Barroso MP, et al. Role of plasma membrane coenzyme Q on the regulation of apoptosis. *Biofactors.* 1999, 9(2-4), 171-177.
763. Crane EL. Biochemical functions of coenzyme Q10. *Am Coll*

- Nutr. 2001, 20(6), 591-598.
764. Brandt U. Proton translocation in the respiratory chain involving ubiquinone – a hypothetical semiquinone switch mechanism for complex I. *Biofactors*. 1999, 9(2-4), 95-101.
765. Yu CA, Zhang L, Deng KP, et al. Structure and reaction mechanisms of multifunctional mitochondrial cytochrome bc1 complex. *Biofactors*. 1999, 9(2-4), 103-109.
766. Crane FL. New functions for coenzyme Q. *Protoplasma*. 2000, 213, 127-133.
767. McLennan HR, Degli Esposti M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. *J Bioenerg Biomembr*. 2000, 32(2), 153-162.
768. Hansford RG, Hogue BA, Mildaziene V. Dependence of H<sub>2</sub>O<sub>2</sub> formation by rat heart mitochondria on substrate availability and donor age. *J Bioenerg Biomembr*. 1997, 29(1), 89-95.
769. Nohl H, Gille L, Schonheit K, Lin Y. Conditions allowing redox cycling ubiquinone in mitochondria to establish a direct couple with molecular oxygen. *Free Radical Bio Med*. 1996, 20, 207-213.
770. Wang GS, Olsson JM, Erickson LC, Stal P. Diet restriction increases ubiquinone contents and inhibits progression of hepatocellular carcinoma in the rat. *Scand J Gastr*. 2000, 35(1), 83-89.
771. Liu HT, Huang YC, Cheng SB, et al. Effects of coenzyme Q10 supplementation on antioxidant capacity and inflammation in hepatocellular carcinoma patients after surgery: a randomized, placebo-controlled trial. *Nutr J*. 2016;15(1):85.
772. Folkers K, Brown R, Judy WV, Morita M. Survival of cancer patients on therapy with coenzyme Q10. *Biochemical and Biophysical Research Communications*. 1993, 192, 1, 241-245.
773. Premkumar VG, Yuvaraj S, Vijayasarathy K, et al. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. *Biol Pharm Bull*. 2007;30(2):367-370.



774. Premkumar VG, Yuvaraj S, Vijayasathya K, et al. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. *Basic Clin Pharmacol Toxicol*. 2007;100(6):387-391.
775. Premkumar VG, Yuvaraj S, Sathish S, et al. Anti-angiogenic potential of acoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. *Vascul Pharmacol*. 2008;48(4-6):191-201.
776. Premkumar VG, Yuvaraj S, Shanthi P, Sachdanandam P. Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy. *Br J Nutr*. 2008;100(6):1179-1182.
777. Kumar S, Marfatia R, Tannenbaum S, Yang C, Avelar E. Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. *Tex Heart Inst J*. 2012;39(3):424-427.
778. Cortes EP, Gupta M, Chou C, Amin VC, Folkers K. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. *Cancer Treat Rep*. 1978 Jun;62(6):887-91.
779. Chen PY, Hou CW, Shibu MA, et al. Protective effect of coenzyme Q10 on doxorubicin-induced cardiomyopathy of rat hearts. *Environ Toxicol*. 2017;32(2):679-689.
780. Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. *Tissue Cell*. 2017;49(3):410-426.
781. Sugiyama S, Yamada K, Hayakawa M, Ozawa T. Approaches that mitigate doxorubicin-induced delayed adverse effects on mitochondrial function in rat hearts; liposome-encapsulated doxorubicin or combination therapy with antioxidant. *Biochem Mol Biol Int*. 1995;36(5):1001-1007.
782. Conklin KA. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. *Integr Cancer Ther*. 2005;4(2):110-130.

783. Sharma A, Fonarow GC, Butler J, et al. Coenzyme Q10 and heart failure: a state-of-the-art review. *Circ Heart Fail.* 2016;9(4):e002639.
784. Awa H, Futamura A, Higashiguchi T, et al. Effects of Combined Treatment with Branched-Chain Amino Acids, Citric Acid, L-Carnitine, Coenzyme Q10, Zinc, and Various Vitamins in Tumor-Bearing Mice. *Biol Pharm Bull.* 2017 Mar 1;40(3):266-271.
785. Najafi M, Shirazi A, Motevaseli E, et al. The melatonin immunomodulatory actions in radiotherapy. *Biophys Rev.* 2017;9(2):139-148.
786. Reiter R, Rosales-Corral SA, Tan DX, et al. Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis. *Int J Mol Sci.* 2017;18(4):843.
787. Yeh CM, Su SC, Lin CW, et al. Melatonin as a potential inhibitory agent in head and neck cancer. *Oncotarget.* 2017;8(52):90545-90556.
788. Su SC, Hsieh MJ, Yang WE, et al. Cancer metastasis: mechanisms of inhibition by melatonin. *J Pineal Res.* 2017;62(1).
789. Goradel NH, Asghari MH, Moloudizargari M, et al. Melatonin as an angiogenesis inhibitor to combat cancer: mechanistic evidence. *Toxicol Appl Pharmacol.* 2017;335:56-63.
790. Wang RX, Liu H, Xu L, et al. Melatonin downregulates nuclear receptor RZR/ROR $\gamma$  expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. *Oncol Lett.* 2016;12(2):897-903.
791. Maestroni GJ. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. *Adv Exp Med Biol.* 1999;467:217-26.
792. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. *J Natl Cancer Inst.* 2002 May 1;94(9):690-7.
793. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. *Br J Cancer.*

- 1994 Jan;69(1):196-9.
794. Lissoni P, Meregalli S, Fossati V, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. *Tumori*. 1994;80(6):464-467.
795. Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. *Int J Clin Oncol*. 2018;23(3):410-420.
796. Lissoni P, Messina G, Lissoni A, Franco R. The psychoneuroendocrine-immunotherapy of cancer: historical evolution and clinical results. *J Res Med Sci*. 2017;22:45.
797. Lissoni P, Barni S, Ardizzola A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. *Cancer*. 1994, 73, 3, 699-701.
798. Barni S, Lissoni P, Paolorossi F, et al. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. *Tumori*. 1990;76(1):58-60.
799. Lissoni P, Barni S, Cattaneo G, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. *Oncology*. 1991;48(6):448-450.
800. Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. *Cancer*. 1994;73(3):699-701.
801. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. *Br J Cancer*. 1995;71(4):854-856.
802. Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. *Br J Cancer*. 1996;74(9):1466-1468.

803. Lissoni P, Barni S, Mandala M, et al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. *Eur J Cancer*. 1999;35(12):1688-1692.
804. Lissoni P, Cazzaniga M, Tancini G, et al. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. *Eur Urol*. 1997;31(2):178-181.
805. Lissoni P, Tancini G, Paolorossi F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. *J Pineal Res*. 1999;26(3):169-173.
806. Wang YM, Jin BZ, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. *Cancer Chemother Pharmacol*. 2012;69(5):1213-1220.
807. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integr Cancer Ther*. 2011;11(4):293-303.
808. Ball LJ, Palesh O, Kriegsfeld LJ. The pathophysiologic role of disrupted circadian and neuroendocrine rhythms in breast carcinogenesis. *Endocr Rev*. 2016;37(5):450-466.
809. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. *Endocr Relat Cancer*. 2015;22(3):R183-R204.
810. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. *Br J Cancer*. 1995;71(4):854-856.
811. Kliukiene J, Tynes T, Andersen A. Risk of breast cancer among Norwegian women with visual impairment. *Br J Cancer*. 2001 84:397-399.
812. Liburdy RP, Sloma TR, Sokolic R, Yaswen P. ELF magnetic fields, breast cancer, and melatonin: 60 Hz fields block melatonin's

- oncostatic action on ER+ breast cancer cell proliferation. *Journal of Pineal Research*. 1993, 14, 2, 89-97.
813. Reiter RJ, Mayo JC, Tan DX, et al. Melatonin as an antioxidant: under promises but over delivers. *Journal of Pineal Research*. 2016, 61, 3, 253-278.
814. Brivio F, Fumagalli L, Fumagalli G, et al. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. *In Vivo*. 2010;24(2):239-241.
815. Galano A, Tan D-X, Reiter RJ. Melatonin: A versatile protector against oxidative DNA damage. *Molecules*. 2018;23:530.
816. Huang J, Shan W, Li N, et al. Melatonin provides protection against cisplatin-induced ovarian damage and loss of fertility in mice. *Reprod. Biomed. Online*. 2020;42:505–519.
817. Gao Y, Xiao X, Zhang C, Yu W, et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways. *J. Pineal Res*. 2017;62:e12380.
818. Akbarzadeh M, Movassaghpour AA., Ghanbari H, et al. The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells. *Sci. Rep*. 2017;7:17062.
819. de Lima Mota A, Jardim-Perassi BV, de Castro TB, et al. Melatonin modifies tumor hypoxia and metabolism by inhibiting HIF-1α and energy metabolic pathway in the in vitro and in vivo models of breast cancer. *Melatonin Res*. 2019;2:83–98.
820. Mortezaee K, Najafi M, Farhood B, et al. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review. *Life Sci*. 2019;228:228–241.
821. Li W, Wang Z, Chen Y, et al. Melatonin treatment induces apoptosis through regulating the nuclear factor-κB and mitogen-activated protein kinase signaling pathways in human gastric cancer SGC7901 cells. *Oncol. Lett*. 2017;13:2737–2744.
822. Chen L, Liu L, Li Y, Gao J. Melatonin increases human cervical

- cancer HeLa cells apoptosis induced by cisplatin via inhibition of JNK/Parkin/mitophagy axis. *Vitr. Cell. Dev. Biol. Anim.* 2018;54:1–10.
823. González A, González-González A, Alonso-González C, et al. Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF. *Oncol. Rep.* 2017;37:2433–2440.
824. Lacerda JZ, Ferreira LC, Lopes BC, et al. Therapeutic potential of melatonin in the regulation of MiR-148a-3p and angiogenic factors in breast cancer. *Microna.* 2019;8:237–247.
825. Marques JHM, Mota AL, Oliveira JG, et al. Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies. *Life Sci.* 2018;208:131–138.
826. Akbarzadeh M, Rahbarghazi R, Nabat E, et al. The impact of different extracellular matrices on melatonin effect in proliferation and stemness properties of ovarian cancer cells. *Biomed. Pharmacother.* 2017;87:288–295.
827. Vimalraj S, Saravanan S, Raghunandhakumar S, Anuradha D. Melatonin regulates tumor angiogenesis via miR-424-5p/VEGFA signaling pathway in osteosarcoma. *Life Sci.* 2020;256:118011.
828. Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1 $\alpha$  and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. *Br. J. Cancer.* 2013;109:83–91.
829. Piotrowski I, Kulcenty K, Suchorska W. Interplay between inflammation and cancer. *Rep. Pract. Oncol. Radiother.* 2020;25:422–427.
830. Ohnishi S, Ma N, Thanan R, et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. *Oxidative Med. Cell. Longev.* 2013;2013:387014.
831. Mannino G, Caradonna F, Cruciata I, et al. Melatonin reduces inflammatory response in human intestinal epithelial cells stimulated by interleukin-1 $\beta$ . *J. Pineal Res.* 2019;67:e12598.
832. Liberti MV, Locasale JW. The Warburg effect: How does it

- benefit cancer cells? *Trends Biochem. Sci.* 2016;41:211–218.
833. Reiter RJ, Sharma R, Ma Q, et al. Circadian and non-circadian melatonin: Influence on glucose metabolism in cancer cells. *J. Curr. Sci. Technol.* 2020;10:85–98.
834. Reiter RJ, Sharma R, Ma Q, et al. Inhibition of mitochondrial pyruvate dehydrogenase kinase: A proposed mechanism by which melatonin causes cancer cells to overcome cytosolic glycolysis, reduce tumor biomass and reverse insensitivity to chemotherapy. *Melatonin Res.* 2019;2:105–119.
835. Sanchez-Sanchez AM, Antolin I, Puente-Moncada N, et al. Melatonin cytotoxicity is associated to Warburg effect inhibition in Ewing sarcoma cells. *PLoS ONE.* 2015;10:e0135420.
836. Hevia D, Gonzalez-Menendez P, Fernandez-Fernandez M, et al. Melatonin decreases glucose metabolism in prostate cancer cells: a <sup>13</sup>C stable isotope-resolved metabolomic study. *Int. J. Mol. Sci.* 2017;18:1620.
837. Su S-C, Hsieh M-J, Yang W-E, et al. Cancer metastasis: Mechanisms of inhibition by melatonin. *J. Pineal Res.* 2017;62:e12370.
838. Wen Y-C, Lin Y-W, Chu C-Y, et al. Melatonin-triggered post-transcriptional and post-translational modifications of ADAMTS1 coordinately retard tumorigenesis and metastasis of renal cell carcinoma. *J. Pineal Res.* 2020;69:e12668.
839. Zhang S, Qi Y, Zhang H, et al. Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line, SGC7901. *Biotech. Histochem.* 2013;88:281–289.
840. Wang RX, Liu H, Xu L, et al. Involvement of nuclear receptor RZR/ROR $\gamma$  in melatonin-induced HIF-1 $\alpha$  inactivation in SGC-7901 human gastric cancer cells. *Oncol. Rep.* 2015;34:2541–2546.
841. Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. *J. Pineal Res.* 1994;17:25–32.
842. Cutando A, Lopez-Valverde A, De Vicente J, et al. Action of melatonin on squamous cell carcinoma and other tumors of the oral cavity (Review) *Oncol. Lett.* 2014;7:923–926.
843. Goncalves Ndo N, Rodrigues RV, Jardim-Perassi BV, et al. Molecular markers of angiogenesis and metastasis in lines of

- oral carcinoma after treatment with melatonin. *Anticancer Agents Med. Chem.* 2014;14:1302–1311.
844. Rodriguez-Garcia A, Mayo JC, Hevia D, et al. Phenotypic changes caused by melatonin increased sensitivity of prostate cancer cells to cytokine-induced apoptosis. *J. Pineal Res.* 2013;54:33–45.
845. Shiu SY, Leung WY, Tam CW, et al. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): Potential implications on prostate cancer chemoprevention and therapy. *J. Pineal Res.* 2013;54:69–79.
846. Paroni R, Terraneo L, Bonomini F, et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: Relationship with hypoxia signalling. *J. Pineal Res.* 2014;57:43–52.
847. Zhang S, Qi Y, Zhang H, et al. Melatonin inhibits cell growth and migration, but promotes apoptosis in gastric cancer cell line, SGC7901. *Biotech. Histochem.* 2013;88:281–289.
848. Wang RX, Liu H, Xu L, et al. Involvement of nuclear receptor RZR/RORγ in melatonin-induced HIF-1α inactivation in SGC-7901 human gastric cancer cells. *Oncol. Rep.* 2015;34:2541–2546.
849. Wang RX, Liu H, Xu L, et al. Melatonin downregulates nuclear receptor RZR/RORγ expression causing growth-inhibitory and anti-angiogenesis activity in human gastric cancer cells in vitro and in vivo. *Oncol. Lett.* 2016;12:897–903.
850. Song J, Ma S-J, Luo J-H, et al. Melatonin induces the apoptosis and inhibits the proliferation of human gastric cancer cells via blockade of the AKT/MDM2 pathway. *Oncol. Rep.* 2018;39:1975–1983.
851. Chen X, Hao A, Li X, et al. Melatonin inhibits tumorigenicity of glioblastoma stem-like cells via the AKT-EZH2-STAT3 signaling axis. *J. Pineal Res.* 2016;61:208–217.
852. Maitra S, Bhattacharya D, Das S, Bhattacharya S. Melatonin and its anti-glioma functions: A comprehensive review. *Rev.*



- Neurosci. 2019;30:527–541.
853. Neamati F, Asemi Z. The effects of melatonin on signaling pathways and molecules involved in glioma. *Fundam. Clin. Pharmacol.* 2020;34:192–199.
854. Sung GJ, Kim SH, Kwak S, et al. Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells. *J. Pineal Res.* 2019;66:e12556.
855. Lai SW, Liu YS, Lu DY, Tsai CF. Melatonin modulates the microenvironment of glioblastoma multiforme by targeting sirtuin 1. *Nutrients.* 2019;11:1343.
856. Fernandez-Gil B, Schiapparelli P, Vazquez-Ramos C, et al. Melatonin: Targeting the cell's powerhouse to fight glioblastoma. *Neuro Oncol.* 2018;20:vi280–vi281.
857. Zheng X, Pang B, Gu G, et al. Melatonin inhibits glioblastoma stem-like cells through suppression of EZH2-NOTCH1 signaling axis. *Int. J. Biol. Sci.* 2017;13:245–253.
858. Martín V, Sanchez-Sanchez AM., Puente-Moncada N, et al. Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells. *J. Pineal Res.* 2014;57:308–316.
859. Zhang Y, Liu Q, Wang F, et al. Melatonin antagonizes hypoxia-mediated glioblastoma cell migration and invasion via inhibition of HIF-1 $\alpha$ . *J. Pineal Res.* 2013;55:121–130.
860. Zhou N, Wei ZX, Qi ZX. Inhibition of autophagy triggers melatonin-induced apoptosis in glioblastoma cells. *BMC Neurosci.* 2019;20:1–12.
861. Mayo JC, Hevia D, Quiros-Gonzalez I, et al. IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer. *J. Pineal Res.* 2017;62:e12373.
862. Tai SY, Huang SP, Bao BY, Wu MT. Urinary melatonin-sulfate/cortisol ratio and the presence of prostate cancer: A case-control study. *Sci. Rep.* 2016;6:29606.
863. Sigurdardottir LG, Markt SC, Rider JR, et al. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. *Eur. Urol.* 2015;67:191–194.

864. Wang S-W, Tai H-C, Tang C-H, et al. Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression. *J. Cell. Physiol.* 2020;236:3979–3990.
865. Zharinov GM, Bogomolov OA, Chepurnaya IV, et al. Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. *Oncotarget.* 2020;11:3723–3729.
866. Paroni R, Terraneo L, Bonomini F, et al. Antitumour activity of melatonin in a mouse model of human prostate cancer: Relationship with hypoxia signalling. *J. Pineal Res.* 2014;57:43–52.
867. Sohn EJ, Won G, Lee J, et al. Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. *J. Cancer.* 2015;6:19.
868. Ma Z, Liu D, Di S, et al. Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. *J. Pineal Res.* 2019;67:e12587.
869. Yun M, Kim EO, Lee D, et al. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. *Cell. Physiol. Biochem.* 2014;34:865–872.
870. Plaimee P, Weerapreeyakul N, Barusrux S, Johns NP. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. *Cell Prolif.* 2015;48:67–77.
871. Chuffa LGA, Fioruci-Fontanelli BA, Mendes LO, et al. Melatonin attenuates the TLR4-mediated inflammatory response through MyD88- and TRIF-dependent signaling pathways in an in vivo model of ovarian cancer. *BMC Cancer.* 2015;15:34.
872. Akbarzadeh M, Nouri M, Banekohal MV, et al. Effects of combination of melatonin and laser irradiation on ovarian cancer cells and endothelial lineage viability. *Lasers Med. Sci.* 2016;31:1565–1572.

873. Zemła A, Grzegorek I, Dzięgiel P, Jabłońska K. Melatonin synergizes the chemotherapeutic effect of cisplatin in ovarian cancer cells independently of MT1 melatonin receptors. *In Vivo*. 2017;31:801.
874. Shen C-J, Chang C-C, Chen Y-T, et al. Melatonin suppresses the growth of ovarian cancer cell lines (OVCAR-429 and PA-1) and potentiates the effect of G1 arrest by targeting CDKs. *Int. J. Mol. Sci.* 2016;17:176.
875. Wang Q, Sun Z, Du L, et al. Melatonin sensitizes human colorectal cancer cells to  $\gamma$ -ray ionizing radiation in vitro and in vivo. *Int. J. Mol. Sci.* 2018;19:3974.
876. Wei J-Y, Li W-M, Zhou L-L, et al. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. *J. Pineal Res.* 2015;58:429–438.
877. Yun CW, Kim S, Lee JH, Lee SH. Melatonin promotes apoptosis of colorectal cancer cells via superoxide-mediated ER stress by inhibiting cellular prion protein expression. *Anticancer Res.* 2018;38:3951–3960.
878. Lee JH, Yoon YM, Han Y-S, et al. Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. *Anticancer Res.* 2018;38:1993.
879. Hong Y, Won J, Lee Y, et al. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. *J. Pineal Res.* 2014;56:264–274.
880. Liu R, Wang H-I, Deng M-j, et al. Melatonin inhibits reactive oxygen species-driven proliferation, epithelial-mesenchymal transition, and vasculogenic Mimicry in oral cancer. *Oxidative Med. Cell. Longev.* 2018;2018:3510970.
881. Yeh C-M, Lin C-W, Yang J-S, et al. Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation. *Oncotarget.* 2016;7:21952–21967.
882. Yang C-Y, Lin C-K, Tsao C-H, et al. Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. *Oncotarget.* 2017;8:33756–33769.

883. Goncalves Ndo N, Rodrigues RV, Jardim-Perassi BV, et al. Molecular markers of angiogenesis and metastasis in lines of oral carcinoma after treatment with melatonin. *Anticancer Agents Med. Chem.* 2014;14:1302–1311.
884. Martín-Renedo J, Mauriz JL, Jorquera F, et al. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. *J. Pineal Res.* 2008;45:532–540.
885. Ordonez R, Fernandez A, Prieto-Dominguez N, et al. Ceramide metabolism regulates autophagy and apoptotic cell death induced by melatonin in liver cancer cells. *J. Pineal Res.* 2015;59:178–189.
886. Carbajo-Pescador S, Ordonez R, Benet M, et al. Inhibition of VEGF expression through blockade of Hif1 $\alpha$  and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. *Br. J. Cancer.* 2013;109:83–91.
887. Cheng L, Liu J, Liu Q, et al. Exosomes from melatonin treated hepatocellular carcinoma cells alter the immunosuppression status through STAT3 pathway in macrophages. *Int. J. Biol. Sci.* 2017;13:723–734.
888. Colombo J, Maciel JMW, Ferreira LC, et al. Effects of melatonin on HIF-1 $\alpha$  and VEGF expression and on the invasive properties of hepatocarcinoma cells. *Oncol. Lett.* 2016;12:231–237.
889. Bu L-J, Yu H-Q, Fan L-L, Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation. *World J. Gastroenterol.* 2017;23:986–998.
890. Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. *Cancer.* 1994;73:3015–3019.
891. Min KJ, Kim HS, Park EJ, Kwon TK. Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. *J. Pineal Res.* 2012;53:99–106.
892. Abraham P, Kollivk, Rabi S. Melatonin attenuates methotrexate-

- induced oxidative stress and renal damage in rats. *Cell Biochem. Funct.* 2010;28:426–433.
893. Park EJ, Woo SM, Min K-j, Kwon TK. Transcriptional and post-translational regulation of Bim controls apoptosis in melatonin-treated human renal cancer Caki cells. *J. Pineal Res.* 2014;56:97–106.
894. Lin Y-W, Lee L-M, Lee W-J, et al. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-κB DNA-binding activity. *J. Pineal Res.* 2016;60:277–290.
895. Farhood B, Goradel NH, Mortezaee K, et al. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. *Clin. Transl. Oncol.* 2019;21:268–279.
896. Martinez-Campa C, Menendez-Menendez J, Alonso-Gonzalez C, et al. What is known about melatonin, chemotherapy and altered gene expression in breast cancer. *Oncol. Lett.* 2017;13:2003–2014.
897. Favero G, Moretti E, Bonomini F, et al. Promising antineoplastic actions of melatonin. *Front. Pharm.* 2018;9:1086.
898. Wang Y-M, Jin B-z, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials. *Cancer Chemother. Pharmacol.* 2012;69:1213–1220.
899. Sookprasert A, Johns NP, Phunmanee A, et al. Melatonin in patients with cancer receiving chemotherapy: A randomized, double-blind, placebo-controlled trial. *Anticancer Res.* 2014;34:7327–7337.
900. Ma Z, Yang Y, Fan C, Han J, et al. Melatonin as a potential anticarcinogen for non-small-cell lung cancer. *Oncotarget.* 2016;7:46768–46784.
901. Mao L, Summers W, Xiang S, et al. Melatonin represses metastasis in Her2-positive human breast cancer cells by suppressing RSK2 expression. *Mol. Cancer Res.* 2016;14:1159–1169.
902. Liu D, Ma Z, Di S, et al. AMPK/PGC1α activation by melatonin

- attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. *Free Radic. Biol. Med.* 2018;129:59–72.
903. Oz E., Erbaş D., Surucu H.S., Duzgun E. Prevention of doxorubicin-induced cardiotoxicity by melatonin. *Mol. Cell. Biochem.* 2006;282:31–37.
904. Kim C, Kim N, Joo H, et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. *J. Cardiovasc. Pharm.* 2005;46:200–210.
905. Govender J, Loos B, Marais E, Engelbrecht AM. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: A review of the protective role of melatonin. *J. Pineal Res.* 2014;57:367–380.
906. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. *Integr. Cancer.* 2012;11:293–303.
907. Wang Q, Sun Z, Du L, et al. Melatonin sensitizes human colorectal cancer cells to  $\gamma$ -ray ionizing radiation in vitro and in vivo. *Int. J. Mol. Sci.* 2018;19:3974.
908. Zou ZW, Liu T, Li Y, et al. Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS. *Redox Biol.* 2018;16:226–236.
909. Najafi M, Shirazi A, Motevaseli E, et al. The melatonin immunomodulatory actions in radiotherapy. *Biophys. Rev.* 2017;9:139–148.
910. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. *Oncology.* 1996;53:43–46.
911. Ben-David MA, Elkayam R, Gelernter I, Pfeffer RM. Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. *ISR Med. Assoc. J.* 2016;18:188–192.
912. Plaimee P, Weerapreeyakul N, Barusrux S, Johns NP. Melatonin

- potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. *Cell Prolif.* 2015;48:67–77.
913. Kim W, Jeong JW, Kim JE. CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells. *Tumour. Biol.* 2014;35:10919–10929.
914. Ma Z, Yang Y, Fan C, et al. Melatonin as a potential anticarcinogen for non-small-cell lung cancer. *Oncotarget.* 2016;7:46768–46784.
915. Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. *J. Pharm. Pharm.* 2002;54:1299–1321.
916. Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. *J. Pineal Res.* 2003;35:12–15.
917. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: An inhibitor of breast cancer. *Endocr. Relat. Cancer.* 2015;22:R183–R204.
918. Basler M, Jetter A, Fink D, et al. Urinary excretion of melatonin and association with breast cancer: Meta-analysis and review of the literature. *Breast Care.* 2014;9:182–187.
919. Innominato PF, Lim AS, Palesh O, et al. The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. *Support. Care Cancer.* 2016;24:1097–1105.
920. Hansen MV, Andersen LT, Madsen MT, et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial. *Breast Cancer Res. Treat.* 2014;145:683–695.
921. Chen WY, Giobbie-Hurder A, Gantman K, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes. *Breast Cancer Res. Treat.* 2014;145:381–388.
922. Di Bella G, Mascia F, Ricchi A, Colori B. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: A preliminary

- report. *Neuro Endocrinol. Lett.* 2013;34:660–668.
923. Lissoni P, Barni S, Tancini G, et al. Clinical study of melatonin in untreatable advanced cancer patients. *Tumori.* 1987;73:475–480.
924. Barni S, Lissoni P, Paolorossi F, et al. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. *Tumori.* 1990;76:58–60.
925. Lissoni P. Is there a role for melatonin in supportive care? *Support. Care Cancer.* 2002;10:110–116.
926. Cerea G, Vaghi M, Ardizzoia A, et al. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: A randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. *Anticancer Res.* 2003;23:1951–1954.
927. Lissoni P. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. *Pathol. Biol.* 2007;55:201–204.
928. Fan L, Sun G, Ma T, et al. Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. *J. Pineal Res.* 2013;55:174–183.
929. Mohamed Y, Basyony MA, El-Desouki NI, et al. The potential therapeutic effect for melatonin and mesenchymal stem cells on hepatocellular carcinoma. *Biomedicine.* 2019;9:24.
930. Basyony MA, El Desouki NI., Abdo WS, et al. Melatonin improves the anticancer effects of mesenchymal stem cell against HCC in rat. *Egypt. J. Exp. Biol.* 2019;15:111–126.
931. Sigurdardottir LG, Valdimarsdottir UA, Fall K, et al. Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies. *Cancer Epidemiol. Biomark. Prev.* 2012;21:1002–1011.
932. Sigurdardottir LG, Markt SC, Rider JR, et al. Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men. *Eur. Urol.* 2015;67:191–194.



933. Mehrzadi MH, Hosseinzadeh A, Juybari KB, Mehrzadi S. Melatonin and urological cancers: A new therapeutic approach. *Cancer Cell Int.* 2020;20:444.
934. Maitra S, Bhattacharya D, Das S, Bhattacharya S. Melatonin and its anti-glioma functions: A comprehensive review. *Rev. Neurosci.* 2019;30:527–541.
935. Neamati F, Asemi Z. The effects of melatonin on signaling pathways and molecules involved in glioma. *Fundam. Clin. Pharmacol.* 2020;34:192–199.
936. Favero G, Moretti E, Bonomini F, et al. Promising Antineoplastic Actions of Melatonin. *Front. Pharm.* 2018;9:1086.
937. Moretti E, Favero G, Rodella LF, Rezzani R. Melatonin's Antineoplastic Potential against Glioblastoma. *Cells.* 2020;9:599.
938. Martín V, Herrera F, Carrera-Gonzalez P, et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. *Cancer Res.* 2006;66:1081–1088.
939. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. *Oncology.* 1996;53:43–46.
940. Lissoni P, Giani L, Zerbini S, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. *Nat. Immun.* 1998;16:27–33.
941. Raloff J. Darkness, melatonin may stall breast and prostate cancers. *ScienceNews.* 2009.
942. Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort. *Cancer Epidemiol Biomarkers Prev.* 2009 Jan;18(1):74-9.
943. Kloog I, Haim A, Stevens RG, Portnov BA. Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men. *Chronobiol Int.* 2009 Jan;26(1):108-25.
944. Aso Y, Akaza H, Kotake T, et al. Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. *Eur*

- Urol. 1995;27(2):104-9.
945. Bogdanov IG, Dalev PG, Gurevich AI, et al. Antitumour glycopeptides from *Lactobacillus bulgaricus* cell wall. *FEBS Lett.* 1975 Oct 1;57(3):259-61.
946. Mei, X. et al. Garlic and gastric cancer: the influence of garlic on the level of nitrate and nitrite in gastric juice. *Acta Nutr Sin.* 1982, 4:5356.
947. Lau BHS, Wooley JL, Marsh CL, et al. Superiority of intralesional immunotherapy with *Corynebacterium parvum* and *Allium Sativum* in control of murine transitional cell carcinoma. *The Journal of Urology.* 1986, 136, 3, 701-705.
948. Lamm DL, Riggs ΔP Enhanced immunocompetence by garlic: Role in bladder cancer and other malignancies. *The Journal of Nutrition.* 2001, 131, 3, 1067S–1070S.
949. Hong YS, Ham YA, Choi JH, et al. Effects of allyl sulfur compounds and garlic extract on the expression of Bcl-2, Bax, and p53 in non small cell lung cancer cell lines. *Exp Mol Med.* 2000, 32, 127–134.
950. Hayes MA, Rushmore TH, Goldberg MT, Inhibition of hepatocarcinogenic responses to 1,2-dimethylhydrazine by diallyl sulfide, a component of garlic oil, *Carcinogenesis.* 1987, 8, 8, 1155-1157.
951. Yang CS, Chhabra SK, Hong JY, Smith TJ. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic, *The Journal of Nutrition.* 2001, 131, 3, 1041S–1045S.
952. Welch C, Wuarin L, Sidell N. Antiproliferative effect of the garlic compound S-allyl cysteine on human neuroblastoma cells in vitro. *Cancer Letters.* 1992, 63, 3, 211-219.
953. Wargovich MJ, Imada O, Stephens LC. Initiation and post-initiation chemopreventive effects of diallyl sulfide in esophageal carcinogenesis. *Cancer Letters.* 1992, 64, 1, 39-42.
954. Omar SH, Al-Wabel NA. Organosulfur compounds and possible mechanism of garlic in cancer. *Saudi Pharm J.* 2010 Jan; 18(1): 51–58.
955. Takeyama H, Hoon DS, Saxton RE, et al. Growth inhibition and

- modulation of cell markers of melanoma by S-allyl cysteine. *Oncology*. 1993, 50, 1.
956. Sumiyoshi H, Wargovich MJ. Chemoprevention of 1,2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds. *Cancer Research*. 1990, 50, 16.
957. Mostafa MG, Mima T, Ohnishi ST, Mori K. S-allylcysteine ameliorates doxorubicin toxicity in the heart and liver in mice. *Planta Med*. 2000 Mar;66(2):148-51.
958. Colic M, Savic M. Garlic extracts stimulate proliferation of rat lymphocytes in vitro by increasing IL-2 and IL-4 production. *Immunopharmacology and Immunotoxicology*. 2000, 22, 1, 163-181.
959. Lau BH, Yamasaki T, Gridley DS. Garlic compounds modulate macrophage and T-lymphocyte functions. *Mol Biother*. 1991, 3.
960. Morioka N, Sze LL, Morton DL, Irie RF. A protein fraction from aged garlic extract enhances cytotoxicity and proliferation of human lymphocytes mediated by interleukin-2 and concanavalin A. *Cancer Immunol Immunother*. 1993 Oct;37(5):316-22.
961. Weisberger AS, Pensky J. Tumor inhibition by a sulfhydryl-blocking agent related to an active principle of garlic (*Allium sativum*). *Cancer Res*. 1958;18(11):1301-1308.
962. Fallah-Rostami F, Tabari MA, Esfandiari B, et al. Immunomodulatory activity of aged garlic extract against implanted fibrosarcoma tumor in mice. *N Am J Med Sci*. 2013;5(3):207-212.
963. Gdula-Argasinska J, Pasko P, Sulkowska-Ziaja K, et al. Anti-inflammatory activities of garlic sprouts, a source of alpha-linolenic acid and 5-hydroxy-L-tryptophan, in RAW 264.7 cells. *Acta Biochim Pol*. 2017;64(3):551-559.
964. Saud SM, Li W, Gray Z, et al. Diallyl disulfide (DADS), a constituent of garlic, inactivates NF-kappaB and prevents colitis-induced colorectal cancer by inhibiting GSK-3beta. *Cancer Prev Res (Phila)*. 2016;9(7):607-615.
965. Arreola R, Quintero-Fabian S, Lopez-Roa RI, et al.

- Immunomodulation and anti-inflammatory effects of garlic compounds. *J Immunol Res.* 2015;2015:401630.
966. Charron CS, Dawson HD, Albaugh GP, et al. A single meal containing raw, crushed garlic influences expression of immunity- and cancer-related genes in whole blood of humans. *J Nutr.* 2015;145(11):2448-2455.
967. Nicastro HL, Ross SA, Milner JA. Garlic and onions: their cancer prevention properties. *Cancer Prev Res (Phila).* 2015;8(3):181-189.
968. Zhou Y, Zhuang W, Hu W, et al. Consumption of large amounts of Allium vegetables reduces risk for gastric cancer in a meta-analysis. *Gastroenterology.* 2011;141:80–9.
969. World Cancer Research Fund / American Institute for Cancer Research. *Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective.* Washington DC: AICR; 2007.
970. Galeone C, Pelucchi C, Levi F, et al. Onion and garlic use and human cancer. *The American Journal of Clinical Nutrition.* 2006;84:1027–32.
971. Millen AE, Subar AF, Graubard BI, et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. *Am J Clin Nutr.* 2007 Dec;86(6):1754-64.
972. Chen YK, Lee CH, Wu IC, et al. Food intake and the occurrence of squamous cell carcinoma in different sections of the esophagus in Taiwanese men. *Nutrition.* 2009;25:753–61.
973. Galeone C, Pelucchi C, Levi F, et al. Onion and garlic use and human cancer. *The American Journal of Clinical Nutrition.* 2006;84:1027–32.
974. Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. *Pharmacogn Rev.* 2010;4(7):106-110.
975. Puccinelli MT, Stan SD. Dietary bioactive diallyl trisulfide in cancer prevention and treatment. *Int J Mol Sci.* 2017;18(8).
976. Cao HX, Zhu KX, Fan JG, Qiao L. Garlic-derived allyl sulfides in cancer therapy. *Anticancer Agents Med Chem.* 2014;14(6):793-799.
977. Yagdi E, Cerella C, Dicato M, Diederich M. Garlic-derived

- natural polysulfanes as hydrogen sulfide donors: friend or foe? *Food Chem Toxicol.* 2016;95:219-233.
978. Tanaka S, Haruma K, Yoshihara M, et al. Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. *J Nutr.* 2006;136(3)(suppl):821S-826S.
979. Ishikawa H, Saeki T, Otani T, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. *J Nutr.* 2006;136(3)(suppl):816s-820s.
980. Stabile H, Fionda C, Gismondi A, Santoni A. Role of distinct natural killer cell subsets in anticancer response. *Front Immunol.* 2017;8:293.
981. Kasuga S, Uda N, Kyo E, et al., Pharmacologic activities of aged garlic extract in comparison with other garlic preparations. *The Journal of Nutrition.* 2001, 131, 3, 1080S–1084S.
982. Abdullah TH, Kandil O, Elkadi A, Carter J. Garlic revisited: therapeutic for the major diseases of our times?. *J Natl Med Assoc.* 1988;80(4):439-445.
983. Li X, Qu L, Dong Y, et al. A review of recent research progress on the astragalus genus. *Molecules.* 2014;19(11):18850-18880.
984. Ye MN, Chen HF, Zhou RJ, Liao MJ. Effects of Astragalus polysaccharide on proliferation and Akt phosphorylation of the basal-like breast cancer cell line [in Chinese]. *Zhong Xi Yi Jie He Xue Bao.* 2011;9(12):1339-1346.
985. Cai T, Zhang C, Zhao Z, et al. The gastric mucosal protective effects of astragaloside IV in mnng-induced GPL rats. *Biomed Pharmacother.* 2018;104:291-299.
986. Zhang JX, Han YP, Bai C, Li Q. Notch1/3 and p53/p21 are a potential therapeutic target for APS-induced apoptosis in non-small cell lung carcinoma cell lines. *Int J Clin Exp Med.* 2015;8(8):12539-12547.
987. Yang Y, Zhao Y, Ai X, et al. Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. *Int J Clin Exp Pathol.* 2014;7(12):8453-8461.
988. Zou YH, Liu XM. Effect of astragalus injection combined with

- chemotherapy on quality of life in patients with advanced non-small cell lung cancer [in Chinese]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 2003;23(10):733-735.
989. McCulloch M, See C, Shu XJ, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. *J Clin Oncol*. 2006;24(3):419-430.
990. Wang SF, Wang Q, Jiao LJ, et al. Astragalus-containing traditional Chinese medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis. *Curr Oncol*. 2016;23(3):e188-e195.
991. He H, Zhou X, Zhao Y. Does the course of astragalus-containing Chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. *Evid Based Complement Alternat Med*. 2013;2013:42620
992. Kang S, Min H. Ginseng, the 'immunity boost': the effects of Panaxginseng on immune system. *J Ginseng Res*. 2012;36(4):354-368.
993. Dai D, Zhang CF, Williams S, et al. Ginseng on cancer: potential role in modulating inflammation-mediated angiogenesis. *Am J Chin Med*. 2017;45(1):13-22.
994. Suh SO, Kroh M, Kim NR, et al. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. *Am J Chin Med*. 2002;30(4):483-494.
995. Yun J, Kim BG, Kang JS, et al. Lipid-soluble ginseng extract inhibits invasion and metastasis of B16F10 melanoma cells. *J Med Food*. 2015;18(1):102-108.
996. Mochizuki M, Yoo YC, Matsuzawa K, et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. *Biol Pharmaceut Bull*. 1995;18(9):1197-1202.
997. Seo EY, Kim WK. Red ginseng extract reduced metastasis of colon cancer cells in vitro and in vivo. *J Ginseng Res*. 2011;35(3):315-324.

998. Nakata H, Kikuchi Y, Tode T, et al. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. *Jpn J Cancer Res.* 1998;89(7):733-740.
999. Kim JH, Park CY, Lee SJ. Effects of sun ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. *J Clin Pharm Ther.* 2006;31(4):331-334.
1000. Kim HS, Kim MK, Lee M, et al. Effect of red ginseng on genotoxicity and health-related quality of life after adjuvant chemotherapy in patients with epithelial ovarian cancer: a randomized, double blind, placebo-controlled trial. *Nutrients.* 2017 Jul 19;9(7):772.
1001. Yennurajalingam S, Reddy A, Tannir NM, et al. High-dose Asian ginseng (*Panax ginseng*) for cancer-related fatigue: a preliminary report. *Integr Cancer Ther.* 2015;14(5):419-427.
1002. Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (*Panax quinquefolius*) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst.* 2013;105(16):1230-1238.
1003. Wang M, Guilbert LJ, Ling L, et al. Immunomodulating activity of CVT-E002, a proprietary extract from North American ginseng (*Panax quinquefolium*). *J Pharm Pharmacol.* 2001;53(11):1515-1523.
1004. High KP, Case D, Hurd D, et al. A randomized, controlled trial of *Panax quinquefolius* extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. *J Support Oncol.* 2012;10(5):195-201.
1005. Bokemeyer C, Fels LM, Dunn T, et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. *Br J Cancer.* 1996;74(12):2036-2041.
1006. Zhao J, Sharma Y, Agarwal R, Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate–caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin-1 $\alpha$  expression in SENCAR mouse epidermis:

- Implications in the prevention of stage I tumor promotion. *Molecular Carcinogenesis*. 1999, 26, 4, 321-333.
1007. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. *Proc Natl Acad Sci U S A*. 1999;96(13):7490-7495.
1008. Scambia G, DeVincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. *Eur J Cancer*. 1996 May;32A(5):877-82.
1009. Jiang C, Agarwal R, Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. *Biochemical and Biophysical Research Communications*. 2000, 276, 1, 371-378.
1010. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. *FEBS Lett*. 1998 Nov 27;440(1-2):8-12.
1011. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. *Proc Natl Acad Sci U S A*. 1999 Jun 22;96(13):7490-5.
1012. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. *Cancer Res*. 1999 Feb 1;59(3):622-32.
1013. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. *J Natl Cancer Inst*. 1997 Apr 16;89(8):556-66.
1014. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. *Curr Cancer Drug Targets*. 2004 Feb;4(1):1-11.
1015. Singh RP, Agarwal R. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. *Mutat Res*. 2004 Nov 2;555(1-2):21-32.



1016. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. *Curr Cancer Drug Targets*. 2004 Feb;4(1):1-11.
1017. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from *Silybum marianum* on antiproliferative end points in human prostate carcinoma cells. *Cancer Res*. 2005 May 15;65(10):4448-57.
1018. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. *J Endocrinol*. 1994 Sep;142(3):407-15.
1019. Sahebnasagh A, Ghasemi A, Akbari J, et al. Successful treatment of acute radiation proctitis with aloe vera: a preliminary randomized controlled clinical trial. *J Altern Complement Med*. 2017;23(11):858-865.
1020. Sahebamee M, Mansourian A, Hajimirzamohammad M, et al. Comparative efficacy of aloe vera and benzydamine mouthwashes on radiation-induced oral mucositis: a triple-blind, randomised, controlled clinical trial. *Oral Health Prev Dent*. 2015;13(4):309-315.
1021. De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. *Crit Rev Oncol Hematol*. 2016;100:147-166.
1022. Lissoni P, Rovelli F, Brivio F, et al. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus *Aloe arborescens* in patients with metastatic cancer. *In Vivo*. 2009;23(1):171-175.
1023. Lissoni P, Giani L, Zerbini S, et al. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. *Nat Immun*. 1998;16(1):27-33.
1024. Sadzuka Y, Sugiyama T, Miyagishima A, et al. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. *Cancer Lett*. 1996 Aug 2;105(2):203-9.

1025. Sugiyama T, Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*. 2003, 1653, 2, 47-59.
1026. Sadzuka Y, Sugiyama T, Sonobe T. Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea. *Cancer Letters*. 2000, 158(2):119-24.
1027. Sugiyama T, Sadzuka Y. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. *Cancer Lett*. 2004 Aug 30;212(2):177-84.
1028. Prudden JF. The treatment of human cancer with agents prepared from bovine cartilage. *J Biol Response Mod*. 1985 Dec;4(6):551-84.
1029. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. *Ann Oncol*. 2002 Aug;13(8):1259-63.
1030. Skopinska-Rozewska E., Krotkiewski M., Sommer E., et al., Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells, *Oncol Rep*, 6, 6, 1341-1344, 1999
1031. Miloszezwska J., Krotkiewski M., The antipromoting effect of alkyloglycerols from shark liver oil, *Cell Mol Biol Lett*, 7, 2, 294, 2002;
1032. Pedrono F., Martin B., Leduc C., et al., Natural alkyglycerols restrain growth and metastasis of grafted tumors in mice, *Nutr Cancer*, 48, 1, 64-69, 2004
1033. Solomon N., Passwater R., Joelsson I., Haimes L., *Shark Liver Oil: Nature's Amazing Healer*, 1997
1034. Brohult A., Brohult J., Brohult S., Biochemical effects of alkoxyglycerols and their use in cancer therapy, *Acta Chem Scand*, 24, 2, 730, 1970
1035. Hallgren B., Niklasson A., Stallberg G., Thorin H., On the

- occurrence of 1-O-alkylglycerols and 1-O-(2-methoxyalkyl) glycerols in human colostrum, human milk, cow's milk, sheep's milk, human red bone marrow, red cells, blood plasma and a uterine carcinoma, *Acta Chem Scand B*, 28, 9, 1029-34, 1974
1036. Brohult A., Brohult J., Brohult S., Joelsson I., Effect of alkoxyglycerols on the frequency of injuries following radiation therapy for carcinoma of the uterine cervix, *Acta Obstet Gynecol Scand*, 56, 4, 441-8, 1977
1037. Brohult A., Brohult J., Brohult S., Joelsson I., Effect of alkoxyglycerols on the frequency of fistulas following radiation therapy for carcinoma of the uterine cervix, *Acta Obstet Gynecol Scand*, 58, 2, 203-7, 1979
1038. Brohult A., Brohult J., Brohult S., Effect of alkoxyglycerols on the serum ornithine carbamoyl transferase in connection with radiation treatment, *Experientia*, 15, 28, 2, 146-7, Feb. 1972
1039. Brohult A., Brohult J., Brohult S., Effect of alkoxyglycerols on the frequency of injuries following radiation therapy, *Experientia*, 1, 29, 1, 81-2, May 1973
1040. Brohult A., Brohult J., Brohult S., Joelsson I., Effect of alkoxyglycerols on the frequency of injuries following radiation therapy for carcinoma of the uterine cervix, *Acta Obstet Gynecol Scand*, 56, 4, 441-8, 1977
1041. Brohult A., Brohult J., Brohult S., Joelsson I., Effect of alkoxyglycerols on the frequency of fistulas following radiation therapy for carcinoma of the uterine cervix, *Acta Obstet Gynecol Scand*, 58, 2, 203-7, 1979
1042. Brohult A., Brohult J., Brohult S., Effect of alkoxyglycerols on the frequency of injuries following radiation therapy, *Experientia*, 1, 29, 1, 81-2, May 1973
1043. Brohult A., Brohult J., Brohult S., Regression of tumour growth after administration of alkoxyglycerols, *Acta Obstet Gynecol Scand*, 57, 1, 79-83, 1978
1044. Boeryd B., Hallgren B., Stallberg G., Studies on the effect of methoxy-substituted glycerol ethers on tumour growth and metastasis formation, *Br J Exp Pathol*, 52, 3, 221-30, Jun. 1971

1045. Samadder P, Richards C, Bittman R, Bhullar RP, Arthur G., The antitumor ether lipid 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH<sub>3</sub>) inhibits the association between Ras and Raf-1, *Anticancer Res*, 23, 3B, 2291-5, May 2003
1046. Arthur G., Bittman R., The inhibition of cell signaling pathways by antitumor ether lipids, *Biochim Biophys Acta*, 1390, 1, 85-102, Feb. 1998
1047. Pedrono F., Khan NA., Legrand AB., Regulation of calcium signalling by 1-O-alkylglycerols in human Jurkat T lymphocytes, *Life Sci*, 74, 22, 2793-801, Apr. 2004
1048. Brohult A., Brohult J., Brohult S., Joelsson I., Reduced mortality in cancer patients after administration of alkoxyglycerols, *Acta Obstet Gynecol Scand*, 65, 7, 779-85, 1986
1049. Solomon N., Passwater R., Joelsson I., Haimes L., Shark Liver Oil: Nature's Amazing Healer, 1997
1050. Pugliese P.T., Jordan K., Cederberg H., Brohult J., Some biological actions of alkylglycerols from shark liver oil, *J Altern Complement Med*, 4, 1, 87-99, 1998
1051. Aroca JD., Sanchez-Pinera P., Corbalan-Garcia S., et al., Correlation between the effect of the anti-neoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine on the membrane and the activity of protein kinase Calpha, *Eur J Biochem*, 268, 24, 6369-78, Dec. 2001
1052. Krotkiewski M., Przybyszewska M., Janik P., Cytostatic and cytotoxic effects of alkylglycerols (Ecomer), *Med Sci Monit*, 9, 11, 1131-5, Nov. 2003
1053. Yamamoto N., St CD, Jr., Homma S., Ngwenya BZ., Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues, *Cancer Res*, 48, 21, 6044-9, Nov. 1988
1054. Solomon N., Passwater R., Joelsson I., Haimes L., Shark Liver Oil: Nature's Amazing Healer, 1997
1055. Wang H., Rajagopal S., Reynolds S., Cederberg H., Chakrabarty S., Differentiation-promoting effect of 1-O (2 methoxy) hexadecyl glycerol in human colon cancer cells, *J Cell Physiol*, 178, 2, 173-8, Feb. 1999

1056. Krotkiewski M., Przybyszewska M., Janik P., Cytostatic and cytotoxic effects of alkylglycerols (Ecomer), *Med Sci Monit*, 9, 11, 1131-5, Nov. 2003
1057. Pedrono F., Martin B., Leduc C., et al., Natural alkylglycerols restrain growth and metastasis of grafted tumors in mice, *Nutr Cancer*, 48, 1, 64-9, 2004
1058. Skopinska-Rozewska E., Krotkiewski M., Sommer E., et al., Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells, *Oncol Rep*, 6, 6, 1341-4, Nov. 1999
1059. Newmark HL., Squalene, olive oil, and cancer risk. Review and hypothesis, *Ann NY Acad Sci*, 889, 193-203, 1999
1060. Smith TJ., Squalene: potential chemopreventive agent, *Expert Opin Investig Drugs*, 9, 8, 1841-8, Aug. 2000
1061. Smith TJ., Squalene: potential chemopreventive agent, *Expert Opin Investig Drugs*, 9, 8, 1841-8, Aug. 2000
1062. Gylling H., Miettinen TA., Postabsorptive metabolism of dietary squalene, *Atherosclerosis*, 106, 2, 169-78, Apr. 1994
1063. Nieper H., *Revolution in Technology, Medicine and Society*, 1985
1064. Ohkuma T., Otagiri K., Tanaka S., Ikekawa T., Intensification of host's immunity by squalene in sarcoma 180 bearing ICR mice, *J Pharmacobiodyn*, 6, 2, 148-51, Feb. 1983
1065. Skopinska-Rozewska E., Chorostowska-Wynimko J., Krotkiewski M., et al., Inhibitory effect of Greenland shark liver oil combined with squalen and arctic birch ashes on angiogenesis and L-1 sarcoma growth in Balb/c mice, *Pol J Vet Sci*, 6, 3 Suppl, 54-6, 2003
1066. Das B., Yeger H., Baruchel H., et al., In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. implications in cancer chemotherapy, *Eur J Cancer*, 39, 17, 2556-65, Nov. 2003
1067. Smith TJ., Yang GY., Seril DN., Liao J., Kim S., Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung

- tumorigenesis by dietary olive oil and squalene, *Carcinogenesis*, 19, 4, 703-6, Apr. 1998
1068. Rao CV., Newmark HL., Reddy BS., Chemopreventive effect of squalene on colon cancer, *Carcinogenesis*, 19, 2, 287-90, Feb. 1998
1069. Murakoshi M., Nishino H., Tokuda H., et al., Inhibition by squalene of the tumor-promoting activity of 12-O-tetradecanoylphorbol-13-acetate in mouse-skin carcinogenesis, *Int J Cancer*, 52, 6, 950-2, Dec. 1992
1070. Price W., *Nutrition and Physical Degeneration*, 2004
1071. Chretien PB, Lipson SD, Makuch R, et al. Effects of thymosin in vitro in cancer patients and correlation with clinical course after thymosin immunotherapy. *Ann NY Acad Sci*. 1979, 332:135-147.
1072. Shoham J, Theodor E, Brenner HJ, et al. Enhancement of the immune system of chemotherapy-treated cancer patients by simultaneous treatment with thymic extract, TP-1. *Cancer Immunol Immunother*. 1980, 9, 173-180.
1073. Hays EF, Beardsley TR. Immunologic effects of human thymic stromal grafts and cell lines. *Clinical Immunology and Immunopathology*. 1984, 33, 3, 381-390.
1074. Cohen MH, Chretien PB, Ihde DC, et al. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. *JAMA*. 1979 Apr 27;241(17):1813-5.
1075. Lipson SD, Chretien PB, Makuch R, et al. Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course. *Cancer*. 1979 Mar;43(3):863-70.
1076. Zhang F, Altorki NK, Mestre JR, et al. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. *Carcinogenesis*. 1999 Mar;20(3):445-51.
1077. Shah BH, Nawaz Z, Pertani SA, et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation

- through inhibition of thromboxane formation and Ca<sup>2+</sup> signaling. *Biochem Pharmacol.* 1999 Oct 1;58(7):1167-72.
1078. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. *Mol Med.* 1998 Jun;4(6):376-83.
1079. Skrzypczak-Jankun E, McCabe NP, Selman SH, Jankun J. Curcumin inhibits lipoxygenase by binding to its central cavity: theoretical and X-ray evidence. *Int J Mol Med.* 2000 Nov;6(5):521-6.
1080. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. *Carcinogenesis.* 2004 Sep;25(9):1671-9.
1081. Lin JK, Lin-Shiau SY. Mechanisms of cancer chemoprevention by curcumin. *Proc Natl Sci Counc Repub China B.* 2001 Apr;25(2):59-66.
1082. Werz O. Inhibition of 5-Lipoxygenase Product Synthesis by Natural Compounds of Plant Origin. *PlantaMed.* 2007;73:1331-1357.
1083. Kawamori T, Lubet R, Steele VE, et al. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. *Cancer Res.* 1999 Feb 1;59(3):597-601.
1084. Plummer S, Holloway K, Manson M, et al. Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. *Oncogene.* 1999, 18, 6013–6020.
1085. Konig H, Hermanek P, Rösch W. Clinical conference: Unusual course of chronic colitis. *Acta Hepatogastroenterol (Stuttg).* 1976 Jun;23(3):227-31.
1086. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Antitumour and antioxidant activity of natural curcuminoids. *Cancer Lett.* 1995 Jul 20;94(1):79-83.
1087. Inano H, Onoda M, Inafuku N, et al. Chemoprevention by curcumin during the promotion stage of tumorigenesis of mammary gland in rats irradiated with γ-rays. *Carcinogenesis.*

- 1999, 20, 6, 1011–1018.
1088. Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. *Environmental Health Perspectives*. 1998.
1089. Ciolino HP, Daschner PJ, Wang TTY, Yeh GC. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. *Biochemical Pharmacology*. 1998, 56, 2, 197-206.
1090. Verma SP, Goldin BR, Lin PS. The inhibition of the estrogenic effects of pesticides and environmental chemicals by curcumin and isoflavonoids. *Environmental Health Perspectives*. 1998.
1091. ElattarTM, Virji AS. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. *Anticancer Res*. 2000 May-Jun;20(3A):1733-8.
1092. Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. *J Cell Biochem Suppl*. 1997;27:26-34.
1093. DoraiT, CaoYC, DoraiB, et al. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. *Prostate*. 2001 Jun 1;47(4):293-303.
1094. Kuo ML, Huang TS, Lin JK. Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. *Biochim Biophys Acta*. 1996 Nov 15;1317(2):95-100.
1095. Lin JK, Chen YC, Huang YT, Lin-Shiau SY. Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. *Journal of Cellular Biochemistry*. 1997, 67, S28-29:39–48.
1096. Jee SH, Shen SC, Kuo ML, et al. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. *Journal of Investigative Dermatology*. 1998, 111, 4, 656-661.
1097. Xu YX, Pindolia KR, Janakiraman N, et al. Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. *Hematopathol*



- Mol Hematol. 1997-1998;11(1):49-62.
1098. Munzenmaier A, Lange C, Glocker E, et al. A secreted/shed product of *Helicobacter pylori* activates transcription factor nuclear factor-kappa B. *J Immunol*. 1997 Dec 15;159(12):6140-7.
1099. De R, Kundu P, Swarnakar S, Ramamurthy T, et al. Antimicrobial activity of curcumin against *Helicobacter pylori* isolates from India and during infections in mice. *Antimicrob Agents Chemother*. 2009;53:1592-1597.
1100. Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (*Curcuma longa*) and curcumin inhibit the growth of *Helicobacter pylori*, a group 1 carcinogen. *Anticancer Res*. 2002;22:4179-4181.
1101. Zaidi SF, Yamamoto T, Refaat A, et al. Modulation of activation-induced cytidine deaminase by curcumin in *Helicobacter pylori*-infected gastric epithelial cells. *Helicobacter*. 2009;14:588-595.
1102. Rajasekaran SA. Therapeutic potential of curcumin in gastrointestinal diseases. *World J Gastrointest Pathophysiol*. 2011;2(1):1-14.
1103. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res*. 2002 Jul 1;62(13):3868-75.
1104. Matsuyama M, Yoshimura R, Mitsuhashi M, et al. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. *Int J Oncol*. 2004 Apr;24(4):821-7.
1105. Kelavkar UP, Nixon JB, Cohen C, et al. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. *Carcinogenesis*. 2001 Nov;22(11):1765-73.
1106. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. *Biochem Biophys Res Commun*. 1997 Jun 18;235(2):418-23.
1107. Sundaram S, Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. *Biochem Biophys Res Commun*. 2006 Jan 6;339(1):93-8.
1108. Gupta S, Srivastava M, Ahmad N, et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. *Cancer*. 2001 Feb 15;91(4):737-43.

1109. Hassan S, Carraway RE. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. *Regul Pept.* 2006 Jan 15;133(1-3):105-14.
1110. Ye YN, Liu ES, Shin VY, Wu WK, Cho CH. Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. *Toxicology.* 2004 Oct 15;203(1-3):179-88.
1111. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. *Proc Natl Acad Sci U S A.* 1998 Oct 27;95(22):13182-7.
1112. Safayhi H, Rall B, Sailer ER, Ammon HP. Inhibition by boswellic acids of human leukocyte elastase. *J Pharmacol Exp Ther.* 1997 Apr;281(1):460-3.
1113. Basch E, Boon H, Davies-Heerema T, et al. Boswellia: an evidence-based systematic review by the Natural Standard Research Collaboration. *J Herb Pharmacother.* 2004;4(3):63-83.
1114. Ammon HP. Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases. *Wien Med Wochenschr.* 2002;152(15-16):373-8.
1115. Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. *Mol Pharmacol.* 1995 Jun;47(6):1212-6.
1116. Roy S, Khanna S, Shah H, et al. Human genome screen to identify the genetic basis of the anti-inflammatory effects of Boswellia in microvascular endothelial cells. *DNA Cell Biol.* 2005 Apr;24(4):244-55.
1117. Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular responses to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. *Antioxid Redox Signal.* 2006 Mar-Apr;8(3-4):653-60.
1118. Katiyar SK. Matrix metalloproteinases in cancer metastasis: molecular targets for prostate cancer prevention by green tea polyphenols and grape seed proanthocyanidins. *Endocr Metab Immune Disord Drug Targets.* 2006 Mar;6(1):17-24.

1119. Roy S, Khanna S, Krishnaraju AV, et al. Regulation of vascular response to inflammation: inducible matrix metalloproteinase-3 expression in human microvascular endothelial cells is sensitive to anti-inflammatory Boswellia. *Antioxid Redox Signal*. 2006 Mar-Apr;8(3-4):653-60.
1120. Rajashekhar G, et al. Continuous endothelial cell activation increases angiogenesis: evidence for the direct role of endothelium linking angiogenesis and inflammation, *J Vasc Res*. 2006, 43 (2):193-204.
1121. Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *Int J Cancer*. 2005 Feb 10;113(4):660-9.
1122. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ. Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. *Mol Carcinog*. 2006 May;45(5):309-19.
1123. Paschka A, Butler R, Young CYF. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. *Cancer Letters*. 1998, 130, 1-2, 1-7.
1124. Jung YD, Kim MS, Shin BA, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. *British Journal of Cancer*. 2001, 84(6), 844–850.
1125. Ahn WS, Huh SW, Bae SM, et al. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G1 arrest, and regulation of gene expression. *DNA and Cell Biology*. 2004, 22, 3, 217-224.
1126. Fujiki H, Suganuma M, Okabe S, Sueoka N, Komori A, Sueoka E, Kozu T, Tada Y, Suga K, Imai K, Nakachi K. Cancer inhibition by green tea. *Mutat Res*. 1998 Jun 18;402(1-2):307-10.
1127. Inoue M, Tajima K, Hirose K, et al. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. *Cancer Causes & Control*

- 1998;9(2):209-16.
1128. Setiawan VW, Zhang ZF, Yu GP, et al. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. *Int J Cancer*. 2001 May 15;92(4):600-4.
1129. Inoue M, Tajima K, Mizutani M, et al. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. *Cancer Lett*. 2001 Jun 26;167(2):175-82.
1130. Bertolini, F., Fusetti, L., Rabascio, C. et al. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. *Leukemia*. 2000, 14, 1477–1482.
1131. August DA, Landau J, Caputo D, Hong J, Lee MJ, Yang CS. Ingestion of green tea rapidly decreases prostaglandin E2 levels in rectal mucosa in humans. *Cancer Epidemiol Biomarkers Prev*. 1999 Aug;8(8):709-13.
1132. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor  $\kappa$ B in cancer cells versus normal cells. *Archives of Biochemistry and Biophysics*. 2000;376(2):338–346.
1133. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. *Biochem Biophys Res Commun*. 1998 Aug 19;249(2):391-6.
1134. Udriou I, Marinaccio J, Sgura A. Epigallocatechin-3-gallate induces telomere shortening and clastogenic damage in glioblastoma cells. *Environ Mol Mutagen*. 2019 Oct;60(8):683-692.

## **ΜΕΡΟΣ 6**

### **BOTANA ME ANTIKAPKINIKH ΔΡΑΣΗ**

1. Duke J.A., Weeds? Or wonder drugs?, *Organic Gardening*, 38-40, Jul.- Aug. 1994

2. Spju R.W., Perdue R.E., Plant folklore: A tool for predicting sources of antitumor activity?, *Cancer Treat Report*, 60, 8, 979-985, 1976
3. Tyler V.E., Significant anticancer herbs, *Herbs of Choice: The therapeutic use of phytomedicinals*, 178-179, 1994
4. Hartwell J.L., *Plants Used Against Cancer. A Survey*, 1971
5. Chang M., *Preface to Anticancer Medicinal Herbs*, 1992
6. Cetal N, Therapeutic effects of jian pi yi shen prescription on the toxicity reaction of postoperative therapy in patients with advanced gastric carcinoma, *Journal of Traditional Chinese Medicine*, 113-116, 1988
7. Dharmananda S., *Chinese Herbal Therapies for Immune Disorders*, 9-25, 1988
8. Dharmananda S., *Chinese Herbal Therapies for Immune Disorders*, 10, 1988
9. Wang R.L., et al., Potentiation by *Rabdosia rubescens* on chemotherapy of advanced esophageal carcinoma, *Chung Hua Chung Liu Tsa Chih* 10, 720-722, 1990
10. Liu X.Y., Ang N.Q., Effect of liu wei di huang or jin gui shen qi decoction as an adjuvant treatment in small cell lung cancer, *Chung His I Chieh Ho Tsa Chih* 10, 720-722, 1990
11. Nyholt D., *The Complete Natural Health Encyclopedia*, 1997
12. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. *Br J Clin Pharmacol*. 1992;34(4):352-358.
13. Kleijnen J, Knipschild P. Ginkgo biloba. *Lancet*. 1992 Nov 7;340(8828):1136-9.
14. Koltai M, Hosford D, Guinot P, et al. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (part I). *Drugs* 1991;42:9-29.
15. Murray F., *Ginkgo Biloba*, 37-38, 1993
16. Konoshima T., et al., Antitumor promoting activities and inhibitory effects on Epstein Barr virus activation of Shi-un-hou and its constituents, *Yokugaku Zashi*, 843-846, 1989
17. Okamoto T., et al., Clinical effects of Fuzen-taiho-to on immunologic and fatty metabolic states in postoperative patients with gastrointestinal cancer, *Gan To Kagaku Ryoho*,

1533-1537, 1989

18. Nagatsu Y., et al., Modification of macrophage functions by Sho-saiko-to, Kampo Medicine leads to enhancement of immune response, *Chemical and Pharmaceutical Bulletin*, 1540-1542, 1989
19. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). *Cancer*. 1995 Sep 1;76(5):743-9.
20. Sharma HM, Dwivedi C, Satter BC, et al., Antineoplastic properties of Maharishi-4 against DMBA-induced mammary tumors in rats. *Pharmacology Biochemistry and Behavior*. 35, 767-773, 1990.
21. Moss R., *Cancer therapy: The independent consumer's guide to non-toxic treatment and prevention*, 134, 1992
22. Sharma H.M., et al., Maharish Ayur-veda: Modern Insights into ancient medicine, *Journal of the American Medical Association*, 2633-2634, 1991
23. Prasad G.C., The use of Ayurvedic drugs in the management of cancer, *Word Congress on Cancer*, Sydney, Australia, 315-319, April 1994
24. Nagabhusan M., et al., Curcumin as an Inhibitor of Cancer. *J. Am. Coll. Nutr.*, 11, 192, 1992
25. Kakav S.S., Roy D., Curcumin inhibits TPA induced expression of C-fos, C-jun and C-myc protooncogene messenger RNA in mouse skin, *Cancer Letters*, 87, 1, 85-89, 1995
26. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (*Curcuma longa*). *Cancer Lett*. 1985 Nov;29(2):197-202.
27. Kuttan R, Turmeric and curcumin as topical agents in cancer therapy, *Tumori* 73, 29-31, 1987
28. Nogabhusan M., Bhide S.V., Curcumin as an inhibitor of cancer, *Journal of the American College of Nutrition*, 11, 2, 1992
29. Verma SP, Salamone E, Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by

- estrogenic pesticides. *Biochem Biophys Res Commun.* 1997 Apr 28;233(3):692-6.
30. Polasa K., Effect of Turmeric on urinary mutagens in smokers, *Mutagen*, 7, 2, 107-109, 1992
  31. Mukundan M.A., Effect of turmeric and curcumin on BP-DNA adducts, *Carcinogenesis*, 14, 493-496, 1993
  32. Krishnawamy K., Indian functional foods: role in prevention of cancer, *Nutr Rev*, 54(11 Pt 2), S127-131, Nov. 1996
  33. Subramanian S.S., Ashwagandha – an ancient ayurvedic drug, *J Health Sci*, 8, 135-139, 1982;
  34. Budhiraja R.D., Sudhir S., Review of biological active withanolides, *J Sci Ind Res*, 46, 488-491, 1987
  35. Kuttan G., Use of *Withania somnifera* Dunal as an adjuvant during radiation therapy, *Indian J Exp Biol*, 34, 9, 854-856, Sep. 1996
  36. Devi P.U., Sharada A.C., Solomon F.E., Kamath M.S., In vivo growth inhibitory effect of *Withania somnifera* (Ashwagandha) on a transplanted mouse tumor, Sarcoma 180, *Indian J Exp Biol*, 30, 3, 169-172, Mar. 1992
  37. Walters R., *Options: The alternative cancer therapy book*, 1993
  38. Lu M., Studies on Chinese rhubarb XII. Effect of anthraquinone derivatives on the respiration and glycolysis of ehrlich ascites carcinoma cells, *Acta Pharmaceutica Sinica* , 15, 1980
  39. Lu M., Biochemical study of Chinese rhubarb XXIX. Inhibitory effects of anthraquinone derivatives on P 388 Leukemia in mice, *Journal of China Pharmacology University*, 1989
  40. Duke J.A., *Handbook of medicinal herbs*, 1985
  41. Rao K.V., McBride T.J., Olseson J.J., Lapachol as one antitumor agent: Recognition and evaluation, *Proc Amer Assoc Cancer Res*, 9, 55, 1967
  42. Rao K.V., McBride T.J., Olseson J.J., Recognition and evaluation of Lapachol as an antitumor agent, *Cancer Res*, 28, 1952-1954, 1968
  43. Moikena D.H., Hokama Y., Effect of crude *Tabebuia* extracts in vitro and in vivo on macrophages and Lewis Lung Carcinoma

- in C 57 B1/6J mice, unpublished manuscript, Department of Pathology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI. Presented to the Minority Biomedical Symposium, New Orleans, LA, April 1986
44. Linardi C., A lapachol derivative active against mouse lymphocyte leukemia P-388, *Journal of Medicinal Chemistry*, 18, 11, 1159-1162, 1975
  45. Wead B., Second opinion: Lapacho and the cancer controversy, 1985
  46. Santana C.F. et al., Preliminary observations with the use of lapachol in human patients bearing malignant neoplasms, *Revista de Instituto de Antibioticos*, 20, 61-68, 1980
  47. Duke J.A. ed., *Handbook of medicinal herbs*, 1985
  48. Hartwell J.L., *Plants used against cancer. A survey*, 1967
  49. Smart C.R., Hogle H.H., Vogel H., et al., Clinical experience with nordihydroguaiaretic acid, *Rocky Mountain Med J.*, 11, 39-43, 1970
  50. Smart C.R., Hogle H.H., Robins R.K., et al., An interesting observation on nordihydroguaiaretic acid – NCS – 4291 NDGA – and a patient with malignant melanoma – A preliminary report, *Cancer Chemother Rep. Part 1*, 53, 2, 147-151, 1969
  51. Heinerman J., *The treatment of cancer with herbs*, 1984
  52. Hajito T., et al., Increased secretion of tumor necrosis factor a, interleukin 1 and interleukin 6 by human mononuclear cells exposed to B-galactoside-specific lectin from clinically applied mistletoe extract, *Cancer Research*, 50, 3322-3326, Jun. 1990
  53. Hajito T., Lanzrein C., Natural killer and antibody dependent cell – mediated cytotoxicity and large granular lymphocyte frequencies in *Viscum album* treated breast cancer patients, *Oncology*, 43, 93-97, 1986
  54. Kiene H., Clinical studies on mistletoe therapy for cancerous disease: A review, *Therapeutikon*, 3:6, 347-533, 1989
  55. Wagner R., Ovarian cancer and mistletoe treatment, *Journal of Anthroposophical Medicine*, 51-53, 1986
  56. Ostermann T, Bussing A. Retrolective studies on the survival of



- cancer patients treated with mistletoe extracts: a meta-analysis. *Explore (NY)*. 2012 Sep-Oct;8(5):277-81.
57. Hugo F, Dittmar T, Treutler EK, et al. The *Viscum album* extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines. *Onkologie*. 2005 Aug;28(8-9):415-20.
  58. Kovacs E, Link S, Toffol-Schmidt U. Comparison of *Viscum album* QuFrF extract with vincristine in an in vitro model of human B cell lymphoma WSU-1 *Arzneimittelforschung*. 2008;58(11):592-7.
  59. Kovacs E, Link S, Toffol-Schmidt U. Cytostatic and cytotoxic effects of mistletoe (*Viscum album* L.) quercus extract Iscador. *Arzneimittelforschung*. 2006 Jun;56(6A):467-73.
  60. Kovacs E, Kuehn JJ. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does *viscum album* treatment affect these parameters? *Biomed Pharmacother*. 2002 May;56(3):152-8.
  61. Kuehn JJ. [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non-Hodgkin lymphoma]. *Dtsch Med Wochenschr*. 1999 Nov 26;124(47):1414-8.
  62. Kameda G, Kempf W, Oschlies I, et al. Nodal anaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferation treated with mistletoe: spontaneous remission or treatment response? *Klin Padiatr*. 2011 Nov;223(6):364-7.
  63. Ostermann T, Bussing A. Retrospective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. *Explore (NY)*. 2012 Sep-Oct;8(5):277-81.
  64. Horneber MA, Bueschel G, Huber R, et al. Mistletoe therapy in oncology. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD003297.
  65. Walters R., *Options: The alternative cancer therapy book*, 1993
  66. Walker M., *The carnivora cure for cancer, AIDS and other pathologies*, *Townsend Letter for Doctors*, 95, 416, Jun. 1991

67. Krishnaswamy M., Purushothaman K. Plumbagin: A study of its anticancer, antibacterial and antifungal properties, *Indian Journal of Experimental Biology*, 18, 876-877, 1980
68. Melo A.M., et al., First observations on the topical use of primin, plumbagin and maytenin in patients with skin cancer, *Revista de Instituto de Antibioticos*, 9-16, 1974
69. Walker M., *German cancer therapies*, 2003
70. Diamond J., Cowden L., Goldberg B., *An alternative medicine definitive guide to cancer*, 1997

## **ΜΕΡΟΣ 7**

### **ΦΑΡΜΑΚΕΥΤΙΚΗ ΚΑΝΝΑΒΗ: ΕΝΑ ΘΑΥΜΑΤΟΥΡΓΟ ΦΑΡΜΑΚΟ ΚΑΤΑ ΤΟΥ ΚΑΡΚΙΝΟΥ**

1. [http://salem-news.com/articles/january112008/cancer\\_treatment\\_11008.php](http://salem-news.com/articles/january112008/cancer_treatment_11008.php)
2. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. *J Natl Cancer Inst*. 2008 Jan 2;100(1):59-69.
3. American Association for Cancer Research. Marijuana cuts lung cancer tumor growth in half, study shows. *ScienceDaily*. 17 April 2007. <https://www.sciencedaily.com/releases/2007/04/070417193338.htm>
4. American Association for Cancer Research. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels. 15 Aug 2004. [http://www.eurekalert.org/pub\\_releases/2004-08/aafc-mii081204.php](http://www.eurekalert.org/pub_releases/2004-08/aafc-mii081204.php)
5. Jacobsson SOP, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. relative involvement of cannabinoid and vanilloid receptors. *Journal of Pharmacology and Experimental Therapeutics*, 2001, 299, 3, 951-959.
6. Massi et al., Antitumor effects of cannabidiol, a non-

- psychotropic cannabinoid, on human glioma cell lines, *Journal of Pharmacology and Experimental Therapeutics Fast Forward*, 308, 838-845, 2004
7. Munson AE, Harris LS, Friedman MA, et al. Antineoplastic activity of cannabinoids. *J Natl Cancer Inst.* 1975 Sep;55(3):597-602.
  8. Armentano P. Emerging Clinical Applications for Cannabis and Cannabinoids: A Review of the Scientific Literature. 2008.
  9. McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., Desprez P.Y., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, *Molecular Cancer Therapeutics*, November 2007 6, 2921
  10. Preet A., Ganju R.K., Groopman J.E., Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo, *Oncogene*, 27, 339-346, 2008
  11. Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M, Velasco G., Iovanna J., Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes, *Cancer Research*, 66, 6748, 2006
  12. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., Sanchez C., Velasco G., Gonzalez-Feria L., A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, *British Journal of Cancer*, 95(2), 197-203, July 2006
  13. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H., Cannabinoids for Cancer Treatment: Progress and Promise, *Cancer Research*, 17, 95,2, January 15, 2008
  14. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., Sanchez C., Velasco G., Gonzalez-Feria L., A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, *British Journal of Cancer*, 17, 95,2, 197-203, July 2006
  15. Parolaro D., Massi P., Cannabinoids as potential new therapy for the treatment of gliomas, *Expert Review of Neurotherapeutics*, 8, 1, 37-49, January 2008

16. Guzman et al. Delta-9-tetrahydrocannabinol induces apoptosis in C6 glioma cells, *FEBS Letters* 436, 6-10, 1998
17. Guzman et al., Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation, *Nature Medicine* 6, 313-319, 2000
18. Guzman et al., Inhibition of tumor angiogenesis by cannabinoids, *The FASEB Journal*, 17, 529-531, 2003
19. Massi et al., Antitumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines, *Journal of Pharmacology and Experimental Therapeutics Fast Forward*, 308, 838-845, 2004
20. Guzman et al., Cannabinoids inhibit the vascular endothelial growth factor pathways in gliomas, *Cancer Research*, 64, 5617-5623, 2004
21. Allister et al., Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells, *Journal of Neurooncology*, 74, 31-40, 2005
22. Torres et al., A combined preclinical therapy of cannabinoids and Temozolomide against glioma, *Molecular Cannabis Therapeutics*, 10, 90, 2011
23. Guzman et al., A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, *British Journal of Cancer*, 2006
24. Parolaro, Massi, Cannabinoids as a potential new drug therapy for the treatment of gliomas, *Expert Reviews of Neurotherapeutics*, 8, 37-49, 2008
25. Galanti et al., Delta9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells, *Acta Oncologica*, 12, 1-9, 2007
26. Calatuzzolo et al., Expression of cannabinoid receptors and neurotrophins in human gliomas, *Neurological Sciences*, 28, 304-310, 2007
27. Foroughi et al., Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas – possible role of cannabis inhalation, *Child's Nervous System*, 27, 671-679, 2011

28. McAlister SD, Christian R.T., Horowitz M.P., Garcia A., Desprez P.Y., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, 6, 11, 2921-7, *Molecular Cancer Therapeutics*, 2007
29. Natalya Kogan, Cannabinoids and cancer, *Mini-Reviews in Medicinal Chemistry*, 5, 941-952, 2005
30. Sarafaraz et al., Cannabinoids for cancer treatment: progress and promise, *Cancer Research*, 68, 339-342, 2008
31. Guzman M., et al., A pilot clinical study of  $\Delta^9$ -tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *British Journal of Cancer*, 95, 197-203, 2006
32. Sanchez C., et al., Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. *Cancer Res*, 61(15):5784-9, 2001
33. Massi P., et al., Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *The Journal of Pharmacology and Experimental Therapeutics*, 308, 3, 838-845, 2004
34. Torres S., et al., A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Molecular Cancer Therapeutics*, 10, 90, 2011
35. Velasco G., et al., Cannabinoids and gliomas. *Mol. Neurobiol.*, 36(1):60-7, 2007
36. Vaccani A., et al., Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *British Journal of Pharmacology*, 144(8):1032-1036, 2005
37. Salazar M., et al., Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. *Journal of Clinical Investigation*, 119(5):1359-1372, 2009
38. Blazquez C., et al., Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res*, 64:5617, 2004
39. Whyte DA, Al-Hammadi S, Balhaj G, et al. Cannabinoids inhibit cellular respiration of human oral cancer cells. *Pharmacology*.

- 2010;85(6):328-35.
40. McAllister S.D., et al., Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat*, 129(1):37-47, 2011
  41. Nasser M.V., et al., Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. *PLoS One*, 6(9):e23901, 2011
  42. Ligresti A., et al., Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *Journal of Pharmacology and Experimental Therapeutics*, 2006
  43. Caffarel M., et al., Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. *Molecular Cancer*, 9:196, 2010
  44. Caffarel M.M., et al., Cannabinoids: a new hope for breast cancer therapy?. *Cancer Treatment Rev*, 38(7):911-8, 2012
  45. Petrocellis L., et al., The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation, *PNAS*, 95, 8375-8380, 1998
  46. Caffarel M., et al., Δ(9)-Tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation, *Cancer Res*, 66:6615, 2006
  47. Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. *Endocrinology*. 2000 Jan;141(1):118-26.
  48. Mimeault M., et al. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production, *Prostate*, 15;56(1):1-12, 2003
  49. Ramos J.A., Bianco F.J., The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications, *Indian Journal of Urology*, 28(1): 9-14, 2012

50. De Petrocellis L, et al., Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms, *Br J Pharmacol*, 168(1):79-102, 2013
51. Ramer R., et al., Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1, *FASEB J*, 26(4):1535-48, 2012
52. Preet A., et al., Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis, *Cancer Prev Res*, 4(1):65-75, 2010
53. Preet A., Δ(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo, *Oncogene*, 27, 339-346, 2008
54. Carracedo A., et al., Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes, *Cancer Res*, 66:6748, 2006
55. Aviello G., et al., Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer, *J Mol Med*, 90(8):925-34, 2012
56. Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. *Pharmacol Res*. 2009 Aug;60(2):117-25.
57. Patsos H.A., et al., The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2, *Gut*, 54:1741-1750, 2005
58. The University of Texas, MD Anderson Cancer Center, Turned-off cannabinoid receptor turns on colorectal tumor growth, 2008
59. Afaq F, et al., Cannabinoid receptors as a target for therapy of ovarian cancer, *American Association Cancer Research*, 47, 2006
60. McKallip R.J., et al., Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease, *Blood*, 100(2):627-34, 2002
61. Jia W., et al., Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria, *Mol Cancer Res*, 4(8):549-62, 2006
62. Gustafsson K., et al., Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by

- receptor activation, *International Journal of Cancer*, 123, 5, 1025-1033, 2008
63. Casanova M.L., et al., Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors, *J Clin Invest*, 111(1):43-50 2003
64. Vara D., et al., Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy, *Cell Death Differ*, 18(7):1099-111, 2011
65. Harrison L. Marijuana May Lower Bladder Cancer Risk. *Medscape*. May 10, 2013. <http://www.medscape.com/viewarticle/803983>

## **ΜΕΡΟΣ 8**

### **ΔΙΑΤΡΟΦΙΚΑ ΣΥΜΠΛΗΡΩΜΑΤΑ ΚΑΙ ΑΛΛΑ ΦΥΤΙΚΑ ΣΥΣΤΑΤΙΚΑ ΠΟΥ ΜΠΟΡΟΥΝ ΝΑ ΧΡΗΣΙΜΟΠΟΙΗΘΟΥΝ ΠΑΡΑΛΛΗΛΑ ΜΕΤΙΣ ΣΥΜΒΑΤΙΚΕΣ ΘΕΡΑΠΕΙΕΣ ΓΙΑ ΤΗ ΜΕΙΩΣΗ ΤΩΝ ΠΑΡΕΝΕΡΓΕΙΩΝ ΤΟΥΣ ΚΑΙ ΤΗΝ ΑΥΞΗΣΗ ΤΗΣ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑΣ ΤΟΥΣ**

1. Moss RW. Do antioxidants interfere with radiation therapy for cancer? *Integrative Cancer Therapies*. Sep 2007;6(3):281-292.
2. Lawenda BD, Kelly KM, Ladas EJ, et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *Journal of the National Cancer Institute*. Jun 4 2008;100(11):773-783.
3. Nakayama A, Alladin KP, Igbokwe O, White JD. Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. *Cancer Investigation*. Dec 2011;29(10):655-667.
4. Ozben T. Antioxidant supplementation on cancer risk and during cancer therapy: an update. *Curr Top Med Chem*. 2015;15(2):170-8.
5. D'Andrea GM. Use of antioxidants during chemotherapy and radiotherapy should be avoided. *CA Cancer J Clin*. 2005 Sep-



- Oct;55(5):319-21.
6. Sagar SM. Review Article: Should patients take or avoid antioxidant supplements during anticancer therapy? An evidence-based review. *Current Oncology*. 2005;12(2):44-54.
  7. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. *Cancer Treatment Reviews*. Aug 2007;33(5):407-418.
  8. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. *International Journal of Cancer*. Sep 15 2008;123(6):1227-1239.
  9. Block K, Koch A, Mead M, et al. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *J Natl Cancer Inst*. 2009 Jan 21;101(2):124-5; author reply 125-6.
  10. Simone CB, 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. *Altern Ther Health Med*. Jan-Feb 2007;13(1):22-28.
  11. Simone CB, 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, Part 2. *Altern Ther Health Med*. Mar-Apr 2007;13(2):40-47.
  12. Moss RW. Do antioxidants interfere with radiation therapy for cancer? *Integrative Cancer Therapies*. Sep 2007;6(3):281-292.
  13. Lamson DW, Brignall MS. Antioxidants and cancer therapy II: quick reference guide. *Altern Med Rev*. 2000 Apr;5(2):152-63.
  14. Koukourakis MI. Amifostine: is there evidence of tumor protection? *Seminars in Oncology*. Dec 2003;30(6 Suppl 18):18-30.
  15. Koukourakis MI, Kyrgias G, Panteliadou M, et al. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy. *American Journal of Clinical Oncology*. Aug 2013;36(4):338-343.

16. Gu J, Zhu S, Li X, et al. Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta-analysis based on randomized controlled trials. *PLoS One*. 2014 May 2;9(5):e95968.
17. Kouvaris JR, Kouloulis VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. *Oncologist*. Jun 2007;12(6):738-747.
18. Lamson DW, Brignall MS. Antioxidants and cancer therapy II: quick reference guide. *Altern Med Rev*. 2000 Apr;5(2):152-63.
19. Simone CB, 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. *Altern Ther Health Med*. Jan-Feb 2007;13(1):22-28.
20. Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: a systematic review. *Journal of Clinical Oncology*. Feb 1 2004;22(3):517-528.
21. Prasad KN, Cole WC, Kumar B, Che Prasad K. Pros and cons of antioxidant use during radiation therapy. *Cancer Treatment Reviews*. Apr 2002;28(2):79-91.
22. Seifried HE, McDonald SS, Anderson DE, et al. The antioxidant conundrum in cancer. *Cancer Research*. Aug 12 2003;63(15):4295-4298.
23. Braun DP, Gupta D, Birdsall TC, et al. Effect of naturopathic and nutritional supplement treatment on tumor response, control, and recurrence in patients with prostate cancer treated with radiation therapy. *J Altern Complement Med*. 2013 Mar;19(3):198-203.
24. Margalit DN, Kasperzyk JL, Martin NE, et al. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study. *Int J Radiat Oncol Biol Phys*. 2012 May 1;83(1):28-32.
25. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. *Journal of Clinical Oncology*. Aug 20 2005;23(24):5805-5813.

26. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. *International Journal of Cancer*. Apr 1 2008;122(7):1679-1683.
27. Schueller P, Puettmann S, Micke O, et al. Selenium influences the radiation sensitivity of C6 rat glioma cells. *Anticancer research*. Sep-Oct 2004;24(5a):2913-2917.
28. Puspitasari IM, Abdulah R, Yamazaki C, et al. Updates on clinical studies of selenium supplementation in radiotherapy. *Radiation Oncology*. 2014;9:125.
29. Muecke R, Micke O, Schomburg L, et al. Selenium supplementation in radiotherapy patients: do we need to measure selenium levels in serum or blood regularly prior radiotherapy? *Radiation Oncology*. Dec 16 2014;9(1):289.
30. Muecke R, Micke O, Schomburg L, et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. *Integrative Cancer Therapies*. Nov 2014;13(6):463-467.
31. Kiremidjian-Schumacher L, Roy M, Glickman R, et al. Selenium and immunocompetence in patients with head and neck cancer. *Biol Trace Elem Res*. 2000 Feb;73(2):97-111.
32. Saada HN, Rezk RG, Eltahawy NA. Lycopene protects the structure of the small intestine against gamma-radiation-induced oxidative stress. *Phytotherapy Research*. Jun 2010;24 Suppl 2:S204-208.
33. Andic F, Garipagaoglu M, Yurdakonar E, et al. Lycopene in the prevention of gastrointestinal toxicity of radiotherapy. *Nutrition and Cancer*. 2009;61(6):784-788.
34. Srinivasan M, Devipriya N, Kalpana KB, Menon VP. Lycopene: An antioxidant and radioprotector against gamma-radiation-induced cellular damages in cultured human lymphocytes. *Toxicology*. Jul 28 2009;262(1):43-49.

35. Meydan D, Gursel B, Bilgici B, et al. Protective effect of lycopene against radiation-induced hepatic toxicity in rats. *J Int Med Res.* 2011;39(4):1239-52.
36. Cikman O, Ozkan A, Aras AB, et al. Radioprotective effects of *Nigella sativa* oil against oxidative stress in liver tissue of rats exposed to total head irradiation. *Journal of Investigative Surgery.* Oct 2014;27(5):262-266.
37. Ustun K, Taysi S, Sezer U, et al. Radio-protective effects of *Nigella sativa* oil on oxidative stress in tongue tissue of rats. *Oral Diseases.* Jan 2014;20(1):109-113.
38. Taysi S, Abdulrahman ZK, Okumus S, et al. The radioprotective effect of *Nigella sativa* on nitrosative stress in lens tissue in radiation-induced cataract in rat. *Cutaneous and Ocular Toxicology.* Jun 2015;34(2):101-106.
39. Assayed ME. Radioprotective effects of blackseed (*Nigella sativa*) oil against hemopoietic damage and immunosuppression in gamma-irradiated rats. *Immunopharmacology and Immunotoxicology.* Jun 2010;32(2):284-296.
40. Cemek M, Enginar H, Karaca T, Unak P. In vivo radioprotective effects of *Nigella sativa* L oil and reduced glutathione against irradiation-induced oxidative injury and number of peripheral blood lymphocytes in rats. *Photochemistry and Photobiology.* Nov-Dec 2006;82(6):1691-1696.
41. Velho-Pereira R, Kumar A, Pandey BN, et al. Radioprotection by Macerated Extract of *Nigella sativa* in Normal Tissues of Fibrosarcoma Bearing Mice. *Indian Journal of Pharmaceutical Sciences.* Sep 2012;74(5):403-414.
42. Majdalawieh AF, Fayyad MW, Nasrallah GK. Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of *Nigella sativa*. *Crit Rev Food Sci Nutr.* 2017 Dec 12;57(18):3911-3928.
43. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in «high risk» patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Mol Aspects Med.* 1994;15 Suppl:s231-40.

44. Ki Y, Kim W, Kim YH, et al. Effect of Coenzyme Q10 on Radiation Nephropathy in Rats. *J Korean Med Sci.* May 2017;32(5):757-763.
45. Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector. *Journal of Radiation Research.* Jul 2007;48(4):263-272.
46. Mihandoost E, Shirazi A. Can melatonin help us in radiation oncology treatments? 2014;2014:578137.
47. Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. *Proc Soc Exp Biol Med.* Oct 2000;225(1):9-22.
48. El-Missiry MA, Fayed TA, El-Sawy MR, El-Sayed AA. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. *Ecotoxicology and Environmental Safety.* Feb 2007;66(2):278-286.
49. Fernandez-Gil B, Moneim AE, Ortiz F, et al. Melatonin protects rats from radiotherapy-induced small intestine toxicity. *PLoS One.* 2017;12(4):e0174474.
50. Zetner D, Andersen LP, Rosenberg J. Melatonin as Protection Against Radiation Injury: A Systematic Review. *Drug research.* Jun 2016;66(6):281-296.
51. Vijayalaxmi, Reiter RJ, Tan DX, et al. Melatonin as a radioprotective agent: a review. *Int J Radiat Oncol Biol Phys.* 2004 Jul 1;59(3):639-53.
52. Sainz RM, Mayo JC, Tan DX, et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. *Prostate.* Apr 01 2005;63(1):29-43.
53. Moretti RM, Marelli MM, Maggi R, et al. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. *Oncology Reports.* Mar-Apr 2000;7(2):347-351.
54. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, et al. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. *Journal of Pineal Research.* Mar 2015;58(2):189-197.

55. Mihandoost E, Shirazi A, Mahdavi SR, Aliasgharzadeh A. Can melatonin help us in radiation oncology treatments? *Biomed Res Int.* 2014;2014:578137.
56. Kucuktulu E. Protective effect of melatonin against radiation induced nephrotoxicity in rats. *Asian Pac J Cancer Prev.* 2012;13(8):4101-5.
57. Wang YM, Jin BZ, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. *Cancer Chemotherapy and Pharmacology.* May 2012;69(5):1213-1220.
58. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integrative Cancer Therapies.* Dec 2012;11(4):293-303.
59. Lissoni P, Merzagalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. *Oncology.* Jan-Feb 1996;53(1):43-46.
60. Verma V. Relationship and interactions of curcumin with radiation therapy. *World J Clin Oncol.* 2016 Jun 10;7(3):275-83.
61. Qiao Q, Jiang Y, Li G. Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation. *Oncology reports.* Jan 2013;29(1):380-386.
62. Chendil D, Ranga RS, Meigooni D, et al. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. *Oncogene.* Feb 26 2004;23(8):1599-1607.
63. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. *Molecular cancer.* 2011;10:12.
64. Sandur SK, Deorukhkar A, Pandey MK, et al. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. *Int J Radiat Oncol Biol Phys.* 2009 Oct 1;75(2):534-42.

65. Aravindan S, Natarajan M, Herman TS, et al. Molecular basis of hypoxic breast cancer cell radio-sensitization: phytochemicals converge on radiation induced Rel signaling. *Radiation Oncology* (London, England). 2013;8:46.
66. Borriello A, Bencivenga D, Caldarelli I, et al. Resveratrol: from basic studies to bedside. *Cancer Treat Res.* 2014;159:167-184.
67. Kma L. Synergistic effect of resveratrol and radiotherapy in control of cancers. *Asian Pacific journal of cancer prevention : APJCP.* 2013;14(11):6197-6208.
68. Dobrzynska MM. Resveratrol as promising natural radioprotector. A review. *Roczniki Panstwowego Zakladu Higieny.* 2013;64(4):255-262.
69. Fang Y, Bradley MJ, Cook KM, et al. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. *The Journal of Surgical Research.* Aug 2013;183(2):645-653.
70. Fang Y, DeMarco VG, Nicholl MB. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. *Cancer Science.* Jun 2012;103(6):1090-1098.
71. Luo H, Wang L, Schulte BA, et al. Resveratrol enhances ionizing radiation-induced premature senescence in lung cancer cells. *International Journal of Oncology.* Dec 2013;43(6):1999-2006.
72. Tan Y, Wei X, Zhang W, et al. Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. *Oncology Reports.* Mar2017;37(3):1833-1841.
73. Yang YP, Chang YL, Huang PI, et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3axis. *Journal of Cellular Physiology.* Mar 2012;227(3):976-993.
74. Kao CL, Huang PI, Tsai PH, et al. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. *Int J Radiat Oncol Biol Phys.* 2009 May 1;74(1):219-28.
75. Wang L, Long L, Wang W, Liang Z. Resveratrol, a potential

- radiation sensitizer for glioma stem cells both in vitro and in vivo. *J Pharmacol Sci.* 2015 Dec;129(4):216-25.
76. Lagerweij T, Hiddingh L, Biesmans D, et al. A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer. *Oncotarget.* Jun 14 2016;7(24):35776-35788.
  77. Malik A, Sultana M, Qazi A, et al. Role of Natural Radiosensitizers and Cancer Cell Radioresistance: An Update. *Anal Cell Pathol (Amst).* 2016;2016:6146595.
  78. Lin C, Yu Y, Zhao HG, et al. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. *Radiother Oncol.* 2012 Sep;104(3):395-400.
  79. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. *J Steroid Biochem Mol Biol.* 2014 Mar;140:116-32.
  80. Liu X, Sun C, Jin X, et al. Genistein enhances the radiosensitivity of breast cancer cells via G(2)/M cell cycle arrest and apoptosis. *Molecules (Basel, Switzerland).* 2013;18(11):13200-13217.
  81. Zhang B, Liu JY, Pan JS, Han SP, Yin XX, Wang B, Hu G. Combined treatment of ionizing radiation with genistein on cervical cancer HeLa cells. *J Pharmacol Sci.* 2006 Sep;102(1):129-35.
  82. Malik A, Sultana M, Qazi A, et al. Role of Natural Radiosensitizers and Cancer Cell Radioresistance: An Update. *Anal Cell Pathol (Amst).* 2016;2016:6146595.
  83. Gruca A, Krawczyk Z, Szeja W, et al. Synthetic genistein glycosides inhibiting EGFR phosphorylation enhance the effect of radiation in HCT 116 colon cancer cells. *Molecules (Basel, Switzerland).* 2014;19(11):18558-18573.
  84. Wang L, Li X, Song YM, et al. Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to  $\gamma$ -radiation by targeting the nuclear factor- $\kappa$ B pathway. *Mol Med Rep.* 2015 Jul;12(1):609-14.
  85. Kim HG, Jang SS, Lee JS, et al. Panax ginseng Meyer prevents radiation-induced liver injury via modulation of oxidative stress and apoptosis. *J Ginseng Res.* 2017 Apr;41(2):159-168.
  86. Deorukhkar A, Ahuja N, Mercado AL, et al. Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner



- to increase DNA damage and sensitize colorectal cancer cells to radiation. *Cancer Med.* 2015 Feb;4(2):278-92.
87. Yang ES, Choi MJ, Kim JH, et al. Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. *Toxicol In Vitro.* Dec 2011;25(8):1803-1810.
  88. Yang ES, Choi MJ, Kim JH, et al. Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. *Chem Biol Interact.* Mar 15 2011;190(1):9-15.
  89. Abdallah NM, Noaman E, Eltahawy NA, et al. Anticancer and Radiosensitization Efficacy of Nanocomposite Withania somnifera Extract in Mice Bearing Tumor Cells. *Asian Pac J Cancer Prev.* 2016;17(9):4367-4375.
  90. Kalthur G, Pathirisery UD. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia. *Integr Cancer Ther.* 2010 Dec;9(4):370-7.
  91. Uma Devi P, Kamath R. Radiosensitizing effect of withaferin A combined with hyperthermia on mouse fibrosarcoma and melanoma. *J Radiat Res.* 2003 Mar;44(1):1-6.
  92. Zhang G, Wang Y, Zhang Y, et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. *Current Molecular Medicine.* Feb 2012;12(2):163-176.
  93. McLaughlin N, Annabi B, Lachambre MP, et al. Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death. *J Neurooncol.* 2006 Nov;80(2):111-21.
  94. Kotowski U, Heiduschka G, Brunner M, et al. Radiosensitization of head and neck cancer cells by the phytochemical agent sulforaphane. *Strahlenther Onkol.* 2011 Sep;187(9):575-80.
  95. Sawai Y, Murata H, Horii M, et al. Effectiveness of sulforaphane as a radiosensitizer for murine osteosarcoma cells. *Oncology Reports.* Mar 2013;29(3):941-945.
  96. Kirste S, Treier M, Wehrle SJ, et al. *Boswellia serrata* acts on

- cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. *Cancer*. Aug 15 2011;117(16):3788-3795.
97. Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. *Integr Cancer Ther*. 2015 May;14(3):201-11.
  98. Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. *Am J Clin Oncol*. 1995 Jun;18(3):216-22.
  99. Kazuta M. [Enhancement of irradiation effect in carcinoma of the uterine cervix with the administration of protein-bound polysaccharide kureha (PS-K)]. *Nihon Sanka Fujinka Gakkai Zasshi*. 1985 Sep;37(9):1908-14.
  100. He H, Zhou X, Wang Q, Zhao Y. Does the couse of astragalus-containing chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. *Evid Based Complement Alternat Med*. 2013;2013:426207.
  101. Manda K, Kriesen S, Hildebrandt G, et al. Omega-3 fatty acid supplementation in cancer therapy: does eicosapentanoic acid influence the radiosensitivity of tumor cells? *Strahlenther Onkol*. 2011 Feb;187(2):127-34.
  102. Benais-Pont G, Dupertuis YM, Kossovsky MP, et al. Omega-3 polyunsaturated fatty acids and ionizing radiation: combined cytotoxicity on human colorectal adenocarcinoma cells. *Nutrition*. 2006 Sep;22(9):931-9.
  103. de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: A systematic review. *Clin Nutr*. 2015 Jun;34(3):359-66.
  104. Gramaglia A, Loi GF, Mongioj V, Baronzio GF. Increased survival in brain metastatic patients treated with stereotactic radiotherapy, omega three fatty acids and bioflavonoids. *Anticancer research*. Nov-Dec 1999;19(6c):5583-5586.

105. Bristol ML, Di X, Beckman MJ, et al. Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3. *Autophagy*. May 1 2012;8(5):739-753.
106. Wilson EN, Bristol ML, Di X, et al. A switch between cytoprotective and cytotoxic autophagy in the radiosensitization of breast tumor cells by chloroquine and vitamin D. *Horm Cancer*. 2011 Oct;2(5):272-85.
107. Sharma K, Goehe RW, Di X, et al. A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. *Autophagy*. 2014;10(12):2346-2361.
108. Findlay VJ, Moretz RE, Wang C, et al. Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer. *Molecular Carcinogenesis*. Feb 2014;53 Suppl 1:E130-139.
109. Gewirtz DA. Autophagy as a mechanism of radiation sensitization in breast tumor cells. *Autophagy*. May-Jun 2007;3(3):249-250.
110. Mineva ND, Wang X, Yang S, et al. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. *J Cell Physiol*. 2009 Sep;220(3):593-9.
111. Xu Y, Fang F, St Clair DK, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1 $\alpha$ ,25-dihydroxyvitamin D(3) in prostate cancer cells. *Molecular Cancer Therapeutics*. Jul 2007;6(7):2048-2056.
112. Ladner HA, Salkeld RM. Vitamin B6 status in cancer patients: effect of tumor site, irradiation, hormones and chemotherapy. *Prog Clin Biol Res*. 1988;259:273-81.
113. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. *Journal of Clinical Oncology*. Nov 20 2010;28(33):4912-4918.
114. Eustace A, Irlam JJ, Taylor J, et al. Necrosis predicts benefit from

- hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. *Radiother Oncol.* Jul 2013;108(1):40-47.
115. Misirlioglu CH, Erkal H, Elgin Y, et al. Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial. *Medical oncology.* 2006;23(2):185-189.
116. Meyer F, Bairati I, Fortin A, et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. *Int J Cancer.* 2008 Apr 1;122(7):1679-83.
117. Hanck AB. Vitamin C and cancer. *Prog Clin Biol Res.* 1988;259:307-320.
118. Lin YS, Lin LC, Lin SW. Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis. *The Laryngoscope.* Jul 2009;119(7):1348-1352.
119. Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in «high risk» patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. *Mol Aspects Med.* 1994;15 Suppl:s231-40.
120. Greenlee H, Kwan ML, Kushi LH, et al. Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. *Cancer.* Apr 15 2012;118(8):2048-2058.
121. Kwan ML, Greenlee H, Lee VS, et al. Multivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat.* Nov 2011;130(1):195-205.
122. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.

- Oncology. Jan-Feb 1996;53(1):43-46.
123. Kirste S, Treier M, Wehrle SJ, et al. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. *Cancer*. Aug 15 2011;117(16):3788-3795.
  124. Erol FS, Topsakal C, Ozveren MF, et al. Protective effects of melatonin and vitamin E in brain damage due to gamma radiation: an experimental study. *Neurosurg Rev*. Jan 2004;27(1):65-69.
  125. Manda K, Reiter RJ. Melatonin maintains adult hippocampal neurogenesis and cognitive functions after irradiation. *Progress in neurobiology*. Jan 11 2010;90(1):60-68.
  126. Lynch AM, Moore M, Craig S, et al. Analysis of interleukin-1 beta-induced cell signaling activation in rat hippocampus following exposure to gamma irradiation. Protective effect of eicosapentaenoic acid. *The Journal of Biological Chemistry*. Dec 19 2003;278(51):51075-51084.
  127. Gramaglia A, Loi GF, Mongioj V, Baronzio GF. Increased survival in brain metastatic patients treated with stereotactic radiotherapy, omega three fatty acids and bioflavonoids. *Anticancer Research*. Nov-Dec 1999;19(6c):5583-5586.
  128. Sezen O, Ertekin MV, Demircan B, et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages. *Neurosurg Rev*. Apr 2008;31(2):205-213; discussion213.
  129. Altas E, Ertekin MV, Gundogdu C, Demirci E. L-carnitine reduces cochlear damage induced by gamma irradiation in Guinea pigs. *Ann Clin Lab Sci*. 2006;36(3):312-318.
  130. Erol FS, Topsakal C, Ozveren MF, et al. Protective effects of melatonin and vitamin E in brain damage due to gamma radiation: an experimental study. *Neurosurg Rev*. Jan 2004;27(1):65-69.
  131. Sezen O, Ertekin MV, Demircan B, et al. Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced brain and retinal damages. *Neurosurg Rev*.

- Apr 2008;31(2):205-213; discussion213.
132. Lamproglou I, Boisserie G, Mazon JJ, et al. Effet de l'extract de Ginkgo biloba (EGb 761) chez le rat sur un modèle expérimental d'encéphalopathie aiguë après irradiation corporelle totale [Effect of Ginkgo biloba extract (EGb 761) on rats in an experimental model of acute encephalopathy after total body irradiation]. *Cancer Radiother.* 2000 May-Jun;4(3):202-6. French.
  133. Ertekin MV, Kocer I, Karslioglu I, et al. Effects of oral Ginkgo biloba supplementation on cataract formation and oxidative stress occurring in lenses of rats exposed to total cranium radiotherapy. *Japanese Journal of Ophthalmology.* Sep-Oct 2004;48(5):499-502.
  134. Ismail AF, El-Sonbaty SM. Fermentation enhances Ginkgo biloba protective role on gamma-irradiation induced neuroinflammatory gene expression and stress hormones in rat brain. *J Photochem Photobiol B.* 2016 May;158:154-63.
  135. Attia A, Rapp SR, Case LD, et al. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. *J Neurooncol.* 2012 Sep;109(2):357-63.
  136. Morris CR, Hamilton-Reeves J, Martindale RG, et al. Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine. *Nutrition in Clinical Practice.* Apr 2017;32(1\_suppl):30s-47s.
  137. Gaurav K, Goel RK, Shukla M, Pandey M. Glutamine: A novel approach to chemotherapy-induced toxicity. *Indian J Med Paediatr Oncol.* 2012 Jan;33(1):13-20.
  138. Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. *Int J Radiat Oncol Biol Phys.* 2000 Feb 1;46(3):535-9.
  139. Tsujimoto T, Yamamoto Y, Wasa M, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. *Oncology Reports.* Jan 2015;33(1):33-39.
  140. Yuce Sari S, Yazici G, Yuce D, et al. The effect of glutamine and arginine-enriched nutritional support on quality of life in head

- and neck cancer patients treated with IMRT. *Clin Nutr ESPEN*. 2016 Dec;16:30-35.
141. Najafzade N, Hemati S, Gookizade A, et al. Preventive effects of zinc sulfate on taste alterations in patients under irradiation for head and neck cancers: A randomized placebo-controlled trial. *J Res Med Sci*. 2013 Feb;18(2):123-6.
  142. Lin LC, Que J, Lin LK, Lin FC. Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study. *Int J Radiat Oncol Biol Phys*. 2006 Jul 1;65(3):745-50.
  143. Lin YS, Lin LC, Lin SW, Chang CP. Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study. *Nutr Cancer*. 2010;62(5):682-691.
  144. Watanabe T, Ishihara M, Matsuura K, et al. Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. *Int J Cancer*. 2010 Oct 15;127(8):1984-90.
  145. Hayashi H, Kobayashi R, Suzuki A, et al. Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy. *Medical Oncology*. Aug 2016;33(8):91.
  146. Biswal BM, Zakaria A, Ahmad NM. Topical application of honey in the management of radiation mucositis: a preliminary study. *Supportive Care in Cancer*. Apr 2003;11(4):242-248.
  147. Song JJ, Twumasi-Ankrah P, Salcido R. Systematic review and meta-analysis on the use of honey to protect from the effects of radiation-induced oral mucositis. *Adv Skin Wound Care*. 2012 Jan;25(1):23-8.
  148. Gujral MS, Patnaik PM, Kaul R, et al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. *Cancer Chemotherapy*

- and Pharmacology. Jul 2001;47 Suppl:S23-28.
149. Rao S, Dinkar C, Vaishnav LK, et al. The Indian Spice Turmeric Delays and Mitigates Radiation-Induced Oral Mucositis in Patients Undergoing Treatment for Head and Neck Cancer: An Investigational Study. *Integr Cancer Ther.* 2014 May;13(3):201-10.
  150. Carulli G, Rocco M, Panichi A, et al. Treatment of oral mucositis in hematologic patients undergoing autologous or allogeneic transplantation of peripheral blood stem cells: a prospective, randomized study with a mouthwash containing camelia sinensis leaf extract. *Hematology Reports.* Jan 25 2013;5(1):21-25.
  151. Gul K, Muge A, Taner A, Sehri E. Oral glutamine supplementation reduces radiotherapy- induced esophagitis in lung cancer patients. *Asian Pac J Cancer Prev.* 2015;16(1):53-8.
  152. Topkan E, Yavuz MN, Onal C, Yavuz AA. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. *Lung cancer.* Mar 2009;63(3):393-399.
  153. Tutanc OD, Aydogan A, Akkucuk S, et al. The efficacy of oral glutamine in prevention of acute radiotherapy-induced esophagitis in patients with lung cancer. *Contemp Oncol (Pozn).* 2013;17(6):520-524.
  154. Zhao H, Zhu W, Xie P, et al. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oralepigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer. *Radiother Oncol.* Jan 2014;110(1):132-136.
  155. de Freitas RB, Boligon AA, Rovani BT, et al. Effect of black grape juice against heart damage from acute gamma TBI in rats. *Molecules.* 2013;18(10):12154-12167.
  156. Saada HN, Said UZ, Meko NH, et al. Grape seed extract *Vitis vinifera* protects against radiation-induced oxidative damage and metabolic disorders in rats. *Phytotherapy Research.*



- Mar2009;23(3):434-438.
157. Pradeep K, Ko KC, Choi MH, et al. Protective effect of hesperidin, a citrus flavanoglycone, against gamma-radiation-induced tissue damage in Sprague-Dawley rats. *Journal of Medicinal Food*. May 2012;15(5):419-427.
  158. Gu J, Liu K, Li H, et al. Astragalus saponin attenuates the expression of fibrosis-related molecules in irradiated cardiac fibroblasts. *Acta Biochimica et Biophysica Sinica*. Jun 2014;46(6):492-501.
  159. Pietrofesa R, Turowski J, Tyagi S, et al. Radiation mitigating properties of the lignan component in flaxseed. *BMC cancer*. 2013;13:179.
  160. Lee JC, Krochak R, Blouin A, et al. Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury. *Cancer Biol Ther*. 2009 Jan;8(1):47-53.
  161. Berman AT, Turowski J, Mick R, et al. Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation. *J Pulm Respir Med*. 2013;3(4):154.
  162. Cho YJ, Yi CO, Jeon BT, et al. Curcumin attenuates radiation-induced inflammation and fibrosis in rat lungs. *Korean J Physiol Pharmacol*. 2013 Aug;17(4):267-74.
  163. Lee JC, Kinniry PA, Arguiri E, et al. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. *Radiation Research*. May 2010;173(5):590-601.
  164. Mahmood J, Jelveh S, Zaidi A, et al. Mitigation of radiation-induced lung injury with EUK-207 and genistein: effects in adolescent rats. *Radiation Research*. Feb 2013;179(2):125-134.
  165. Para AE, Bezjak A, Yeung IW, et al. Effects of genistein following fractionated lung irradiation in mice. *Radiotherapy and Oncology*. Sep 2009;92(3):500-510.
  166. Calveley VL, Jelveh S, Langan A, et al. Genistein can mitigate the effect of radiation on rat lung tissue. *Radiation Research*. May 2010;173(5):602-611.

167. Hillman GG, Singh-Gupta V, Runyan L, et al. Soy isoflavones radiosensitize lung cancer while mitigating normal tissue injury. *Radiotherapy and Oncology*. Nov 2011;101(2):329-336.
168. Tahamtan R, Shabestani Monfared A, Tahamtani Y, et al. Radioprotective effect of melatonin on radiation-induced lung injury and lipid peroxidation in rats. *Cell J*. 2015 Spring;17(1):111-20.
169. Jang SS, Kim HG, Lee JS, et al. Melatonin reduces X-ray radiation-induced lung injury in mice by modulating oxidative stress and cytokine expression. *Int J Radiat Biol*. 2013 Feb;89(2):97-105.
170. Serin M, Gulbaş H, Gurses I, et al. The histopathological evaluation of the effectiveness of melatonin as a protectant against acute lung injury induced by radiation therapy in a rat model. *Int J Radiat Biol*. 2007 Mar;83(3):187-93.
171. Huang Y, Liu W, Liu H, et al. Grape seed pro-anthocyanidins ameliorates radiation-induced lung injury. *J Cell Mol Med*. 2014 Jul;18(7):1267-77.
172. Huang Y, Zhao H, Cao K, et al. Radioprotective Effect of Grape Seed Proanthocyanidins In Vitro and In Vivo. *Oxid Med Cell Longev*. 2016;2016:5706751.
173. Yang X, Liu T, Chen B, et al. Grape seed proanthocyanidins prevent irradiation-induced differentiation of human lung fibroblasts by ameliorating mitochondrial dysfunction. *Sci Rep*. Dec 2017;7(1):62.
174. Song L, Wang D, Cui X, Hu W. The protective action of taurine and L-arginine in radiation pulmonary fibrosis. *J Environ Pathol Toxicol Oncol*. 1998;17(2):151-7.
175. Robb WB, Condron C, Moriarty M, et al. Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice. *Ir J Med Sci*. 2010 Mar;179(1):99-105.
176. Wang J, Xu HW, Li BS, et al. Preliminary study of protective effects of flavonoids against radiation-induced lung injury in mice. *Asian Pac J Cancer Prev*. 2012;13(12):6441-6.
177. He H, Zhou X, Wang Q, Zhao Y. Does the cause of astragalus-containing chinese herbal prescriptions and radiotherapy

- benefit to non-small-cell lung cancer treatment: a meta-analysis of randomized trials. *Evid Based Complement Alternat Med.* 2013;2013:426207.
178. Kuhn KS, Muscaritoli M, Wischmeyer P, Stehle P. Glutamine as indispensable nutrient in oncology: experimental and clinical evidence *Eur J Nutr.* Jun 2010;49(4):197-210.
179. Savarese DM, Savy G, Vahdat L, et al. Prevention of chemotherapy and radiation toxicity with glutamine. *Cancer Treatment Reviews.* Dec 2003;29(6):501-513.
180. Gul K, Muge A, Taner A, Sehri E. Oral glutamine supplementation reduces radiotherapy- induced esophagitis in lung cancer patients. *Asian Pacific journal of cancer prevention : APJCP.* 2015;16(1):53-58.
181. Huang EY, Leung SW, Wang CJ, et al. Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. *Int J Radiat Oncol Biol Phys.* 2000 Feb 1;46(3):535-9.
182. Vidal-Casariago A, Calleja-Fernández A, de Urbina-González JJ, et al. Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial. *JPEN J Parenter Enteral Nutr.* 2014 Feb;38(2):205-13.
183. Membrive Conejo I, Reig Castillejo A, Rodríguez de Dios N, et al. Prevention of acute radiation enteritis: efficacy and tolerance of glutamine. *Clin Transl Oncol.* 2011 Oct;13(10):760-3.
184. Rotovnik Kozjek N, Kompan L, Soeters P, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Clin Nutr.* 2011 Oct;30(5):567-70.
185. Cao DD, Xu HL, Xu M, et al. Therapeutic role of glutamine in management of radiation enteritis: a meta-analysis of 13 randomized controlled trials. *Oncotarget.* May 02 2017;8(18):30595-30605.
186. Kucuktulu E, Guner A, Kahraman I, et al. The protective effects of glutamine on radiation-induced diarrhea. *Support Care Cancer.* 2013 Apr;21(4):1071-5.
187. Visich KL, Yeo TP. The prophylactic use of probiotics in the

- prevention of radiation therapy-induced diarrhea. *Clin J Oncol Nurs*. 2010 Aug;14(4):467-73.
188. Fuccio L, Guido A, Eusebi LH, et al. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. *Journal of Clinical Gastroenterology*. Jul 2009;43(6):506-513.
189. Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. *Aliment Pharmacol Ther*. 2014 Sep;40(5):409-21.
190. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. *World J Gastroenterol*. 2007 Feb 14;13(6):912-5.
191. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of *Antibiophilus* in patients with radiation-induced diarrhoea. *Eur J Gastroenterol Hepatol*. 2001 Apr;13(4):391-6.
192. Liu MM, Li ST, Shu Y, Zhan HQ. Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials. *PLoS One*. 2017;12(6):e0178870.
193. Garcia-Peris P, Velasco C, Hernandez M, et al. Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial. *Eur J Clin Nutr*. 2016 Feb;70(2):170-4.
194. Muecke R, Schomburg L, Glatzel M, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. *Int J Radiat Oncol Biol Phys*. 2010 Nov 1;78(3):828-35.
195. Muecke R, Micke O, Schomburg L, et al. Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. *Integr Cancer Ther*. 2014 Nov;13(6):463-7.
196. Murphy J, Stacey D, Crook J, et al. Testing control of radiation-

- induced diarrhea with a psyllium bulking agent: a pilot study. *Can Oncol Nurs J.* 2000 Summer;10(3):96-100.
197. Belcaro G, Hosoi M, Pellegrini L, et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. *Phytother Res.* 2014 Mar;28(3):444-50.
198. Feher J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. *Curr Pharm Biotechnol.* 2012 Jan;13(1):210-7.
199. Soto C, Recoba R, Barron H, et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. *Comparative Biochemistry and Physiology. Toxicology & Pharmacology.* Nov 2003;136(3):205-212.
200. Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? *J Altern Complement Med.* 2003 Jun;9(3):411-6.
201. Ramadan LA, Roushdy HM, Abu Senna GM, et al. Radioprotective effect of silymarin against radiation induced hepatotoxicity. *Pharmacological Research.* Jun 2002;45(6):447-454.
202. Nascimento M, Aguilar-Nascimento JE, Caporossi C, et al. Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: a randomized, double-blind, placebo-controlled pilot trial. *Int J Radiat Oncol Biol Phys.* 2014 Oct 1;90(2):289-95.
203. Stojcev Z, Krokowicz Ł, Krokowicz P, et al. Early treatment and prevention of the radiation proctitis-composite enemas containing sodium butyrate. *Int J Colorectal Dis.* 2013;28(12):1731-1732.
204. Hille A, Herrmann MK, Kertesz T, et al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation. *Strahlenther Onkol.* 2008 Dec;184(12):686-92.
205. Ehrenpreis ED, Jani A, Levitsky J, et al. A prospective,

- randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. *Dis Colon Rectum*. 2005 Jan;48(1):1-8.
206. Kennedy M, Bruninga K, Mutlu EA, et al. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. *Am J Gastroenterol*. 2001 Apr;96(4):1080-4.
207. Hejazi J, Rastmanesh R, Taleban FA, et al. A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer. *Journal of Cancer Science and Therapy*. 2013;5(10):320-324.
208. Hamilton K, Bennett NC, Purdie G, Herst PM. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo controlled pilot study. *Support Care Cancer*. 2015 Jan;23(1):95-102.
209. Bonetta A, Di Pierro F. Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and urinary symptoms during radiotherapy for prostate carcinoma. *Cancer Manag Res*. 2012;4:281-6.
210. Bonetta A, Roviello G, Generali D, et al. Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma. *Res Rep Urol*. 2017;9:65-69.
211. Togni S, Maramaldi G, Bonetta A, et al. Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. *Eur Rev Med Pharmacol Sci*. 2015 Apr;19(8):1338-44.
212. Pommier P, Gomez F, Sunyach MP, et al. Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer. *Journal of Clinical Oncology*. Apr 15 2004;22(8):1447-1453.
213. Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation

- dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. *Radiation Research*. Jul 2013;180(1):34-43.
214. Di Franco R, Calvanese M, Murino P, et al. Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of Resveratrol, Lycopene, Vitamin C and anthocianin (Ixor(R)). *Radiation Oncology*. 2012;7:12.
215. Chan RJ, Webster J, Chung B, et al. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. *BMC Cancer*. 2014;14:53.
216. Eda K, Uzer K, Murat T, Cenk U. The effects of enteral glutamine on radiotherapy induced dermatitis in breast cancer. *Clinical Nutrition*. Apr 2016;35(2):436-439.
217. Micke O, Bruns F, Mucke R, et al. Selenium in the treatment of radiation-associated secondary lymphedema. *Int J Radiat Oncol Biol Phys*. 2003 May 1;56(1):40-9.
218. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (*Panax quinquefolius*) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst*. 2013 Aug 21;105(16):1230-8.
219. Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition*. Feb 2006;22(2):136-145.
220. Palatty PL, Haniadka R, Valder B, et al. Ginger in the prevention of nausea and vomiting: a review. *Crit Rev Food Sci Nutr*. 2013;53(7):659-69.
221. Mahajan MK, Singh V. Assessment of efficacy of pyridoxine in control of radiation induced sickness. *J Indian Med Assoc*. 1998 Mar;96(3):82-3.
222. He H, Zhou X, Wang Q, Zhao Y. Does the course of astragalus-containing chinese herbal prescriptions and radiotherapy benefit to non-small-cell lung cancer treatment: a meta-analysis

- of randomized trials. *Evid Based Complement Alternat Med.* 2013;2013:426207.
223. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. *Integrative Cancer Therapies.* Dec 2012;11(4):293-303.
224. Wang YM, Jin BZ, Ai F, et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. *Cancer Chemotherapy and Pharmacology.* May 2012;69(5):1213-1220.
225. Najafi M, Shirazi A, Motevaseli E, et al. The melatonin immunomodulatory actions in radiotherapy. *Biophysical Reviews.* Apr 2017;9(2):139-148.
226. Topkan E, Yavuz AA, Ozyilkan O. Cancer cachexia: pathophysiologic aspects and treatment options. *Asian Pac J Cancer Prev.* 2007 Jul-Sep;8(3):445-51.
227. Laine A, Iyengar P, Pandita TK. The role of inflammatory pathways in cancer-associated cachexia and radiation resistance. *Mol Cancer Res.* 2013 Sep;11(9):967-72.
228. Fietkau R, Lewitzki V, Kuhnt T, et al. A disease-specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: results of a randomized, controlled, multicenter trial. *Cancer.* Sep 15 2013;119(18):3343-3353.
229. Gramignano G, Lusso MR, Madeddu C, et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. *Nutrition.* Feb 2006;22(2):136-145.
230. Zhu BD, Li X, Zhao QC, Huang XL. [Enhancement of antioxidant capability of cancer patients during chemotherapy by reduced glutathione]. *Ai Zheng.* 2004 Apr;23(4):452-5.
231. Conklin KA. Cancer chemotherapy and antioxidants. *J Nutr.* 2004 Nov;134(11):3201S-3204S.



232. Victorino VJ, Pizzatti L, Michelletti P, Panis C. Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle. *Current Medicinal Chemistry*. 2014;21(28):3211-3226.
233. Nakayama A, Alladin KP, Igbokwe O, White JD. Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. *Cancer Invest*. 2011 Dec;29(10):655-67.
234. Block KI. Antioxidants and cancer therapy: furthering the debate. *Integrative Cancer Therapies*. Dec 2004;3(4):342-348.
235. Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. *Gynecologic Oncology*. 2003;88(3):434-439.
236. Sak K. Chemotherapy and dietary phytochemical agents. *Chemotherapy Research and Practice*. 2012;2012:282570.
237. Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. *Cancer Res*. 2003 Aug 1;63(15):4295-8.
238. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. *Integr Cancer Ther*. 2004;3(4):294-300.
239. Yasueda A, Urushima H, Ito T. Efficacy and Interaction of Antioxidant Supplements as Adjuvant Therapy in Cancer Treatment: A Systematic Review. *Integrative Cancer Therapies*. Oct 26 2015.
240. Block KI, Koch AC, Mead MN, et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. *Cancer Treatment Reviews*. Aug 2007;33(5):407-418.
241. Pathak AK, Bhutani M, Guleria R, et al. Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. *J Am Coll Nutr*. 2005 Feb;24(1):16-21.
242. Abdallah HM, Al-Abd AM, El-Dine RS, El-Halawany AM. P-glycoprotein inhibitors of natural origin as potential tumor

- chemo-sensitizers: A review. *J Adv Res.* Jan 2015;6(1):45-62.
243. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. *J Pharm Pharm Sci.* 2009;12(1):46-78.
244. Vaclavikova R, Horsky S, Simek P, Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. *Naunyn Schmiedebergs Arch Pharmacol.* 2003 Sep;368(3):200-9.
245. Wang BL, Shen YM, Zhang QW, et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer. *International Journal of Nanomedicine.* 2013;8:3521-3531.
246. Zhou QM, Zhang H, Lu YY, et al. Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. *Cancer Science.* Nov 2009;100(11):2040-2045.
247. Zhou QM, Wang XF, Liu XJ, et al. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. *European Journal of Cancer.* Sep 2011;47(14):2240-2247.
248. Zhou QM, Wang XF, Liu XJ, et al. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. *Acta Pharmacologica Sinica.* Nov 2011;32(11):1402-1410.
249. Zhou QM, Chen QL, Du J, et al. Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis. *International Journal of Molecular Sciences.* 2014;15(9):16284-16301.
250. Shakibaei M, Buhrmann C, Kraehe P, et al. Curcumin chemosensitizes 5-fluorouracil resistant MMR-deficient human colon cancer cells in high density cultures. *PLoS One.* 2014;9(1):e85397.
251. Bava SV, Sreekanth CN, Thulasidasan AK, et al. Akt is upstream

- and MAPKs are downstream of NF- $\kappa$ B in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. *Int J Biochem Cell Biol.* 2011 Mar;43(3):331-41.
252. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. *Oncogene.* Jul 14 2011;30(28):3139-3152.
253. Zhang H, Yu T, Wen L, et al. Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. *Experimental and therapeutic medicine.* Nov 2013;6(5):1317-1321.
254. Teiten MH, Eifes S, Dicato M, Diederich M. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. *Toxins.* Jan 2010;2(1):128-162.
255. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. *Clin Cancer Res.* 1998;4(1):153-6.
256. Sugiyama T, Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. *Biochimica et Biophysica Acta.* Dec 5 2003;1653(2):47-59.
257. Sugiyama T, Sadzuka Y, Nagasawa K, et al. Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin. *Japanese Journal of Cancer Research.* Jul 1999;90(7):775-780.
258. Maciejczyk A, Surowiak P. Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. *Ginekologia Polska.* Jul 2013;84(7):590-595.
259. Zhao JL, Zhao J, Jiao HJ. Synergistic growth-suppressive effects of quercetin and cisplatin on HepG2 human hepatocellular carcinoma cells. *Applied Biochemistry and Biotechnology.* Jan 2014;172(2):784-791
260. Chuang-Xin L, Wen-Yu W, Yao C, et al. Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and

- apoptosis of esophageal cancer cells by inhibiting NF-kappaB. *Oncology letters*. Oct 2012;4(4):775-778.
261. Yuan Z, Wang H, Hu Z, et al. Quercetin Inhibits Proliferation and Drug Resistance in KB/VCR Oral Cancer Cells and Enhances Its Sensitivity to Vincristine. *Nutrition and Cancer*. Jan 2015;67(1):126-136.
262. Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. *Nanomedicine*. Dec 2011;7(6):834-840.
263. Murphy RA, Mourtzakis M, Chu QS, et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. *Cancer*. 2011;117(16):3774-3780.
264. Bougnoux P, Hajjaji N, Ferrasson MN, et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. *British Journal of Cancer*. Dec 15 2009;101(12):1978-1985.
265. Granci V, Cai F, Lecumberri E, et al. Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. *The British journal of nutrition*. Apr 14 2013;109(7):1188-1195.
266. Ma Y, Chapman J, Levine M, et al. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. *Sci Transl Med*. 2014;6(222):222ra18.
267. Biswal BM, Sulaiman SA, Ismail HC, et al. Effect of *Withania somnifera* (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. *Integr Cancer Ther*. 2013 Jul;12(4):312-22.
268. del Giglio AB, Cubero D de I, Lerner TG, et al. Purified dry extract of *Paullinia cupana* (guaraná) (PC-18) for chemotherapy-related fatigue in patients with solid tumors: an early discontinuation study. *J Diet Suppl*. 2013 Dec;10(4):325-34.
269. de Oliveira Campos MP, Riechelmann R, Martins LC, et al. Guarana (*Paullinia cupana*) improves fatigue in breast

- cancer patients undergoing systemic chemotherapy. *J Altern Complement Med.* 2011 Jun;17(6):505-12.
270. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (*Panax quinquefolius*) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *Journal of the National Cancer Institute.* Aug 21 2013;105(16):1230-1238.
271. Silverio R, Laviano A, Rossi Fanelli F, Seelaender M. I-carnitine and cancer cachexia: Clinical and experimental aspects. *J Cachexia Sarcopenia Muscle.* 2011 Mar;2(1):37-44.
272. Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. *British Journal of Cancer.* Jun 17 2002;86(12):1854-1857.
273. Cruciani RA, Dvorkin E, Homel P, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. *J Pain Symptom Manage.* 2006 Dec;32(6):551-9.
274. Takagi K, Yamamori H, Furukawa K, et al. Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer. *Nutrition.* Jun 2001;17(6):478-479.
275. Demidov LV, Manziuk LV, Kharkevitch GY, et al. Adjuvant fermented wheat germ extract (Avenar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. *Cancer Biother Radiopharm.* 2008 Aug;23(4):477-82.
276. Boros LG, Nichelatti M, Shoenfeld Y. Fermented wheat germ extract (Avenar) in the treatment of cancer and autoimmune diseases. *Ann NY Acad Sci.* 2005 Jun;1051:529-42.
277. Garami M, Schuler D, Babosa M, et al. Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients. *J Pediatr Hematol Oncol.* 2004 Oct;26(10):631-5.
278. Salva S, Marranzino G, Villena J, et al. Probiotic

- Lactobacillus strains protect against myelosuppression and immunosuppression in cyclophosphamide-treated mice. *International Immunopharmacology*. Sep 2014;22(1):209-221.
279. Zhang XH, Wang L, Dong ZZ. [Study on zinc resistance to the immunosuppression caused by cyclophosphamidum in the mouse]. *Sheng Li Xue Bao*. 1992 Oct;44(5):528-32.
280. Senthilnathan P, Padmavathi R, Banu SM, Sakthisekaran D. Enhancement of antitumor effect of paclitaxel in combination with immunomodulatory *Withania somnifera* on benzo(a)pyrene induced experimental lung cancer. *Chem Biol Interact*. 2006 Feb 25;159(3):180-5.
281. Gupta YK, Sharma SS, Rai K, Katiyar CK. Reversal of paclitaxel induced neutropenia by *Withania somnifera* in mice. *Indian J Physiol Pharmacol*. 2001 Apr;45(2):253-7.
282. Islambulchilar M, Asvadi I, Sanaat Z, et al. Effect of taurine on febrile episodes in acute lymphoblastic leukemia. *Adv Pharm Bull*. Mar 2015;5(1):103-108.
283. May MB, Glode AE. Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. *Cancer Management and Research*. 2016;8:49-55.
284. Hernandez SL, Sheyner I, Stover KT, Stewart JT. Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis. *Am J Hosp Palliat Care*. 2015 Feb;32(1):5-7.
285. Haniadka R, Rajeev AG, Palatty PL, et al. *Zingiber officinale* (ginger) as an anti-emetic in cancer chemotherapy: a review. *J Altern Complement Med*. 2012 May;18(5):440-4.
286. Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (*Zingiber officinale*) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. *Support Care Cancer*. 2012 Jul;20(7):1479-89.
287. Yekta ZP, Ebrahimi SM, Hosseini M, et al. Ginger as a miracle against chemotherapy-induced vomiting. *Iran J Nurs Midwifery Res*. 2012 Jul;17(5):325-9.
288. Panahi Y, Saadat A, Sahebkar A, et al. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a

- pilot, randomized, open-label clinical trial. *Integr Cancer Ther.* 2012 Sep;11(3):204-11.
289. Islambulchilar M, Asvadi I, Sanaat Z, et al. Taurine attenuates chemotherapy-induced nausea and vomiting in acute lymphoblastic leukemia. *Amino acids.* Oct 17 2014.
290. Xu XT, Dai ZH, Xu Q, et al. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers. *J Dig Dis.* 2013 Jun;14(6):288-98.
291. Campone M, Berton-Rigaud D, Joly-Lobbedez F, et al. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. *Oncologist.* 2013;18(11):1190-1.
292. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. *European Journal of Cancer.* Aug 2005;41(12):1746-1750.
293. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. *Tumori.* Mar-Apr 2005;91(2):135-138.
294. Gedlicka C, Kornek GV, Schmid K, Scheithauer W. Amelioration of docetaxel/cisplatin induced polyneuropathy by  $\alpha$ -lipoic acid. *Annals of Oncology.* 2003;14(2):339-340.
295. Vahdat L, Papadopoulos K, Lange D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. *Clinical Cancer Research.* May 2001;7(5):1192-1197.
296. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. *The oncologist.* Mar 2007;12(3):312-319.
297. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. *J Clin Oncol.* 1995 Jan;13(1):26-32.
298. Lin PC, Lee MY, Wang WS, et al. N-acetylcysteine has

- neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. *Support Care Cancer*. 2006 May;14(5):484-7.
299. Ghoreishi Z, Esfahani A, Djazayeri A, et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. *BMC Cancer*. 2012 Aug 15;12:355.
300. Eum S, Choi HD, Chang MJ, et al. Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials. *Int J Vitam Nutr Res*. 2013;83(2):101-11.
301. Roffe L, Schmidt K, Ernst E. Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. *J Clin Oncol*. 2004 Nov 1;22(21):4418-24.
302. Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. *Integr Cancer Ther*. 2005 Jun;4(2):110-30.
303. Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, et al. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. *European Journal of Pharmacology*. Aug 25 2010;640(1-3):143-149.
304. De Leonardis V, De Scalzi M, Neri B, et al. Echocardiographic assessment of anthracycline cardiotoxicity during different therapeutic regimens. *Int J Clin Pharmacol Res*. 1987;7(4):307-11.
305. Patil L, Balaraman R. Effect of green tea extract on Doxorubicin induced cardiovascular abnormalities: antioxidant action. *Iranian Journal of Pharmaceutical Research*. Winter 2011;10(1):89-96.
306. Khan G, Haque SE, Anwer T, et al. Cardioprotective effect of green tea extract on doxorubicin-induced cardiotoxicity in rats. *Acta Pol Pharm*. 2014 Sep-Oct;71(5):861-8.
307. Bagchi D, Ray SD, Bagchi M, et al. Mechanistic pathways of antioxidant cytoprotection by a novel IH636 grape seed proanthocyanidin extract. *Indian J Exp Biol*. 2002;40(6):717-726.
308. Ray SD, Patel D, Wong V, Bagchi D. In vivo protection of dna damage associated apoptotic and necrotic cell deaths during



- acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract. *Res Commun Mol Pathol Pharmacol.* 2000;107(1-2):137-66.
309. Boghdady NA. Antioxidant and antiapoptotic effects of proanthocyanidin and ginkgo biloba extract against doxorubicin-induced cardiac injury in rats. *Cell Biochemistry and Function.* Jun 2013;31(4):344-351.
310. Li J, Liu H, Ramachandran S, Waypa GB, et al. Grape seed proanthocyanidins ameliorate Doxorubicin-induced cardiotoxicity. *The American Journal of Chinese Medicine.* 2010;38(3):569-584.
311. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. *European Journal of Cancer.* Nov 2008;44(17):2608-2614.
312. Muraki K, Koyama R, Honma Y, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. *Journal of Thoracic Disease.* Dec 2012;4(6):562-568.
313. Hirai S, Kaida S, Ito T, et al. [Magnesium premedication prevents Cisplatin-induced nephrotoxicity in patients with esophageal and hypopharyngeal cancer]. *Gan To Kagaku Ryoho.* 2013 Jun;40(6):743-7.
314. Yoshida T, Niho S, Toda M, et al. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. *Japanese Journal of Clinical Oncology.* Apr 2014;44(4):346-354.
315. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. *Annals of Oncology.* Jun 1997;8(6):569-573.
316. Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal

- toxicity: possible reversal by N-acetylcysteine treatment. *Journal of the American Society of Nephrology*. Oct 1997;8(10):1640-1644.
317. Nisar S, Feinfeld DA. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. *Renal Failure*. Jul 2002;24(4):529-533.
318. Chen N, Aleksa K, Woodland C, et al. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity: in vitro studies in renal tubular cells. *Translational Research*. Jul 2007;150(1):51-57.
319. Chen N, Aleksa K, Woodland C, et al. N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. *British journal of pharmacology*. Apr 2008;153(7):1364-1372.
320. Chen N, Hanly L, Rieder M, et al. The effect of N-acetylcysteine on the antitumor activity of ifosfamide. *Canadian Journal of Physiology and Pharmacology*. May 2011;89(5):335-343.
321. Hemati S, Arbab JN, Rafienia M, Ghavamnasiri M. The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: A randomized, placebo-controlled study. *J Res Med Sci*. 2012;17:S49–58.
322. Ghorbani A. Renal protective effect of selenium on cisplatin-induced nephrotoxicity. *J Ren Inj Prev*. 2013;1(1):31-32.
323. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. *Toxicology*. Feb 15 2004;195(2-3):221-230.
324. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. *Biol Trace Elem Res*. 1997 Mar;56(3):331-41.
325. Nishijima S, Yanase T, Hata Y, et al. [Orally administered polaprezinc significantly improves taste disorders in ovarian cancer patient undergoing chemotherapy]. *Gan To Kagaku Ryoho*. 2011 Apr;38(4):689-92.
326. Asano S, Ueno K, Niitani M, et al. [Examination of taste threshold and serum zinc level change after chemotherapy].

- Gan To Kagaku Ryoho. 2012 Sep;39(9):1389-93.
327. Corrie PG, Bulusu R, Wilson CB, et al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. *Br J Cancer*. 2012 Aug 7;107(4):585-7.
328. Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review. *PLoS One*. 2013;8(8):e72245.
329. Bozkurt Duman B, Kara B, Oguz Kara I, et al. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. *J BUON*. 2011 Oct-Dec;16(4):759-64.
330. Yamamoto D, Yamamoto C, Iwase S, et al. Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine. *Breast Care (Basel)*. 2010;5(6):415-416.
331. Abd El-Atti S, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. *JPEN J Parenter Enteral Nutr*. 2009 Sep-Oct;33(5):569-70.
332. Wang YH, Yao N, Wei KK, et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. *European journal of clinical nutrition*. Nov 2016;70(11):1246-1253.
333. Sun J, Wang H, Hu H. Glutamine for chemotherapy induced diarrhea: a meta-analysis. *Asia Pac J Clin Nutr*. 2012;21(3):380-5.
334. Raeessi MA, Raeessi N, Panahi Y, et al. «Coffee plus honey» versus «topical steroid» in the treatment of chemotherapy-induced oral mucositis: a randomised controlled trial. *BMC Complement Altern Med*. 2014 Aug 8;14:293.
335. Xu JL, Xia R, Sun ZH, et al. Effects of honey use on the management of radio/chemotherapy-induced mucositis: a meta-analysis of randomized controlled trials. *Int J Oral Maxillofac Surg*. 2016 Dec;45(12):1618-1625.
336. Moslehi A, Taghizadeh-Ghehi M, Gholami K, et al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. *Bone*

- Marrow Transplant. 2014 Jun;49(6):818-23.
337. Jahangard-Rafsanjani Z, Gholami K, Hadjibabaie M, et al. The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial. *Bone Marrow Transplant*. 2013 Jun;48(6):832-6.
338. Tsujimoto T, Yamamoto Y, Wasa M, et al. L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. *Oncol Rep*. Jan 2015;33(1):33-39.
339. Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. *Cell Metab*. 2015;22(1):86-99.
340. Stipp D. How Intermittent Fasting Might Help You Live a Longer and Healthier Life - Scientific American. <http://www.scientificamerican.com/article/how-intermittent-fasting-might-help-you-live-longer-healthier-life/>. 7/24/2015.
341. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. *Oncogene*. 2011;30(30):3305-3316.
342. Brandhorst S, Wei M, Hwang S, Morgan TE, Longo VD. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. *Experimental gerontology*. Oct 2013;48(10):1120-1128.
343. Safdie F, Brandhorst S, Wei M, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. *PloS One*. 2012;7(9):e44603.
344. de Groot S, Vreeswijk MP, Welters MJ, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. *BMC Cancer*. 2015;15:652.
345. Hine C, Mitchell JR. Saying no to drugs: fasting protects hematopoietic stem cells from chemotherapy and aging. *Cell Stem Cell*. Jun 5 2014;14(6):704-705.
346. Cheng CW, Adams GB, Perin L, et al. Prolonged fasting

- reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. *Cell Stem Cell*. Jun 5 2014;14(6):810-823.
347. Lee C, Safdie FM, Raffaghello L, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. *Cancer Research*. 2010;70(4):1564-1572.
348. Raffaghello L, Safdie F, Bianchi G, et al. Fasting and differential chemotherapy protection in patients. *Cell Cycle*. 2010 Nov 15;9(22):4474-6.
349. Safdie FM, Dorff T, Quinn D, et al. Fasting and cancer treatment in humans: A case series report. *Aging*. Dec 2009;1(12):988-1007.
350. Lee C, Raffaghello L, Brandhorst S, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. *Sci Transl Med*. 2012;4(124):124ra127.
351. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. *Cell Metab*. 2014;19(2):181–192.
352. Ho KY, Veldhuis JD, Johnson ML, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. *J Clin Invest*. 1988 Apr; 81(4): 968–975.
353. Hartman ML, Veldhuis JD, Johnson ML, et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. *J Clin Endocrinol Metab*. 1992 Apr;74(4):757-65.
354. Blackman MR, Sorkin JD, Münzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. *JAMA*. 2002 Nov 13;288(18):2282-92.
355. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. *N Engl J Med*. 1990 Jul 5;323(1):1-6.
356. Heilbronn LK, Smith SR, Martin CK, Anton SD, Ravussin E. Alternate-day fasting in nonobese subjects: effects on body weight, body composition, and energy metabolism. *Am J Clin*

- Nutr. 2005 Jan;81(1):69-73.
357. Alirezaei M, Kemball CC, Flynn CT, et al. Short-term fasting induces profound neuronal autophagy. *Autophagy*. 2010 Aug 16;6(6):702–710.
358. Kim I, Lemasters JJ. Mitochondrial degradation by autophagy (mitophagy) in GFP-LC3 transgenic hepatocytes during nutrient deprivation. *Am J Physiol Cell Physiol*. 2011 Feb;300(2):C308-17.
359. Zhu Y, Yan Y, Gius DR, Vassilopoulos A. Metabolic regulation of Sirtuins upon fasting and the implication for cancer. *Curr Opin Oncol*. 2013 Nov;25(6):630-6.
360. Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: Two potential diets for successful brain aging. *Ageing Res Rev*. 2006 Aug;5(3):332–353.
361. Mekker A, Tchang VS, Haeberli L, et al. Immune senescence: relative contributions of age and cytomegalovirus infection. *PLoS Pathogens*. 2012;8(8):e1002850.
362. Tarazona R, Sanchez-Correa B, Casas-Aviles I, et al. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy. *Cancer Immunol Immunother*. Feb 2017;66(2):233-245.
363. Pera A, Campos C, Lopez N, et al. Immunosenescence: Implications for response to infection and vaccination in older people. *Maturitas*. Sep 2015;82(1):50-55.
364. Vuolo L, Di Somma C, Faggiano A, Colao A. Vitamin D and cancer. *Frontiers in Endocrinology*. 2012;3:58.
365. Aranow C. Vitamin D and the immune system. *J Investig Med*. 2011 Aug;59(6):881-6.
366. Buras RR, Schumaker LM, Davoodi F, et al. Vitamin D receptors in breast cancer cells. *Breast Cancer Res Treat*. 1994;31(2-3):191-202.
367. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. *Nutrients*. Jul 05 2013;5(7):2502-2521.
368. Lang PO, Aspinall R. Can we translate vitamin D immunomodulating effect on innate and adaptive immunity to vaccine response? *Nutrients*. Mar 20 2015;7(3):2044-2060.

369. Barragan M, Good M, Kolls JK. Regulation of Dendritic Cell Function by Vitamin D. *Nutrients*. Sep 21 2015;7(9):8127-8151.
370. Enioutina EY, Bareyan D, Daynes RA. TLR ligands that stimulate the metabolism of vitamin D3 in activated murine dendritic cells can function as effective mucosal adjuvants to subcutaneously administered vaccines. *Vaccine*. Jan 30 2008;26(5):601-613.
371. Enioutina EY, Bareyan D, Daynes RA. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. *J Immunol*. Apr 01 2009;182(7):4296-4305.
372. Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. *J Infect Dis*. Feb 15 2006;193(4):598-600.
373. Sadarangani SP, Whitaker JA, Poland GA. «Let there be light»: the role of vitamin D in the immune response to vaccines. *Expert review of vaccines*. 2015;14(11):1427-1440.
374. Wiers KM, Lathers DM, Wright MA, Young MR. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. *Journal of Immunotherapy*. Jan 2000;23(1):115-124.
375. Camisaschi C, Vallacchi V, Vergani E, et al. Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. *Vaccines*. Nov 04 2016;4(4).
376. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. *Cancer Immunol Immunother*. May 2004;53(5):422-430.
377. Wiers KM, Lathers DM, Wright MA, Young MR. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. *Journal of Immunotherapy*. Jan 2000;23(1):115-124.
378. Grattan BJ, Freake HC. Zinc and cancer: implications for LIV-1 in breast cancer. *Nutrients*. Jul 2012;4(7):648-675.
379. Cabrera AJ. Zinc, aging, and immunosenescence: an overview.

- Pathobiol Aging Age Relat Dis. 2015;5:25592.
380. Haase H, Rink L. The immune system and the impact of zinc during aging. *Immun Ageing*. 2009 Jun 12;6:9.
381. Mitchell WA, Meng I, Nicholson SA, Aspinall R. Thymic output, ageing and zinc. *Biogerontology*. Oct-Dec 2006;7(5-6):461-470.
382. Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link between the integrity of the immune system and zinc status. *The Journal of Nutrition*. May 2000;130(5S Suppl):1399s-1406s.
383. Beck FW, Prasad AS, Kaplan J, et al. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. *Am J Physiol*. 1997 Jun;272(6 Pt 1):E1002-7.
384. Barnett JB, Dao MC, Hamer DH, et al. Effect of zinc supplementation on serum zinc concentration and T cell proliferation in nursing home elderly: a randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr*. 2016 Mar;103(3):942-51.
385. Wong CP, Song Y, Elias VD, et al. Zinc supplementation increases zinc status and thymopoiesis in aged mice. *The Journal of nutrition*. Jul 2009;139(7):1393-1397.
386. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. *Oncogene*. Oct 06 2008;27(45):5932-5943.
387. Souza-Fonseca-Guimaraes F. NK cell-based immunotherapies: awakening the innate anti-cancer response. *Discovery Medicine*. Mar 2016;21(115):197-203.
388. Mocchegiani E, Romeo J, Malavolta M, et al. Zinc: dietary intake and impact of supplementation on immune function in elderly. *Age*. Jun 2013;35(3):839-860
389. Mocchegiani E, Muzzioli M, Giacconi R, et al. Metallothioneins/ PARP-1/IL-6 interplay on natural killer cell activity in elderly: parallelism with nonagenarians and old infected humans. Effect of zinc supply. *Mech Ageing Dev*. Apr 2003;124(4):459-468.
390. Mariani E, Neri S, Cattini L, et al. Effect of zinc supplementation on plasma IL-6 and MCP-1 production and NK cell function in healthy elderly: interactive influence of +647 MT1a and -174 IL-6



- polymorphic alleles. *Exp Gerontol.* May 2008;43(5):462-471.
391. Muzzioli M, Stecconi R, Moresi R, Provinciali M. Zinc improves the development of human CD34+ cell progenitors towards NK cells and increases the expression of GATA-3 transcription factor in young and old ages. *Biogerontology.* Oct 2009;10(5):593-604.
392. Perez-Martinez A, Valentin J, Fernandez L, et al. Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma in vitro and in vivo. *Cytotherapy.* May 2015;17(5):601-612.
393. Ghoneum M, Abedi S. Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). *J Pharm Pharmacol.* Dec 2004;56(12):1581-1588.
394. Cholujova D, Jakubikova J, Czako B, et al. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. *Cancer Immunol Immunother.* Mar 2013;62(3):437-445.
395. Ghoneum M, Agrawal S. Mgn-3/biobran enhances generation of cytotoxic CD8+ T cells via upregulation of dec-205 expression on dendritic cells. *Int J Immunopathol Pharmacol.* 2014 Oct-Dec;27(4):523-30.
396. Zhang L, Shao WF, Yuan LF, et al. Decreasing pro-inflammatory cytokine and reversing the immunosenescence with extracts of Pu-erh tea in senescence accelerated mouse (SAM). *Food Chem.* Dec 15 2012;135(4):2222-2228.
397. Zhang K, Ma X, He W, et al. Extracts of *Cistanche deserticola* Can Antagonize Immunosenescence and Extend Life Span in Senescence-Accelerated Mouse Prone 8 (SAM-P8) Mice. *Evid Based Complement Alternat Med.* 2014;2014:601383.
398. Singh M, Ramos I, Asafu-Adjei D, et al. Curcumin improves the therapeutic efficacy of *Listeria(at)*-*Mage-b* vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. *Cancer Med.* Aug 2013;2(4):571-582.
399. Luo F, Song X, Zhang Y, Chu Y. Low-dose curcumin leads to the inhibition of tumor growth via enhancing CTL-mediated antitumor immunity. *International Immunopharmacology.* Sep

- 2011;11(9):1234-1240.
400. Milano F, Mari L, van de Luitgaarden W, et al. Nano-curcumin inhibits proliferation of esophageal adenocarcinoma cells and enhances the T cell mediated immune response. *Frontiers in oncology*. 2013;3:137.
401. Lu Y, Miao L, Wang Y, et al. Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. *Mol Ther*. 2016;24(2):364-374.
402. Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAP $\alpha$  vaccine elicits effective antitumor response by targeting indoleamine-2,3-dioxygenase and inhibiting EMT induced by TNF- $\alpha$  in melanoma. *Oncotarget*. Sep 22 2015;6(28):25932-25942.
403. Singh M, Ramos I, Asafu-Adjei D, et al. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1. *Cancer Med*. Aug 2013;2(4):571-582.
404. Jiang GM, Xie WY, Wang HS, et al. Curcumin combined with FAP $\alpha$  vaccine elicits effective antitumor response by targeting indoleamine-2,3-dioxygenase and inhibiting EMT induced by TNF- $\alpha$  in melanoma. *Oncotarget*. Sep 22 2015;6(28):25932-25942.
405. Lu Y, Miao L, Wang Y, et al. Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. *Mol Ther*. 2016;24(2):364-374.
406. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. *Cancer Prevention Research*. Feb 2012;5(2):205-215.
407. Liu D, You M, Xu Y, Li F, Zhang D, Li X, Hou Y. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. *International Immunopharmacology*. Oct 2016;39:265-272.
408. Wang X, Quinn PJ. The location and function of vitamin E in membranes (review). *Molecular Membrane Biology*. Jul-Sep

- 2000;17(3):143-156.
409. Morel S, Didierlaurent A, Bourguignon P, et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. *Vaccine*. Mar 16 2011;29(13):2461-2473.
410. Meydani SN, Meydani M, Blumberg JB, et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. *JAMA*. May 07 1997;277(17):1380-1386.
411. De la Fuente M, Hernanz A, Guayerbas N, et al. Vitamin E ingestion improves several immune functions in elderly men and women. *Free Radical Research*. Mar 2008;42(3):272-280.
412. Hanson MG, Ozenci V, Carlsten MC, et al. A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients. *Cancer Immunol Immunother*. Jul 2007;56(7):973-984.
413. Hafid SR, Radhakrishnan AK, Nesaretnam K. Tocotrienols are good adjuvants for developing cancer vaccines. *BMC Cancer*. Jan 06 2010;10:5.
414. Abdul Hafid SR, Chakravarthi S, Nesaretnam K, Radhakrishnan AK. Tocotrienol-adjuvanted dendritic cells inhibit tumor growth and metastasis: a murine model of breast cancer. *PloS One*. 2013;8(9):e74753.
415. Mahalingam D, Radhakrishnan AK, Amom Z, et al. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. *European Journal of Clinical Nutrition*. Jan 2011;65(1):63-69.
416. Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal*. Apr 01 2012;16(7):705-743.
417. Broome CS, McArdle F, Kyle JA, et al. An increase in selenium intake improves immune function and poliovirus handling in adults with marginal selenium status. *The American Journal of*

- Clinical Nutrition. Jul 2004;80(1):154-162.
418. Mahdavi M, Mavandadnejad F, Yazdi MH, et al. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model. *Journal of Infection and Public Health*. 2017;10(1):102-109.
  419. Yazdi MH, Varastehmoradi B, Faghfuri E, et al. Adjuvant Effect of Biogenic Selenium Nanoparticles Improves the Immune Responses and Survival of Mice Receiving 4T1 Cell Antigens as Vaccine in Breast Cancer Murine Model. *Journal of Nanoscience and Nanotechnology*. Dec 2015;15(12):10165-10172.
  420. Wang H, Chan YL, Li TL, et al. Reduction of splenic immunosuppressive cells and enhancement of anti-tumor immunity by synergy of fish oil and selenium yeast. *PloS One*. 2013;8(1):e52912.
  421. Kiremidjian-Schumacher L, Roy M. Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions. *Biofactors*. 2001;14(1-4):161-168.
  422. Wood SM, Beckham1 C, Yosioka2 A, Darban3 H, Watson RR. beta-Carotene and selenium supplementation enhances immune response in aged humans. *Integr Med*. 2000 Mar 21;2(2):85-92.
  423. Tang ML, Ponsonby AL, Orsini F, et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol*. Mar 2015;135(3):737-744.e738.
  424. Liu J, Chen FH, Qiu SQ, et al. Probiotics enhance the effect of allergy immunotherapy on regulating antigen specific B cell activity in asthma patients. *American journal of translational research*. 2016;8(12):5256-5270.
  425. Shida K, Nomoto K. Probiotics as efficient immunopotentiators: translational role in cancer prevention. *The Indian Journal of Medical Research*. Nov 2013;138(5):808-814.
  426. Nagao F, Nakayama M, Muto T, Okumura K. Effects of a fermented milk drink containing *Lactobacillus casei* strain Shirota

- on the immune system in healthy human subjects. *Bioscience, Biotechnology, and Biochemistry*. Dec 2000;64(12):2706-2708.
427. Makino S, Ikegami S, Kume A, Horiuchi H, Sasaki H, Oritani N. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with *Lactobacillus delbrueckii* ssp. *bulgaricus* OLL1073R-1. *The British Journal of Nutrition*. Oct 2010;104(7):998-1006.
428. Sugawara G, Nagino M, Nishio H, et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. *Ann Surg*. Nov 2006;244(5):706-714.
429. Silveira MM, Conceicao FR, Mendonca M, et al. *Saccharomyces boulardii* improves humoral immune response to DNA vaccines against leptospirosis. *J Med Microbiol*. Feb 2017;66(2):184-190.
430. Maruyama M, Abe R, Shimono T, et al. The effects of non-viable *Lactobacillus* on immune function in the elderly: a randomised, double-blind, placebo-controlled study. *International Journal of Food Sciences and Nutrition*. 2016;67(1):67-73.
431. Miyazawa K, Kawase M, Kubota A, et al. Heat-killed *Lactobacillus gasseri* can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study. *Benef Microbes*. 2015;6(4):441-449.
432. Sivan A, Corrales L, Hubert N, et al. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*. Nov 27 2015;350(6264):1084-1089.
433. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. Nov 27 2015;350(6264):1079-1084.
434. Ding J, Feng T, Ning Y, et al. beta-Glucan enhances cytotoxic T lymphocyte responses by activation of human monocyte-derived dendritic cells via the PI3K/AKT pathway. *Human Immunology*. Mar 2015;76(2-3):146-154.
435. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. *Ganoderma lucidum* (Reishi mushroom) for cancer treatment. *The Cochrane Database of Systematic Reviews*. Apr 05 2016;4:Cd007731.

436. Gao Y, Tang W, Dai X, et al. Effects of water-soluble *Ganoderma lucidum* polysaccharides on the immune functions of patients with advanced lung cancer. *Journal of Medicinal Food*. Summer 2005;8(2):159-168.
437. Chen X, Hu ZP, Yang XX, et al. Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. *International Immunopharmacology*. Mar 2006;6(3):499-508.
438. Levitz SM, Huang H, Ostroff GR, Specht CA. Exploiting fungal cell wall components in vaccines. *Seminars in Immunopathology*. Mar 2015;37(2):199-207.
439. Wang M, Zhang L, Yang R, et al. Improvement of immune responses to influenza vaccine (H5N1) by sulfated yeast beta-glucan. *International journal of biological macromolecules*. Dec 2016;93(Pt A):203-207.
440. Huang H, Ostroff GR, Lee CK, et al. Characterization and optimization of the glucan particle-based vaccine platform. *Clinical and Vaccine Immunology*. Oct 2013;20(10):1585-1591.
441. Fritz H, Kennedy DA, Ishii M, et al. Polysaccharide K and *Coriolus versicolor* extracts for lung cancer: a systematic review. *Integrative Cancer Therapies*. May 2015;14(3):201-211.
442. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. *Oncology Reports*. Apr 2006;15(4):861-868.

## **ΜΕΡΟΣ 9**

### **ΡΙΖΙΚΗ ΥΦΕΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ. ΜΙΑ ΕΡΕΥΝΑ ΓΙΑ ΤΗΝ ΟΛΙΣΤΙΚΗ ΠΡΟΣΕΓΓΙΣΗ ΑΝΤΙΜΕΤΩΠΙΣΗΣ ΤΟΥ ΚΑΡΚΙΝΟΥ**

1. Turner K. *Radical Remission: Surviving Cancer Against All Odds*. HarperCollins Publishers. New York. 2014.
2. Temoshok L, Heller BW, Sagebiel RW, et al. The relationship of psychosocial factors to prognostic indicators in cutaneous malignant melanoma. *J Psychosom Res*. 1985;29(2):139-53.

3. Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. *Eur J Cancer*. 2005 Aug;41(12):1710-4.
4. Roud PC. Psychosocial variables associated with the exceptional survival of patients with advanced malignant disease. *Int J Psychiatry Med*. 1986-1987;16(2):113-22.
5. Huebscher R. Spontaneous remission of cancer: an example of health promotion. *Nurse Pract Forum*. 1992 Dec;3(4):228-35.
6. Schilder JN, de Vries MJ, Goodkin K, et al. Psychological changes preceding spontaneous remission of cancer. *Clinical Case Studies*. 2004;3(4):288-312.
7. Cunningham AJ, Edmonds CV, Phillips C, et al. A prospective, longitudinal study of the relationship of psychological work to duration of survival in patients with metastatic cancer. *Psychooncology*. 2000 Jul-Aug;9(4):323-39.
8. Cunningham AJ, Watson K. How psychological therapy may prolong survival in cancer patients: new evidence and a simple theory. *Integr Cancer Ther*. 2004 Sep;3(3):214-29.
9. Katz LS, Epstein S. The relation of cancer-prone personality to exceptional recovery from cancer: a preliminary study. *Adv Mind Body Med*. 2005 Fall-Winter;21(3-4):6-20.
10. Sanfey AG, Chang LJ. Of the two minds when making a decision. *Scientific American*. June 3, 2008. <https://www.scientificamerican.com/article/of-two-minds-when-making/>
11. Gershon M. *The Second Brain: The Scientific Basis of Gut Instinct and a Groundbreaking New Understanding of Nervous Disorders of the Stomach and Intestines*, 1st ed. New York Harper, 1998.
12. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. *Science*. 1997 Feb 28;275(5304):1293-5.
13. Bem DJ. Feeling the future: experimental evidence for anomalous retroactive influences on cognition and affect. *J Pers Soc Psychol*. 2011 Mar;100(3):407-25.
14. Dijksterhuis A, Bos MW, Nordgren LF, van Baaren RB. On making

- the right choice: the deliberation-without-attention effect. *Science*. 2006 Feb 17;311(5763):1005-7.
15. Dijksterhuis A. Think different: the merits of unconscious thought in preference development and decision making. *J Pers Soc Psychol*. 2004 Nov;87(5):586-98.
  16. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. *N Engl J Med*. 1991 Aug 29;325(9):606-12.
  17. Pert CB. *Molecules of Emotion: Why You Feel the Way You Feel*. New York: Scribner. 1997.
  18. McGregor BA, Antoni MH, Boyers A, et al. Cognitive-behavioral stress management increases benefit finding and immune function among women with early-stage breast cancer. *J Psychosom Res*. 2004 Jan;56(1):1-8.
  19. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. *Arch Gen Psychiatry*. 1993 Sep;50(9):681-9.
  20. Abate M, Citro M, Caputo M, Pisanti S, Martinelli R. Psychological Stress and Cancer: New Evidence of An Increasingly Strong Link. *Transl Med UniSa*. 2020;23:53-57.
  21. Dai S, Mo Y, Wang Y, et al. Chronic Stress Promotes Cancer Development. *Front Oncol*. 2020;10:1492.
  22. Turner K. *Radical Remission: Surviving Cancer Against All Odds*. HarperCollins Publishers. New York. 2014.
  23. Yu M. Somatic mitochondrial DNA mutations in human cancers. *Adv Clin Chem*. 2012;57:99-138.
  24. Yu M. Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. *Life Sci*. 2011 Jul 18;89(3-4):65-71.
  25. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. *Nature*. 2012 Nov 15;491(7424):364-73.
  26. Fielding JW, Fagg SL, Jones BG, et al. An interim report of a prospective, randomized, controlled study of adjuvant



- chemotherapy in operable gastric cancer: British Stomach Cancer Group. *World J Surg.* 1983 May;7(3):390-9.
27. Segerstrom SC, Glover DA, Craske MG, Fahey JL. Worry affects the immune response to phobic fear. *Brain Behav Immun.* 1999 Jun;13(2):80-92.
  28. Bennett MP, Lengacher CA. Humor and laughter may influence health. I. History and background. *Evid Based Complement Alternat Med.* 2006 Mar;3(1):61-3.
  29. Wilkins J, Eisenbraun AJ. Humor theories and the physiological benefits of laughter. *Adv Mind Body Med.* 2009 Summer;24(2):8-12.
  30. Berk LS, Tan SA, Fry WF, Napier BJ, Lee JW, Hubbard RW, Lewis JE, Eby WC. Neuroendocrine and stress hormone changes during mirthful laughter. *Am J Med Sci.* 1989 Dec;298(6):390-6.
  31. Berk LS, Felten DL, Tan SA, Bittman BB, Westengard J. Modulation of neuroimmune parameters during the eustress of humor-associated mirthful laughter. *Altern Ther Health Med.* 2001 Mar;7(2):62-72, 74-6.
  32. Bennett MP, Zeller JM, Rosenberg L, McCann J. The effect of mirthful laughter on stress and natural killer cell activity. *Altern Ther Health Med.* 2003 Mar-Apr;9(2):38-45.
  33. Sarkar DK, Murugan S, Zhang C, Boyadjieva N. Regulation of cancer progression by  $\beta$ -endorphin neuron. *Cancer Res.* 2012;72(4):836-840.
- Ames E, Murphy WJ. Advantages and clinical applications of natural killer cells in cancer immunotherapy. *Cancer Immunol Immunother.* 2014 Jan;63(1):21-8.
34. Sakai Y, Takayanagi K, Ohno M, Inose R, Fujiwara H. A trial of improvement of immunity in cancer patients by laughter therapy. *Jpn Hosp.* 2013 Jul;(32):53-9.
  35. Lamers SM, Bolier L, Westerhof GJ, Smit F, Bohlmeijer ET. The impact of emotional well-being on long-term recovery and survival in physical illness: a meta-analysis. *J Behav Med.* 2012 Oct;35(5):538-47.
  36. Chida Y, Steptoe A. Positive psychological well-being and

- mortality: a quantitative review of prospective observational studies. *Psychosom Med.* 2008 Sep;70(7):741-56.
37. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. *J Urol.* 2005 Sep;174(3):1065-9; discussion 1069-70.
  38. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. *Proc Natl Acad Sci U S A.* 2008 Jun 17;105(24):8369-74.
  39. Ishak WW, Kahloon M, Fakhry H. Oxytocin role in enhancing well-being: a literature review. *J Affect Disord.* 2011 Apr;130(1-2):1-9.
  40. Steptoe A, Dockray S, Wardle J. Positive affect and psychobiological processes relevant to health. *J Pers.* 2009 Dec;77(6):1747-76.
  41. Berkman LF, Syme SL. Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. *Am J Epidemiol.* 1979 Feb;109(2):186-204.
  42. Glass TA, de Leon CM, Marottoli RA, Berkman LF. Population based study of social and productive activities as predictors of survival among elderly Americans. *BMJ.* 1999 Aug 21;319(7208):478-83.
  43. Giles LC, Glonek GF, Luszcz MA, Andrews GR. Effect of social networks on 10 year survival in very old Australians: the Australian longitudinal study of aging. *J Epidemiol Community Health.* 2005 Jul;59(7):574-9.
  44. House JS, Robbins C, Metzner HL. The association of social relationships and activities with mortality: prospective evidence from the Tecumseh Community Health Study. *Am J Epidemiol.* 1982 Jul;116(1):123-40.
  45. Reynolds P, Boyd PT, Blacklow RS, et al. The relationship between social ties and survival among black and white breast cancer patients. National Cancer Institute Black/White Cancer Survival Study Group. *Cancer Epidemiol Biomarkers Prev.* 1994 Apr-May;3(3):253-9.
  46. Berkman LF, Syme SL. Social networks, host resistance, and

- mortality: a nine-year follow-up study of Alameda County residents. *Am J Epidemiol*. 1979 Feb;109(2):186-204.
47. Glass TA, de Leon CM, Marottoli RA, Berkman LF. Population based study of social and productive activities as predictors of survival among elderly Americans. *BMJ*. 1999 Aug 21;319(7208):478-83.
  48. Reynolds P, Boyd PT, Blacklow RS, et al. The relationship between social ties and survival among black and white breast cancer patients. National Cancer Institute Black/White Cancer Survival Study Group. *Cancer Epidemiol Biomarkers Prev*. 1994 Apr-May;3(3):253-9.
  49. Chou AF, Stewart SL, Wild RC, Bloom JR. Social support and survival in young women with breast carcinoma. *Psychooncology*. 2012 Feb;21(2):125-33.
  50. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. *J Clin Oncol*. 2006 Mar 1;24(7):1105-11.
  51. Waxler-Morrison N, Hislop TG, Mears B, Kan L. Effects of social relationships on survival for women with breast cancer: a prospective study. *Soc Sci Med*. 1991;33(2):177-83.
  52. Weihs KL, Simmens SJ, Mizrahi J, et al. Dependable social relationships predict overall survival in Stages II and III breast carcinoma patients. *J Psychosom Res*. 2005 Nov;59(5):299-306.
  53. Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. *PLoS Med*. 2010 Jul 27;7(7):e1000316.
  54. Krongrad A, Lai H, Burke MA, et al. Marriage and mortality in prostate cancer. *Journal of Urology*. 1996 Nov; 156(5): 1696-1700.
  55. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. *J Clin Oncol*. 1999 Jul;17(7):2256-63.
  56. Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. *Crit Rev Oncol Hematol*. 2010;75(2):122-137.
  57. Uchino BN, Cacioppo JT, Kiecolt-Glaser JK. The relationship

- between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. *Psychol Bull.* 1996 May;119(3):488-531.
58. Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. *J Behav Med.* 2006 Aug;29(4):377-87.
  59. Dockray S, Steptoe A. Positive affect and psychobiological processes. *Neurosci Biobehav Rev.* 2010 Sep;35(1):69-75.
  60. Ader R, ed. *Psychoneuroimmunology*. 4th ed. Burlington, MA: Elsevier Academic Press. 2011.
  61. Giles LC, Glonek GF, Luszcz MA, Andrews GR. Effect of social networks on 10 year survival in very old Australians: the Australian longitudinal study of aging. *J Epidemiol Community Health.* 2005 Jul;59(7):574-9.
  62. House JS, Robbins C, Metzner HL. The association of social relationships and activities with mortality: prospective evidence from the Tecumseh Community Health Study. *Am J Epidemiol.* 1982 Jul;116(1):123-40.
  63. Steptoe A, Shankar A, Demakakos P, Wardle J. Social isolation, loneliness, and all-cause mortality in older men and women. *Proc Natl Acad Sci U S A.* 2013 Apr 9;110(15):5797-801.
  64. Kroenke CH, Kubzansky LD, Schernhammer ES, Holmes MD, Kawachi I. Social networks, social support, and survival after breast cancer diagnosis. *J Clin Oncol.* 2006 Mar 1;24(7):1105-11.
  65. Cacioppo JT, Ernst JM, Burleson MH, et al. Lonely traits and concomitant physiological processes: the MacArthur social neuroscience studies. *Int J Psychophysiol.* 2000 Mar;35(2-3):143-54.
  66. Uchino BN, Cacioppo JT, Kiecolt-Glaser JK. The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. *Psychol Bull.* 1996 May;119(3):488-531.
  67. Kiecolt-Glaser JK, Garner W, Speicher C, et al. Psychosocial modifiers of immunocompetence in medical students. *Psychosom Med.* 1984 Jan-Feb;46(1):7-14.

68. Kiecolt-Glaser JK, Ricker D, George J, et al. Urinary cortisol levels, cellular immunocompetency, and loneliness in psychiatric inpatients. *Psychosom Med.* 1984 Jan-Feb;46(1):15-23.
69. Pressman SD, Cohen S, Miller GE, et al. Loneliness, social network size, and immune response to influenza vaccination in college freshmen. *Health Psychol.* 2005 May;24(3):297-306.
70. Tooley GA, Armstrong SM, Norman TR, Sali A. Acute increases in night-time plasma melatonin levels following a period of meditation. *Biol Psychol.* 2000 May;53(1):69-78.
71. Ganz FD. Sleep and immune function. *Crit Care Nurse.* 2012 Apr;32(2):e19-25.
72. Tamarkin L, Danforth D, Lichter A, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. *Science.* 1982 May 28;216(4549):1003-5.
73. Davis S, Mirick DK. Circadian disruption, shift work and the risk of cancer: a summary of the evidence and studies in Seattle. *Cancer Causes Control.* 2006 May;17(4):539-45.
74. Hölzel BK, Carmody J, Vangel M, et al. Mindfulness practice leads to increases in regional brain gray matter density. *Psychiatry Res.* 2011 Jan 30;191(1):36-43.
75. Khansari DN, Murgu AJ, Faith RE. Effects of stress on the immune system. *Immunol Today.* 1990 May;11(5):170-5.
76. Pruetz SB. Stress and the immune system. *Pathophysiology.* 2003 May;9(3):133-153.
77. Segerstrom SC, Miller GE. Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. *Psychol Bull.* 2004 Jul;130(4):601-30.
78. Davidson RJ, Kabat-Zinn J, Schumacher J, et al. Alterations in brain and immune function produced by mindfulness meditation. *Psychosom Med.* 2003 Jul-Aug;65(4):564-70.
79. Jacobs TL, Epel ES, Lin J, et al. Intensive meditation training, immune cell telomerase activity, and psychological mediators. *Psychoneuroendocrinology.* 2011 Jun;36(5):664-81.
80. Dusek JA, Otu HH, Wohlhueter AL, et al. Genomic counter-stress changes induced by the relaxation response. *PLoS One.* 2008 Jul

- 2;3(7):e2576.
81. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome. *Lancet*. 1979 Oct 13;2(8146):785-7.
  82. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. *J Clin Oncol*. 1999 Jul;17(7):2256-63.
  83. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. *Ann Oncol*. 2000 Apr;11(4):469-74.
  84. Vos MS, Putter H, van Houwelingen HC, de Haes HC. Denial and physical outcomes in lung cancer patients, a longitudinal study. *Lung Cancer*. 2010 Feb;67(2):237-43.
  85. Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. *Lancet*. 1999 Oct 16;354(9187):1331-6.
  86. Pinqart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. *Psychol Med*. 2010 Nov;40(11):1797-810.
  87. Pirl WF, Greer JA, Traeger L, et al. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. *J Clin Oncol*. 2012 Apr 20;30(12):1310-5.
  88. Faller H, Schmidt M. Prognostic value of depressive coping and depression in survival of lung cancer patients. *Psychooncology*. 2004 May;13(5):359-63.
  89. Goodwin JS, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. *J Am Geriatr Soc*. 2004 Jan;52(1):106-11.
  90. Yu H, Wang Y, Ge X, Wu X, Mao X. Depression and survival in Chinese patients with gastric cancer: a prospective study. *Asian Pac J Cancer Prev*. 2012;13(1):391-4.
  91. Johansson M, Rydén A, Finizia C. Mental adjustment to cancer and its relation to anxiety, depression, HRQL and survival in patients with laryngeal cancer - a longitudinal study. *BMC Cancer*. 2011;11:283.
  92. Lazure KE, Lydiatt WM, Denman D, Burke WJ. Association between depression and survival or disease recurrence in

- patients with head and neck cancer enrolled in a depression prevention trial. *Head Neck*. 2009 Jul;31(7):888-92.
93. Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. *Eur J Cancer*. 2005 Aug;41(12):1710-4.
94. Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. *J Clin Oncol*. 2011 Feb 1;29(4):413-20.
95. Karppinen H, Laakkonen M-L, Strandberg TE, et al. Will-to-live and survival in a ten-year follow-up among older people. *Age and Ageing*. 2012 Nov;41(6): 789–794.



ΕΚΔΟΣΕΙΣ ETRA  
Τ. 2109811753  
[www.etra.gr](http://www.etra.gr)